UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM N-CSR

CERTIFIED SHAREHOLDER REPORT OF REGISTERED MANAGEMENT

INVESTMENT COMPANIES

Investment Company Act file number: 811-21656

 

Name of Fund:   BlackRock Energy and Resources Trust (BGR)

 

Fund Address:   100 Bellevue Parkway, Wilmington, DE 19809

Name and address of agent for service: John M. Perlowski, Chief Executive Officer, BlackRock Energy and Resources Trust, 55 East 52nd Street, New York, NY 10055

Registrant’s telephone number, including area code: (800) 882-0052, Option 4

Date of fiscal year end: 12/31/2021

Date of reporting period: 06/30/2021


Item 1 –

Report to Stockholders

(a) The Report to Shareholders is attached herewith.


 

 

LOGO

  JUNE 30, 2021

 

  

2021 Semi-Annual Report

(Unaudited)

 

 

BlackRock Energy and Resources Trust (BGR)

BlackRock Enhanced Capital and Income Fund, Inc. (CII)

BlackRock Enhanced Equity Dividend Trust (BDJ)

BlackRock Enhanced Global Dividend Trust (BOE)

BlackRock Enhanced International Dividend Trust (BGY)

BlackRock Health Sciences Trust (BME)

BlackRock Health Sciences Trust II (BMEZ)

BlackRock Innovation and Growth Trust (BIGZ)

BlackRock Resources & Commodities Strategy Trust (BCX)

BlackRock Science and Technology Trust (BST)

BlackRock Science and Technology Trust II (BSTZ)

BlackRock Utilities, Infrastructure & Power Opportunities Trust (BUI)

 

 

 

Not FDIC Insured • May Lose Value • No Bank Guarantee


Supplemental Information  (unaudited)

 

Section 19(a) Notices

BlackRock Energy and Resources Trust’s (BGR), BlackRock Enhanced Capital and Income Fund, Inc.’s (CII), BlackRock Enhanced Equity Dividend Trust’s (BDJ), BlackRock Enhanced Global Dividend Trust’s (BOE), BlackRock Enhanced International Dividend Trust’s (BGY), BlackRock Health Sciences Trust’s (BME), BlackRock Health Sciences Trust II’s (BMEZ), BlackRock Innovation and Growth Trust’s (BIGZ), BlackRock Resources & Commodities Strategy Trust’s (BCX), BlackRock Science and Technology Trust’s (BST), BlackRock Science and Technology Trust II’s (BSTZ) and BlackRock Utilities, Infrastructure & Power Opportunities Trust’s (BUI) (collectively, the “Trusts”, or individually a “Trust”) amounts and sources of distributions reported are estimates and are being provided to you pursuant to regulatory requirements and are not being provided for tax reporting purposes. The actual amounts and sources for tax reporting purposes will depend upon each Trust’s investment experience during the remainder of its fiscal year and may be subject to changes based on tax regulations. Each Trust will provide a Form 1099-DIV each calendar year that will tell you how to report these distributions for U.S. federal income tax purposes.

June 30, 2021

 

     Total Cumulative Distributions
for the Fiscal Period
   

% Breakdown of the Total Cumulative

Distributions for the Fiscal Period

 

Trust Name

   

Net

Income

 

 

   

Net Realized
Capital Gains
Short-Term
 
 
 
   

Net Realized
Capital Gains
Long-Term
 
 
 
   
Return of
Capital 
 
(a)  
   

Total Per
Common
Share
 
 
 
   
Net
Income
 
 
   

Net Realized
Capital Gains
Short-Term
 
 
 
   

Net Realized
Capital Gains
Long-Term
 
 
 
   
Return of
Capital
 
 
   

Total Per
Common
Share
 
 
 

BGR

  $ 0.153140     $ —     $ —     $ 0.071860     $
 
 
0.225000
 
 
    68 %      — %      — %      32 %      100 % 

CII

    0.029888       —       0.495112       —       0.525000       6       —       94       —       100  

BDJ

    0.229141       —       0.070859       —       0.300000       76       —       24       —       100  

BOE

    0.117999       0.017791       0.242210       —       0.378000       31       5       64       —       100  

BGY

    0.101324       —       0.101476       —       0.202800       50       —       50       —       100  

BME

    0.005112       0.042915       1.151973       —       1.200000       —       4       96       —       100  

BMEZ

    —       0.780000       —       —       0.780000       —       100       —       —       100  

BIGZ

    —       —       —       0.100000       0.100000       —       —       —       100       100  

BCX

    0.116959       —       —       0.123041       0.240000       49       —       —       51       100  

BST

    —       0.064543       1.213457       —       1.278000       —       5       95       —       100  

BSTZ

    —       0.508730       0.405270       —       0.914000       —       56       44       —       100  

BUI

    0.219802       —       0.150526       0.355672       0.726000       30       —       21       49       100  

 

  (a)

Each Trust estimates that it has distributed more than its net income and net realized capital gains; therefore, a portion of the distribution may be a return of capital. A return of capital may occur, for example, when some or all of the shareholder’s investment in a Trust is returned to the shareholder. A return of capital does not necessarily reflect a Trust’s investment performance and should not be confused with “yield” or “income.” When distributions exceed total return performance, the difference will reduce a Trust’s net asset value per share.

 

Section 19(a) notices for the Trusts, as applicable, are available on the BlackRock website at blackrock.com.

Section 19(b) Disclosure

The Trusts, acting pursuant to a U.S. Securities and Exchange Commission (“SEC”) exemptive order and with the approval of each Trust’s Board of Trustees (the “Board”), each have adopted a managed distribution plan, consistent with its investment objectives and policies to support a level distribution of income, capital gains and/or return of capital (the “Plan”). In accordance with the Plans, the Trusts currently distribute the following fixed amounts per share on a monthly basis:

 

Exchange Symbol   Amount Per
Common Share
 

BGR

  $ 0.0375  

CII

    0.0875  

BDJ

    0.0500  

BOE

    0.0630  

BGY

    0.0338  

BME

    0.2000  

BMEZ

    0.1450  

BIGZ

    0.1000  

BCX

    0.0400  

BST

    0.2260  

BSTZ

    0.1710  

BUI

    0.1210  

The fixed amounts distributed per share are subject to change at the discretion of each Trust’s Board. Under its Plan, each Trust will distribute all available net income to its shareholders as required by the Internal Revenue Code of 1986, as amended (the “Code”). If sufficient income (inclusive of net income and short-term capital gains) is not earned on a monthly basis, the Trusts will distribute long-term capital gains and/or return of capital to shareholders in order to maintain a level distribution. Each monthly distribution to shareholders is expected to be at the fixed amount established by the Board; however, each Trust may make additional distributions from time to time, including additional capital gain distributions at the end of the taxable year, if required to meet requirements imposed by the Code and/or the Investment Company Act of 1940, as amended (the “1940 Act”).

Shareholders should not draw any conclusions about each Trust’s investment performance from the amount of these distributions or from the terms of the Plan. Each Trust’s total return performance is presented in its financial highlights table.

 

 

2  

2 0 2 1   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S


Supplemental Information  (unaudited)  (continued)

 

The Board may amend, suspend or terminate a Trust’s Plan at any time without prior notice to the Trust’s shareholders if it deems such actions to be in the best interests of the Trust or its shareholders. The suspension or termination of the Plan could have the effect of creating a trading discount (if the Trust’s stock is trading at or above net asset value) or widening an existing trading discount. The Trusts are subject to risks that could have an adverse impact on their ability to maintain level distributions. Examples of potential risks include, but are not limited to, economic downturns impacting the markets, changes in interest rates, decreased market volatility, companies suspending or decreasing corporate dividend distributions and changes in the Code. Please refer to BME, BST and BUI’s prospectuses for a more complete description of each Trust’s risks.

 

 

S U P P L E M E N T A L  I N F O R M A T  I O N

  3


The Markets in Review

Dear Shareholder,

The 12-month reporting period as of June 30, 2021 was a remarkable period of adaptation and recovery, as the global economy dealt with the implications of the coronavirus (or “COVID-19”) pandemic. The United States, along with most of the world, began the reporting period emerging from a severe recession, prompted by pandemic-related restrictions that disrupted many aspects of daily life. However, easing restrictions and robust government intervention led to a strong rebound, and the economy grew at a significant pace for the reporting period, recovering much of the output lost at the beginning of the pandemic.

Equity prices rose with the broader economy, as investors became increasingly optimistic about the economic outlook. Stocks rose through the summer of 2020, fed by strong fiscal and monetary support and positive economic indicators. The implementation of mass vaccination campaigns and passage of an additional $1.9 trillion of fiscal stimulus further boosted stocks, and many equity indices neared or surpassed all-time highs late in the reporting period. In the United States, both large- and small-capitalization stocks posted a significant advance. International equities also gained, as both developed countries and emerging markets rebounded substantially.

The 10-year U.S. Treasury yield (which is inversely related to bond prices) had fallen sharply prior to the beginning of the reporting period, which meant bonds were priced for extreme risk avoidance and economic disruption. Despite expectations of doom and gloom, the economy expanded rapidly, stoking inflation concerns in early 2021, which led to higher yields and a negative overall return for most U.S. Treasuries. In the corporate bond market, support from the U.S. Federal Reserve (the “Fed”) assuaged credit concerns and led to substantial returns for high-yield corporate bonds, although investment-grade corporates declined slightly.

The Fed remained committed to accommodative monetary policy by maintaining near zero interest rates and by reiterating that inflation could exceed its 2% target for a sustained period without triggering a rate increase. Late in the period the Fed elaborated on their expected timeline, raising the likelihood of slower bond purchasing and the possibility of higher rates in 2023.

Looking ahead, while coronavirus-related disruptions have clearly hindered worldwide economic growth, we believe that the global expansion will continue to accelerate as vaccination efforts ramp up and pent-up consumer demand leads to higher spending. While we expect inflation to increase somewhat as the expansion continues, we believe the recent uptick owes more to temporary supply disruptions than a lasting change in fundamentals. The change in Fed policy also means that moderate inflation is less likely to be followed by interest rate hikes that could threaten the economic expansion.

Overall, we favor a moderately positive stance toward risk, with an overweight in equities. Sectors that are better poised to manage the transition to a lower-carbon world, such as technology and healthcare, are particularly attractive in the long-term. U.S. small-caps and European equities are likely to benefit from the continuing vaccine-led restart. We are underweight long-term on credit, but inflation-protected U.S. Treasuries, Asian fixed income, and Chinese government bonds offer potential opportunities. We believe that international diversification and a focus on sustainability can help provide portfolio resilience, and the disruption created by the coronavirus appears to be accelerating the shift toward sustainable investments.

In this environment, our view is that investors need to think globally, extend their scope across a broad array of asset classes, and be nimble as market conditions change. We encourage you to talk with your financial advisor and visit blackrock.com for further insight about investing in today’s markets.

Sincerely,

 

LOGO

Rob Kapito

President, BlackRock Advisors, LLC

LOGO

Rob Kapito

President, BlackRock Advisors, LLC

 

Total Returns as of June 30, 2021
     6-Month   12-Month

U.S. large cap equities
(S&P 500® Index)

  15.25%   40.79%
   

U.S. small cap equities
(Russell 2000® Index)

  17.54     62.03  
   

International equities
(MSCI Europe, Australasia, Far East Index)

  8.83     32.35  
   

Emerging market equities
(MSCI Emerging Markets Index)

  7.45     40.90  
   

3-month Treasury bills
(ICE BofA 3-Month
U.S. Treasury Bill Index)

  0.02     0.09  
   

U.S. Treasury securities
(ICE BofA 10-Year
U.S. Treasury Index)

  (4.10)   (5.89)
   

U.S. investment grade bonds
(Bloomberg Barclays U.S. Aggregate Bond Index)

  (1.60)   (0.33)
   

Tax-exempt municipal bonds
(S&P Municipal Bond Index)

  1.24     4.20  
   

U.S. high yield bonds
(Bloomberg Barclays
U.S. Corporate High Yield 2% Issuer Capped Index)

  3.61     15.34  
Past performance is not an indication of future results. Index performance is shown for illustrative purposes only. You cannot invest directly in an index.
 

 

 

4  

T H I S   P A G E   I S   N O T   P A R T   O F   Y O U R   F U N D   R E P O R T


Table of Contents

 

      Page  

Supplemental Information

     2  

The Markets in Review

     4  

Option Over-Writing Strategy

     6  

Derivative Financial Instruments

     6  

Semi-Annual Report:

  

Trust Summary

     7  

Financial Statements:

  

Schedules of Investments

     42  

Statements of Assets and Liabilities

     138  

Statements of Operations

     141  

Statements of Changes in Net Assets

     144  

Statements of Cash Flows

     150  

Financial Highlights

     153  

Notes to Financial Statements

     165  

Disclosure of Investment Advisory Agreements and Sub-Advisory Agreements

     178  

Disclosure of Investment Advisory Agreement

     183  

Additional Information

     186  

Glossary of Terms Used in this Report

     189  

 

 

  5


Option Over-Writing Strategy

 

Overview

In general, the goal of each of the Trusts is to provide total return through a combination of current income and realized and unrealized gains (capital appreciation). The Trusts seek to pursue these goals primarily by investing in a portfolio of equity securities and also by employing a strategy of writing (selling) call and put options in an effort to generate current gains from option premiums and to enhance each Trust’s risk-adjusted return. Each Trust’s objectives cannot be achieved in all market conditions.

Each Trust primarily writes single stock covered call options, and may also from time to time write single stock put options. When writing (selling) a covered call option, a Trust holds an underlying equity security and enters into an option transaction which allows the counterparty to purchase the equity security at an agreed-upon price (“strike price”) within an agreed-upon time period. The Trust receives cash premiums from the counterparties upon writing (selling) the option, which along with net investment income and net realized gains, if any, are generally available to support current or future distributions paid by the Trust. During the option term, the counterparty may elect to exercise the option if the market value of the equity security rises above the strike price, and the Trust is obligated to sell the equity security to the counterparty at the strike price, realizing a gain or loss. Premiums received increase gains or reduce losses realized on the sale of the equity security. If the option remains unexercised upon its expiration, the Trust realizes gains equal to the premiums received. Alternatively, an option may be closed out by an offsetting purchase or sale of an option prior to expiration. The Trust realizes a capital gain from a closing purchase or sale transaction if the premium paid is less than the premium received from writing the option. The Trust realizes a capital loss from a closing purchase or sale transaction if the premium received is less than the premium paid to purchase the option.

Writing covered call options entails certain risks, which include, but are not limited to, the following: an increase in the value of the underlying equity security above the strike price can result in the exercise of a written option (sale by a Trust to the counterparty) when the Trust might not otherwise have sold the security; exercise of the option by the counterparty may result in a sale below the current market value and a gain or loss being realized by the Trust; and limiting the potential appreciation that could be realized on the underlying equity security to the extent of the strike price of the option. The premium that a Trust receives from writing a covered call option may not be sufficient to offset the potential appreciation on the underlying equity security above the strike price of the option that could have otherwise been realized by the Trust. As such, an option over-writing strategy may outperform the general equity market in flat or falling markets but underperform in rising markets.

Option Over-Writing Strategy Illustration

To illustrate these concepts, assume the following: (1) a common stock purchased at and currently trading at $37.15 per share; (2) a three-month call option is written by a Trust with a strike price of $40 (i.e., 7.7% higher than the current market price); and (3) the Trust receives $2.45, or 6.6% of the common stock’s value, as a premium. If the stock price remains unchanged, the option expires and there would be a 6.6% return for the three-month period. If the stock were to decline in price by 6.6% (i.e., decline to $34.70 per share), the option strategy would “break-even” from an economic perspective resulting in neither a gain nor a loss. If the stock were to climb to a price of $40 or above, the option would be exercised and the stock would return 7.7% coupled with the option premium received of 6.6% for a total return of 14.3%. Under this scenario, the Trust loses the benefit of any appreciation of the stock above $40, and thus is limited to a 14.3% total return. The premium from writing the call option serves to offset some of the unrealized loss on the stock in the event that the price of the stock declines, but if the stock were to decline more than 6.6% under this scenario, the Trust’s downside protection is eliminated and the stock could eventually become worthless.

Each Trust intends to write covered call and other options to varying degrees depending upon market conditions. Please refer to each Trust’s Schedule of Investments and the Notes to Financial Statements for details of written options.

Derivative Financial Instruments

The Trusts may invest in various derivative financial instruments. These instruments are used to obtain exposure to a security, commodity, index, market, and/or other assets without owning or taking physical custody of securities, commodities and/or other referenced assets or to manage market, equity, credit, interest rate, foreign currency exchange rate, commodity and/or other risks. Derivative financial instruments may give rise to a form of economic leverage and involve risks, including the imperfect correlation between the value of a derivative financial instrument and the underlying asset, possible default of the counterparty to the transaction or illiquidity of the instrument. The Trusts’ successful use of a derivative financial instrument depends on the investment adviser’s ability to predict pertinent market movements accurately, which cannot be assured. The use of these instruments may result in losses greater than if they had not been used, may limit the amount of appreciation a Trust can realize on an investment and/or may result in lower distributions paid to shareholders. The Trusts’ investments in these instruments, if any, are discussed in detail in the Notes to Financial Statements.

 

 

6  

2 0 2 1   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S


Trust Summary  as of June 30, 2021    BlackRock Energy and Resources Trust (BGR)

 

Investment Objective

BlackRock Energy and Resources Trust’s (BGR) (the “Trust”) investment objective is to provide total return through a combination of current income and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its total assets in equity securities of energy and natural resources companies and equity derivatives with exposure to the energy and natural resources industry. The Trust may invest directly in such securities or synthetically through the use of derivatives. The Trust seeks to pursue this goal primarily by investing in a portfolio of equity securities and also by employing a strategy of writing (selling) call and put options.

No assurance can be given that the Trust’s investment objective will be achieved.

Trust Information

 

Symbol on New York Stock Exchange

  BGR

Initial Offering Date

  December 29, 2004

Current Distribution Rate on Closing Market Price as of June 30, 2021 ($9.81)(a)

  4.59%

Current Monthly Distribution per Common Share(b)

  $0.0375

Current Annualized Distribution per Common Share(b)

  $0.4500

 

  (a) 

Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. The current distribution rate may consist of income, net realized gains and/or a return of capital. Past performance is not an indication of future results.

 
  (b) 

The distribution rate is not constant and is subject to change. A portion of the distribution may be deemed a return of capital or net realized gain.

 

Market Price and Net Asset Value Per Share Summary

 

     06/30/21      12/31/20      Change     High      Low    

Market Price

  $ 9.81      $  7.10        38.17 %    $  10.37      $  7.02    

Net Asset Value

     10.19        8.17        24.72       10.54        8.17    

Market Price and Net Asset Value History for the Past Five Years

 

LOGO

 

 

T R U S T   S U M M A R Y

  7


Trust Summary  as of June 30, 2021 (continued)    BlackRock Energy and Resources Trust (BGR)

 

Performance and Portfolio Management Commentary

Returns for the six months ended June 30, 2021 were as follows:

 

    Returns Based On  
     Market Price     NAV  

BGR(a)(b)

    41.66 %      27.87 % 

MSCI World Energy Call Overwrite Index(c)

    N/A       30.85  

 

  (a) 

All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices.

 
  (b) 

The Trust’s discount to NAV narrowed during the period, which accounts for the difference between performance based on market price and performance based on NAV.

 
  (c)

MSCI World Energy Call Overwrite Index incorporates an option overlay component on the MSCI World Energy Index with a 33% overwrite level.

 

N/A — Not applicable as the index does not have a market price.

Past performance is not an indication of future results.

Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles.

The following discussion relates to the Trust’s absolute performance based on NAV:

What factors influenced performance?

Energy stocks delivered strong returns in the past six months. The uptrend began in November 2020, prior to the beginning of the reporting period, when the release of a vaccine for the coronavirus provided a path to a re-opening of the global economy. Oil prices rallied on expectations of improving demand, leading to an impressive gain for the energy sector.

While the Trust produced a robust absolute return for the period, from an allocation standpoint, an underweight position in the integrated sub-sector detracted from performance. On the other hand, an overweight in the exploration and production (“E&P”) sub-sector contributed positively. Stock selection in the refining and marketing category was an additional contributor.

Among individual holdings, a position in the Brazilian state-owned integrated oil producer Petroleo Brasileiro SA, was the largest detractor from performance. The stock declined following an unexpected change in the company’s chief executive officer, which the market saw as the first step in deeper government influence in its longer-term strategy. An underweight in Exxon Mobil Corp., a large index component that outpaced its sector peers on the strength of improving earnings, also detracted.

An overweight position in the Canadian oil and gas producer Tourmaline Oil Corp. was a top contributor. The company announced the purchase of privately owned Black Swan Energy, a move that was well received by investors. An overweight in the exploration and production company Arc Resources, Ltd., which reported strong results, also contributed to returns. A zero weighting in the Finland-based refiner Neste oyj—which lagged after reporting weaker-than-expected guidance—was a further positive.

The Trust utilized an options overlay strategy in which calls are written on a portion of the portfolio’s holdings. The Trust’s options overlay strategy contributed positively to relative performance for the six-month period.

Describe recent portfolio activity.

The Trust selectively added to exploration & production companies, based on its view that global oil demand was steadily recovering. The Trust also rotated exposure in the integrated oil industry in an effort to capitalize on differences in relative performance. The investment adviser remains biased toward higher-quality oil producers, which it expects can benefit from continued strength in oil prices.

Describe portfolio positioning at period end.

The integrated energy sub-sector represented the Trust’s largest allocation, followed by the exploration & production, distribution, refining & marketing and oil services industries, respectively.

At period end, the Trust was overweight in the exploration & production industry. This positioning reflects the investment adviser’s tilt toward higher-quality producers. On the other hand, the Trust was underweight in distribution and oil services industries. The investment adviser believes many parts of the oil services sub-sector may continue to face headwinds due to the overcapacity built in the last upcycle.

As of June 30, 2021, the Trust had in place an option overwriting program whereby 34.4% of the underlying equities were overwritten with call options. These call options were typically written at prices above the prevailing market prices (estimated to be 3% out of the money) with an average time until expiration of 52 days.

The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions. These views are not intended to be a forecast of future events and are no guarantee of future results.

 

 

8  

2 0 2 1   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S


Trust Summary  as of June 30, 2021 (continued)    BlackRock Energy and Resources Trust (BGR)

 

Overview of the Trust’s Total Investments

 

TEN LARGEST HOLDINGS

Security(a)   Percent of
Total Investments
 

Chevron Corp.

    13 % 

Royal Dutch Shell PLC

    11  

TotalEnergies SE

    8  

ConocoPhillips

    7  

Exxon Mobil Corp.

    7  

Canadian Natural Resources Ltd.

    4  

Suncor Energy, Inc.

    4  

Pioneer Natural Resources Co.

    4  

Hess Corp.

    4  

Valero Energy Corp.

    3  

INDUSTRY ALLOCATION

Industry(a)(b)   06/30/21     12/31/20  

Oil, Gas & Consumable Fuels

    97 %      96 % 

Energy Equipment & Services

    2       4  

Food Products

    1       —  
 

 

(a)

Excludes short-term securities and options written.

(b)

For Trust compliance purposes, the Trust’s industry classifications refer to one or more of the industry sub-classifications used by one or more widely recognized market indexes or ratings group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.

 

 

T R U S T   S U M M A R Y

  9


Trust Summary  as of June 30, 2021    BlackRock Enhanced Capital and Income Fund, Inc. (CII)

 

Investment Objective

BlackRock Enhanced Capital and Income Fund, Inc.’s (CII) (the “Trust”) investment objective is to provide current income and capital appreciation. The Trust seeks to achieve its investment objective by investing in a portfolio of equity securities of U.S. and foreign issuers. The Trust may invest directly in such securities or synthetically through the use of derivatives. The Trust also seeks to achieve its investment objective by employing a strategy of writing (selling) call and put options.

No assurance can be given that the Trust’s investment objective will be achieved.

Trust Information

 

Symbol on New York Stock Exchange

  CII

Initial Offering Date

  April 30, 2004

Current Distribution Rate on Closing Market Price as of June 30, 2021 ($20.59)(a)

  5.10%

Current Monthly Distribution per Common Share(b)

  $ 0.0875

Current Annualized Distribution per Common Share(b)

  $ 1.0500

 

  (a) 

Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. Past performance is not an indication of future results.

 
  (b)

The monthly distribution per Common Share, declared on July 1, 2021, was increased to $0.0930 per share. The yield on closing market price, tax equivalent yield, current monthly distribution per Common Share, and current annualized distribution per Common Share do not reflect the new distribution rate. The new distribution rate is not constant and is subject to change in the future.

 

Market Price and Net Asset Value Per Share Summary

 

     06/30/21      12/31/20      Change     High      Low    

Market Price

  $  20.59      $  17.40        18.33 %    $  20.84      $  17.14    

Net Asset Value

    21.44        19.12        12.13       21.58        18.93    

Market Price and Net Asset Value History for the Past Five Years

 

LOGO

 

 

10  

2 0 2 1   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S


Trust Summary  as of June 30, 2021 (continued)    BlackRock Enhanced Capital and Income Fund, Inc. (CII)

 

Performance and Portfolio Management Commentary

Returns for the six months ended June 30, 2021 were as follows:

 

    Returns Based On  
     Market Price     NAV  

CII(a)(b)

    21.54 %      15.17 % 

MSCI USA Call Overwrite Index(c)

    N/A       13.18  

 

  (a) 

All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices.

 
  (b) 

The Trust’s discount to NAV narrowed during the period, which accounts for the difference between performance based on market price and performance based on NAV. (c) MSCI USA Call Overwrite Index incorporates an option overlay component on the MSCI USA Index with a 55% overwrite level.

 

N/A — Not applicable as the index does not have a market price.

Past performance is not an indication of future results.

Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles.

The following discussion relates to the Trust’s absolute performance based on NAV:

What factors influenced performance?

The largest contributor to the Trust’s performance was a combination of stock selection and an overweight allocation to the communication services sector. Most notably, stock selection and an overweight allocation to the interactive media & services industry proved beneficial. Stock selection and an underweight allocation to the entertainment industry and an underweight position in diversified telecommunication services companies also boosted performance in the sector. In financials, stock selection and an overweight allocation to the consumer finance industry boosted the Trust’s return. Other notable contributors during the period included stock selection in health care and an underweight allocation to the utilities sector.

The largest detractor from returns came from the Trust’s investment decisions in the consumer discretionary sector. Notably, stock selection in the multiline retail industry proved costly, as did stock selection and an overweight allocation to internet & direct marketing retail companies. Within materials, the Trust’s decision not to invest in the metals & mining industry weighed on from results. Other detractors at the industry level included stock selection within the information technology (“IT”) sector in IT services, as well as personal products companies within consumer staples.

The Trust utilized an options overlay strategy in which calls are written on a portion of the portfolio’s holdings. The Trust’s options overlay strategy detracted from relative performance for the six-month period.

Describe recent portfolio activity.

During the period, a combination of portfolio trading activity and market price changes resulted in the Trust adding exposure to the consumer discretionary, communication services, and energy sectors. The Trust reduced exposure to consumer staples, IT, and industrials.

Describe portfolio positioning at period end.

At period end, the Trust’s largest absolute allocations were to the IT, consumer discretionary, and communication services sectors. Relative to the benchmark, the Trust’s most significant overweight exposures were to the communication services, consumer discretionary, and financials sectors. The Trust maintained its most significant relative underweight sector exposures to consumer staples, utilities, and real estate.

As of June 30, 2021, the Trust had an options overwriting program in place whereby approximately 47% of the underlying equities were overwritten with call options. These call options were typically written at prices above prevailing market prices (estimated to be 2.8% out of the money) with an average time until expiration of 51 days.

The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions. These views are not intended to be a forecast of future events and are no guarantee of future results.

 

 

T R U S T   S U M M A R Y

  11


Trust Summary  as of June 30, 2021 (continued)    BlackRock Enhanced Capital and Income Fund, Inc. (CII)

 

Overview of the Trust’s Total Investments

 

TEN LARGEST HOLDINGS

Security(a)   Percent of
Total Investments
 

Microsoft Corp.

    7 % 

Alphabet, Inc.

    6  

Amazon.com, Inc.

    6  

Apple, Inc.

    4  

Facebook, Inc.

    4  

Visa, Inc.

    3  

UnitedHealth Group, Inc.

    3  

Applied Materials, Inc.

    3  

Comcast Corp.

    3  

Berkshire Hathaway, Inc.

    2  

SECTOR ALLOCATION

Sector(a)(b)   06/30/21     12/31/20  

Information Technology

    27 %      29 % 

Consumer Discretionary.

    16       14  

Communication Services

    15       14  

Financials

    12       12  

Health Care

    11       11  

Industrials

    7       8  

Materials

    4       3  

Energy

    4       3  

Consumer Staples

    3       5  

Real Estate

    1       1  
 

 

(a) 

Excludes short-term securities and options written.

(b) 

For Trust compliance purposes, the Trust’s sector classifications refer to one or more of the sector sub-classifications used by one or more widely recognized market indexes or rating group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such sector sub-classifications for reporting ease.

 

 

12  

2 0 2 1   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S


Trust Summary  as of June 30, 2021    BlackRock Enhanced Equity Dividend Trust (BDJ)

 

Investment Objective

BlackRock Enhanced Equity Dividend Trust’s (BDJ) (the “Trust”) primary investment objective is to provide current income and current gains, with a secondary investment objective of long-term capital appreciation. The Trust seeks to achieve its investment objectives by investing in common stocks that pay dividends and have the potential for capital appreciation and by employing a strategy of writing (selling) call and put options. The Trust invests, under normal market conditions, at least 80% of its total assets in dividend paying equities. The Trust may invest directly in such securities or synthetically through the use of derivatives.

No assurance can be given that the Trust’s investment objectives will be achieved.

Trust Information

 

Symbol on New York Stock Exchange

  BDJ

Initial Offering Date

  August 31, 2005

Current Distribution Rate on Closing Market Price as of June 30, 2021 ($10.13)(a)

  5.92%

Current Monthly Distribution per Common Share(b)

  $0.0500

Current Annualized Distribution per Common Share(b)

  $0.6000

 

  (a) 

Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. Past performance is not an indication of future results.

 
  (b) 

The distribution rate is not constant and is subject to change.

 

Market Price and Net Asset Value Per Share Summary

 

     06/30/21      12/31/20      Change      High      Low  

Market Price

  $ 10.13      $ 8.47        19.60 %     $ 10.68      $ 8.22  

Net Asset Value

    10.44        9.35        11.66        10.75        9.17  

Market Price and Net Asset Value History for the Past Five Years

 

LOGO

 

 

T R U S T   S U M M A R Y

  13


Trust Summary  as of June 30, 2021 (continued)    BlackRock Enhanced Equity Dividend Trust (BDJ)

 

Performance and Portfolio Management Commentary

Returns for the six months ended June 30, 2021 were as follows:

 

    Returns Based On  
     Market Price     NAV  

BDJ(a)(b)

    23.41 %      15.22 % 

MSCI USA Value Call Overwrite Index(c)

    N/A       15.09  

 

  (a) 

All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices.

 
  (b) 

The Trust’s discount to NAV narrowed during the period, which accounts for the difference between performance based on market price and performance based on NAV.

 
  (c) 

MSCI USA Value Call Overwrite Index incorporates an option overlay component on the MSCI USA Value Index with a 55% overwrite level.

 

N/A — Not applicable as the index does not have a market price.

Past performance is not an indication of future results.

Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles.

The following discussion relates to the Trust’s absolute performance based on NAV:

What factors influenced performance?

The largest contributor to the Trust’s performance was a combination of stock selection and an overweight allocation to financials. In particular, stock selection and overweight allocations to the banks and capital markets industries proved beneficial, as did stock selection in insurance. In energy, stock selection and an overweight allocation to the oil & gas refining & marketing sub-industry boosted the Trust’s return, as did an overweight position in companies engaged in the oil & gas storage & transportation and exploration & production businesses. Other modest contributors during the period included underweight allocations to the utilities and communication services sectors.

The largest detractor from returns came from the Trust’s stock selection in the information technology (“IT”) sector. Notably, stock selection decisions in the IT services and software industries weighed on performance, as did stock selection among technology hardware, storage & peripherals companies. In industrials, an underweight allocation to building products companies and investment decisions in the aerospace & defense, electrical equipment, and machinery industries all detracted from performance. Other detractors included the Trust’s lack of investment in the real estate sector, which was based on the view that valuations were unattractive, as well as stock selection among companies in the consumer discretionary sector.

The Trust utilized an options overlay strategy in which calls are written on a portion of the portfolio’s holdings. The Trust’s options overlay strategy detracted from relative performance for the six-month period.

Describe recent portfolio activity.

During the period, a combination of portfolio trading activity and market price changes resulted in the Trust adding exposure to the consumer discretionary, industrials, and health care sectors. The Trust reduced exposure to IT, consumer staples, and financials.

Describe portfolio positioning at period end.

At period end, the Trust’s largest absolute allocations were to the financials, health care, and IT sectors. Relative to the benchmark, the Trust’s most significant overweight exposures were to the financials, energy, and communication services sectors. The Trust maintained its most significant relative underweight sector exposures to real estate, industrials, and consumer staples.

As of June 30, 2021, the Trust had an options overwriting program in place whereby approximately 50% of the underlying equities were overwritten with call options. These call options were typically written at prices above prevailing market prices (estimated to be 2.3% out of the money) with an average time until expiration of 48 days.

The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions. These views are not intended to be a forecast of future events and are no guarantee of future results.

 

 

14  

2 0 2 1   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S


Trust Summary  as of June 30, 2021 (continued)    BlackRock Enhanced Equity Dividend Trust (BDJ)

 

Overview of the Trust’s Total Investments

 

TEN LARGEST HOLDINGS

 

Security(a)   Percent of
Total Investments
 

Wells Fargo & Co.

    4 % 

Citigroup, Inc.

    4  

Anthem, Inc.

    3  

American International Group, Inc.

    3  

Bank of America Corp.

    3  

Cisco Systems, Inc.

    3  

Verizon Communications, Inc.

    2  

Morgan Stanley

    2  

General Motors Co.

    2  

Comcast Corp.

    2  

SECTOR ALLOCATION

 

Sector(a)(b)   06/30/21     12/31/20  

Financials

    28 %      28 % 

Health Care

    19       18  

Information Technology

    11       13  

Industrials

    8       7  

Consumer Discretionary

    7       5  

Energy

    7       7  

Consumer Staples

    7       9  

Communication Services

    6       7  

Utilities

    5       4  

Materials

    2       2  
 

 

(a) 

Excludes short-term securities and options written.

(b) 

For Trust compliance purposes, the Trust’s sector classifications refer to one or more of the sector sub-classifications used by one or more widely recognized market indexes or rating group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such sector sub-classifications for reporting ease.

 

 

T R U S T   S U M M A R Y

  15


Trust Summary  as of June 30, 2021    BlackRock Enhanced Global Dividend Trust (BOE)

 

Investment Objective

BlackRock Enhanced Global Dividend Trust’s (BOE) (the “Trust”) primary investment objective is to provide current income and current gains, with a secondary investment objective of long-term capital appreciation. The Trust seeks to achieve its investment objectives by investing primarily in equity securities issued by companies located in countries throughout the world and by employing a strategy of writing (selling) call and put options. Under normal circumstances, the Trust invests at least 80% of its net assets in dividend-paying equity securities and at least 40% of its assets outside of the U.S. (unless market conditions are not deemed favorable by Trust management, in which case the Trust would invest at least 30% of its assets outside of the U.S.). The Trust may invest in securities of companies of any market capitalization, but intends to invest primarily in securities of large capitalization companies. The Trust may invest directly in such securities or synthetically through the use of derivatives.

No assurance can be given that the Trust’s investment objectives will be achieved.

Trust Information

 

Symbol on New York Stock Exchange

  BOE

Initial Offering Date

  May 31, 2005

Current Distribution Rate on Closing Market Price as of June 30, 2021 ($12.55)(a)

  6.02%

Current Monthly Distribution per Common Share(b)

  $0.0630

Current Annualized Distribution per Common Share(b)

  $0.7560

 

  (a) 

Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. Past performance is not an indication of future results.

 
  (b) 

The distribution rate is not constant and is subject to change.

 

Market Price and Net Asset Value Per Share Summary

 

     06/30/21      12/31/20      Change      High      Low  

Market Price

  $ 12.55      $ 10.91        15.03 %     $ 12.82      $ 10.66  

Net Asset Value

    13.28        12.28        8.14        13.49        12.02  

Market Price and Net Asset Value History for the Past Five Years

 

LOGO

 

 

16  

2 0 2 1   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S


Trust Summary  as of June 30, 2021 (continued)    BlackRock Enhanced Global Dividend Trust (BOE)

 

Performance and Portfolio Management Commentary

Returns for the six months ended June 30, 2021 were as follows:

 

    Returns Based On  
     Market Price     NAV  

BOE(a)(b)

    18.78 %      11.67 % 

MSCI ACWI Call Overwrite Index(c)

    N/A       11.92  

 

  (a) 

All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices.

 
  (b) 

The Trust’s discount to NAV narrowed during the period, which accounts for the difference between performance based on market price and performance based on NAV.

 
  (c) 

MSCI ACWI Call Overwrite Index incorporates an option overlay component on the MSCI ACWI Index with a 45% overwrite level.

 

N/A — Not applicable as the index does not have a market price.

Past performance is not an indication of future results.

Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles.

The following discussion relates to the Trust’s absolute performance based on NAV:

What factors influenced performance?

Stock selection within the consumer discretionary sector was the largest contributor to the Trust’s performance, particularly within the textiles & apparel industry. Other contributors included the Trust’s underweight allocation to the utilities sector and stock selection within utilities and information technology (“IT”). At the individual stock level, financial software company Intuit Inc. was a top contributor, as the stock gained upward momentum during and after the U.S. tax reporting season. Regional bank Citizens Financial Group, Inc. also contributed as interested rates rose in the U.S., which boosted the bank’s net interest margin. Drug maker AstraZeneca PLC was also additive.

The largest detractor from performance came from the Trust’s overweight allocation to, and stock selection within, the consumer staples sector, most notably within the food products industry. Other detractors included an underweight position to energy and stock selection among financials. At the individual stock level, the Trust’s position in baby formula producer China Feihe Ltd. was the most substantial detractor amid concerns of the negative business impact of a potential drop in birth rates. Reckitt Benckiser Group PLC also detracted, as its health and nutrition divisions experienced declines in sales. The Trust’s position in Unilever NV also weighed on relative performance.

The Trust utilized an options overlay strategy in which calls are written on a portion of the portfolio’s holdings. The Trust’s options overlay strategy contributed positively to relative performance for the six-month period.

Describe recent portfolio activity.

During the period, the Trust added exposure to the financial sector, most notably within the capital markets industry. Exposure to the consumer discretionary sector also increased, especially within textiles, apparel & luxury goods. Conversely, the Trust reduced exposure to industrials, particularly within the aerospace & defense industry, and consumer staples, largely within tobacco.

Describe portfolio positioning at period end.

At period end, the Trust’s largest sector exposures were in IT and health care, driven by holdings in the IT services and pharmaceuticals industries respectively. The Trust had no exposure to the energy or materials sectors. Regionally, the majority of the portfolio was listed in the United States or Europe, with significant exposure to the United Kingdom.

As of June 30, 2021, the Trust had an options overwriting program in place whereby approximately 45% of the underlying equities were overwritten with call options. These call options were typically written at prices above prevailing market prices (estimated to be 2.3% out of the money) with an average time until expiration of 49 days.

The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions. These views are not intended to be a forecast of future events and are no guarantee of future results.

 

 

T R U S T   S U M M A R Y

  17


Trust Summary  as of June 30, 2021 (continued)    BlackRock Enhanced Global Dividend Trust (BOE)

 

Overview of the Trust’s Total Investments

 

TEN LARGEST HOLDINGS

Security(a)   Percent of
Total Investments
 

Microsoft Corp.

    4 % 

Sanofi

    4  

Reckitt Benckiser Group PLC

    4  

RELX PLC

    3  

Taiwan Semiconductor Manufacturing Co. Ltd.

    3  

Intercontinental Exchange, Inc.

    3  

TELUS Corp.

    3  

UnitedHealth Group, Inc.

    3  

Fidelity National Information Services, Inc.

    3  

Bristol-Myers Squibb Co.

    3  

GEOGRAPHIC ALLOCATION

Country/Geographic Region   06/30/21     12/31/20  

United States

    52 %      56 % 

United Kingdom

    20       18  

France

    10       4  

Taiwan

    3       2  

Canada

    3       3  

China

    3       —  

Denmark

    2       1  

Spain

    2       2  

Netherlands

    1       2  

Singapore

    1       3  

Mexico

    1       —  

Ireland

    1       1  

Australia

    1       2  

India

    —       — (b) 

Germany

    —       1  

Switzerland

    —       4  

Finland

    —       1  
 

 

(a) Excludes short-term securities and options written.

(b) Rounds to less than 1% of total investments.

 

 

18  

2 0 2 1   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S


Trust Summary  as of June 30, 2021    BlackRock Enhanced International Dividend Trust (BGY)

 

Investment Objective

BlackRock Enhanced International Dividend Trust’s (BGY) (the “Trust”) primary investment objective is to provide current income and current gains, with a secondary objective of long-term capital appreciation. The Trust seeks to achieve its investment objectives by investing primarily in equity securities issued by companies of any market capitalization located in countries throughout the world and by employing a strategy of writing (selling) call and put options. The Trust invests, under normal circumstances, at least 80% of its net assets in dividend-paying equity securities issued by non-U.S. companies of any market capitalization, but intends to invest primarily in securities of large capitalization companies. The Trust may invest directly in such securities or synthetically through the use of derivatives.

No assurance can be given that the Trust’s investment objectives will be achieved.

Trust Information

 

Symbol on New York Stock Exchange

  BGY

Initial Offering Date

  May 30, 2007

Current Distribution Rate on Closing Market Price as of June 30, 2021 ($6.55)(a)

  6.19%

Current Monthly Distribution per Common Share(b)

  $0.0338

Current Annualized Distribution per Common Share(b)

  $0.4056

 

  (a) 

Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. Past performance is not an indication of future results.

 
  (b) 

The distribution rate is not constant and is subject to change.

 

Market Price and Net Asset Value Per Share Summary

 

     06/30/21     12/31/20     Change     High     Low  

Market Price

  $ 6.55     $ 5.87       11.58 %    $   6.70     $   5.75  

Net Asset Value

    6.84       6.49       5.39       7.02       6.36  

Market Price and Net Asset Value History for the Past Five Years

 

LOGO

 

 

T R U S T   S U M M A R Y

  19


Trust Summary  as of June 30, 2021 (continued)    BlackRock Enhanced International Dividend Trust (BGY)

 

Performance and Portfolio Management Commentary

Returns for the six months ended June 30, 2021 were as follows:

 

    Returns Based On  
     Market Price     NAV  

BGY(a)(b)

    15.26 %      8.87 % 

MSCI ACWI ex USA Call Overwrite Index(c)

    N/A       9.49  

 

  (a) 

All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices.

 
  (b)

The Trust’s discount to NAV narrowed during the period, which accounts for the difference between performance based on market price and performance based on NAV.

 
  (c) 

MSCI ACWI ex USA Call Overwrite Index incorporates an option overlay component on the MSCI ACWI ex USA Index with a 45% overwrite level.

 

N/A — Not applicable as the index does not have a market price.

Past performance is not an indication of future results.

Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles.

The following discussion relates to the Trust’s absolute performance based on NAV:

What factors influenced performance?

From a sector perspective, the Trust’s exposure to the consumer discretionary, health care, and industrials sectors contributed the most to performance. The Trust’s underweight allocation to Japanese equities was the most significant contributor at the regional level. Among individual securities, luxury goods specialist LVMH Moet Hennessy SE, drug manufacturer AstraZeneca PLC, and beer, wine, and spirits producer Diageo PLC contributed the most to relative returns.

By contrast, the largest detractors from performance at the sector level resulted from the Trust’s exposure to financials, consumer staples, and materials. The Trust’s positions in North American-listed companies had the greatest negative impact on performance at the regional level. Among individual positions, the most significant detractors included baby formula producer China Feihe Ltd., consumer products giant Unilever NV, and health technology company Koninklijke Philips NV.

The Trust utilized an options overlay strategy in which calls are written on a portion of the portfolio’s holdings. The Trust’s options overlay strategy detracted from relative performance for the six-month period.

Describe recent portfolio activity.

During the period, the Trust increased its exposure to the consumer discretionary, financials, and utilities sectors. The Trust reduced exposure to health care, industrials, and materials. At the regional level, the Trust increased exposure to emerging market-listed companies, while reducing exposure to Europe ex-U.K.-listed companies

Describe portfolio positioning at period end.

At period end, the Trust had overweight allocations to consumer staples, health care, and industrials. It was underweight materials, financials, and consumer discretionary stocks.

As of June 30, 2021, the Trust had an option overwriting program in place whereby 42% of the underlying equities were overwritten with call options. These call options were typically written at prices above prevailing market prices (estimated to be 2.0% out of the money) with an average time until expiration of 48 days.

The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions. These views are not intended to be a forecast of future events and are no guarantee of future results.

 

 

20  

2 0 2 1   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S


Trust Summary  as of June 30, 2021 (continued)    BlackRock Enhanced International Dividend Trust (BGY)

 

Overview of the Trust’s Total Investments

 

TEN LARGEST HOLDINGS

Security(a)   Percent of
Total Investments
 

Sanofi

    5 % 

Reckitt Benckiser Group PLC

    5  

Taiwan Semiconductor Manufacturing Co. Ltd.

    5  

RELX PLC

    5  

Ferguson PLC

    5  

Diageo PLC

    5  

TELUS Corp.

    5  

AstraZeneca PLC

    4  

Unilever PLC

    4  

Prudential PLC

    4  

GEOGRAPHIC ALLOCATION

Country/Geographic Region   06/30/21     12/31/20  

United Kingdom

    35 %      35 % 

France

    17       9  

United States

    10       4  

China

    6       1  

Spain

    5       6  

Taiwan

    5       4  

Canada

    4       5  

Singapore

    4       5  

Denmark

    4       3  

India

    3       2  

Netherlands

    3       6  

Mexico

    2       —  

Australia

    2       5  

Germany

    —       3  

Switzerland

    —       9  

Finland

    —       3  
 

 

(a) Excludes short-term securities and options written.

 

 

T R U S T   S U M M A R Y

  21


Trust Summary  as of June 30, 2021    BlackRock Health Sciences Trust (BME)

 

Investment Objective

BlackRock Health Sciences Trust’s (BME) (the “Trust”) investment objective is to provide total return through a combination of current income, current gains and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its total assets in equity securities of companies engaged in the health sciences and related industries and equity derivatives with exposure to the health sciences industry. The Trust seeks to pursue this goal primarily by investing in a portfolio of equity securities and by employing a strategy of writing (selling) call and put options.

No assurance can be given that the Trust’s investment objective will be achieved.

Trust Information

 

Symbol on New York Stock Exchange

  BME

Initial Offering Date

  March 31, 2005

Current Distribution Rate on Closing Market Price as of June 30, 2021 ($48.50)(a)

  4.95%

Current Monthly Distribution per Common Share(b)

  $0.2000

Current Annualized Distribution per Common Share(b)

  $2.4000

 

  (a) 

Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. Past performance is not an indication of future results.

 
  (b) 

The distribution rate is not constant and is subject to change.

 

Market Price and Net Asset Value Per Share Summary

 

     06/30/21     12/31/20     Change     High     Low  

Market Price

    $  48.50       $  47.59       1.91 %      $  50.54       $  44.15  

Net Asset Value

    47.73       45.66       4.53       47.87       43.57  

Market Price and Net Asset Value History for the Past Five Years

 

LOGO

 

 

22  

2 0 2 1   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S


Trust Summary  as of June 30, 2021  (continued)    BlackRock Health Sciences Trust (BME)

 

Performance and Portfolio Management Commentary

Returns for the six months ended June 30, 2021 were as follows:

 

    Returns Based On  
     Market Price     NAV  

BME(a)(b)

    4.60 %      7.29 % 

MSCI USA IMI Health Care Call Overwrite Index(c)

    N/A       10.67  

 

  (a)

All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices.

 
  (b)

The Trust’s premium to NAV narrowed during the period, which accounts for the difference between performance based on market price and performance based on NAV.

 
  (c) 

MSCI USA IMI Health Care Call Overwrite Index incorporates an option overlay component on the MSCI IMI Health Care Index with a 33% overwrite level.

 

N/A — Not applicable as the index does not have a market price.

Past performance is not an indication of future results.

Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles.

The following discussion relates to the Trust’s absolute performance based on NAV:

What factors influenced performance?

Weakness in the biotechnology and health care providers & services sub-sectors was the primary cause of the Trust’s underperformance during the six-month period.

Among individual positions, an underweight in the biotechnology stock Moderna, Inc. was the largest detractor. The company received emergency use approval for its COVID-19 vaccine in the United States, United Kingdom and Europe, boosting its stock price. An overweight position in the biotechnology firm Seagen, Inc. also detracted. The company, which specializes in antibody drug conjugate treatments for cancer, experienced favorable clinical development that led to strong price appreciation in 2020. However, the stock lost ground in the first half of 2021 amid the broader rotation away from faster-growing companies.

On the positive side, stock selection in the pharmaceuticals sub-sector contributed to performance.

A private investment in the biotechnology company Acumen Pharmaceuticals, Inc., which underwent a successful initial public offering, was the largest contributor. An overweight position in the contract research and development company Wuxi AppTec Co., Ltd., which reported strong growth, was also helped results. An underweight in Merck & Co., Inc.—which suspended its COVID-19 vaccine development—was an additional contributor of note.

The Trust utilized an options overlay strategy in which calls are written on a portion of the portfolio’s holdings. The Trust’s option writing strategy detracted from relative performance for the six-month period.

Describe recent portfolio activity.

The Trust slightly reduced its weightings in the health care providers & services and medical devices & supplies sub-sectors, and it increased its allocations to biotechnology and pharmaceuticals.

Describe portfolio positioning at period end.

The investment adviser continued to monitor policy developments in the United States. Health care measures introduced by the Biden Administration have been limited in scope so far. While drug price reform is still a concern, it appears unlikely to have a significant long-term impact on the sector.

The investment adviser believes two key trends—aging demographics in both developed and developing countries, together with innovation in medical technology and biopharmaceutical drugs—remain the key drivers of performance in the health care sector. In the short term, the investment adviser is closely watching the ongoing developments related to COVID-19.

The Trust was overweight in the medical devices sector in anticipation of a recovery as economic conditions return to normal. Within the sector, the investment adviser was focused on companies pursuing minimally invasive surgical technologies on the belief they can improve patient outcomes and replace old standards of care. The Trust was also overweight in the biotechnology sub-sector, and it was underweight in pharmaceuticals and health care providers & services.

As of June 30, 2021, the Trust had an options overwriting program in place whereby 38% of the underlying equities were overwritten with call options. These options were typically written at prices above the prevailing market prices (estimated to be 4.9% out of the money) with an average time until expiration of 51 days.

The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions. These views are not intended to be a forecast of future events and are no guarantee of future results.

 

 

T R U S T   S U M M A R Y

  23


Trust Summary  as of June 30, 2021 (continued)    BlackRock Health Sciences Trust (BME)

 

Overview of the Trust’s Total Investments

 

TEN LARGEST HOLDINGS

Security(a)   Percent of
Total Investments
 

UnitedHealth Group, Inc.

    6 % 

Abbott Laboratories

    5  

Eli Lilly & Co.

    4  

Thermo Fisher Scientific, Inc.

    4  

Johnson & Johnson

    4  

Medtronic PLC

    3  

Pfizer, Inc.

    3  

Humana, Inc.

    3  

Intuitive Surgical, Inc.

    3  

Amgen, Inc.

    3  

INDUSTRY ALLOCATION

Industry(a)(b)   06/30/21     12/31/20  

Health Care Equipment & Supplies

    27 %      30 % 

Biotechnology

    21       19  

Health Care Providers & Services

    21       21  

Pharmaceuticals

    20       19  

Life Sciences Tools & Services

    10       9  

Health Care Technology

    1       1  

Diversified Financial Services

    —       1  

Other*

    — (c)       — (c)  
 

 

(a)

Excludes short-term securities and options written.

(b)

For Trust compliance purposes, the Trust’s industry classifications refer to one or more of the industry sub-classifications used by one or more widely recognized market indexes or ratings group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.

(c) 

Rounds to less than 1% of total investments.

*

Includes one or more investment categories that individually represents less than 1% of the Trust’s total investments. Please refer to the Schedule of Investments for details.

 

 

24  

2 0 2 1   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S


Trust Summary  as of June 30, 2021    BlackRock Health Sciences Trust II (BMEZ)

 

Investment Objective

BlackRock Health Sciences Trust II’s (BMEZ) (the “Trust”) investment objective is to provide total return and income through a combination of current income, current gains and long-term capital appreciation. Under normal market conditions, the Trust will invest at least 80% of its total assets in equity securities of companies principally engaged in the health sciences group of industries and equity derivatives with exposure to the health sciences group of industries. Equity derivatives in which the Trust invests include purchased and sold (written) call and put options on equity securities of companies in the health sciences group of industries.

No assurance can be given that the Trust’s investment objective will be achieved.

Trust Information

 

Symbol on New York Stock Exchange

  BMEZ

Initial Offering Date

  January 30, 2020

Current Distribution Rate on Closing Market Price as of June 30, 2021 ($28.92)(a)

  6.02%

Current Monthly Distribution per Common Share(b)

  $0.1450

Current Annualized Distribution per Common Share(b)

  $1.7400

 

  (a)

Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. Past performance is not an indication of future results.

 
  (b)

The distribution rate is not constant and is subject to change.

 

Market Price and Net Asset Value Per Share Summary

 

      06/30/21       12/31/20       Change       High       Low  

Market Price

    $ 28.92       $ 28.65       0.94 %      $  30.94       $  25.10  

Net Asset Value

    30.43       30.73       (0.98)       32.95       27.50  

Market Price and Net Asset Value History Since Inception

 

LOGO

 

 

T R U S T   S U M M A R Y

  25


Trust Summary  as of June 30, 2021 (continued)    BlackRock Health Sciences Trust II (BMEZ)

 

Performance and Portfolio Management Commentary

Returns for the six months ended June 30, 2021 were as follows:

 

    Returns Based On  
     Market Price     NAV  

BMEZ(a)(b)

    3.78 %      1.79 % 

MSCI ACWI 25% Call Overwrite Index(c)

    N/A       12.21  

 

  (a)

All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices.

 
  (b)

The Trust’s discount to NAV narrowed during the period, which accounts for the difference between performance based on market price and performance based on NAV. (c) MSCI ACWI 25% Call Overwrite Index incorporates an option overlay component on the MSCI ACWI Index with a 25% overwrite level.

 

N/A — Not applicable as the index does not have a market price.

Past performance is not an indication of future results.

Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles.

The following discussion relates to the Trust’s absolute performance based on NAV:

What factors influenced performance?

The Trust focused on innovative, small- and mid-sized health care companies. The listed benchmark, which incorporates all sectors of the market and emphasizes large-cap stocks, is therefore used for reference purposes only.

At the sub-sector level, stock selection in the biotechnology and health care providers & services sub-sectors detracted from performance.

Among individual positions, the biotechnology firms Mersana Therapeutics, Inc. and Seagen, Inc. were the largest detractors. Both companies specialize in antibody drug conjugate treatments for cancer, and they experienced favorable clinical development that led to strong price appreciation in 2020. However, the stocks lost ground in the first quarter of 2021 amid the broader rotation away from faster-growing companies. A position in Sigilon Therapeutics, Inc., a biotechnology company focusing on rare chronic diseases, also detracted from results.

Positive stock selection within the pharmaceuticals and medical devices & supplies sub-sectors contributed to Trust performance.

A private investment in biotech company Design Therapeutics, Inc. was the largest contributor. The U.S.-based firm, which develops novel, small-molecule therapeutic candidates called gene targeted chimeras, went public during the period. Another private investment in a biotechnology company, Acumen Pharmaceuticals, Inc., also had a successful initial public offering and made a strong contribution to performance. The contract research organization PPD, Inc., which was acquired at a premium, was another key contributor.

The Trust utilized an options overlay strategy in which calls are written on a portion of the portfolio’s holdings. The Trust’s option overlay strategy contributed positively to relative performance for the period.

Describe recent portfolio activity.

The investment adviser continued to deploy capital in both public and private markets across the next-generation health science universe.

The Trust’s weighting in the biotechnology industry decreased during the period, while its allocation to health care providers & services increased. Its weightings in medical devices & supplies and pharmaceuticals remained the same.

More broadly speaking, the Trust reduced its weighting in companies with clinical development setbacks or competitive concerns. It added positions in innovative therapeutic companies with strong clinical pipelines, as well as innovative health care providers & services companies.

Describe portfolio positioning at period end.

The Trust held 35% of its assets in medical devices & supplies, 38% in biotechnology, 18% in health care providers & services, and 6% in the pharmaceuticals industry. These allocations were the result of bottom-up stock selection and not a top-down view.

The Trust held 25 private investments, comprising 7.5% of total assets for a total commitment of approximately $258 million. In addition, the Trust held approximately 2.5% of its assets in private investments of public equity, for additional private exposure across 10 different special purpose acquisition company entities.

As of June 30, 2021, the Trust had in place an option overwriting program whereby 22% of the underlying equities were overwritten with call options. These call options were typically written at prices above the prevailing market prices (estimated to be 8.1% out of the money) with an average time until expiration of 53 days.

The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions. These views are not intended to be a forecast of future events and are no guarantee of future results.

 

 

26  

2 0 2 1   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S


Trust Summary  as of June 30, 2021 (continued)    BlackRock Health Sciences Trust II (BMEZ)

 

Overview of the Trust’s Total Investments

 

TEN LARGEST HOLDINGS

Security(a)   Percent of
Total Investments
 

Genmab A/S

    3 % 

Seagen, Inc.

    3  

Oak Street Health, Inc.

    2  

Wuxi Biologics Cayman, Inc.

    2  

Intuitive Surgical, Inc.

    2  

WuXi AppTec Co. Ltd.

    2  

Straumann Holding AG

    2  

Teleflex, Inc.

    2  

Amedisys, Inc.

    2  

Alcon, Inc.

    2  

INDUSTRY ALLOCATION

Industry(a)(b)   06/30/21     12/31/20  

Biotechnology

    40 %      42 % 

Health Care Equipment & Supplies

    25       24  

Health Care Providers & Services

    15       13  

Life Sciences Tools & Services

    10       10  

Pharmaceuticals

    5       6  

Health Care Technology

    2       2  

Diversified Financial Services

    1       2  

Health Care Services

    1       —  

Internet & Direct Marketing Retail

    1       1  

Other*

    —       — (c) 
 

 

(a)

Excludes short-term securities and options written.

(b)

For Trust compliance purposes, the Trust’s industry classifications refer to one or more of the industry sub-classifications used by one or more widely recognized market indexes or ratings group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.

(c) 

Rounds to less than 1% of total investments.

*

Includes one or more investment categories that individually represents less than 1% of the Trust’s total investments. Please refer to the Schedule of Investments for details.

 

 

T R U S T   S U M M A R Y

  27


Trust Summary  as of June 30, 2021    BlackRock Innovation and Growth Trust (BIGZ)

 

Investment Objective

BlackRock Innovation and Growth Trust’s (BIGZ) (the “Trust”) investment objective is to provide total return and income through a combination of current income, current gains and long-term capital appreciation. The Trust will invest primarily in equity securities issued by mid- and small-capitalization companies that the Trust’s adviser believes have above-average earnings growth potential. In selecting investments for the Trust, the Trust’s adviser focuses on mid- and small-capitalization growth companies that are “innovative.” These are companies that have introduced, or are seeking to introduce, a new product or service that potentially changes the marketplace. The Trust utilizes an option writing (selling) strategy in an effort to generate current gains from options premiums and to enhance the Trust’s risk-adjusted returns.

No assurance can be given that the Trust’s investment objective will be achieved.

Trust Information

 

 

Symbol on New York Stock Exchange

  BIGZ

Initial Offering Date

  March 29, 2021

Current Distribution Rate on Closing Market Price as of June 30, 2021 ($20.31)(a)

  5.91%

Current Monthly Distribution per Common Share(b)

  $0.1000

Current Annualized Distribution per Common Share(b)

  $1.2000

 

  (a)

Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. The current distribution rate may consist of income, net realized gains and/or a return of capital. Past performance is not an indication of future results.

 
  (b)

The distribution rate is not constant and is subject to change. A portion of the distribution may be deemed a return of capital or net realized gain.

 

Net Asset Value Per Share Summary

 

      06/30/21       03/29/21 (a)      Change       High       Low  

Market Price

    $  20.31       $  20.00       1.55 %      $  23.05       $  18.61  

Net Asset Value

    19.77       20.00       (1.15)       21.01       17.09  

 

  (a)

Commencement of operations.

 

 

 

28  

2 0 2 1   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S


Trust Summary  as of June 30, 2021 (continued)    BlackRock Innovation and Growth Trust (BIGZ)

 

Overview of the Trust’s Total Investments

 

TEN LARGEST HOLDINGS

Security(a)   Percent of
Total Investments
 

Axon Enterprise, Inc.

    3 % 

Amyris, Inc.

    3  

Phreesia, Inc.

    3  

Vroom Inc.

    3  

Avalara, Inc.

    3  

Entegris, Inc.

    3  

10X Genomics, Inc.

    3  

Lightspeed POS, Inc.

    3  

Bio-Techne Corp.

    3  

Freshpet, Inc.

    3  

INDUSTRY ALLOCATION

Industry(a)(b)   06/30/21  

Software

    17 % 

Semiconductors & Semiconductor Equipment

    9  

Life Sciences Tools & Services

    8  

Health Care Equipment & Supplies

    7  

Health Care Technology

    7  

IT Services

    6  

Aerospace & Defense

    5  

Specialty Retail

    4  

Hotels, Restaurants & Leisure

    4  

Diversified Consumer Services

    4  

Food Products

    4  

Biotechnology

    3  

Chemicals

    3  

Auto Components

    2  

Electronic Equipment, Instruments & Components

    2  

Entertainment

    2  

Electrical Equipment

    2  

Building Products

    2  

Personal Products

    2  

Machinery

    2  

Beverages

    1  

Equity Real Estate Investment Trusts (REITs)

    1  

Capital Markets

    1  

Road & Rail

    1  

Health Care Providers & Services

    1  
 

 

(a)

Excludes short-term securities and options written.

(b)

For Trust compliance purposes, the Trust’s industry classifications refer to one or more of the industry sub-classifications used by one or more widely recognized market indexes or ratings group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.

 

 

T R U S T   S U M M A R Y

  29


Trust Summary  as of June 30, 2021    BlackRock Resources & Commodities Strategy Trust (BCX)

 

Investment Objective

BlackRock Resources & Commodities Strategy Trust’s (BCX) (the “Trust”) primary investment objective is to seek high current income and current gains, with a secondary objective of capital appreciation. The Trust will seek to achieve its investment objectives, under normal market conditions, by investing at least 80% of its total assets in equity securities issued by commodity or natural resources companies, derivatives with exposure to commodity or natural resources companies or investments in securities and derivatives linked to the underlying price movement of commodities or natural resources. While permitted, the Trust does not currently expect to invest in securities and derivatives linked to the underlying price movement of commodities or natural resources. The Trust seeks to pursue this goal primarily by investing in a portfolio of equity securities and also by employing a strategy of writing (selling) call and put options.

No assurance can be given that the Trust’s investment objectives will be achieved.

Trust Information

 

 

Symbol on New York Stock Exchange

  BCX

Initial Offering Date

  March 30, 2011

Current Distribution Rate on Closing Market Price as of June 30, 2021 ($9.42)(a)

  5.10%

Current Monthly Distribution per Common Share(b)

  $0.0400

Current Annualized Distribution per Common Share(b)

  $0.4800

 

  (a)

Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. The current distribution rate may consist of income, net realized gains and/or a return of capital. Past performance is not an indication of future results.

 
  (b)

The distribution rate is not constant and is subject to change. A portion of the distribution may be deemed a return of capital or net realized gain.

 

Market Price and Net Asset Value Per Share Summary

 

      06/30/21       12/31/20       Change       High       Low  

Market Price

    $   9.42       $ 7.41       27.13 %      $  10.22       $  7.33  

Net Asset Value

    9.90       8.45       17.16       10.39       8.38  

Market Price and Net Asset Value History for the Past Five Years

 

LOGO

 

 

30  

2 0 2 1   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S


Trust Summary  as of June 30, 2021 (continued)    BlackRock Resources & Commodities Strategy Trust (BCX)

 

Performance and Portfolio Management Commentary

Returns for the six months ended June 30, 2021 were as follows:

 

    Returns Based On  
     Market Price     NAV  

BCX(a)(b)

    30.44 %      20.22 % 

MSCI ACWI Select Liquidity Natural Resources Call Overwrite Index(c)

    N/A       22.00  

 

  (a)

All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices.

 
  (b)

The Trust’s discount to NAV narrowed during the period, which accounts for the difference between performance based on market price and performance based on NAV.

 
  (c)

MSCI ACWI Select Liquidity Natural Resources Call Overwrite Index incorporates an option overlay component on the MSCI ACWI Select Liquidity Natural Resources Index with a 33% overwrite level.

 

N/A — Not applicable as the index does not have a market price.

Past performance is not an indication of future results.

Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles.

The following discussion relates to the Trust’s absolute performance based on NAV:

What factors influenced performance?

Natural resource equities delivered strong returns in the first half of 2021. The gradual re-opening of the world economy led to accelerated growth, fueling robust end-market demand across the commodities complex and boosting shares of the related companies.

Security selection in the mining sector contributed to relative performance, while allocation within the energy sector moderately detracted.

At the individual stock level, an off-benchmark position in the Brazilian state-owned integrated oil producer Petroleo Brasileiro SA was the largest detractor from relative performance. The stock declined following an unexpected change in the company’s chief executive officer, which the market saw as the first step in deeper government influence in its longer-term strategy. An underweight position in Nucor Corp., which benefited from higher steel prices, also detracted.

An overweight position in the mining company Vale SA was a leading contributor due to rising iron ore prices and the company’s announcement of a stock buyback program. An overweight position in ConocoPhillips also contributed to relative performance, as rising oil prices were a tailwind for large, integrated energy companies. A zero weighting in the Finland-based refiner Neste Oyj—which lagged after reporting weaker-than-expected guidance—was a further positive.

The Trust utilized an options overlay strategy in which calls are written on a portion of the portfolio’s holdings. The Trust’s option writing strategy detracted from relative performance for the six-month period.

Describe recent portfolio activity.

During the first half of 2021, the investment adviser increased the Fund’s weighting in energy based on its positive outlook for oil prices. The investment adviser funded this addition by reducing the portfolio’s weighting in the mining and agriculture sub-sectors.

Describe portfolio positioning at period end.

The Trust was overweight in the energy sector. The investment adviser believed vaccine developments provided a path to recovery for global oil demand. At the same time, non-OPEC production was likely to move into structural decline.

The Trust was underweight in mining, but the investment adviser believed mined commodity demand was likely to be supported by fiscal stimulus and increased infrastructure spending in 2021 and, in the longer term, by the transition to a lower-carbon world economy. The portfolio was also underweight in agriculture. However, expected improvements in crop prices should benefit upstream agriculture companies. In addition, the investment adviser continued to see structural growth opportunities in the nutrition industry.

As of June 30, 2021, the Trust had an options overwriting program in place whereby 32.4% of the underlying equities were overwritten with call options. These options were typically written at prices above prevailing market prices (estimated to be 4% out of the money) with an average time until expiration of 49 days.

The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions. These views are not intended to be a forecast of future events and are no guarantee of future results.

 

 

T R U S T   S U M M A R Y

  31


Trust Summary  as of June 30, 2021 (continued)    BlackRock Resources & Commodities Strategy Trust (BCX)

 

Overview of the Trust’s Total Investments

 

TEN LARGEST HOLDINGS

Security(a)  

Percent of

Total Investments

 

Vale SA

    7 % 

TotalEnergies SE

    6  

Chevron Corp.

    5  

Royal Dutch Shell PLC

    5  

Anglo American PLC

    5  

CF Industries Holdings, Inc.

    4  

Nutrien Ltd.

    4  

Canadian Natural Resources Ltd.

    3  

Glencore PLC

    3  

ConocoPhillips

    3  

INDUSTRY ALLOCATION

Industry(a)(b)   06/30/21     12/31/20  

Oil, Gas & Consumable Fuels

    41 %      34 % 

Metals & Mining

    30       35  

Chemicals

    13       14  

Food Products

    6       5  

Containers & Packaging

    6       7  

Electronic Equipment, Instruments & Components

    2       2  

Machinery

    2       1  

Paper & Forest Products

    — (c)      —  

Energy Equipment & Services

    —       1  

Specialty Retail

    —       1  
 

 

(a) 

Excludes short-term securities, options purchased and options written.

(b) 

For Trust compliance purposes, the Trust’s industry classifications refer to one or more of the industry sub-classifications used by one or more widely recognized market indexes or ratings group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.

(c) 

Represents less than 1% of the Trust’s total investments.

 

 

32  

2 0 2 1   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S


Trust Summary  as of June 30, 2021    BlackRock Science and Technology Trust (BST)

 

Investment Objective

BlackRock Science and Technology Trust’s (BST) (the “Trust”) investment objective is to provide income and total return through a combination of current income, current gains and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its total assets in equity securities of U.S. and non-U.S. science and technology companies in any market capitalization range, selected for their rapid and sustainable growth potential from the development, advancement and use of science and/or technology (high growth science and technology stocks), and/or potential to generate current income from advantageous dividend yields (cyclical science and technology stocks). The Trust seeks to pursue this goal primarily by investing in a portfolio of equity securities and also by employing a strategy of writing (selling) call and put options.

No assurance can be given that the Trust’s investment objective will be achieved.

Trust Information

 

Symbol on New York Stock Exchange

  BST

Initial Offering Date

  October 30, 2014

Current Distribution Rate on Closing Market Price as of June 30, 2021 ($59.59)(a)

  4.55%

Current Monthly Distribution per Common Share(b)

  $0.2260

Current Annualized Distribution per Common Share(b)

  $2.7120

 

  (a) 

Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. Past performance is not an indication of future results.

 
  (b) 

The distribution rate is not constant and is subject to change.

 

Market Price and Net Asset Value Per Share Summary

 

     06/30/21      12/31/20     Change     High      Low    

Market Price

  $  59.59      $  53.30       11.80 %    $  61.37      $  49.49    

Net Asset Value

    55.94        51.94 (a)      7.70       57.77        49.07    

 

  (a) 

For financial reporting purposes, the market value of a certain investment was adjusted as of the report date. Accordingly, the net asset value (“NAV”) per share and total return performance based on NAV presented herein are different than the information previously published as of December 31, 2020.

 

Market Price and Net Asset Value History for the Past Five Years

 

LOGO

 

 

T R U S T   S U M M A R Y

  33


Trust Summary  as of June 30, 2021 (continued)    BlackRock Science and Technology Trust (BST)

 

Performance and Portfolio Management Commentary

Returns for the six months ended June 30, 2021 were as follows:

 

    Returns Based On  
     Market Price     NAV  

BST(a)(b)

    14.46 %      10.26 % 

MSCI ACWI IT Call Overwrite Index(c)

    N/A       9.63  

 

  (a) 

All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices.

 
  (b) 

The Trust’s premium to NAV widened during the period, which accounts for the difference between performance based on market price and performance based on NAV.

 
  (c) 

MSCI ACWI IT Call Overwrite Index incorporates an option overlay component on the MSCI ACWI IT Index with a 33% overwrite level.

 

N/A — Not applicable as the index does not have a market price.

Past performance is not an indication of future results.

Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles.

The following discussion relates to the Trust’s absolute performance based on NAV:

What factors influenced performance?

Stock selection within the internet sub-sector was the largest contributor to the Trust’s performance. Among individual stocks, the Trust’s position in privately held fintech company Klarna contributed the most to relative returns following a fundraising round that significantly increased its valuation. Elsewhere, an overweight position in South Korean super-app company Kakao Corp. was also among the largest contributors. Kakao’s core business continued to grow strongly, benefiting from surging demand for advertising as economies reopened. Kakao also announced plans to spin off several businesses, including financial services affiliates Kakao Bank and Kakao Pay.

The largest detractor from performance was the Trust’s security selection in the software sub-sector. Among individual positions, the Trust’s out-of-benchmark position in artificial intelligence company C3.AI, Inc. was the most significant detractor, as the market rotation from growth to value had a substantial negative impact on its stock. Lastly, an underweight position in Microsoft Corp. also weighed on returns, as the software giant benefited from strong growth in its Azure cloud-computing business due to sharply increased spending on digital transformation.

The Trust utilized an options overlay strategy in which calls are written on a portion of the portfolio’s holdings. The Trust’s options overlay strategy contributed positively to relative performance for the six-month period.

Describe recent portfolio activity.

During the period, the Trust increased its exposure to semiconductors and decreased its exposure to software companies. From a regional perspective, the Trust’s allocation to Asia decreased, while its allocation to the United States increased.

Describe portfolio positioning at period end.

At period end, the Trust’s largest sub-sector exposures were in internet, software and semiconductors. The Trust’s software exposure focused on companies offering enterprise software solutions, cloud computing services and software as a service. The Trust was underweight in the hardware sub-sector, due to there being more innovative opportunities elsewhere.

As of June 30, 2021, the Trust had an options overwriting program in place whereby 28% of the underlying equities were overwritten with call options. These call options were typically written at prices above prevailing market prices (estimated to be 5.8% out of the money) with an average time until expiration of 48 days.

The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions. These views are not intended to be a forecast of future events and are no guarantee of future results.

 

 

34  

2 0 2 1   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S


Trust Summary  as of June 30, 2021 (continued)    BlackRock Science and Technology Trust (BST)

 

Overview of the Trust’s Total Investments

 

TEN LARGEST HOLDINGS

Security(a)  

Percent of

Total Investments

 

Apple, Inc.

    4 % 

Microsoft Corp.

    4  

Kakao Corp.

    3  

Alphabet, Inc.

    3  

Amazon.com, Inc.

    2  

Klarna Holdings AB

    3  

PayPal Holdings, Inc.

    2  

Marvell Technology, Inc.

    2  

Mastercard, Inc.

    2  

ASML Holding NV

    2  

SECTOR ALLOCATION

Sector(a)(b)   06/30/21     12/31/20  

Software

    23 %      27 % 

IT Services

    20       19  

Semiconductors & Semiconductor Equipment

    19       15  

Interactive Media & Services

    12       10  

Internet & Direct Marketing Retail

    5       10  

Technology Hardware, Storage & Peripherals

    4       4  

Entertainment

    3       3  

Banks

    3       1  

Road & Rail

    3       2  

Automobiles

    2       3  

Electronic Equipment, Instruments & Components

    1       1  

Diversified Consumer Services

    1       2  

Specialty Retail

    1       —  

Diversified Financial Services

    1       1  

Professional Services

    1       — (c) 

Auto Components

    1       —  

Health Care Technology

    —       1  

Diversified Telecommunication Services

    —       1  

Other*

    — (c)      — (c) 
 

 

(a) 

Excludes short-term securities and options written.

(b) 

For Trust compliance purposes, the Trust’s industry classifications refer to one or more of the industry sub-classifications used by one or more widely recognized market indexes or ratings group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.

(c) 

Rounds to less than 1% of total investments.

*

Includes one or more investment categories that individually represents less than 1% of the Trust’s total investments. Please refer to the Consolidated Schedule of Investments for details.

 

 

T R U S T   S U M M A R Y

  35


Trust Summary  as of June 30, 2021    BlackRock Science and Technology Trust II (BSTZ)

 

Investment Objective

BlackRock Science and Technology Trust II’s (BSTZ) (the “Trust”) investment objective is to provide total return and income through a combination of current income, current gains and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its total assets in equity securities issued by U.S. and non-U.S. science and technology companies in any market capitalization range, selected for their rapid and sustainable growth potential from the development, advancement and use of science and/or technology. The Trust seeks to pursue this goal primarily by investing in a portfolio of equity securities and also by employing a strategy of writing (selling) call and put options.

No assurance can be given that the Trust’s investment objective will be achieved.

Trust Information

 

Symbol on New York Stock Exchange

  BSTZ

Initial Offering Date

  June 27, 2019

Current Distribution Rate on Closing Market Price as of June 30, 2021 ($41.71)(a)

  4.92%

Current Monthly Distribution per Common Share(b)

  $0.1710

Current Annualized Distribution per Common Share(b)

  $2.0520

 

  (a) 

Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. Past performance is not an indication of future results.

 
  (b) 

The distribution rate is not constant and is subject to change.

 

Market Price and Net Asset Value Per Share Summary

 

     06/30/21      12/31/20      Change     High      Low    

Market Price

  $  41.71      $  36.38        14.65 %    $  41.77      $  32.10    

Net Asset Value

    42.97        38.72        10.98       44.16        35.93    

Market Price and Net Asset Value History Since Inception

 

LOGO

The Trust commenced operations on June 27, 2019.

 

 

36  

2 0 2 1   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S


Trust Summary  as of June 30, 2021 (continued)    BlackRock Science and Technology Trust II (BSTZ)

 

Performance and Portfolio Management Commentary

Returns for the six months ended June 30, 2021 were as follows:

 

    Returns Based On  
     Market Price     NAV  

BSTZ(a)(b)

    17.42 %      13.65 % 

MSCI ACWI 25% Call Overwrite Index(c)

    N/A       12.21  

 

  (a) 

All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices.

 
  (b) 

The Trust’s discount to NAV narrowed during the period, which accounts for the difference between performance based on market price and performance based on NAV.

 
  (c) 

MSCI ACWI 25% Call Overwrite Index incorporates an option overlay component on the MSCI ACWI Index with a 25% overwrite level.

 

N/A — Not applicable as the index does not have a market price.

Past performance is not an indication of future results.

Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles.

The following discussion relates to the Trust’s absolute performance based on NAV:

What factors influenced performance?

Stock selection within the services sub-sector was the largest contributor to the Trust’s performance. Among individual stocks, the Trust’s position in privately held fintech company Klarna contributed the most to relative returns following a fundraising round that significantly increased its valuation. Elsewhere, an overweight position in South Korean super-app company Kakao Corp. was also among the largest contributors. Kakao’s core business continued to grow strongly, benefiting from surging demand for advertising as economies reopened. Kakao also announced plans to spin off several businesses, including financial services affiliates Kakao Bank and Kakao Pay.

The largest detractor from returns was the Trust’s security selection in the software sub-sector. Among individual positions, the Trust’s out-of-benchmark position in artificial intelligence company C3.AI, Inc. was the most significant detractor, as the market rotation from growth to value had a substantial negative impact on its stock. Lastly, the Trust’s position in commercial electric vehicle manufacturer Arrival Ltd. also weighed on performance, as the company’s stock came under pressure during the market rotation as well.

The Trust utilized an options overlay strategy in which calls are written on a portion of the portfolio’s holdings. The Trust’s options overlay strategy detracted from relative performance for the six-month period.

Describe recent portfolio activity.

During the period, the Trust deployed capital to companies that are likely to experience increased demand in the current economic environment, as well as companies seeing long-term secular demand strength. These include companies benefiting from social distancing and the migration toward greater levels of remote work in areas such as cloud computing, digital transformation, and gaming.

The Trust continued to explore new opportunities and managed exposure to private assets, given the current allocation to private equity. During the period, the Trust participated in several follow-on funding rounds, adding to existing investments in quantum computing specialist, PsiQuantum, artificial intelligence systems and analytics platform provider SambaNova Systems, Inc., and end-to-end machine-learning platform company Snorkel AI Inc.

Describe portfolio positioning at period end.

At period end, the Trust held 34% of assets in software, 20% in internet, 19% in semiconductors, 16% in services, 5% in hardware, 4% in new industries, and 3% in content & infrastructure. These industry exposures were the result of bottom-up stock selection.

As of June 30, 2021, the Trust had an options overwriting program in place whereby 23% of the underlying equities were overwritten with call options. These call options were typically written at prices above prevailing market prices (estimated to be 7.2% out of the money) with an average time until expiration of 50 days.

The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions. These views are not intended to be a forecast of future events and are no guarantee of future results.

 

 

T R U S T   S U M M A R Y

  37


Trust Summary  as of June 30, 2021 (continued)    BlackRock Science and Technology Trust II (BSTZ)

 

Overview of the Trust’s Total Investments

 

TEN LARGEST HOLDINGS

Security(a)  

Percent of

Total Investments

 

Klarna Holdings AB

    4 % 

Kakao Corp.

    3  

Marvell Technology, Inc.

    2  

Square, Inc.

    2  

Snap, Inc.

    2  

Twilio, Inc.

    2  

Locaweb Servicos de Internet SA

    2  

Tesla, Inc.

    2  

Lasertec Corp.

    2  

SambaNova Systems, Inc.

    2  

INDUSTRY ALLOCATION

Industry(a)(b)   06/30/21     12/31/20  

Software

    28 %      30 % 

IT Services

    18       19  

Semiconductors & Semiconductor Equipment

    18       15  

Interactive Media & Services

    9       7  

Internet & Direct Marketing Retail

    5       7  

Entertainment

    4       3  

Banks

    4       2  

Automobiles

    3       6  

Electronic Equipment, Instruments & Components

    2       2  

Road & Rail

    2       1  

Diversified Consumer Services

    2       2  

Specialty Retail

    1       1  

Food Products

    1       1  

Multi-line Retail

    1       1  

Diversified Telecommunication Services

    1       1  

Communications Equipment

    1       —  

Capital Markets

    —       1  

Health Care Technology

    —       1  

Other*

    — (c)      — (c) 
 

 

(a) 

Excludes short-term securities and options written.

(b) 

For Trust compliance purposes, the Trust’s industry classifications refer to one or more of the industry sub-classifications used by one or more widely recognized market indexes or ratings group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.

(c) 

Rounds to less than 1% of total investments.

*

Includes one or more investment categories that individually represents less than 1% of the Trust’s total investments. Please refer to the Consolidated Schedule of Investments for details.

 

 

38  

2 0 2 1  B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S


Trust Summary  as of June 30, 2021    BlackRock Utilities, Infrastructure & Power Opportunities Trust (BUI)

 

Investment Objective

BlackRock Utilities, Infrastructure & Power Opportunities Trust’s (BUI) (the “Trust”) investment objective is to provide total return through a combination of current income, current gains and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its total assets in equity securities issued by companies that are engaged in the Utilities, Infrastructure and Power Opportunities business segments anywhere in the world and by employing a strategy of writing (selling) call and put options. The Trust considers the “Utilities” business segment to include products, technologies and services connected to the management, ownership, operation, construction, development or financing of facilities used to generate, transmit or distribute electricity, water, natural resources or telecommunications, the “Infrastructure” business segment to include companies that own or operate infrastructure assets or that are involved in the development, construction, distribution or financing of infrastructure assets and the “Power Opportunities” business segment to include companies with a significant involvement in, supporting, or necessary to renewable energy technology and development, alternative fuels, energy efficiency, automotive and sustainable mobility and technologies that enable or support the growth and adoption of new power and energy sources. Under normal circumstances, the Trust invests a substantial amount of its total assets in foreign issuers, issuers that primarily trade in a market located outside the United States or issuers that do a substantial amount of business outside the United States. The Trust may invest directly in such securities or synthetically through the use of derivatives.

No assurance can be given that the Trust’s investment objective will be achieved.

Trust Information

 

Symbol on New York Stock Exchange

  BUI

Initial Offering Date

  November 25, 2011

Current Distribution Rate on Closing Market Price as of June 30, 2021 ($25.75)(a)

  5.64%

Current Monthly Distribution per Common Share(b)

  $0.1210

Current Annualized Distribution per Common Share(b)

  $1.4520

 

  (a) 

Current distribution rate on closing market price is calculated by dividing the current annualized distribution per share by the closing market price. The current distribution rate may consist of income, net realized gains and/or a return of capital. Past performance is not an indication of future results.

 
  (b) 

The distribution rate is not constant and is subject to change. A portion of the distribution may be deemed a return of capital or net realized gain.

 

Market Price and Net Asset Value Per Share Summary

 

     06/30/21      12/31/20      Change     High      Low    

Market Price

  $  25.75      $  25.04        2.84 %    $  27.27      $  24.00    

Net Asset Value

    24.87        23.80        4.50       25.39        23.05    

Market Price and Net Asset Value History for the Past Five Years

 

LOGO

 

 

T R U S T   S U M M A R Y

  39


Trust Summary  as of June 30, 2021 (continued)    BlackRock Utilities, Infrastructure & Power Opportunities Trust (BUI)

 

Performance and Portfolio Management Commentary

Returns for the six months ended June 30, 2021 were as follows:

 

    Returns Based On  
     Market Price     NAV  

BUI(a)(b)

    5.89 %      7.60 % 

MSCI World Select Energy, Utilities and Industry Call Overwrite Index(c)

    N/A       6.61  

 

  (a)

All returns reflect reinvestment of dividends and/or distributions at actual reinvestment prices.

 
  (b)

The Trust’s premium to NAV narrowed during the period, which accounts for the difference between performance based on market price and performance based on NAV.

 
  (c)

MSCI World Select Energy, Utilities and Industry Call Overwrite Index incorporates an option overlay component on the MSCI World Select Energy, Utilities and Industry Index with a 33% overwrite level.

 

N/A — Not applicable as the index does not have a market price.

Past performance is not an indication of future results.

Performance results may include adjustments made for financial reporting purposes in accordance with U.S. generally accepted accounting principles.

The following discussion relates to the Trust’s absolute performance based on NAV:

What factors influenced performance?

The largest contributor to returns was the Trust’s position in wind-power specialist China Longyuan Power Group Corp., which benefited from greater clarity regarding how renewable energy would be priced under China’s on-grid tariff policy. Positive contributors also included the Trust’s holdings in the building and industrial efficiency area, which are expected to benefit from stronger demand as economies reopen. Individual holdings following this theme included energy-efficient heating, ventilation, and air conditioning specialist Trane Technologies PLC, which reported strong results in the first quarter of 2021 and boosted future earnings guidance on improving market demand. Johnson Controls International PLC also reported business results above expectations, with stronger sales in Asia driving relative performance.

The largest detractor from returns came from the Trust’s clean power utility holdings. Other perceived bond proxy stocks also detracted from results, due largely to the rise in yields on U.S. Treasury securities. Among individual stock positions, Iberdrola SA, RWE AG and EDP SA notably weighed on performance.

The Trust utilized an options overlay strategy in which calls are written on a portion of the portfolio’s holdings. The Trust’s options overlay strategy detracted from relative performance for the six-month period.

Describe recent portfolio activity.

During the period, the Trust reduced solar exposure following strong share price performance in 2020. The Trust also reduced exposure to electric battery (“EV”) battery manufacturers and select automotive technology names following a period of strong stock performance. By contrast, the Trust added to positions in select EV supply chain companies.

Describe portfolio positioning at period end.

At period end, the utilities sector accounted for approximately 49% of the Trust’s assets. The Trust had approximately 30% and 9% of its assets invested in the industrials and energy sectors respectively, and the remainder was invested in other infrastructure- and power-related sectors.

As of June 30, 2021, the Trust had an options overwriting program in place whereby approximately 33.5% of the underlying equities were overwritten with call options. These call options were typically written at prices above prevailing market prices (estimated to be 2.7% out of the money) with an average time until expiration of 50 days.

The views expressed reflect the opinions of BlackRock as of the date of this report and are subject to change based on changes in market, economic or other conditions. These views are not intended to be a forecast of future events and are no guarantee of future results.

 

 

40  

2 0 2 1   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S


Trust Summary  as of June 30, 2021 (continued)    BlackRock Utilities, Infrastructure & Power Opportunities Trust (BUI)

 

Overview of the Trust’s Total Investments

 

TEN LARGEST HOLDINGS

Security(a)   Percent of
Total Investments
 

NextEra Energy, Inc.

    7 % 

Enel SpA

    5  

Iberdrola SA

    4  

Johnson Controls International PLC

    3  

RWE AG

    3  

Vestas Wind Systems A/S

    3  

Waste Management, Inc.

    3  

Trane Technologies PLC

    3  

Atlas Copco AB

    3  

Vinci SA

    3  

INDUSTRY ALLOCATION

Industry(a)(b)   06/30/21     12/31/20  

Electric Utilities

    29 %      33 % 

Multi-Utilities

    13       14  

Electrical Equipment

    9       7  

Building Products

    9       7  

Oil, Gas & Consumable Fuels

    9       8  

Independent Power and Renewable Electricity Producers

    7       8  

Commercial Services & Supplies

    5       4  

Chemicals

    5       5  

Semiconductors & Semiconductor Equipment

    4       5  

Construction & Engineering

    4       4  

Machinery

    3       2  

Electronic Equipment, Instruments & Components

    3       3  
 

 

  (a)

Excludes short-term securities and options written.

 
  (b)

For Trust compliance purposes, the Trust’s industry classifications refer to one or more of the industry sub-classifications used by one or more widely recognized market indexes or ratings group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.

 

 

 

T R U S T   S U M M A R Y

  41


Schedule of Investments (unaudited)

June 30, 2021

  

BlackRock Energy and Resources Trust (BGR)

(Percentages shown are based on Net Assets)

 

Security   Shares      Value  

Common Stocks

    
Energy Equipment & Services — 1.9%  

Baker Hughes Co.(a)

    242,022      $ 5,535,043  
    

 

 

 
Food Products — 0.8%         

Darling Ingredients, Inc.(a)(b)

    37,850        2,554,875  
    

 

 

 
Oil, Gas & Consumable Fuels — 97.5%         

Aker BP ASA

    139,271        4,439,015  

ARC Resources Ltd.

    441,700        3,759,225  

BP PLC

    1,597,200        7,004,345  

Cairn Energy PLC

    947,199        1,913,244  

Canadian Natural Resources Ltd.

    359,124        13,036,931  

Cenovus Energy, Inc.

    452,200        4,326,470  

Chevron Corp.(a)(c)

    370,673        38,824,290  

CNOOC Ltd.

    2,680,000        3,040,282  

ConocoPhillips(a)

    350,687        21,356,876  

Devon Energy Corp.(a)

    265,100        7,738,269  

EOG Resources, Inc.(a)

    35,734        2,981,645  

Equinor ASA

    340,950        7,217,401  

Exxon Mobil Corp.(a)(c)

    338,464          21,350,309  

Hess Corp.

    119,400        10,426,008  

Kinder Morgan, Inc.(a)

    418,414        7,627,687  

Kosmos Energy Ltd.(b)

    857,817        2,968,047  

LUKOIL PJSC, ADR

    36,891        3,423,941  

Marathon Petroleum Corp.(a)

    165,300        9,987,426  

Oil Search Ltd.

    864,463        2,469,680  

Pioneer Natural Resources Co.

    71,689        11,650,896  

Royal Dutch Shell PLC, Class B, ADR(a)

    805,775        31,288,243  

Santos Ltd.

    856,180        4,547,613  

Suncor Energy, Inc.

    494,355        11,840,432  

TC Energy Corp.

    188,267        9,316,149  

TotalEnergies SE

    526,867        23,868,018  
Security   Shares      Value  
Oil, Gas & Consumable Fuels (continued)  

Tourmaline Oil Corp.

    136,800      $ 3,909,990  

Valero Energy Corp.(a)

    131,974        10,304,530  

Williams Cos., Inc.(a)

    318,201        8,448,237  
    

 

 

 
       289,065,199  
    

 

 

 

Total Long-Term Investments — 100.2%
(Cost: $243,962,247)

 

     297,155,117  
    

 

 

 

Short-Term Securities

    
Money Market Funds — 1.0%             

BlackRock Liquidity Funds, T-Fund, Institutional Class, 0.01%(d)(e)

    2,837,978        2,837,978  
    

 

 

 

Total Short-Term Securities — 1.0%
(Cost: $2,837,978)

 

     2,837,978  
    

 

 

 

Total Investments Before Options Written — 101.2%
(Cost: $246,800,225)

 

     299,993,095  
    

 

 

 

Options Written — (1.0)%
(Premiums Received: $(3,240,569))

 

     (2,803,335 ) 
    

 

 

 

Total Investments, Net of Options Written — 100.2%
(Cost: $243,559,656)

 

     297,189,760  

Liabilities in Excess of Other Assets — (0.2)%

 

     (684,308 ) 
    

 

 

 

Net Assets — 100.0%

     $   296,505,452  
    

 

 

 

 

(a) 

All or a portion of the security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written.

(b) 

Non-income producing security.

(c) 

All or a portion of the security has been pledged as collateral in connection with outstanding OTC derivatives.

(d) 

Affiliate of the Trust.

(e) 

Annualized 7-day yield as of period end.

 

 

For Trust compliance purposes, the Trust’s industry classifications refer to one or more of the industry sub-classifications used by one or more widely recognized market indexes or rating group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.

Affiliates

Investments in issuers considered to be affiliate(s) of the Trust during the six-months ended June 30, 2021 for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

 

 

 
Affiliated Issuer    Value at
12/31/20
     Purchases
at Cost
     Proceeds
from Sales
    Net
Realized
Gain (Loss)
     Change in
Unrealized
Appreciation
(Depreciation)
     Value at
06/30/21
     Shares
Held at
06/30/21
     Income
     Capital Gain
Distributions
from
Underlying
Funds
 

 

 

BlackRock Liquidity Funds, T-Fund, Institutional Class

   $   3,418,486      $ —      $ (580,508 )(a)    $ —      $ —      $   2,837,978        2,837,978      $ 245      $ —  
          

 

 

    

 

 

    

 

 

       

 

 

    

 

 

 

 

  (a) 

Represents net amount purchased (sold).

 

Derivative Financial Instruments Outstanding as of Period End

Exchange-Traded Options Written

 

Description    Number of
Contracts
       Expiration
Date
       Exercise Price       

Amount

Notional (000)

       Value  
Call                                                   

Chevron Corp.

     281          07/02/21        USD     110.00        USD     2,943        $ (984 ) 

Devon Energy Corp.

     278          07/02/21        USD     27.50        USD     811          (48,650 ) 

EOG Resources, Inc.

     108          07/02/21        USD     83.50        USD     901          (15,336 ) 

Marathon Petroleum Corp.

     160          07/02/21        USD     61.00        USD     967          (5,440 ) 

Valero Energy Corp.

     182          07/02/21        USD     80.00        USD     1,421          (6,279 ) 

 

 

42  

2 0 2 1   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S


Schedule of Investments (unaudited) (continued)

June 30, 2021

  

BlackRock Energy and Resources Trust (BGR)

    

 

Exchange-Traded Options Written (continued)

 

 

 
Description    Number of
Contracts
       Expiration
Date
       Exercise Price       

Amount

Notional (000)

       Value  

 

 
Call (continued)                                                   

ConocoPhillips

     65          07/09/21        USD     58.00        USD     396        $ (20,637 ) 

Kinder Morgan, Inc.

     634          07/09/21        USD     18.50        USD     1,156          (7,291 ) 

Marathon Petroleum Corp.

     159          07/09/21        USD     61.01        USD     961          (15,633 ) 

Suncor Energy, Inc.

     169          07/09/21        CAD     31.00        CAD     502          (2,454 ) 

Tourmaline Oil Corp.

     358          07/09/21        CAD     33.00        CAD     1,268          (75,522 ) 

ARC Resources Ltd.

     440          07/16/21        CAD     10.00        CAD     464          (25,202 ) 

ARC Resources Ltd.

     266          07/16/21        CAD     10.50        CAD     281          (8,369 ) 

Baker Hughes Co.

     439          07/16/21        USD     26.00        USD     1,004          (3,293 ) 

Chevron Corp.

     359          07/16/21        USD     110.00        USD     3,760          (16,873 ) 

ConocoPhillips

     132          07/16/21        USD     60.00        USD     804          (26,466 ) 

Darling Ingredients, Inc.

     65          07/16/21        USD     75.00        USD     439          (2,600 ) 

Devon Energy Corp.

     496          07/16/21        USD     31.00        USD     1,448          (26,288 ) 

Exxon Mobil Corp.

     877          07/16/21        USD     60.00        USD     5,532          (304,757 ) 

Kinder Morgan, Inc.

     409          07/16/21        USD     19.00        USD     746          (3,477 ) 

Marathon Petroleum Corp.

     60          07/16/21        USD     60.00        USD     363          (10,380 ) 

Royal Dutch Shell PLC, Class B, ADR

     515          07/16/21        USD     37.50        USD     2,000          (105,575 ) 

Royal Dutch Shell PLC, Class B, ADR

     426          07/16/21        USD     40.00        USD     1,654          (19,170 ) 

Royal Dutch Shell PLC, Class B, ADR

     148          07/16/21        USD     42.50        USD     575          (1,850 ) 

Suncor Energy, Inc.

     1,076          07/16/21        CAD     29.00        CAD     3,195          (105,899 ) 

TC Energy Corp.

     468          07/16/21        CAD     62.00        CAD     2,871          (18,122 ) 

Tourmaline Oil Corp.

     280          07/16/21        CAD     30.00        CAD     992          (124,798 ) 

Valero Energy Corp.

     67          07/16/21        USD     85.00        USD     523          (2,814 ) 

Chevron Corp.

     290          07/23/21        USD     112.00        USD     3,037          (14,065 ) 

ConocoPhillips

     748          07/23/21        USD     60.40        USD     4,555          (178,866 ) 

Exxon Mobil Corp.

     224          07/23/21        USD     64.00        USD     1,413          (27,664 ) 

Marathon Petroleum Corp.

     195          07/23/21        USD     62.50        USD     1,178          (18,622 ) 

Valero Energy Corp.

     252          07/23/21        USD     83.50        USD     1,968          (24,822 ) 

Williams Cos., Inc.

     852          07/23/21        USD     28.50        USD     2,262          (8,520 ) 

Devon Energy Corp.

     360          07/30/21        USD     30.00        USD     1,051          (47,340 ) 

EOG Resources, Inc.

     30          07/30/21        USD     85.00        USD     250          (9,270 ) 

Kinder Morgan, Inc.

     273          07/30/21        USD     19.00        USD     498          (5,460 ) 

Marathon Petroleum Corp.

     54          07/30/21        USD     63.50        USD     326          (5,238 ) 

ConocoPhillips

     164          08/06/21        USD     63.00        USD     999          (28,290 ) 

Kinder Morgan, Inc.

     273          08/06/21        USD     18.50        USD     498          (11,876 ) 

ARC Resources Ltd.

     940          08/20/21        CAD     9.50        CAD     992          (104,647 ) 

ARC Resources Ltd.

     266          08/20/21        CAD     10.50        CAD     281          (15,879 ) 

Baker Hughes Co.

     480          08/20/21        USD     24.00        USD     1,098          (43,200 ) 

Canadian Natural Resources Ltd.

     627          08/20/21        CAD     47.00        CAD     2,822          (69,296 ) 

Canadian Natural Resources Ltd.

     170          08/20/21        CAD     45.00        CAD     765          (30,171 ) 

Cenovus Energy, Inc.

     831          08/20/21        CAD     13.00        CAD     986          (28,491 ) 

Cenovus Energy, Inc.

     831          08/20/21        CAD     13.50        CAD     986          (21,452 ) 

Chevron Corp.

     474          08/20/21        USD     110.00        USD     4,965          (96,222 ) 

ConocoPhillips

     108          08/20/21        USD     65.00        USD     658          (15,876 ) 

ConocoPhillips

     115          08/20/21        USD     60.00        USD     700          (38,525 ) 

Darling Ingredients, Inc.

     48          08/20/21        USD     70.00        USD     324          (15,600 ) 

Exxon Mobil Corp.

     185          08/20/21        USD     62.50        USD     1,167          (51,892 ) 

Royal Dutch Shell PLC, Class B, ADR

     426          08/20/21        USD     40.00        USD     1,654          (52,185 ) 

Suncor Energy, Inc.

     484          08/20/21        CAD     31.00        CAD     1,437          (43,145 ) 

Suncor Energy, Inc.

     169          08/20/21        CAD     32.00        CAD     502          (10,702 ) 

TC Energy Corp.

     247          08/20/21        CAD     64.00        CAD     1,515          (11,955 ) 

Williams Cos., Inc.

     357          08/20/21        USD     27.00        USD     948          (26,775 ) 

Canadian Natural Resources Ltd.

     615          09/17/21        CAD     46.00        CAD     2,768          (111,133 ) 

Royal Dutch Shell PLC, Class B, ADR

     515          09/17/21        USD     40.00        USD     2,000          (78,537 ) 
                          

 

 

 
                           $   (2,249,875 ) 
                          

 

 

 

OTC Options Written

 

 

 
Description    Counterparty      Number of
Contracts
       Expiration
Date
  Exercise Price
       Notional
Amount (000)
  Value  

 

 
Call                                                     

Aker BP ASA

   UBS AG        21,600        07/07/21     NOK       250.60        NOK      5,928   $   (59,821 ) 

 

 

S C H E D U L E   O F   I N V E S T M E N T S

  43


Schedule of Investments (unaudited) (continued)

June 30, 2021

  

BlackRock Energy and Resources Trust (BGR)

    

 

OTC Options Written (continued)

 

Description    Counterparty   Number of
Contracts
    Expiration
Date
   

Exercise Price

   

Notional
Amount (000)

    Value  

Call (continued)

                

Equinor ASA

   Credit Suisse International     70,000       07/07/21       NOK       183.44       NOK       12,758     $ (18,093 ) 

BP PLC

   Morgan Stanley & Co. International PLC     114,000       07/08/21       GBP       3.20       GBP       361       (7,318 ) 

LUKOIL PJSC, ADR

   Morgan Stanley & Co. International PLC     7,000       07/08/21       USD       81.31       USD       650       (78,632 ) 

Santos Ltd.

   JPMorgan Chase Bank N.A.     46,600       07/08/21       AUD       7.04       AUD       330       (6,443 ) 

TotalEnergies SE

   Goldman Sachs International     43,500       07/08/21       EUR       39.62       EUR       1,662       (6,928 ) 

BP PLC

   UBS AG     560,000       07/14/21       GBP       3.34       GBP       1,775       (17,025 ) 

Equinor ASA

   Credit Suisse International     29,400       07/15/21       NOK       193.35       NOK       5,359       (2,130 ) 

Santos Ltd.

   UBS AG     253,000       07/15/21       AUD       7.44       AUD       1,792       (15,733 ) 

Oil Search Ltd.

   UBS AG     109,400       07/20/21       AUD       3.74       AUD       417       (13,884 ) 

Royal Dutch Shell PLC, Class B, ADR

   Barclays Bank PLC     103,100       07/28/21       USD       38.45       USD       4,003       (195,953 ) 

Equinor ASA

   HSBC Bank PLC     28,600       07/29/21       NOK       193.02       NOK       5,213       (5,250 ) 

TotalEnergies SE

   Goldman Sachs International     54,600       07/29/21       EUR       41.73       EUR       2,086       (9,412 ) 

Aker BP ASA

   Goldman Sachs International     31,400       08/04/21       NOK       286.13       NOK       8,617       (19,975 ) 

Oil Search Ltd.

   Morgan Stanley & Co. International PLC     219,000       08/05/21       AUD       3.92       AUD       834       (19,355 ) 

LUKOIL PJSC, ADR

   Goldman Sachs International     7,000       08/10/21       USD       94.01       USD       650       (10,044 ) 

TotalEnergies SE

   Goldman Sachs International     72,900       08/11/21       EUR       40.66       EUR       2,785       (30,143 ) 

TotalEnergies SE

   Credit Suisse International     29,200       08/18/21       EUR       38.74       EUR       1,116       (37,321 ) 
                

 

 

 
                 $   (553,460 ) 
                

 

 

 

Balances Reported in the Statements of Assets and Liabilities for Options Written

 

Description    Swap
Premiums
Paid
       Swap
Premiums
Received
       Unrealized
Appreciation
       Unrealized
Depreciation
       Value  

Options Written

   $ N/A        $ N/A        $ 1,128,649        $ (691,415 )       $   (2,803,335)  

Derivative Financial Instruments Categorized by Risk Exposure

As of period end, the fair values of derivative financial instruments located in the Statements of Assets and Liabilities were as follows:

 

      Commodity
Contracts
     Credit
Contracts
     Equity
Contracts
     Foreign
Currency
Exchange
Contracts
     Interest
Rate
Contracts
     Other
Contracts
     Total  

Liabilities — Derivative Financial Instruments

                    

Options written

                    

Options written at value

   $ —      $ —      $   2,803,335      $ —      $ —      $ —      $   2,803,335  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

For the six months ended June 30, 2021, the effect of derivative financial instruments in the Statements of Operations was as follows:

 

      Commodity
Contracts
     Credit
Contracts
     Equity
Contracts
     Foreign
Currency
Exchange
Contracts
     Interest
Rate
Contracts
     Other
Contracts
     Total  

Net Realized Gain (Loss) from

                    

Options purchased(a)

   $ —      $ —      $ (25,247 )     $ —      $ —      $ —      $ (25,247 ) 

Options written

     —        —        (7,788,133 )       —        —        —        (7,788,133 ) 
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 
   $ —      $ —      $   (7,813,380 )     $ —      $ —      $ —      $   (7,813,380 ) 
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Net Change in Unrealized Appreciation (Depreciation) on

                    

Options written

   $ —      $ —      $ 270,941      $ —      $ —      $ —      $ 270,941  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

 

  (a) 

Options purchased are included in net realized gain (loss) from investments — unaffiliated.

 

 

 

44  

2 0 2 1   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S


Schedule of Investments (unaudited) (continued)

June 30, 2021

  

BlackRock Energy and Resources Trust (BGR)

    

 

Average Quarterly Balances of Outstanding Derivative Financial Instruments

 

Options

        

Average value of option contracts purchased

   $ — (a)  

Average value of option contracts written

   $ 2,484,265  

 

  (a) 

Derivative not held at any quarter-end. The risk exposure table serves as an indicator of activity during the period.

 

For more information about the Trust’s investment risks regarding derivative financial instruments, refer to the Notes to Financial Statements.

Derivative Financial Instruments — Offsetting as of Period End

The Trust’s derivative assets and liabilities (by type) were as follows:

 

      Assets        Liabilities  

Derivative Financial Instruments

       

Options

   $ —        $ 2,803,335  
  

 

 

      

 

 

 

Total derivative assets and liabilities in the Statements of Assets and Liabilities

     —          2,803,335  
  

 

 

      

 

 

 

Derivatives not subject to a Master Netting Agreement or similar agreement (“MNA”)

     —          (2,249,875 ) 
  

 

 

      

 

 

 

Total derivative assets and liabilities subject to an MNA

   $ —        $ 553,460  
  

 

 

      

 

 

 

The following table presents the Trust’s derivative liabilities by counterparty net of amounts available for offset under an MNA and net of the related collateral pledged by the Trust:

 

Counterparty     



Derivative
Liabilities
Subject to
an MNA by
Counterparty
 
 

 
 
      

Derivatives
Available
for Offset
 
 
 
      

Non-Cash
Collateral
Pledged
 
 
(a)  
    

Cash
Collateral
Pledged
 
 
 
      

Net Amount
of Derivative
Liabilities
 
 
(b)  

Barclays Bank PLC

   $ 195,953        $ —        $ (195,953 )     $ —        $ —  

Credit Suisse International

     57,544          —          (57,544 )       —          —  

Goldman Sachs International

     76,502          —          (76,502 )       —          —  

HSBC Bank PLC

     5,250          —          —        —          5,250  

JPMorgan Chase Bank N.A.

     6,443          —          (6,443 )       —          —  

Morgan Stanley & Co. International PLC

     105,305          —          —        —          105,305  

UBS AG

     106,463          —          —        —          106,463  
  

 

 

      

 

 

      

 

 

    

 

 

      

 

 

 
   $ 553,460        $ —        $ (336,442 )     $ —        $ 217,018  
  

 

 

      

 

 

      

 

 

    

 

 

      

 

 

 

 

  (a) 

Excess of collateral pledged to the individual counterparty is not shown for financial reporting purposes.

 
  (b) 

Net amount represents the net amount payable due to counterparty in the event of default. Net amount may be offset further by the options written receivable/payable on the Statements of Assets and Liabilities.

 

Fair Value Hierarchy as of Period End

Various inputs are used in determining the fair value of financial instruments. For a description of the input levels and information about the Trust’s policy regarding valuation of financial instruments, refer to the Notes to Financial Statements.

The following table summarizes the Trust’s financial instruments categorized in the fair value hierarchy. The breakdown of the Trust’s financial instruments into major categories is disclosed in the Schedule of Investments above.

 

      Level 1        Level 2        Level 3        Total  

Assets

                 

Investments

                 

Long-Term Investments

                 

Common Stocks

                 

Energy Equipment & Services

   $ 5,535,043        $ —        $ —        $ 5,535,043  

Food Products

     2,554,875          —          —          2,554,875  

Oil, Gas & Consumable Fuels

     231,141,660          57,923,539          —          289,065,199  

Short-Term Securities

                 

Money Market Funds

     2,837,978          —          —          2,837,978  
  

 

 

      

 

 

      

 

 

      

 

 

 
   $   242,069,556        $   57,923,539        $ —        $   299,993,095  
  

 

 

      

 

 

      

 

 

      

 

 

 

 

 

S C H E D U L E   O F   I N V E S T M E N T S

  45


Schedule of Investments (unaudited) (continued)

June 30, 2021

  

BlackRock Energy and Resources Trust (BGR)

    

 

Fair Value Hierarchy as of Period End (continued)

 

      Level 1        Level 2        Level 3        Total  

Derivative Financial Instruments(a)

                 

Liabilities

                 

Equity Contracts

   $   (2,055,376 )       $     (747,959 )       $ —        $   (2,803,335 ) 
  

 

 

      

 

 

      

 

 

      

 

 

 

 

  (a) 

Derivative financial instruments are options written. Options written are shown at value.

 

See notes to financial statements.

 

 

46  

2 0 2 1   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S


Schedule of Investments (unaudited)

June 30, 2021

  

BlackRock Enhanced Capital and Income Fund, Inc. (CII)

(Percentages shown are based on Net Assets)

 

Security   Shares      Value  
Common Stocks             
Aerospace & Defense — 1.3%             

BAE Systems PLC, ADR

    419,110      $   12,267,350  
    

 

 

 
Air Freight & Logistics — 1.1%             

C.H. Robinson Worldwide, Inc.

    108,961        10,206,377  
    

 

 

 
Automobiles — 2.4%             

General Motors Co.(a)

    378,241        22,380,520  
    

 

 

 
Banks — 3.5%             

Bank of America Corp.(b)

    361,233        14,893,637  

JPMorgan Chase & Co.

    118,371        18,411,425  
    

 

 

 
       33,305,062  
Beverages — 1.2%             

Coca-Cola Co.

    206,726        11,185,944  
    

 

 

 
Capital Markets — 3.2%             

Intercontinental Exchange, Inc.

    91,727        10,887,995  

Morgan Stanley

    210,531        19,303,587  
    

 

 

 
       30,191,582  
Chemicals — 3.2%             

Axalta Coating Systems Ltd.(a)

    315,885        9,631,334  

Corteva, Inc.

    470,538        20,868,360  
    

 

 

 
       30,499,694  
Communications Equipment — 3.2%             

Ciena Corp.(a)

    173,442        9,867,115  

Cisco Systems, Inc.

    391,381        20,743,193  
    

 

 

 
       30,610,308  
Construction & Engineering — 1.2%             

Quanta Services, Inc.

    122,628        11,106,418  
    

 

 

 
Consumer Finance — 2.7%             

Ally Financial, Inc.

    257,986        12,858,022  

Capital One Financial Corp.

    80,000        12,375,200  
    

 

 

 
       25,233,222  
Containers & Packaging — 0.3%             

Sealed Air Corp.

    48,730        2,887,252  
    

 

 

 
Diversified Financial Services — 2.5%             

Berkshire Hathaway, Inc., Class B(a)

    83,518        23,211,323  
    

 

 

 
Electronic Equipment, Instruments &
Components — 0.8%
            

CDW Corp.

    42,014        7,337,745  
    

 

 

 
Entertainment — 0.9%             

World Wrestling Entertainment, Inc., Class A

    148,554        8,599,791  
    

 

 

 
Health Care Equipment & Supplies — 1.0%  

Koninklijke Philips NV, NY Shares.

    184,969        9,192,959  
    

 

 

 
Health Care Providers & Services — 6.5%             

Anthem, Inc.

    33,475        12,780,755  

Humana, Inc.

    14,998        6,639,915  

Laboratory Corp. of America Holdings(a)

    61,085        16,850,297  

UnitedHealth Group, Inc.

    63,513        25,433,146  
    

 

 

 
       61,704,113  
Health Care Technology — 0.6%             

Veeva Systems, Inc., Class A(a)

    19,276        5,993,872  
    

 

 

 
Hotels, Restaurants & Leisure — 0.8%             

Las Vegas Sands Corp.(a)

    143,088        7,539,307  
    

 

 

 
Security   Shares      Value  
Insurance — 0.6%             

Fidelity National Financial, Inc.

    123,857      $   5,382,825  
    

 

 

 
Interactive Media & Services(a) — 9.6%             

Alphabet, Inc., Class A(b)

    24,129        58,917,951  

Facebook, Inc., Class A

    90,639        31,516,087  
    

 

 

 
       90,434,038  
Internet & Direct Marketing Retail(a) — 6.5%             

Alibaba Group Holding Ltd., ADR

    41,183        9,339,481  

Amazon.com, Inc.

    15,274        52,545,003  
    

 

 

 
       61,884,484  
IT Services — 6.0%             

Fidelity National Information Services, Inc.

    92,641        13,124,450  

FleetCor Technologies, Inc.(a)

    52,432        13,425,738  

Visa, Inc., Class A(b)

    130,830        30,590,671  
    

 

 

 
       57,140,859  
Machinery — 2.0%             

Fortive Corp.

    140,563        9,802,864  

Otis Worldwide Corp.

    115,577        9,450,731  
    

 

 

 
       19,253,595  
Media — 3.5%             

Comcast Corp., Class A

    427,482        24,375,024  

Fox Corp., Class A

    240,348        8,924,121  
    

 

 

 
       33,299,145  
Multi-line Retail — 2.9%             

Dollar General Corp.

    54,488        11,790,658  

Dollar Tree, Inc.(a)

    158,802        15,800,799  
    

 

 

 
       27,591,457  
Oil, Gas & Consumable Fuels — 3.5%             

BP PLC, ADR

    224,139        5,921,753  

ConocoPhillips

    273,568        16,660,291  

EQT Corp.(a)

    476,047        10,596,806  
    

 

 

 
       33,178,850  
Personal Products — 1.4%             

Unilever PLC, ADR

    229,338        13,416,273  
    

 

 

 
Pharmaceuticals — 2.8%             

Novo Nordisk A/S, ADR

    91,523        7,666,882  

Sanofi, ADR

    348,302        18,341,583  
    

 

 

 
       26,008,465  
Professional Services — 0.4%             

Robert Half International, Inc.

    38,970        3,467,161  
    

 

 

 
Real Estate Management & Development — 1.2%  

CBRE Group, Inc., Class A(a)

    137,284        11,769,357  
    

 

 

 
Road & Rail — 1.4%             

Norfolk Southern Corp.

    49,110        13,034,285  
    

 

 

 
Semiconductors & Semiconductor
Equipment — 4.7%
            

Applied Materials, Inc.

    175,230        24,952,752  

Taiwan Semiconductor Manufacturing Co. Ltd., ADR

    165,870        19,930,939  
    

 

 

 
       44,883,691  
Software — 7.9%             

CDK Global, Inc.

    271,354        13,483,580  

Microsoft Corp.(b)

    225,821        61,174,909  
    

 

 

 
       74,658,489  
Specialty Retail — 3.3%             

Lowe’s Cos., Inc.

    39,697        7,700,027  
 

 

 

S C H E D U L E   O F   I N V E S T M E N T S

  47


Schedule of Investments (unaudited) (continued)

June 30, 2021

  

BlackRock Enhanced Capital and Income Fund, Inc. (CII)

(Percentages shown are based on Net Assets)

 

Security   Shares     Value  
Specialty Retail (continued)            

O’Reilly Automotive, Inc.(a)

    18,969     $ 10,740,438  

Ross Stores, Inc.

    104,558       12,965,192  
   

 

 

 
      31,405,657  
Technology Hardware, Storage & Peripherals — 4.4%  

Apple, Inc.(b)

    303,518       41,569,825  
   

 

 

 
Wireless Telecommunication Services — 1.4%  

Vodafone Group PLC, ADR

    776,328       13,298,499  
   

 

 

 

Total Long-Term Investments — 99.9%
(Cost: $563,386,172)

      945,129,794  
   

 

 

 

Short-Term Securities

   

Money Market Funds — 1.4%

   

BlackRock Liquidity Funds, T-Fund, Institutional Class, 0.01%(c)(d)

    12,748,208       12,748,208  
   

 

 

 

Total Short-Term Securities — 1.4%
(Cost: $12,748,208)

      12,748,208  
   

 

 

 

Total Investments Before Options Written — 101.3%
(Cost: $576,134,380)

 

    957,878,002  
   

 

 

 

Options Written — (1.3)%
(Premiums Received: $(11,084,600))

      (11,763,153 ) 
   

 

 

 

Total Investments, Net of Options Written — 100.0%
(Cost: $565,049,780)

 

    946,114,849  

Other Assets Less Liabilities — 0.0%

      43,048  
   

 

 

 

Net Assets — 100.0%

    $   946,157,897  
   

 

 

 

 

(a) 

Non-income producing security.

(b) 

All or a portion of the security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written.

(c) 

Affiliate of the Trust.

(d) 

Annualized 7-day yield as of period end.

 

 

For Trust compliance purposes, the Trust’s industry classifications refer to one or more of the industry sub-classifications used by one or more widely recognized market indexes or rating group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.

Affiliates

Investments in issuers considered to be affiliate(s) of the Trust during the six-months ended June 30, 2021 for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

 

Affiliated Issuer    Value at
12/31/20
     Purchases
at Cost
     Proceeds
from Sales
     Net
Realized
Gain (Loss)
     Change in
Unrealized
Appreciation
(Depreciation)
     Value at
06/30/21
     Shares
Held at
06/30/21
     Income      Capital Gain
Distributions
from
Underlying
Funds
 

BlackRock Liquidity Funds, T-Fund, Institutional Class

   $   11,614,004      $   1,134,204 (a)     $ —      $ —      $ —      $   12,748,208        12,748,208      $ 1,133      $ —  
           

 

 

    

 

 

    

 

 

       

 

 

    

 

 

 

 

  (a) 

Represents net amount purchased (sold).

 

Derivative Financial Instruments Outstanding as of Period End

Exchange-Traded Options Written

 

Description    Number of
Contracts
     Expiration
Date
     Exercise Price     

Notional

Amount (000)

     Value  

Call

                    

Alphabet, Inc., Class A

     46        07/02/21        USD        2,280.00        USD        11,232      $   (747,730 ) 

Amazon.com, Inc.

     8        07/02/21        USD        3,350.00        USD        2,752        (75,760 ) 

Berkshire Hathaway, Inc., Class B

     199        07/02/21        USD        292.50        USD        5,531        (1,194 ) 

BP PLC, ADR

     178        07/02/21        USD        27.00        USD        470        (1,513 ) 

Ciena Corp.

     118        07/02/21        USD        56.00        USD        671        (10,089 ) 

Ciena Corp.

     118        07/02/21        USD        57.00        USD        671        (4,071 ) 

Cisco Systems, Inc.

     94        07/02/21        USD        53.50        USD        498        (470 ) 

Comcast Corp., Class A

     367        07/02/21        USD        57.50        USD        2,093        (6,423 ) 

 

 

48  

2 0 2 1   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S


Schedule of Investments (unaudited) (continued)

June 30, 2021

  

BlackRock Enhanced Capital and Income Fund, Inc. (CII)

    

 

Exchange-Traded Options Written (continued)

 

Description    Number of
Contracts
       Expiration
Date
      

Exercise Price

      

Notional
Amount (000)

       Value  
Call (continued)                                                   

Comcast Corp., Class A

     220          07/02/21        USD     57.00        USD     1,254        $ (8,800 ) 

JPMorgan Chase & Co.

     83          07/02/21        USD     167.50        USD     1,291          (249 ) 

Morgan Stanley

     637          07/02/21        USD     91.00        USD     5,841          (71,662 ) 

Taiwan Semiconductor Manufacturing Co. Ltd., ADR

     14          07/02/21        USD     119.00        USD     168          (2,226 ) 

Alphabet, Inc., Class A

     40          07/09/21        USD     2,400.00        USD     9,767          (206,400 ) 

Anthem, Inc.

     69          07/09/21        USD     400.00        USD     2,634          (2,760 ) 

Apple, Inc.

     205          07/09/21        USD     129.00        USD     2,808          (162,462 ) 

Bank of America Corp.

     410          07/09/21        USD     43.50        USD     1,690          (2,255 ) 

Berkshire Hathaway, Inc., Class B

     165          07/09/21        USD     292.50        USD     4,586          (3,713 ) 

BP PLC, ADR

     289          07/09/21        USD     28.50        USD     764          (1,445 ) 

Cisco Systems, Inc.

     523          07/09/21        USD     54.00        USD     2,772          (5,230 ) 

Cisco Systems, Inc.

     371          07/09/21        USD     53.00        USD     1,966          (12,985 ) 

Coca-Cola Co.

     215          07/09/21        USD     55.00        USD     1,163          (2,688 ) 

Comcast Corp., Class A

     30          07/09/21        USD     58.50        USD     171          (795 ) 

ConocoPhillips

     65          07/09/21        USD     58.00        USD     396          (20,638 ) 

Dollar General Corp.

     23          07/09/21        USD     207.50        USD     498          (20,815 ) 

Fox Corp., Class A

     175          07/09/21        USD     38.50        USD     650          (3,500 ) 

General Motors Co.

     183          07/09/21        USD     65.00        USD     1,083          (1,098 ) 

Humana, Inc.

     26          07/09/21        USD     437.50        USD     1,151          (21,580 ) 

JPMorgan Chase & Co.

     196          07/09/21        USD     165.91        USD     3,049          (1,089 ) 

Microsoft Corp.

     256          07/09/21        USD     252.50        USD     6,935          (476,160 ) 

Taiwan Semiconductor Manufacturing Co. Ltd., ADR

     198          07/09/21        USD     120.00        USD     2,379          (37,125 ) 

Visa, Inc., Class A

     97          07/09/21        USD     235.00        USD     2,268          (18,915 ) 

Vodafone Group PLC, ADR

     861          07/09/21        USD     19.00        USD     1,475          (1,722 ) 

Alibaba Group Holding Ltd., ADR

     100          07/16/21        USD     225.00        USD     2,268          (64,750 ) 

Ally Financial, Inc.

     440          07/16/21        USD     48.50        USD     2,193          (87,379 ) 

Amazon.com, Inc.

     1          07/16/21        USD     3,450.00        USD     344          (5,075 ) 

Apple, Inc.

     289          07/16/21        USD     135.00        USD     3,958          (93,202 ) 

Applied Materials, Inc.

     120          07/16/21        USD     140.00        USD     1,709          (61,200 ) 

Axalta Coating Systems Ltd.

     453          07/16/21        USD     33.00        USD     1,381          (4,530 ) 

Bank of America Corp.

     430          07/16/21        USD     42.00        USD     1,773          (26,445 ) 

C.H. Robinson Worldwide, Inc.

     207          07/16/21        USD     100.00        USD     1,939          (2,070 ) 

Capital One Financial Corp.

     138          07/16/21        USD     160.00        USD     2,135          (19,872 ) 

CBRE Group, Inc., Class A

     453          07/16/21        USD     88.56        USD     3,884          (25,495 ) 

CDK Global, Inc.

     452          07/16/21        USD     54.95        USD     2,246          (48 ) 

CDW Corp.

     73          07/16/21        USD     170.00        USD     1,275          (44,165 ) 

Ciena Corp.

     235          07/16/21        USD     55.00        USD     1,337          (39,362 ) 

Cisco Systems, Inc.

     183          07/16/21        USD     52.50        USD     970          (13,817 ) 

Cisco Systems, Inc.

     94          07/16/21        USD     55.00        USD     498          (611 ) 

ConocoPhillips

     61          07/16/21        USD     60.00        USD     371          (12,231 ) 

Corteva, Inc.

     1,173          07/16/21        USD     46.19        USD     5,202          (25,425 ) 

Dollar General Corp.

     152          07/16/21        USD     210.00        USD     3,289          (107,920 ) 

Dollar Tree, Inc.

     373          07/16/21        USD     105.00        USD     3,711          (11,563 ) 

EQT Corp.

     686          07/16/21        USD     24.00        USD     1,527          (20,580 ) 

Facebook, Inc., Class A

     289          07/16/21        USD     315.00        USD     10,049          (971,762 ) 

Fidelity National Financial, Inc.

     131          07/16/21        USD     47.00        USD     569          (1,965 ) 

Fidelity National Information Services, Inc.

     22          07/16/21        USD     155.00        USD     312          (110 ) 

FleetCor Technologies, Inc.

     43          07/16/21        USD     280.50        USD     1,101          (859 ) 

Fortive Corp.

     389          07/16/21        USD     72.00        USD     2,713          (22,695 ) 

General Motors Co.

     57          07/16/21        USD     62.50        USD     337          (2,166 ) 

Intercontinental Exchange, Inc.

     343          07/16/21        USD     115.00        USD     4,071          (142,345 ) 

JPMorgan Chase & Co.

     166          07/16/21        USD     170.00        USD     2,582          (3,237 ) 

Laboratory Corp. of America Holdings

     194          07/16/21        USD     270.00        USD     5,351          (171,690 ) 

Laboratory Corp. of America Holdings

     19          07/16/21        USD     280.00        USD     524          (7,125 ) 

Las Vegas Sands Corp.

     195          07/16/21        USD     65.00        USD     1,027          (2,535 ) 

Lowe’s Cos., Inc.

     139          07/16/21        USD     200.00        USD     2,696          (12,997 ) 

Microsoft Corp.

     271          07/16/21        USD     255.00        USD     7,341          (440,375 ) 

Norfolk Southern Corp.

     90          07/16/21        USD     280.00        USD     2,389          (3,600 ) 

Novo Nordisk A/S, ADR

     281          07/16/21        USD     80.90        USD     2,354          (92,936 ) 

O’Reilly Automotive, Inc.

     68          07/16/21        USD     560.00        USD     3,850          (82,280 ) 

Quanta Services, Inc.

     189          07/16/21        USD     95.00        USD     1,712          (8,978 ) 

Robert Half International, Inc.

     216          07/16/21        USD     90.00        USD     1,922          (22,680 ) 

 

 

S C H E D U L E   O F   I N V E S T M E N T S

  49


Schedule of Investments (unaudited) (continued)

June 30, 2021

  

BlackRock Enhanced Capital and Income Fund, Inc. (CII)

    

 

Exchange-Traded Options Written (continued)

 

Description    Number of
Contracts
       Expiration
Date
      

Exercise Price

      

Notional
Amount (000)

       Value  
Call (continued)                                                   

Ross Stores, Inc.

     50          07/16/21        USD     130.00        USD     620        $ (2,250 ) 

Taiwan Semiconductor Manufacturing Co. Ltd., ADR

     125          07/16/21        USD     120.00        USD     1,502          (38,438 ) 

Unilever PLC, ADR

     183          07/16/21        USD     61.21        USD     1,071          (1,722 ) 

Veeva Systems, Inc., Class A

     61          07/16/21        USD     268.00        USD     1,897          (262,296 ) 

Visa, Inc., Class A

     59          07/16/21        USD     235.00        USD     1,380          (17,700 ) 

Vodafone Group PLC, ADR

     663          07/16/21        USD     18.66        USD     1,136          (741 ) 

Vodafone Group PLC, ADR

     862          07/16/21        USD     19.00        USD     1,477          (2,155 ) 

World Wrestling Entertainment, Inc., Class A

     220          07/16/21        USD     55.00        USD     1,274          (72,600 ) 

Amazon.com, Inc.

     4          07/23/21        USD     3,300.00        USD     1,376          (66,800 ) 

Amazon.com, Inc.

     14          07/23/21        USD     3,450.00        USD     4,816          (94,500 ) 

Apple, Inc.

     292          07/23/21        USD     128.00        USD     3,999          (271,560 ) 

Applied Materials, Inc.

     175          07/23/21        USD     146.00        USD     2,492          (56,000 ) 

BP PLC, ADR

     61          07/23/21        USD     27.50        USD     161          (2,257 ) 

Cisco Systems, Inc.

     196          07/23/21        USD     55.00        USD     1,039          (2,646 ) 

Coca-Cola Co.

     366          07/23/21        USD     55.50        USD     1,980          (14,640 ) 

Comcast Corp., Class A

     439          07/23/21        USD     57.50        USD     2,503          (35,120 ) 

ConocoPhillips

     520          07/23/21        USD     60.40        USD     3,167          (124,346 ) 

Dollar General Corp.

     15          07/23/21        USD     212.50        USD     325          (8,700 ) 

Facebook, Inc., Class A

     76          07/23/21        USD     337.50        USD     2,643          (113,620 ) 

Fox Corp., Class A

     245          07/23/21        USD     38.00        USD     910          (14,088 ) 

General Motors Co.

     4          07/23/21        USD     64.00        USD     24          (146 ) 

Lowe’s Cos., Inc.

     56          07/23/21        USD     195.00        USD     1,086          (17,304 ) 

Microsoft Corp.

     251          07/23/21        USD     270.00        USD     6,800          (158,757 ) 

Morgan Stanley

     32          07/23/21        USD     95.00        USD     293          (4,240 ) 

Norfolk Southern Corp.

     103          07/23/21        USD     282.50        USD     2,734          (5,665 ) 

Ross Stores, Inc.

     315          07/23/21        USD     121.00        USD     3,906          (151,200 ) 

Vodafone Group PLC, ADR

     862          07/23/21        USD     19.00        USD     1,477          (3,017 ) 

CDK Global, Inc.

     289          07/28/21        USD     54.00        USD     1,436          (2,137 ) 

Veeva Systems, Inc., Class A

     60          07/28/21        USD     300.00        USD     1,866          (93,348 ) 

Anthem, Inc.

     48          07/30/21        USD     392.50        USD     1,833          (27,360 ) 

Applied Materials, Inc.

     447          07/30/21        USD     144.00        USD     6,365          (210,090 ) 

Bank of America Corp.

     90          07/30/21        USD     43.00        USD     371          (5,130 ) 

Bank of America Corp.

     272          07/30/21        USD     41.50        USD     1,121          (30,600 ) 

BP PLC, ADR

     533          07/30/21        USD     28.00        USD     1,408          (19,188 ) 

Ciena Corp.

     136          07/30/21        USD     58.00        USD     774          (16,252 ) 

Cisco Systems, Inc.

     659          07/30/21        USD     54.00        USD     3,493          (29,985 ) 

Coca-Cola Co.

     624          07/30/21        USD     55.00        USD     3,376          (41,184 ) 

ConocoPhillips

     134          07/30/21        USD     64.00        USD     816          (14,472 ) 

ConocoPhillips

     134          07/30/21        USD     62.00        USD     816          (23,986 ) 

Dollar Tree, Inc.

     373          07/30/21        USD     105.00        USD     3,711          (29,094 ) 

General Motors Co.

     306          07/30/21        USD     63.00        USD     1,811          (21,726 ) 

JPMorgan Chase & Co.

     117          07/30/21        USD     155.00        USD     1,820          (45,922 ) 

Lowe’s Cos., Inc.

     102          07/30/21        USD     197.50        USD     1,978          (25,602 ) 

Microsoft Corp.

     261          07/30/21        USD     265.00        USD     7,070          (262,305 ) 

UnitedHealth Group, Inc.

     151          07/30/21        USD     412.50        USD     6,047          (73,235 ) 

Visa, Inc., Class A

     20          07/30/21        USD     240.00        USD     468          (6,500 ) 

Vodafone Group PLC, ADR

     642          07/30/21        USD     18.50        USD     1,100          (5,457 ) 

Alibaba Group Holding Ltd., ADR

     159          08/06/21        USD     230.00        USD     3,606          (119,250 ) 

Alphabet, Inc., Class A

     25          08/06/21        USD     2,450.00        USD     6,104          (186,125 ) 

Apple, Inc.

     341          08/06/21        USD     140.00        USD     4,670          (94,798 ) 

Bank of America Corp.

     846          08/06/21        USD     43.00        USD     3,488          (57,951 ) 

Capital One Financial Corp.

     246          08/06/21        USD     162.50        USD     3,805          (72,693 ) 

Cisco Systems, Inc.

     182          08/06/21        USD     53.50        USD     965          (14,651 ) 

Coca-Cola Co.

     97          08/06/21        USD     55.00        USD     525          (7,372 ) 

ConocoPhillips

     93          08/06/21        USD     63.00        USD     566          (16,043 ) 

Dollar Tree, Inc.

     79          08/06/21        USD     100.00        USD     786          (21,251 ) 

Facebook, Inc., Class A

     129          08/06/21        USD     362.50        USD     4,485          (107,715 ) 

General Motors Co.

     387          08/06/21        USD     63.00        USD     2,290          (44,311 ) 

Microsoft Corp.

     122          08/06/21        USD     277.50        USD     3,305          (50,630 ) 

Morgan Stanley

     341          08/06/21        USD     91.00        USD     3,127          (116,792 ) 

Sealed Air Corp.

     153          08/06/21        USD     60.01        USD     907          (25,273 ) 

Taiwan Semiconductor Manufacturing Co. Ltd., ADR

     243          08/06/21        USD     122.00        USD     2,920          (85,050 ) 

 

 

50  

2 0 2 1   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S


Schedule of Investments (unaudited) (continued)

June 30, 2021

  

BlackRock Enhanced Capital and Income Fund, Inc. (CII)

    

 

Exchange-Traded Options Written (continued)

 

Description    Number of
Contracts
       Expiration
Date
      

Exercise Price

      

Notional
Amount (000)

       Value  
Call (continued)                                                   

UnitedHealth Group, Inc.

     71          08/06/21        USD     405.00        USD     2,843        $ (63,722 ) 

Vodafone Group PLC, ADR

     1,000          08/06/21        USD     17.50        USD     1,713          (35,000 ) 

Koninklijke Philips NV, NY Shares

     414          08/16/21        USD     55.50        USD     2,058          (9,759 ) 

Ally Financial, Inc.

     464          08/20/21        USD     54.00        USD     2,313          (37,293 ) 

Alphabet, Inc., Class A

     41          08/20/21        USD     2,440.00        USD     10,011          (377,200 ) 

Apple, Inc.

     785          08/20/21        USD     135.00        USD     10,751          (457,262 ) 

Bank of America Corp.

     227          08/20/21        USD     43.00        USD     936          (20,317 ) 

BP PLC, ADR

     351          08/20/21        USD     29.00        USD     927          (13,338 ) 

C.H. Robinson Worldwide, Inc.

     174          08/20/21        USD     105.00        USD     1,630          (19,140 ) 

CBRE Group, Inc., Class A

     411          08/20/21        USD     89.00        USD     3,524          (83,269 ) 

CDK Global, Inc.

     208          08/20/21        USD     55.00        USD     1,034          (12,480 ) 

CDW Corp.

     74          08/20/21        USD     170.00        USD     1,292          (66,970 ) 

Cisco Systems, Inc.

     163          08/20/21        USD     55.00        USD     864          (14,018 ) 

Comcast Corp., Class A

     440          08/20/21        USD     60.00        USD     2,509          (33,220 ) 

ConocoPhillips

     358          08/20/21        USD     65.00        USD     2,180          (52,626 ) 

ConocoPhillips

     358          08/20/21        USD     60.00        USD     2,180          (119,930 ) 

Dollar Tree, Inc.

     175          08/20/21        USD     120.00        USD     1,741          (2,625 ) 

EQT Corp.

     980          08/20/21        USD     23.31        USD     2,181          (108,566 ) 

Fidelity National Financial, Inc.

     649          08/20/21        USD     47.42        USD     2,821          (18,614 ) 

Fidelity National Information Services, Inc.

     216          08/20/21        USD     155.00        USD     3,060          (15,120 ) 

FleetCor Technologies, Inc.

     44          08/20/21        USD     280.00        USD     1,127          (9,570 ) 

Fortive Corp.

     496          08/20/21        USD     72.88        USD     3,459          (65,396 ) 

General Motors Co.

     387          08/20/21        USD     62.50        USD     2,290          (62,500 ) 

Intercontinental Exchange, Inc.

     234          08/20/21        USD     115.00        USD     2,778          (132,210 ) 

Las Vegas Sands Corp.

     62          08/20/21        USD     60.00        USD     327          (6,262 ) 

Microsoft Corp.

     261          08/20/21        USD     260.00        USD     7,070          (396,067 ) 

Norfolk Southern Corp.

     116          08/20/21        USD     270.00        USD     3,079          (74,240 ) 

Novo Nordisk A/S, ADR

     295          08/20/21        USD     85.00        USD     2,471          (57,525 ) 

O’Reilly Automotive, Inc.

     62          08/20/21        USD     560.00        USD     3,511          (141,670 ) 

Otis Worldwide Corp.

     573          08/20/21        USD     85.00        USD     4,685          (85,950 ) 

Quanta Services, Inc.

     583          08/20/21        USD     95.00        USD     5,280          (137,005 ) 

Robert Half International, Inc.

     164          08/20/21        USD     92.49        USD     1,459          (34,300 ) 

Sanofi, ADR

     943          08/20/21        USD     53.28        USD     4,966          (111,286 ) 

Sealed Air Corp.

     153          08/20/21        USD     60.00        USD     907          (30,600 ) 

Unilever PLC, ADR

     530          08/20/21        USD     62.50        USD     3,101          (13,250 ) 

Visa, Inc., Class A

     59          08/20/21        USD     235.00        USD     1,380          (39,677 ) 

World Wrestling Entertainment, Inc., Class A

     300          08/20/21        USD     65.00        USD     1,737          (57,750 ) 

Otis Worldwide Corp.

     155          09/17/21        USD     85.00        USD     1,267          (30,613 ) 
                          

 

 

 
                           $   (11,181,963)  
                          

 

 

 

OTC Options Written

 

Description    Counterparty    Number of
Contracts
     Expiration
Date
     Exercise Price      Notional
Amount (000)
     Value  

Call

                     

Koninklijke Philips NV, NY Shares

   Barclays Bank PLC      38,500        07/06/21        USD       57.61        USD       1,913      $ —  

BAE Systems PLC, ADR

   Bank of America N.A.      27,200        07/07/21        USD       29.95        USD       796        (3,085 ) 

BAE Systems PLC, ADR

   Citibank N.A.      27,200        07/13/21        USD       30.55        USD       796        (2,516 ) 

Koninklijke Philips NV, NY Shares

   Barclays Bank PLC      36,600        07/13/21        USD       60.70        USD       1,819        —  

BAE Systems PLC, ADR

   Citibank N.A.      26,200        07/20/21        USD       30.65        USD       767        (3,833 ) 

BAE Systems PLC, ADR

   Citibank N.A.      26,200        07/27/21        USD       30.65        USD       767        (5,499 ) 

Axalta Coating Systems Ltd.

   Citibank N.A.      65,100        07/28/21        USD       32.25        USD       1,985        (15,877 ) 

Unilever PLC, ADR

   Credit Suisse International      8,900        07/29/21        USD       59.90        USD       521        (4,148 ) 

Applied Materials, Inc.

   Morgan Stanley & Co. LLC      44,600        08/06/21        USD       140.00        USD       6,351        (337,845 ) 

Facebook, Inc., Class A

   Morgan Stanley & Co. LLC      7,700        08/06/21        USD       355.00        USD       2,677        (85,855 ) 

Sanofi, ADR

   Barclays Bank PLC      27,600        08/09/21        USD       53.00        USD       1,453        (30,562 ) 

BAE Systems PLC, ADR

   Citibank N.A.      38,100        08/11/21        USD       30.50        USD       1,115        (14,077 ) 

Corteva, Inc.

   Barclays Bank PLC      39,800        08/20/21        USD       45.02        USD       1,765        (48,813 ) 

Ally Financial, Inc.

   Citibank N.A.      34,000        09/07/21        USD       55.26        USD       1,695        (29,080 ) 
                     

 

 

 
                      $     (581,190 ) 
                     

 

 

 

 

 

S C H E D U L E   O F   I N V E S T M E N T S

  51


Schedule of Investments (unaudited) (continued)

June 30, 2021

  

BlackRock Enhanced Capital and Income Fund, Inc. (CII)

    

 

Balances Reported in the Statements of Assets and Liabilities for Options Written

 

Description    Swap
Premiums
Paid
     Swap
Premiums
Received
     Unrealized
Appreciation
     Unrealized
Depreciation
     Value  

Options Written

   $ N/A      $ N/A      $ 3,199,816      $ (3,878,369 )     $   (11,763,153)  

Derivative Financial Instruments Categorized by Risk Exposure

As of period end, the fair values of derivative financial instruments located in the Statements of Assets and Liabilities were as follows:

 

      Commodity
Contracts
     Credit
Contracts
     Equity
Contracts
     Foreign
Currency
Exchange
Contracts
     Interest
Rate
Contracts
     Other
Contracts
     Total  

Liabilities — Derivative Financial Instruments

                    

Options written

                    

Options written at value

   $ —      $ —      $   11,763,153      $ —      $ —      $ —      $   11,763,153  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

For the six months ended June 30, 2021, the effect of derivative financial instruments in the Statements of Operations was as follows:

 

      Commodity
Contracts
     Credit
Contracts
     Equity
Contracts
     Foreign
Currency
Exchange
Contracts
     Interest
Rate
Contracts
     Other
Contracts
     Total  

Net Realized Gain (Loss) from

                    

Options written

   $ —      $ —      $   (15,068,271 )     $ —      $ —      $ —      $   (15,068,271 ) 
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Net Change in Unrealized Appreciation (Depreciation) on

                    

Options written

   $ —      $ —      $ (153,841 )     $ —      $ —      $ —      $ (153,841 ) 
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Average Quarterly Balances of Outstanding Derivative Financial Instruments

 

Options

        

Average value of option contracts written.

   $ 12,321,347  

For more information about the Trust’s investment risks regarding derivative financial instruments, refer to the Notes to Financial Statements.

Derivative Financial Instruments — Offsetting as of Period End

The Trust’s derivative assets and liabilities (by type) were as follows:

 

      Assets      Liabilities  

Derivative Financial Instruments

     

Options

   $ —      $ 11,763,153  
  

 

 

    

 

 

 

Total derivative assets and liabilities in the Statements of Assets and Liabilities

     —        11,763,153  
  

 

 

    

 

 

 

Derivatives not subject to a Master Netting Agreement or similar agreement (“MNA”)

     —        (11,181,963 ) 
  

 

 

    

 

 

 

Total derivative assets and liabilities subject to an MNA

   $ —      $ 581,190  
  

 

 

    

 

 

 

 

 

52  

2 0 2 1   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S


Schedule of Investments (unaudited) (continued)

June 30, 2021

  

BlackRock Enhanced Capital and Income Fund, Inc. (CII)

    

 

The following table presents the Trust’s derivative liabilities by counterparty net of amounts available for offset under an MNA and net of the related collateral pledged by the Trust:

 

Counterparty

    



Derivative
Liabilities
Subject to
an MNA by
Counterparty
 
 
 
 
 
    

Derivatives
Available
for Offset
 
 
 
    

Non-Cash
Collateral
Pledged
 
 
 
    

Cash
Collateral
Pledged
 
 
(a) 
    


Net
Amount of
Derivative
Liabilities
 
 
 
(b) 

Bank of America N.A.

   $ 3,085      $ —      $ —      $ —      $ 3,085  

Barclays Bank PLC

     79,375        —        —        (79,375 )       —  

Citibank N.A.

     70,882        —        —        —        70,882  

Credit Suisse International

     4,148        —        —        —        4,148  

Morgan Stanley & Co. LLC

     423,700        —        —        —        423,700  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 
   $ 581,190      $ —      $ —      $ (79,375 )     $ 501,815  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

 

  (a) 

Excess of collateral pledged to the individual counterparty is not shown for financial reporting purposes.

 
  (b) 

Net amount represents the net amount payable due to counterparty in the event of default. Net amount may be offset further by the options written receivable/payable on the Statements of Assets and Liabilities.

 

Fair Value Hierarchy as of Period End

Various inputs are used in determining the fair value of financial instruments. For a description of the input levels and information about the Trust’s policy regarding valuation of financial instruments, refer to the Notes to Financial Statements.

The following table summarizes the Trust’s financial instruments categorized in the fair value hierarchy. The breakdown of the Trust’s financial instruments into major categories is disclosed in the Schedule of Investments above.

 

      Level 1      Level 2      Level 3      Total  

Assets

           

Investments

           

Long-Term Investments

           

Common Stocks

   $ 945,129,794      $ —      $ —      $ 945,129,794  

Short-Term Securities

           

Money Market Funds

     12,748,208        —        —        12,748,208  
  

 

 

    

 

 

    

 

 

    

 

 

 
   $   957,878,002      $ —      $ —      $   957,878,002  
  

 

 

    

 

 

    

 

 

    

 

 

 

Derivative Financial Instruments(a)

           

Liabilities

           

Equity Contracts

   $ (9,947,691 )     $ (1,815,462 )     $ —      $ (11,763,153 ) 
  

 

 

    

 

 

    

 

 

    

 

 

 

 

  (a) 

Derivative financial instruments are options written. Options written are shown at value.

 

See notes to financial statements.

 

 

S C H E D U L E   O F   I N V E S T M E N T S

  53


Schedule of Investments (unaudited) 

June 30, 2021

  

BlackRock Enhanced Equity Dividend Trust (BDJ)

(Percentages shown are based on Net Assets)

 

Security   Shares     Value  

Common Stocks

 

Aerospace & Defense — 3.2%  

BAE Systems PLC

    5,386,436     $ 38,922,480  

Huntington Ingalls Industries, Inc.(a)

    53,934       11,366,591  

Raytheon Technologies Corp.(a)

    135,790       11,584,245  
   

 

 

 
      61,873,316  
Auto Components — 0.7%  

Lear Corp.(a)

    74,027       12,975,453  
   

 

 

 
Automobiles — 2.2%            

General Motors Co.(a)(b)

    713,775       42,234,067  
   

 

 

 
Banks — 11.5%            

Bank of America Corp.(a)

    1,258,512       51,888,450  

Citigroup, Inc.(a)(c)

    963,102       68,139,466  

First Citizens BancShares, Inc., Class A

    6,193       5,157,159  

JPMorgan Chase & Co.(a)(c)

    170,826       26,570,276  

Wells Fargo & Co.(a)(c)

    1,585,647       71,813,953  
   

 

 

 
      223,569,304  
Beverages(a) — 2.0%  

Coca-Cola Co.

    327,169       17,703,114  

Constellation Brands, Inc., Class A

    89,256       20,876,086  
   

 

 

 
      38,579,200  
Capital Markets — 6.0%  

Apollo Global Management, Inc.

    159,648       9,930,105  

Blackstone Group, Inc.(a)

    24,290       2,359,531  

Charles Schwab Corp.(a)

    395,944       28,828,683  

Intercontinental Exchange, Inc.(a)

    50,280       5,968,236  

Morgan Stanley(a)

    487,468       44,695,941  

Raymond James Financial, Inc.(a)

    190,727       24,775,437  
   

 

 

 
      116,557,933  
Chemicals(a) — 1.5%  

Corteva, Inc.

    205,111       9,096,673  

DuPont de Nemours, Inc.

    78,275       6,059,268  

PPG Industries, Inc.

    83,693       14,208,560  
   

 

 

 
      29,364,501  
Communications Equipment(a) — 3.2%  

Cisco Systems, Inc.

    962,947       51,036,191  

Motorola Solutions, Inc.

    52,915       11,474,618  
   

 

 

 
      62,510,809  
Consumer Finance(a) — 1.5%  

American Express Co.

    79,951       13,210,303  

Capital One Financial Corp.

    100,478       15,542,942  
   

 

 

 
      28,753,245  
Containers & Packaging — 0.5%  

Sealed Air Corp.(a)

    171,134       10,139,689  
   

 

 

 
Diversified Financial Services(a) — 1.0%  

Berkshire Hathaway, Inc., Class B(b)

    15,288       4,248,841  

Equitable Holdings, Inc.

    517,620       15,761,529  
   

 

 

 
      20,010,370  
Diversified Telecommunication Services — 2.4%  

Verizon Communications, Inc.(a)(c)

    831,146       46,569,110  
   

 

 

 
Electric Utilities(a) — 1.8%  

American Electric Power Co., Inc.

    73,086       6,182,345  

Edison International

    255,905       14,796,427  
Security   Shares     Value  
Electric Utilities (continued)            

Exelon Corp.

    202,073     $ 8,953,855  

Southern Co.

    91,620       5,543,926  
   

 

 

 
      35,476,553  
Food Products — 1.1%  

Danone SA

    309,692       21,788,350  
   

 

 

 
Health Care Equipment & Supplies — 5.2%  

Alcon, Inc.

    168,135       11,792,569  

Koninklijke Philips NV

    557,253       27,658,784  

Medtronic PLC(a)

    288,750       35,842,538  

Zimmer Biomet Holdings, Inc.(a)

    155,694       25,038,709  
   

 

 

 
      100,332,600  
Health Care Providers & Services(a) — 7.4%  

Anthem, Inc.(c)

    150,532       57,473,118  

Cigna Corp.

    78,585       18,630,146  

CVS Health Corp.

    295,924       24,691,898  

Humana, Inc.

    36,205       16,028,678  

McKesson Corp.

    52,847       10,106,460  

UnitedHealth Group, Inc.

    42,646       17,077,164  
   

 

 

 
      144,007,464  
Household Durables — 1.2%  

Newell Brands, Inc.(a)

    452,299       12,424,654  

Panasonic Corp.

    863,400       9,941,631  
   

 

 

 
      22,366,285  
Industrial Conglomerates — 2.9%  

General Electric Co.(a)

    2,496,516       33,603,105  

Siemens AG, Registered Shares

    147,459       23,413,345  
   

 

 

 
      57,016,450  
Insurance — 7.0%  

Allstate Corp.(a)

    104,026       13,569,152  

American International Group, Inc.(a)

    1,192,859       56,780,088  

Arthur J. Gallagher & Co.(a)

    155,349       21,761,288  

Fidelity National Financial, Inc.(a)

    388,882       16,900,812  

First American Financial Corp.

    51,777       3,228,296  

MetLife, Inc.(a)

    403,436       24,145,645  
   

 

 

 
      136,385,281  
IT Services(a) — 3.5%  

Cognizant Technology Solutions Corp., Class A

    371,067       25,700,100  

Fidelity National Information Services, Inc.

    151,670       21,487,089  

Visa, Inc., Class A

    91,685       21,437,787  
   

 

 

 
      68,624,976  
Machinery — 0.4%  

Komatsu Ltd.

    351,100       8,697,996  
   

 

 

 
Media(a) — 3.5%  

Comcast Corp., Class A

    729,313       41,585,427  

Fox Corp., Class A

    714,955       26,546,279  
   

 

 

 
      68,131,706  
Multi-line Retail — 0.9%  

Dollar General Corp.(a)

    76,421       16,536,740  
   

 

 

 
Multi-Utilities — 2.7%  

Ameren Corp.(a)

    141,462       11,322,619  

CenterPoint Energy, Inc.

    207,760       5,094,275  

NiSource, Inc.(a)

    445,849       10,923,301  

Public Service Enterprise Group, Inc.(a)

    411,287       24,570,285  
   

 

 

 
      51,910,480  
 

 

 

54  

2 0 2 1   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S


Schedule of Investments (unaudited) (continued)

June 30, 2021

  

BlackRock Enhanced Equity Dividend Trust (BDJ)

(Percentages shown are based on Net Assets)

 

Security   Shares     Value  
Oil, Gas & Consumable Fuels — 6.9%  

BP PLC

    7,833,652     $ 34,353,620  

ConocoPhillips(a)

    470,532       28,655,399  

Enterprise Products Partners LP(a)

    1,536,284       37,070,533  

Equinor ASA

    525,949       11,133,553  

Marathon Petroleum Corp.(a)

    394,028       23,807,172  
   

 

 

 
      135,020,277  
Personal Products — 2.1%  

Unilever PLC, ADR(a)

    684,756       40,058,226  
   

 

 

 
Pharmaceuticals — 5.7%            

AstraZeneca PLC

    327,708       39,372,191  

Bayer AG, Registered Shares

    514,687       31,290,495  

Sanofi

    387,557       40,717,737  
   

 

 

 
      111,380,423  
Professional Services — 0.6%  

Leidos Holdings, Inc.(a)

    106,936       10,811,230  
   

 

 

 
Road & Rail — 0.9%  

Union Pacific Corp.(a)

    79,217       17,422,195  
   

 

 

 
Software(a) — 3.4%  

CDK Global, Inc.

    215,220       10,694,282  

Microsoft Corp.(c)

    72,937       19,758,633  

Open Text Corp.

    230,141       11,691,163  

SS&C Technologies Holdings, Inc.

    343,714       24,768,031  
   

 

 

 
      66,912,109  
Specialty Retail(a) — 2.4%  

Lowe’s Cos., Inc.

    72,554       14,073,299  

Ross Stores, Inc.

    266,110       32,997,640  
   

 

 

 
      47,070,939  
Technology Hardware, Storage & Peripherals — 0.7%  

Samsung Electronics Co. Ltd., Registered Shares, GDR

    7,501       13,379,291  
   

 

 

 
Tobacco — 1.5%  

Altria Group, Inc.(a)

    224,383       10,698,581  

British American Tobacco PLC

    451,005       17,510,518  
   

 

 

 
      28,209,099  
Wireless Telecommunication Services — 0.2%  

Rogers Communications, Inc., Class B

    66,628       3,542,098  
   

 

 

 

Total Common Stocks — 97.7%
(Cost: $1,352,313,173)

 

    1,898,217,765  
   

 

 

 
Security   Shares     Value  

Preferred Securities

 

Preferred Stocks — 0.3%  
Household Products — 0.3%  

Henkel AG & Co. KGaA, Preference Shares

    59,585     $ 6,293,006  
   

 

 

 

Total Preferred Securities — 0.3%
(Cost: $5,026,537)

      6,293,006  
   

 

 

 

Total Long-Term Investments — 98.0%
(Cost: $1,357,339,710)

 

    1,904,510,771  
   

 

 

 

Short-Term Securities

   
Money Market Funds — 2.5%            

BlackRock Liquidity Funds, T-Fund, Institutional Class, 0.01%(d)(e)

    48,566,704       48,566,704  
   

 

 

 

Total Short-Term Securities — 2.5%
(Cost: $48,566,704)

 

    48,566,704  
   

 

 

 

Total Investments Before Options Written — 100.5%
(Cost: $1,405,906,414)

 

    1,953,077,475  
   

 

 

 

Options Written — (0.7)%
(Premiums Received: $(22,612,707))

 

    (13,785,732 ) 
   

 

 

 

Total Investments, Net of Options Written — 99.8% (Cost: $1,383,293,707)

 

    1,939,291,743  

Other Assets Less Liabilities — 0.2%

 

    3,463,091  
   

 

 

 

Net Assets — 100.0%

 

  $   1,942,754,834  
   

 

 

 

 

(a) 

All or a portion of the security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written.    

(b) 

Non-income producing security.

(c) 

All or a portion of the security has been pledged as collateral in connection with outstanding OTC derivatives.    

(d) 

Affiliate of the Trust.

(e) 

Annualized 7-day yield as of period end.

 

 

For Trust compliance purposes, the Trust’s industry classifications refer to one or more of the industry sub-classifications used by one or more widely recognized market indexes or rating group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.

 

 

S C H E D U L E   O F   I N V E S T M E N T S

  55


Schedule of Investments (unaudited) (continued)

June 30, 2021

  

BlackRock Enhanced Equity Dividend Trust (BDJ)

    

 

Affiliates

Investments in issuers considered to be affiliate(s) of the Trust during the six-months ended June 30, 2021 for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

 

Affiliated Issuer   Value at
12/31/20
    Purchases
at Cost
    Proceeds
from Sales
    Net
Realized
Gain (Loss)
    Change in
Unrealized
Appreciation
(Depreciation)
    Value at
06/30/21
   

Shares

Held at

06/30/21

    Income     Capital Gain
Distributions
from
Underlying
Funds
 

BlackRock Liquidity Funds, T-Fund, Institutional Class

  $   12,016,637     $   36,550,067 (a)    $ —     $ —     $ —     $ 48,566,704       48,566,704     $ 1,352     $ —  

SL Liquidity Series, LLC, Money Market Series(b)

    —       0 (a)       —       —       —       —       —       4,054 (c)      —  
       

 

 

   

 

 

   

 

 

     

 

 

   

 

 

 
        $ —     $ —     $   48,566,704       $   5,406     $ —  
       

 

 

   

 

 

   

 

 

     

 

 

   

 

 

 

 

  (a) 

Represents net amount purchased (sold).

 
  (b) 

As of period end, the entity is no longer an affiliate.

 
  (c) 

All or a portion represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of fees and collateral investment expenses, and other payments to and from borrowers of securities.

 

Derivative Financial Instruments Outstanding as of Period End

Exchange-Traded Options Written

 

Description    Number of
Contracts
     Expiration
Date
    

Exercise Price

    

Notional
Amount (000)

     Value  

Call

                    

American International Group, Inc.

     943        07/02/21        USD        51.00        USD        4,489      $ (943 ) 

Anthem, Inc.

     159        07/02/21        USD        397.50        USD        6,071        (5,565 ) 

Charles Schwab Corp.

     386        07/02/21        USD        74.50        USD        2,810        (3,474 ) 

Cigna Corp.

     85        07/02/21        USD        270.00        USD        2,015        (850 ) 

Cisco Systems, Inc.

     327        07/02/21        USD        53.50        USD        1,733        (1,635 ) 

Cognizant Technology Solutions Corp., Class A

     153        07/02/21        USD        71.50        USD        1,060        (1,530 ) 

Comcast Corp., Class A

     661        07/02/21        USD        57.50        USD        3,769        (11,568 ) 

Comcast Corp., Class A

     163        07/02/21        USD        57.00        USD        929        (6,520 ) 

Constellation Brands, Inc., Class A

     90        07/02/21        USD        240.00        USD        2,105        (2,250 ) 

CVS Health Corp.

     208        07/02/21        USD        86.50        USD        1,736        (1,144 ) 

DuPont de Nemours, Inc.

     62        07/02/21        USD        87.00        USD        480        (1,860 ) 

Fox Corp., Class A

     605        07/02/21        USD        38.50        USD        2,246        (3,025 ) 

General Motors Co.

     301        07/02/21        USD        60.00        USD        1,781        (6,020 ) 

Humana, Inc.

     33        07/02/21        USD        450.00        USD        1,461        (1,980 ) 

JPMorgan Chase & Co.

     279        07/02/21        USD        167.50        USD        4,340        (837 ) 

Marathon Petroleum Corp.

     555        07/02/21        USD        61.00        USD        3,353        (18,870 ) 

Morgan Stanley

     1,040        07/02/21        USD        91.00        USD        9,536        (117,000 ) 

Wells Fargo & Co.

     1,169        07/02/21        USD        48.00        USD        5,294        (2,923 ) 

SS&C Technologies Holdings, Inc.

     687        07/07/21        USD        74.75        USD        4,951        (21,551 ) 

American International Group, Inc.

     1,345        07/09/21        USD        53.00        USD        6,402        (44,385 ) 

Anthem, Inc.

     159        07/09/21        USD        400.00        USD        6,071        (6,360 ) 

Bank of America Corp.

     1,876        07/09/21        USD        43.50        USD        7,735        (10,318 ) 

Berkshire Hathaway, Inc., Class B

     152        07/09/21        USD        292.50        USD        4,224        (3,420 ) 

Capital One Financial Corp.

     106        07/09/21        USD        157.50        USD        1,640        (13,939 ) 

Charles Schwab Corp.

     448        07/09/21        USD        71.50        USD        3,262        (85,344 ) 

Charles Schwab Corp.

     447        07/09/21        USD        72.00        USD        3,255        (72,637 ) 

Citigroup, Inc.

     377        07/09/21        USD        80.50        USD        2,667        (754 ) 

Coca-Cola Co.

     201        07/09/21        USD        55.00        USD        1,088        (2,513 ) 

Cognizant Technology Solutions Corp., Class A

     256        07/09/21        USD        72.50        USD        1,773        (7,680 ) 

Comcast Corp., Class A

     949        07/09/21        USD        58.50        USD        5,411        (25,149 ) 

ConocoPhillips

     501        07/09/21        USD        58.00        USD        3,051        (159,067 ) 

Constellation Brands, Inc., Class A

     209        07/09/21        USD        242.50        USD        4,888        (12,018 ) 

Dollar General Corp.

     153        07/09/21        USD        207.50        USD        3,311        (138,465 ) 

Enterprise Products Partners LP

     3,018        07/09/21        USD        24.00        USD        7,282        (108,648 ) 

Fox Corp., Class A

     1,186        07/09/21        USD        38.50        USD        4,404        (23,720 ) 

General Electric Co.

     1,082        07/09/21        USD        14.50        USD        1,456        (4,328 ) 

General Motors Co.

     470        07/09/21        USD        65.00        USD        2,781        (2,820 ) 

JPMorgan Chase & Co.

     257        07/09/21        USD        165.91        USD        3,997        (1,428 ) 

Lowe’s Cos., Inc.

     155        07/09/21        USD        195.00        USD        3,007        (26,118 ) 

Marathon Petroleum Corp.

     555        07/09/21        USD        61.01        USD        3,353        (54,569 ) 

 

 

56  

2 0 2 1   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S


Schedule of Investments (unaudited) (continued)

June 30, 2021

  

BlackRock Enhanced Equity Dividend Trust (BDJ)

    

 

Exchange-Traded Options Written (continued)

 

Description    Number of
Contracts
       Expiration
Date
      

Exercise Price

       Notional
Amount (000)
       Value  

Call (continued)

                                

McKesson Corp.

     53          07/09/21          USD          197.50          USD          1,014        $ (3,710 ) 

Medtronic PLC

     226          07/09/21          USD          130.00          USD          2,805          (2,599 ) 

Microsoft Corp.

     102          07/09/21          USD          252.50          USD          2,763          (189,720 ) 

Ross Stores, Inc.

     465          07/09/21          USD          123.00          USD          5,766          (111,600 ) 

Union Pacific Corp.

     242          07/09/21          USD          230.00          USD          5,322          (2,420 ) 

UnitedHealth Group, Inc.

     78          07/09/21          USD          405.00          USD          3,123          (19,110 ) 

Visa, Inc., Class A

     165          07/09/21          USD          235.00          USD          3,858          (32,175 ) 

Wells Fargo & Co.

     1,731          07/09/21          USD          47.00          USD          7,840          (38,082 ) 

Allstate Corp.

     305          07/16/21          USD          140.00          USD          3,978          (2,288 ) 

Altria Group, Inc.

     637          07/16/21          USD          50.00          USD          3,037          (8,918 ) 

Ameren Corp.

     265          07/16/21          USD          85.00          USD          2,121          (3,975 ) 

American Electric Power Co., Inc.

     401          07/16/21          USD          85.00          USD          3,392          (35,087 ) 

American Express Co.

     174          07/16/21          USD          165.00          USD          2,875          (50,373 ) 

American International Group, Inc.

     908          07/16/21          USD          52.50          USD          4,322          (6,356 ) 

Anthem, Inc.

     129          07/16/21          USD          390.00          USD          4,925          (29,992 ) 

Arthur J. Gallagher & Co.

     575          07/16/21          USD          150.00          USD          8,055          (15,813 ) 

Bank of America Corp.

     1,362          07/16/21          USD          42.00          USD          5,616          (83,763 ) 

Capital One Financial Corp.

     225          07/16/21          USD          160.00          USD          3,481          (32,400 ) 

CDK Global, Inc.

     479          07/16/21          USD          54.95          USD          2,380          (51 ) 

Cisco Systems, Inc.

     634          07/16/21          USD          52.50          USD          3,360          (47,867 ) 

Cisco Systems, Inc.

     327          07/16/21          USD          55.00          USD          1,733          (2,126 ) 

Citigroup, Inc.

     320          07/16/21          USD          77.50          USD          2,264          (5,920 ) 

Cognizant Technology Solutions Corp., Class A

     600          07/16/21          USD          77.50          USD          4,156          (15,000 ) 

Comcast Corp., Class A

     737          07/16/21          USD          57.50          USD          4,202          (42,746 ) 

ConocoPhillips

     608          07/16/21          USD          60.00          USD          3,703          (121,904 ) 

Corteva, Inc.

     43          07/16/21          USD          46.19          USD          191          (932 ) 

CVS Health Corp.

     853          07/16/21          USD          87.75          USD          7,117          (89,362 ) 

Dollar General Corp.

     125          07/16/21          USD          210.00          USD          2,705          (88,750 ) 

Edison International

     678          07/16/21          USD          60.00          USD          3,920          (5,085 ) 

Enterprise Products Partners LP

     1,272          07/16/21          USD          23.75          USD          3,069          (84,486 ) 

Equitable Holdings, Inc.

     980          07/16/21          USD          35.00          USD          2,984          (9,800 ) 

Exelon Corp.

     341          07/16/21          USD          47.00          USD          1,511          (3,410 ) 

Fidelity National Financial, Inc.

     1,091          07/16/21          USD          47.00          USD          4,741          (16,365 ) 

Fidelity National Information Services, Inc.

     338          07/16/21          USD          155.00          USD          4,788          (1,690 ) 

General Electric Co.

     2,462          07/16/21          USD          14.00          USD          3,314          (38,161 ) 

General Motors Co.

     1,044          07/16/21          USD          62.50          USD          6,177          (39,672 ) 

JPMorgan Chase & Co.

     174          07/16/21          USD          170.00          USD          2,706          (3,393 ) 

Lear Corp.

     243          07/16/21          USD          195.00          USD          4,259          (11,543 ) 

Lowe’s Cos., Inc.

     39          07/16/21          USD          200.00          USD          756          (3,647 ) 

Marathon Petroleum Corp.

     721          07/16/21          USD          60.00          USD          4,356          (124,733 ) 

McKesson Corp.

     76          07/16/21          USD          200.00          USD          1,453          (6,460 ) 

Medtronic PLC

     766          07/16/21          USD          130.00          USD          9,508          (16,469 ) 

MetLife, Inc.

     368          07/16/21          USD          65.00          USD          2,202          (2,208 ) 

Microsoft Corp.

     55          07/16/21          USD          255.00          USD          1,490          (89,375 ) 

Morgan Stanley

     505          07/16/21          USD          95.00          USD          4,630          (51,510 ) 

Motorola Solutions, Inc.

     300          07/16/21          USD          220.00          USD          6,506          (45,000 ) 

Newell Brands, Inc.

     971          07/16/21          USD          29.40          USD          2,667          (15,552 ) 

NiSource, Inc.

     1,497          07/16/21          USD          26.00          USD          3,668          (14,970 ) 

Open Text Corp.

     669          07/16/21          USD          47.25          USD          3,399          (237,851 ) 

Public Service Enterprise Group, Inc.

     1,284          07/16/21          USD          62.25          USD          7,671          (13,777 ) 

Raymond James Financial, Inc.

     500          07/16/21          USD          135.00          USD          6,495          (26,250 ) 

Raytheon Technologies Corp.

     181          07/16/21          USD          90.00          USD          1,544          (2,987 ) 

Ross Stores, Inc.

     419          07/16/21          USD          130.00          USD          5,196          (18,855 ) 

SS&C Technologies Holdings, Inc.

     839          07/16/21          USD          75.00          USD          6,046          (60,827 ) 

Unilever PLC, ADR

     918          07/16/21          USD          61.21          USD          5,370          (8,637 ) 

Union Pacific Corp.

     117          07/16/21          USD          230.00          USD          2,573          (3,510 ) 

UnitedHealth Group, Inc.

     41          07/16/21          USD          410.00          USD          1,642          (15,068 ) 

Verizon Communications, Inc.

     641          07/16/21          USD          57.50          USD          3,592          (4,808 ) 

Visa, Inc., Class A

     163          07/16/21          USD          235.00          USD          3,811          (48,900 ) 

Wells Fargo & Co.

     1,173          07/16/21          USD          47.50          USD          5,313          (58,063 ) 

Zimmer Biomet Holdings, Inc.

     642          07/16/21          USD          170.00          USD          10,325          (22,470 ) 

American International Group, Inc.

     623          07/23/21          USD          52.00          USD          2,965          (7,476 ) 

 

 

S C H E D U L E   O F   I N V E S T M E N T S

  57


Schedule of Investments (unaudited) (continued)

June 30, 2021

  

BlackRock Enhanced Equity Dividend Trust (BDJ)

    

 

Exchange-Traded Options Written (continued)

 

Description    Number of
Contracts
       Expiration
Date
       Exercise Price        Notional
Amount (000)
       Value  
Call (continued)                                                   

Charles Schwab Corp.

     896          07/23/21        USD     72.50        USD     6,524        $     (201,152 ) 

Cigna Corp.

     22          07/23/21        USD     252.50        USD     522          (1,925 ) 

Cigna Corp.

     94          07/23/21        USD     245.00        USD     2,228          (18,565 ) 

Cisco Systems, Inc.

     717          07/23/21        USD     55.00        USD     3,800          (9,680 ) 

Citigroup, Inc.

     1,504          07/23/21        USD     80.00        USD     10,641          (24,064 ) 

Coca-Cola Co.

     46          07/23/21        USD     55.50        USD     249          (1,840 ) 

Comcast Corp., Class A

     850          07/23/21        USD     57.50        USD     4,847          (68,000 ) 

ConocoPhillips

     337          07/23/21        USD     60.40        USD     2,052          (80,585 ) 

Constellation Brands, Inc., Class A

     197          07/23/21        USD     247.50        USD     4,608          (18,223 ) 

CVS Health Corp.

     277          07/23/21        USD     87.00        USD     2,311          (10,803 ) 

Dollar General Corp.

     145          07/23/21        USD     212.50        USD     3,138          (84,100 ) 

DuPont de Nemours, Inc.

     238          07/23/21        USD     84.00        USD     1,842          (5,236 ) 

Enterprise Products Partners LP

     2,401          07/23/21        USD     25.50        USD     5,794          (20,409 ) 

Fox Corp., Class A

     1,187          07/23/21        USD     38.00        USD     4,407          (68,252 ) 

General Motors Co.

     274          07/23/21        USD     64.00        USD     1,621          (10,001 ) 

Humana, Inc.

     46          07/23/21        USD     447.50        USD     2,037          (31,740 ) 

Lowe’s Cos., Inc.

     161          07/23/21        USD     195.00        USD     3,123          (49,749 ) 

Marathon Petroleum Corp.

     336          07/23/21        USD     62.50        USD     2,030          (32,088 ) 

McKesson Corp.

     82          07/23/21        USD     200.00        USD     1,568          (14,555 ) 

MetLife, Inc.

     407          07/23/21        USD     64.50        USD     2,436          (6,512 ) 

Microsoft Corp.

     53          07/23/21        USD     270.00        USD     1,436          (33,522 ) 

Morgan Stanley

     505          07/23/21        USD     95.00        USD     4,630          (66,912 ) 

Raytheon Technologies Corp.

     145          07/23/21        USD     91.00        USD     1,237          (3,698 ) 

Raytheon Technologies Corp.

     91          07/23/21        USD     90.00        USD     776          (3,868 ) 

Ross Stores, Inc.

     573          07/23/21        USD     121.00        USD     7,105          (275,040 ) 

Verizon Communications, Inc.

     1,154          07/23/21        USD     58.00        USD     6,466          (17,310 ) 

Visa, Inc., Class A

     35          07/23/21        USD     235.00        USD     818          (15,838 ) 

Wells Fargo & Co.

     730          07/23/21        USD     47.00        USD     3,306          (58,035 ) 

CDK Global, Inc.

     231          07/28/21        USD     54.00        USD     1,148          (1,708 ) 

Altria Group, Inc.

     1,209          07/30/21        USD     49.00        USD     5,765          (85,234 ) 

American Express Co.

     165          07/30/21        USD     165.00        USD     2,726          (77,962 ) 

American International Group, Inc.

     1,241          07/30/21        USD     50.00        USD     5,907          (60,188 ) 

Anthem, Inc.

     156          07/30/21        USD     392.50        USD     5,956          (88,920 ) 

Bank of America Corp.

     512          07/30/21        USD     43.00        USD     2,111          (29,184 ) 

Bank of America Corp.

     1,197          07/30/21        USD     41.50        USD     4,935          (134,662 ) 

Cigna Corp.

     113          07/30/21        USD     237.50        USD     2,679          (61,020 ) 

Cisco Systems, Inc.

     639          07/30/21        USD     54.00        USD     3,387          (29,075 ) 

Citigroup, Inc.

     308          07/30/21        USD     72.50        USD     2,179          (46,354 ) 

Coca-Cola Co.

     1,036          07/30/21        USD     55.00        USD     5,606          (68,376 ) 

Cognizant Technology Solutions Corp., Class A

     431          07/30/21        USD     72.50        USD     2,985          (31,247 ) 

Comcast Corp., Class A

     368          07/30/21        USD     58.50        USD     2,098          (34,040 ) 

ConocoPhillips

     83          07/30/21        USD     62.00        USD     505          (14,857 ) 

CVS Health Corp.

     198          07/30/21        USD     86.50        USD     1,652          (13,761 ) 

DuPont de Nemours, Inc.

     208          07/30/21        USD     79.00        USD     1,610          (29,328 ) 

General Electric Co.

     3,513          07/30/21        USD     14.50        USD     4,728          (87,825 ) 

General Motors Co.

     1,408          07/30/21        USD     63.00        USD     8,331          (99,968 ) 

Humana, Inc.

     120          07/30/21        USD     435.00        USD     5,313          (217,800 ) 

JPMorgan Chase & Co.

     229          07/30/21        USD     155.00        USD     3,562          (89,882 ) 

Lowe’s Cos., Inc.

     44          07/30/21        USD     197.50        USD     853          (11,044 ) 

Medtronic PLC

     251          07/30/21        USD     127.00        USD     3,116          (32,755 ) 

MetLife, Inc.

     722          07/30/21        USD     62.00        USD     4,321          (63,536 ) 

Microsoft Corp.

     82          07/30/21        USD     265.00        USD     2,221          (82,410 ) 

PPG Industries, Inc.

     305          07/30/21        USD     175.00        USD     5,178          (79,300 ) 

Union Pacific Corp.

     76          07/30/21        USD     225.00        USD     1,671          (23,408 ) 

Verizon Communications, Inc.

     712          07/30/21        USD     58.00        USD     3,989          (14,596 ) 

Wells Fargo & Co.

     1,802          07/30/21        USD     46.50        USD     8,161          (207,230 ) 

American Express Co.

     100          08/06/21        USD     167.50        USD     1,652          (40,750 ) 

American International Group, Inc.

     945          08/06/21        USD     50.00        USD     4,498          (74,182 ) 

Bank of America Corp.

     445          08/06/21        USD     43.00        USD     1,835          (30,482 ) 

Capital One Financial Corp.

     227          08/06/21        USD     162.50        USD     3,511          (67,078 ) 

Cisco Systems, Inc.

     634          08/06/21        USD     53.50        USD     3,360          (51,037 ) 

Citigroup, Inc.

     490          08/06/21        USD     75.00        USD     3,467          (45,325 ) 

 

 

58  

2 0 2 1   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S


Schedule of Investments (unaudited) (continued)

June 30, 2021

  

BlackRock Enhanced Equity Dividend Trust (BDJ)

 

Exchange-Traded Options Written (continued)

 

Description    Number of
Contracts
       Expiration
Date
       Exercise Price        Notional
Amount (000)
       Value  
Call (continued)                                                   

Coca-Cola Co.

     516          08/06/21        USD     55.00        USD     2,792        $ (39,216 ) 

Cognizant Technology Solutions Corp., Class A

     600          08/06/21        USD     73.50        USD     4,156          (51,000 ) 

ConocoPhillips

     858          08/06/21        USD     63.00        USD     5,225          (148,005 ) 

Enterprise Products Partners LP

     1,135          08/06/21        USD     24.00        USD     2,739          (72,640 ) 

General Electric Co.

     1,803          08/06/21        USD     13.50        USD     2,427          (114,490 ) 

General Motors Co.

     215          08/06/21        USD     63.00        USD     1,272          (24,618 ) 

Medtronic PLC

     246          08/06/21        USD     124.00        USD     3,054          (70,233 ) 

Microsoft Corp.

     27          08/06/21        USD     277.50        USD     731          (11,205 ) 

Morgan Stanley

     637          08/06/21        USD     91.00        USD     5,841          (218,172 ) 

PPG Industries, Inc.

     240          08/06/21        USD     175.00        USD     4,074          (49,800 ) 

Raytheon Technologies Corp.

     91          08/06/21        USD     86.00        USD     776          (20,157 ) 

Sealed Air Corp.

     485          08/06/21        USD     60.01        USD     2,874          (80,114 ) 

Southern Co.

     503          08/06/21        USD     62.00        USD     3,044          (38,982 ) 

UnitedHealth Group, Inc.

     115          08/06/21        USD     405.00        USD     4,605          (103,212 ) 

Verizon Communications, Inc.

     1,198          08/06/21        USD     56.00        USD     6,712          (91,647 ) 

Edison International

     729          08/13/21        USD     59.00        USD     4,215          (45,477 ) 

Allstate Corp.

     267          08/20/21        USD     130.00        USD     3,483          (126,825 ) 

Ameren Corp.

     513          08/20/21        USD     85.00        USD     4,106          (26,933 ) 

American International Group, Inc.

     555          08/20/21        USD     52.50        USD     2,642          (26,085 ) 

Arthur J. Gallagher & Co.

     428          08/20/21        USD     147.25        USD     5,995          (44,128 ) 

Bank of America Corp.

     1,529          08/20/21        USD     43.00        USD     6,304          (136,845 ) 

CDK Global, Inc.

     477          08/20/21        USD     55.00        USD     2,370          (28,620 ) 

Cisco Systems, Inc.

     573          08/20/21        USD     55.00        USD     3,037          (49,278 ) 

Citigroup, Inc.

     853          08/20/21        USD     72.50        USD     6,035          (172,732 ) 

Comcast Corp., Class A

     283          08/20/21        USD     60.00        USD     1,614          (21,367 ) 

ConocoPhillips

     86          08/20/21        USD     65.00        USD     524          (12,642 ) 

ConocoPhillips

     114          08/20/21        USD     60.00        USD     694          (38,190 ) 

CVS Health Corp.

     99          08/20/21        USD     90.00        USD     826          (6,881 ) 

Enterprise Products Partners LP

     623          08/20/21        USD     25.00        USD     1,503          (23,363 ) 

Equitable Holdings, Inc.

     1,090          08/20/21        USD     31.84        USD     3,319          (75,408 ) 

Exelon Corp.

     340          08/20/21        USD     47.00        USD     1,507          (11,900 ) 

Exelon Corp.

     430          08/20/21        USD     47.25        USD     1,905          (16,657 ) 

Fidelity National Financial, Inc.

     1,047          08/20/21        USD     47.42        USD     4,550          (30,029 ) 

Fidelity National Information Services, Inc.

     207          08/20/21        USD     155.00        USD     2,933          (14,490 ) 

Fidelity National Information Services, Inc.

     181          08/20/21        USD     145.00        USD     2,564          (55,657 ) 

Fox Corp., Class A

     962          08/20/21        USD     41.00        USD     3,572          (127,465 ) 

General Electric Co.

     4,870          08/20/21        USD     14.00        USD     6,555          (253,240 ) 

General Motors Co.

     215          08/20/21        USD     62.50        USD     1,272          (34,722 ) 

Huntington Ingalls Industries, Inc.

     299          08/20/21        USD     220.00        USD     6,301          (140,530 ) 

Intercontinental Exchange, Inc.

     276          08/20/21        USD     115.00        USD     3,276          (155,940 ) 

Lear Corp.

     164          08/20/21        USD     185.00        USD     2,875          (73,800 ) 

Leidos Holdings, Inc.

     211          08/20/21        USD     110.00        USD     2,133          (17,935 ) 

Medtronic PLC

     99          08/20/21        USD     130.00        USD     1,229          (11,187 ) 

MetLife, Inc.

     722          08/20/21        USD     62.50        USD     4,321          (82,669 ) 

Microsoft Corp.

     82          08/20/21        USD     260.00        USD     2,221          (124,435 ) 

Newell Brands, Inc.

     1,516          08/20/21        USD     27.69        USD     4,164          (185,768 ) 

NiSource, Inc.

     955          08/20/21        USD     26.00        USD     2,340          (19,100 ) 

Open Text Corp.

     598          08/20/21        USD     50.75        USD     3,038          (65,893 ) 

Public Service Enterprise Group, Inc.

     978          08/20/21        USD     61.28        USD     5,843          (95,427 ) 

Raymond James Financial, Inc.

     548          08/20/21        USD     135.00        USD     7,119          (142,480 ) 

Raytheon Technologies Corp.

     238          08/20/21        USD     90.00        USD     2,030          (27,370 ) 

Sealed Air Corp.

     485          08/20/21        USD     60.00        USD     2,874          (97,000 ) 

SS&C Technologies Holdings, Inc.

     364          08/20/21        USD     75.00        USD     2,623          (59,150 ) 

Unilever PLC, ADR

     1,463          08/20/21        USD     62.50        USD     8,559          (36,575 ) 

Verizon Communications, Inc.

     294          08/20/21        USD     57.50        USD     1,647          (13,524 ) 

Visa, Inc., Class A

     141          08/20/21        USD     235.00        USD     3,297          (94,822 ) 

Fidelity National Information Services, Inc.

     108          09/17/21        USD     155.00        USD     1,530          (22,140 ) 
                          

 

 

 
                           $   (10,543,668 ) 
                          

 

 

 

 

 

S C H E D U L E   O F   I N V E S T M E N T S

  59


Schedule of Investments (unaudited) (continued)

June 30, 2021

  

BlackRock Enhanced Equity Dividend Trust (BDJ)

    

 

OTC Options Written

 

Description    Counterparty    Number of
Contracts
     Expiration
Date
    

Exercise Price

    

Notional
Amount (000)

     Value  

Call

                                                                 

AstraZeneca PLC

   UBS AG      132,900        07/07/21        GBP       82.62        GBP       11,540      $ (778,478 ) 

BAE Systems PLC

   Credit Suisse International      571,000        07/07/21        GBP       5.33        GBP       2,981        (15,644 ) 

Danone S.A.

   Barclays Bank PLC      28,700        07/07/21        EUR       59.62        EUR       1,704        (14,903 ) 

Equinor ASA

   Credit Suisse International      470,917        07/07/21        NOK       183.44        NOK       85,792        (121,719 ) 

Sanofi

   Barclays Bank PLC      94,300        07/07/21        EUR       88.17        EUR       8,332        (117,069 ) 

BP PLC

   Morgan Stanley & Co. International PLC      400,000        07/08/21        GBP       3.20        GBP       1,260        (25,675 ) 

First American Financial Corp.

   Credit Suisse International      28,700        07/12/21        USD       67.41        USD       1,789        (1,385 ) 

Alcon AG

   Credit Suisse International      56,200        07/14/21        CHF       63.97        CHF       3,641        (87,266 ) 

Bayer AG, Registered Shares

   Morgan Stanley & Co. International PLC      68,000        07/14/21        EUR       53.57        EUR       3,482        (16,630 ) 

BAE Systems PLC

   UBS AG      506,000        07/15/21        GBP       5.35        GBP       2,641        (26,422 ) 

Koninklijke Philips Electronics NV

   Morgan Stanley & Co. International PLC      208,600        07/15/21        EUR       46.61        EUR       8,717        (1,174 ) 

Alcon AG

   Credit Suisse International      37,200        07/20/21        CHF       64.99        CHF       2,410        (41,885 ) 

BAE Systems PLC

   Goldman Sachs International      506,000        07/20/21        GBP       5.34        GBP       2,641        (37,890 ) 

Bayer AG, Registered Shares

   Goldman Sachs International      76,000        07/20/21        EUR       52.88        EUR       3,892        (43,160 ) 

BP PLC

   Credit Suisse International      1,100,000        07/20/21        GBP       3.24        GBP       3,465        (81,244 ) 

Sanofi

   UBS AG      97,200        07/20/21        EUR       88.43        EUR       8,589        (152,489 ) 

AstraZeneca PLC

   Goldman Sachs International      2,500        07/27/21        GBP       81.73        GBP       217        (18,570 ) 

Samsung Electronics Co. Ltd., Registered Shares, GDR

   Credit Suisse International      4,200        07/27/21        USD       1,888.25        USD       7,491        (28,832 ) 

British American Tobacco PLC

   Goldman Sachs International      27,600        07/29/21        GBP       29.02        GBP       773        (4,906 ) 

Unilever PLC, ADR

   Credit Suisse International      138,500        07/29/21        USD       59.89        USD       8,102        (64,542 ) 

Leidos Holdings, Inc.

   Goldman Sachs International      24,200        08/02/21        USD       102.88        USD       2,447        (50,622 ) 

Zimmer Biomet Holdings, Inc.

   Barclays Bank PLC      22,300        08/03/21        USD       161.28        USD       3,586        (107,497 ) 

BP PLC

   Goldman Sachs International      1,633,400        08/04/21        GBP       3.31        GBP       5,145        (128,343 ) 

Sanofi

   Morgan Stanley & Co. International PLC      23,900        08/04/21        EUR       89.05        EUR       2,112        (45,241 ) 

Siemens AG, Registered Shares

   Goldman Sachs International      81,200        08/04/21        EUR       139.88        EUR       10,850        (145,583 ) 

Danone S.A.

   Goldman Sachs International      66,500        08/05/21        EUR       57.94        EUR       3,948        (169,394 ) 

Panasonic Corp.

   Morgan Stanley & Co. International PLC      237,000        08/05/21        JPY       1,334.09        JPY       304,664        (53,242 ) 

Leidos Holdings, Inc.

   Goldman Sachs International      24,200        08/06/21        USD       102.88        USD       2,447        (54,706 ) 

British American Tobacco PLC

   Credit Suisse International      220,400        08/10/21        GBP       27.98        GBP       6,171        (164,641 ) 

Komatsu Ltd.

   Goldman Sachs International      193,000        08/10/21        JPY       2,977.02        JPY       532,777        (43,279 ) 

Koninklijke Philips Electronics NV

   Morgan Stanley & Co. International PLC      97,900        08/10/21        EUR       42.66        EUR       4,091        (96,002 ) 

Panasonic Corp.

   Morgan Stanley & Co. International PLC      237,000        08/11/21        JPY       1,334.09        JPY       304,664        (60,291 ) 

BAE Systems PLC

   Credit Suisse International      571,600        08/12/21        GBP       5.31        GBP       2,984        (75,907 ) 

Bayer AG, Registered Shares

   Credit Suisse International      61,900        08/12/21        EUR       53.08        EUR       3,170        (74,646 ) 

Danone S.A.

   Credit Suisse International      28,700        08/12/21        EUR       60.33        EUR       1,704        (34,279 ) 

AstraZeneca PLC

   Goldman Sachs International      44,800        08/18/21        GBP       88.32        GBP       3,890        (100,295 ) 

Corteva, Inc.

   Barclays Bank PLC      129,000        08/20/21        USD       45.02        USD       5,721        (158,213 ) 
                     

 

 

 
                      $   (3,242,064 ) 
                     

 

 

 

Balances Reported in the Statements of Assets and Liabilities for Options Written

 

Description    Swap
Premiums
Paid
     Swap
Premiums
Received
     Unrealized
Appreciation
     Unrealized
Depreciation
     Value  

Options Written

   $ N/A      $ N/A      $   11,386,765      $   (2,559,790 )     $   (13,785,732 ) 

Derivative Financial Instruments Categorized by Risk Exposure

As of period end, the fair values of derivative financial instruments located in the Statements of Assets and Liabilities were as follows:

 

      Commodity
Contracts
     Credit
Contracts
     Equity
Contracts
     Foreign
Currency
Exchange
Contracts
     Interest
Rate
Contracts
     Other
Contracts
     Total  

Liabilities — Derivative Financial Instruments

                    

Options written

                    

Options written at value

   $ —      $ —      $   13,785,732      $ —      $ —      $ —      $   13,785,732  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

 

 

60  

2 0 2 1   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S


Schedule of Investments (unaudited) (continued)

June 30, 2021

  

BlackRock Enhanced Equity Dividend Trust (BDJ)

    

 

For the six months ended June 30, 2021, the effect of derivative financial instruments in the Statements of Operations was as follows:

 

      Commodity
Contracts
       Credit
Contracts
       Equity
Contracts
       Foreign
Currency
Exchange
Contracts
       Interest
Rate
Contracts
       Other
Contracts
       Total  

Net Realized Gain (Loss) from

                                

Options written

   $ —        $ —        $   (62,390,351 )       $ —        $ —        $ —        $   (62,390,351 ) 
  

 

 

      

 

 

      

 

 

      

 

 

      

 

 

      

 

 

      

 

 

 

Net Change in Unrealized Appreciation (Depreciation) on

                                

Options written

   $ —        $ —        $ 18,576,411        $ —        $ —        $ —        $ 18,576,411  
  

 

 

      

 

 

      

 

 

      

 

 

      

 

 

      

 

 

      

 

 

 

Average Quarterly Balances of Outstanding Derivative Financial Instruments

 

Options

        

Average value of option contracts written

   $ 22,047,465  

For more information about the Trust’s investment risks regarding derivative financial instruments, refer to the Notes to Financial Statements.

Derivative Financial Instruments — Offsetting as of Period End

The Trust’s derivative assets and liabilities (by type) were as follows:

 

      Assets        Liabilities  

Derivative Financial Instruments

       

Options

   $ —        $ 13,785,732  
  

 

 

      

 

 

 

Total derivative assets and liabilities in the Statements of Assets and Liabilities

     —          13,785,732  
  

 

 

      

 

 

 

Derivatives not subject to a Master Netting Agreement or similar agreement (“MNA”)

     —          (10,543,668 ) 
  

 

 

      

 

 

 

Total derivative assets and liabilities subject to an MNA

   $ —        $ 3,242,064  
  

 

 

      

 

 

 

The following table presents the Trust’s derivative liabilities by counterparty net of amounts available for offset under an MNA and net of the related collateral pledged by the Trust:

 

Counterparty     



Derivative
Liabilities
Subject to
an MNA by
Counterparty
 
 

 
 
      

Derivatives
Available
for Offset
 
 
 
      

Non-Cash
Collateral
Pledged
 
 
(a)  
    

Cash
Collateral
Pledged
 
 
 
      

Net Amount
of Derivative
Liabilities
 
 
 

Barclays Bank PLC

   $ 397,682        $ —        $ (397,682 )     $ —        $ —  

Credit Suisse International

     791,990          —          (791,990 )       —          —  

Goldman Sachs International

     796,748          —          (796,748 )       —          —  

Morgan Stanley & Co. International PLC

     298,255          —          (298,255 )       —          —  

UBS AG

     957,389          —          (957,389 )       —          —  
  

 

 

      

 

 

      

 

 

    

 

 

      

 

 

 
   $ 3,242,064        $ —        $   (3,242,064 )     $ —        $ —  
  

 

 

      

 

 

      

 

 

    

 

 

      

 

 

 

 

  (a) 

Excess of collateral pledged to the individual counterparty is not shown for financial reporting purposes.

 

Fair Value Hierarchy as of Period End

Various inputs are used in determining the fair value of financial instruments. For a description of the input levels and information about the Trust’s policy regarding valuation of financial instruments, refer to the Notes to Financial Statements.

The following table summarizes the Trust’s financial instruments categorized in the fair value hierarchy. The breakdown of the Trust’s financial instruments into major categories is disclosed in the Schedule of Investments above.

 

      Level 1        Level 2        Level 3        Total  

Assets

                 

Investments

                 

Long-Term Investments

                 

Common Stocks

                 

Aerospace & Defense

   $     22,950,836        $     38,922,480        $                 —        $ 61,873,316  

Auto Components

     12,975,453          —          —          12,975,453  

Automobiles

     42,234,067          —          —          42,234,067  

 

 

S C H E D U L E   O F  I N V E S T M E N T S

  61


Schedule of Investments (unaudited) (continued)

June 30, 2021

  

BlackRock Enhanced Equity Dividend Trust (BDJ)

    

 

Fair Value Hierarchy as of Period End (continued)

 

      Level 1        Level 2        Level 3        Total  

Common Stocks (continued)

                 

Banks

   $ 223,569,304        $ —        $                 —        $ 223,569,304  

Beverages

     38,579,200          —          —          38,579,200  

Capital Markets

     116,557,933          —          —          116,557,933  

Chemicals

     29,364,501          —          —          29,364,501  

Communications Equipment

     62,510,809          —          —          62,510,809  

Consumer Finance

     28,753,245          —          —          28,753,245  

Containers & Packaging

     10,139,689          —          —          10,139,689  

Diversified Financial Services

     20,010,370          —          —          20,010,370  

Diversified Telecommunication Services

     46,569,110          —          —          46,569,110  

Electric Utilities

     35,476,553          —          —          35,476,553  

Food Products

     —          21,788,350          —          21,788,350  

Health Care Equipment & Supplies

     60,881,247          39,451,353          —          100,332,600  

Health Care Providers & Services

     144,007,464          —          —          144,007,464  

Household Durables

     12,424,654          9,941,631          —          22,366,285  

Industrial Conglomerates

     33,603,105          23,413,345          —          57,016,450  

Insurance

     136,385,281          —          —          136,385,281  

IT Services

     68,624,976          —          —          68,624,976  

Machinery

     —          8,697,996          —          8,697,996  

Media

     68,131,706          —          —          68,131,706  

Multi-line Retail

     16,536,740          —          —          16,536,740  

Multi-Utilities

     51,910,480          —          —          51,910,480  

Oil, Gas & Consumable Fuels

     89,533,104          45,487,173          —          135,020,277  

Personal Products

     40,058,226          —          —          40,058,226  

Pharmaceuticals

     —          111,380,423          —          111,380,423  

Professional Services

     10,811,230          —          —          10,811,230  

Road & Rail

     17,422,195          —          —          17,422,195  

Software

     66,912,109          —          —          66,912,109  

Specialty Retail

     47,070,939          —          —          47,070,939  

Technology Hardware, Storage & Peripherals

     —          13,379,291          —          13,379,291  

Tobacco

     10,698,581          17,510,518          —          28,209,099  

Wireless Telecommunication Services

     3,542,098          —          —          3,542,098  

Preferred Securities

                 

Preferred Stocks

     —          6,293,006          —          6,293,006  

Short-Term Securities

                 

Money Market Funds

     48,566,704          —          —          48,566,704  
  

 

 

      

 

 

      

 

 

      

 

 

 
   $   1,616,811,909        $   336,265,566        $ —        $   1,953,077,475  
  

 

 

      

 

 

      

 

 

      

 

 

 

Derivative Financial Instruments(a)

                 

Liabilities

                 

Equity Contracts

   $ (9,294,278 )       $ (4,491,454 )       $ —        $ (13,785,732 ) 
  

 

 

      

 

 

      

 

 

      

 

 

 

 

  (a) 

Derivative financial instruments are options written. Options written are shown at value.

 

See notes to financial statements.

 

 

62  

2 0 2 1   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S


Schedule of Investments (unaudited)

June 30, 2021

  

BlackRock Enhanced Global Dividend Trust (BOE)

(Percentages shown are based on Net Assets)

 

Security   Shares     Value  

Common Stocks

   
Australia — 0.8%            

Ansell Ltd.

    204,149     $ 6,659,424  

Ensogo Ltd.(a)(b)

    418,198       3  
   

 

 

 
      6,659,427  
Canada — 3.0%            

TELUS Corp.

    1,123,115       25,187,639  
   

 

 

 
China — 2.7%            

China Feihe Ltd.(c)

    6,927,000       14,934,767  

Enn Energy Holdings Ltd.

    440,200       8,366,322  
   

 

 

 
      23,301,089  
Denmark — 1.9%            

Novo Nordisk A/S, Class B

    194,490       16,280,487  
   

 

 

 
France — 9.7%            

EssilorLuxottica SA

    98,185       18,138,031  

LVMH Moet Hennessy Louis Vuitton SE

    22,601       17,779,230  

Sanofi

    310,447       32,616,362  

Schneider Electric SE

    86,866       13,693,951  
   

 

 

 
      82,227,574  
India — 0.1%            

Jasper Infotech Private Ltd., Series I, (Acquired 05/07/14, Cost: $2,637,143)(a)(d)

    3,540       596,065  
   

 

 

 
Ireland — 1.0%            

Medtronic PLC(e)

    69,323       8,605,064  
   

 

 

 
Mexico — 1.0%            

Wal-Mart de Mexico SAB de CV

    2,711,755       8,851,906  
   

 

 

 
Netherlands — 1.2%            

Koninklijke Philips NV

    212,109       10,527,852  
   

 

 

 
Singapore — 1.1%            

DBS Group Holdings Ltd.

    404,868       9,007,220  
   

 

 

 
Spain — 1.6%            

Amadeus IT Group SA(b)

    187,496       13,217,832  
   

 

 

 
Taiwan — 3.3%            

Taiwan Semiconductor Manufacturing Co. Ltd.

    1,303,000       28,064,051  
   

 

 

 
United Kingdom — 20.3%            

AstraZeneca PLC

    185,779       22,320,256  

BAE Systems PLC

    1,181,873       8,540,235  

Diageo PLC

    436,211       20,906,932  

Ferguson PLC

    154,647       21,515,598  

Prudential PLC

    988,163       18,800,560  

Reckitt Benckiser Group PLC

    339,584       30,002,298  

RELX PLC

    1,094,255       29,183,055  

Unilever PLC

    365,139       21,336,365  
   

 

 

 
        172,605,299  
United States(e) — 52.0%            

AbbVie, Inc.

    199,709       22,495,222  

American Tower Corp.

    63,487       17,150,378  

Assurant, Inc.

    114,506       17,883,547  

Bristol-Myers Squibb Co.

    361,261       24,139,460  
Security   Shares     Value  
United States (continued)            

Citizens Financial Group, Inc.

    433,858     $ 19,901,066  

Comcast Corp., Class A

    310,461       17,702,486  

Estee Lauder Cos., Inc., Class A

    54,454       17,320,728  

Fidelity National Information Services, Inc.

    175,153       24,813,925  

Hasbro, Inc.

    169,569       16,027,662  

Intercontinental Exchange, Inc.

    228,372       27,107,756  

Intuit, Inc.

    35,568       17,434,367  

Lockheed Martin Corp.

    35,426       13,403,427  

M&T Bank Corp.

    111,794       16,244,786  

Microsoft Corp.

    121,800       32,995,620  

Otis Worldwide Corp.

    175,604       14,359,139  

Paychex, Inc.

    68,032       7,299,834  

Philip Morris International, Inc.

    139,042       13,780,453  

Progressive Corp.

    121,762       11,958,246  

Raytheon Technologies Corp.

    159,777       13,630,576  

Synchrony Financial

    282,180       13,691,374  

TE Connectivity Ltd.

    81,313       10,994,331  

Texas Instruments, Inc.

    123,300       23,710,590  

UnitedHealth Group, Inc.

    62,598       25,066,743  

Visa, Inc., Class A

    99,254       23,207,570  
   

 

 

 
      442,319,286  
   

 

 

 

Total Long-Term Investments — 99.7%
(Cost: $700,161,001)

 

    847,450,791  
   

 

 

 

Short-Term Securities

 

Money Market Funds — 0.6%  

BlackRock Liquidity Funds, T-Fund, Institutional Class, 0.01%(f)(g)

    5,226,715       5,226,715  
   

 

 

 

Total Short-Term Securities — 0.6%
(Cost: $5,226,715)

 

    5,226,715  
   

 

 

 

Total Investments Before Options Written — 100.3%
(Cost: $705,387,716)

 

    852,677,506  
   

 

 

 

Options Written — (1.0)%

   

(Premiums Received: $(7,350,560))

 

    (8,541,611 ) 
   

 

 

 

Total Investments, Net of Options Written — 99.3% (Cost: $698,037,156)

 

    844,135,895  

Other Assets Less Liabilities — 0.7%

 

    5,833,652  
   

 

 

 

Net Assets — 100.0%

 

  $   849,969,547  
   

 

 

 

 

(a) 

Security is valued using significant unobservable inputs and is classified as Level 3 in the fair value hierarchy.

(b) 

Non-income producing security.

(c) 

Security exempt from registration pursuant to Rule 144A under the Securities Act of 1933, as amended. These securities may be resold in transactions exempt from registration to qualified institutional investors.

(d) 

Restricted security as to resale, excluding 144A securities. The Trust held restricted securities with a current value of $596,065, representing 0.1% of its net assets as of period end, and an original cost of $2,637,143.

(e) 

All or a portion of the security has been pledged as collateral in connection with outstanding OTC derivatives.

(f) 

Affiliate of the Trust.

(g) 

Annualized 7-day yield as of period end.

 

 

 

S C H E D U L E   O F   I N V E S T M E N T S

  63


Schedule of Investments (unaudited) (continued)

June 30, 2021

  

BlackRock Enhanced Global Dividend Trust (BOE)

    

 

Affiliates

Investments in issuers considered to be affiliate(s) of the Trust during the six-months ended June 30, 2021 for purposes of
Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:    

 

Affiliated Issuer    Value at
12/31/20
    Purchases
at Cost
    Proceeds
from Sales
    Net
Realized
Gain (Loss)
    Change in
Unrealized
Appreciation
(Depreciation)
    Value at
06/30/21
    Shares
Held at
06/30/21
    Income     Capital Gain
Distributions
from
Underlying
Funds
 

BlackRock Liquidity Funds, T-Fund, Institutional Class

   $ —     $ 5,226,715 (a)    $ —     $ —     $ —     $ 5,226,715       5,226,715     $ 604     $ —  
        

 

 

   

 

 

   

 

 

     

 

 

   

 

 

 

 

  (a) 

Represents net amount purchased (sold).

 

Derivative Financial Instruments Outstanding as of Period End

Exchange-Traded Options Written

 

Description    Number of
Contracts
       Expiration
Date
       Exercise Price       

Notional

Amount (000)

       Value  

Call

                                

Comcast Corp., Class A

     171          07/02/21          USD          57.00          USD          975        $ (6,840 ) 

Comcast Corp., Class A

     516          07/09/21          USD          58.50          USD          2,942          (13,674 ) 

Hasbro, Inc.

     187          07/09/21          USD          98.00          USD          1,768          (9,350 ) 

Microsoft Corp.

     172          07/09/21          USD          252.50          USD          4,659            (319,920 ) 

Synchrony Financial

     655          07/09/21          USD          51.00          USD          3,178          (31,112 ) 

Texas Instruments, Inc.

     36          07/09/21          USD          190.00          USD          692          (13,590 ) 

UnitedHealth Group, Inc.

     85          07/09/21          USD          405.00          USD          3,404          (20,825 ) 

Visa, Inc., Class A

     65          07/09/21          USD          235.00          USD          1,520          (12,675 ) 

Assurant, Inc.

     274          07/16/21          USD          160.00          USD          4,279          (29,455 ) 

Bristol-Myers Squibb Co.

     236          07/16/21          USD          67.50          USD          1,577          (10,266 ) 

Citizens Financial Group, Inc.

     134          07/16/21          USD          52.50          USD          615          (1,005 ) 

Citizens Financial Group, Inc.

     424          07/16/21          USD          47.50          USD          1,945          (20,140 ) 

Comcast Corp., Class A

     133          07/16/21          USD          57.50          USD          758          (7,714 ) 

Estee Lauder Cos., Inc., Class A

     123          07/16/21          USD          300.00          USD          3,912          (233,085 ) 

Fidelity National Information Services, Inc.

     250          07/16/21          USD          155.00          USD          3,542          (1,250 ) 

Hasbro, Inc.

     166          07/16/21          USD          97.50          USD          1,569          (10,375 ) 

Intercontinental Exchange, Inc.

     637          07/16/21          USD          115.00          USD          7,561          (264,355 ) 

Intuit, Inc.

     6          07/16/21          USD          440.00          USD          294          (30,540 ) 

Lockheed Martin Corp.

     86          07/16/21          USD          395.00          USD          3,254          (5,375 ) 

M&T Bank Corp.

     140          07/16/21          USD          170.00          USD          2,034          (21,000 ) 

Medtronic PLC

     70          07/16/21          USD          130.00          USD          869          (1,505 ) 

Microsoft Corp.

     200          07/16/21          USD          255.00          USD          5,418          (325,000 ) 

Paychex, Inc.

     374          07/16/21          USD          105.00          USD          4,013          (112,200 ) 

Progressive Corp.

     290          07/16/21          USD          100.00          USD          2,848          (31,175 ) 

Raytheon Technologies Corp.

     277          07/16/21          USD          90.00          USD          2,363          (4,571 ) 

TE Connectivity Ltd.

     85          07/16/21          USD          145.00          USD          1,149          (1,700 ) 

TE Connectivity Ltd.

     140          07/16/21          USD          140.00          USD          1,893          (9,450 ) 

Texas Instruments, Inc.

     332          07/16/21          USD          190.00          USD          6,384          (151,890 ) 

UnitedHealth Group, Inc.

     24          07/16/21          USD          410.00          USD          961          (8,820 ) 

Visa, Inc., Class A

     32          07/16/21          USD          235.00          USD          748          (9,600 ) 

AbbVie, Inc.

     266          07/23/21          USD          118.00          USD          2,996          (7,714 ) 

American Tower Corp.

     183          07/23/21          USD          270.00          USD          4,944          (91,500 ) 

Bristol-Myers Squibb Co.

     309          07/23/21          USD          67.00          USD          2,065          (24,566 ) 

Comcast Corp., Class A

     170          07/23/21          USD          57.50          USD          969          (13,600 ) 

Hasbro, Inc.

     187          07/23/21          USD          98.50          USD          1,768          (17,765 ) 

Microsoft Corp.

     55          07/23/21          USD          270.00          USD          1,490          (34,787 ) 

Raytheon Technologies Corp.

     110          07/23/21          USD          90.00          USD          938          (4,675 ) 

Synchrony Financial

     614          07/23/21          USD          50.50          USD          2,979          (53,725 ) 

Visa, Inc., Class A

     136          07/23/21          USD          235.00          USD          3,180          (61,540 ) 

American Tower Corp.

     183          07/30/21          USD          270.00          USD          4,944          (108,885 ) 

Bristol-Myers Squibb Co.

     259          07/30/21          USD          67.00          USD          1,731          (32,245 ) 

Comcast Corp., Class A

     66          07/30/21          USD          58.50          USD          376          (6,105 ) 

Intuit, Inc.

     200          07/30/21          USD          477.50          USD          9,803          (399,000 ) 

Medtronic PLC

     142          07/30/21          USD          127.00          USD          1,763          (18,531 ) 

Microsoft Corp.

     43          07/30/21          USD          265.00          USD          1,165          (43,215 ) 

 

 

64  

2 0 2 1   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S


Schedule of Investments (unaudited) (continued)

June 30, 2021

  

BlackRock Enhanced Global Dividend Trust (BOE)

    

 

Exchange-Traded Options Written (continued)

 

Description    Number of
Contracts
       Expiration
Date
       Exercise Price       

Notional

Amount (000)

       Value  

Call (continued)

                                

Philip Morris International, Inc.

     312          07/30/21          USD          101.00          USD          3,092        $ (46,800 ) 

Texas Instruments, Inc.

     165          07/30/21          USD          195.00          USD          3,173          (70,950 ) 

UnitedHealth Group, Inc.

     110          07/30/21          USD          412.50          USD          4,405          (53,350 ) 

Visa, Inc., Class A

     81          07/30/21          USD          240.00          USD          1,894          (26,325 ) 

Assurant, Inc.

     355          08/02/21          USD          160.01          USD          5,544          (72,071 ) 

AbbVie, Inc.

     432          08/06/21          USD          114.00          USD          4,866          (81,864 ) 

Bristol-Myers Squibb Co.

     275          08/06/21          USD          67.00          USD          1,838          (38,912 ) 

Bristol-Myers Squibb Co.

     154          08/06/21          USD          68.00          USD          1,029          (15,939 ) 

Lockheed Martin Corp.

     73          08/06/21          USD          390.00          USD          2,762          (29,565 ) 

Microsoft Corp.

     35          08/06/21          USD          277.50          USD          948          (14,525 ) 

Raytheon Technologies Corp.

     111          08/06/21          USD          86.00          USD          947          (24,587 ) 

UnitedHealth Group, Inc.

     62          08/06/21          USD          405.00          USD          2,483          (55,645 ) 

Estee Lauder Cos., Inc., Class A

     122          08/13/21          USD          310.00          USD          3,881          (165,912 ) 

Bristol-Myers Squibb Co.

     391          08/20/21          USD          67.50          USD          2,613          (55,913 ) 

Citizens Financial Group, Inc.

     424          08/20/21          USD          50.00          USD          1,945          (26,500 ) 

Comcast Corp., Class A

     341          08/20/21          USD          60.00          USD          1,944          (25,746 ) 

Intercontinental Exchange, Inc.

     73          08/20/21          USD          120.00          USD          867          (20,075 ) 

Intercontinental Exchange, Inc.

     317          08/20/21          USD          115.00          USD          3,763          (179,105 ) 

M&T Bank Corp.

     363          08/20/21          USD          160.00          USD          5,275          (88,935 ) 

Medtronic PLC

     169          08/20/21          USD          130.00          USD          2,098          (19,097 ) 

Microsoft Corp.

     43          08/20/21          USD          260.00          USD          1,165          (65,252 ) 

Otis Worldwide Corp.

     617          08/20/21          USD          85.00          USD          5,045          (92,550 ) 

Philip Morris International, Inc.

     312          08/20/21          USD          100.00          USD          3,092          (76,596 ) 

Progressive Corp.

     259          08/20/21          USD          97.50          USD          2,544          (90,650 ) 

Raytheon Technologies Corp.

     220          08/20/21          USD          90.00          USD          1,877          (25,300 ) 

TE Connectivity Ltd.

     140          08/20/21          USD          140.00          USD          1,893          (38,150 ) 

TELUS Corp.

     2,323          08/20/21          CAD          28.00          CAD          6,458          (74,023 ) 

Texas Instruments, Inc.

     145          08/20/21          USD          200.00          USD          2,788          (50,387 ) 

Visa, Inc., Class A

     33          08/20/21          USD          235.00          USD          772          (22,193 ) 

Fidelity National Information Services, Inc.

     377          09/17/21          USD          155.00          USD          5,341          (77,285 ) 

Otis Worldwide Corp.

     348          09/17/21          USD          85.00          USD          2,846          (68,730 ) 
                                

 

 

 
                                 $   (4,429,242 ) 
                                

 

 

 

OTC Options Written

 

Description    Counterparty      Number of
Contracts
       Expiration
Date
       Exercise Price       

Notional

Amount (000)

       Value  

Call

                                     

AstraZeneca PLC

   UBS AG        10,600          07/07/21          GBP          82.62          GBP          920        $ (62,091 ) 

LVMH Moet Hennessy Louis Vuitton SE

   Barclays Bank PLC        10,200          07/07/21          EUR          661.37          EUR          6,745          (99,326 ) 

TELUS Corp.

   Credit Suisse International        78,400          07/07/21          CAD          26.52          CAD          2,180          (81,178 ) 

Reckitt Benckiser Group PLC

   Morgan Stanley & Co. International PLC        51,000          07/08/21          GBP          65.56          GBP          3,262          (8,734 ) 

Relx PLC

   UBS AG        96,700          07/08/21          EUR          22.02          EUR          2,174          (62,421 ) 

Schneider Electric SE

   Morgan Stanley & Co. International PLC        32,300          07/08/21          EUR          131.89          EUR          4,286          (83,041 ) 

Citizens Financial Group, Inc.

   JPMorgan Chase Bank N.A.        97,000          07/12/21          USD          47.50          USD          4,449          (41,942 ) 

TELUS Corp.

   Goldman Sachs International        97,500          07/13/21          CAD          26.00          CAD          2,711          (141,898 ) 

China Feihe Ltd.

   JPMorgan Chase Bank N.A.        640,000          07/14/21          HKD          22.46          HKD          10,726          (2 ) 

Diageo PLC

   Credit Suisse International        95,000          07/14/21          GBP          35.05          GBP          3,288          (42,931 ) 

Enn Energy Holdings Ltd.

   JPMorgan Chase Bank N.A.        121,000          07/14/21          HKD          146.22          HKD          17,884          (65,901 ) 

Novo Nordisk A/S, Class B

   UBS AG        26,200          07/14/21          DKK          496.74          DKK          13,765          (124,702 ) 

Reckitt Benckiser Group PLC

   Barclays Bank PLC        43,700          07/14/21          GBP          65.21          GBP          2,795          (19,457 ) 

Relx PLC

   Barclays Bank PLC        100,000          07/14/21          EUR          21.72          EUR          2,248          (98,571 ) 

Unilever PLC

   Credit Suisse International        53,700          07/14/21          GBP          43.54          GBP          2,272          (4,972 ) 

Wal-Mart de Mexico SAB de CV

   Citibank N.A.        610,000          07/14/21          MXN          65.19          MXN          39,693          (57,282 ) 

Ansell Ltd.

   UBS AG        16,000          07/15/21          AUD          40.95          AUD          696          (32,347 ) 

BAE Systems PLC

   UBS AG        163,400          07/15/21          GBP          5.35          GBP          853          (8,532 ) 

DBS Group Holdings Ltd.

   UBS AG        48,000          07/15/21          SGD          30.07          SGD          1,431          (11,107 ) 

Ferguson PLC

   Morgan Stanley & Co. International PLC        29,700          07/15/21          GBP          98.05          GBP          2,985          (127,187 ) 

Koninklijke Philips Electronics NV

   Morgan Stanley & Co. International PLC        30,300          07/15/21          EUR          46.62          EUR          1,266          (170 ) 

Amadeus IT Group SA

   UBS AG        9,849          07/20/21          EUR          65.57          EUR          584          (2,340 ) 

Ansell Ltd.

   JPMorgan Chase Bank N.A.        19,200          07/20/21          AUD          39.17          AUD          835          (62,845 ) 

 

 

S C H E D U L E   O F  I N V E S T M E N T S

  65


Schedule of Investments (unaudited) (continued)

June 30, 2021

  

BlackRock Enhanced Global Dividend Trust (BOE)

    

 

OTC Options Written (continued)

 

Description    Counterparty      Number of
Contracts
       Expiration
Date
       Exercise Price       

Notional

Amount (000)

       Value  

Call (continued)

                                     

BAE Systems PLC

   Goldman Sachs International        163,400          07/20/21          GBP          5.34          GBP          853        $ (12,236 ) 

China Feihe Ltd.

   Goldman Sachs International        640,000          07/20/21          HKD          20.29          HKD          10,726          (1,160 ) 

Enn Energy Holdings Ltd.

   JPMorgan Chase Bank N.A.        121,000          07/20/21          HKD          146.98          HKD          17,884          (69,684 ) 

EssilorLuxottica SA

   Credit Suisse International        22,100          07/20/21          EUR          148.51          EUR          3,440          (219,690 ) 

Novo Nordisk A/S, Class B

   Credit Suisse International        61,300          07/20/21          DKK          496.00          DKK          32,207          (304,673 ) 

Sanofi

   UBS AG        62,200          07/20/21          EUR          88.44          EUR          5,496          (97,580 ) 

Schneider Electric SE

   UBS AG        6,200          07/20/21          EUR          133.32          EUR          823          (17,428 ) 

Unilever PLC

   Credit Suisse International        44,400          07/20/21          GBP          43.15          GBP          1,878          (11,951 ) 

Ansell Ltd.

   UBS AG        40,600          07/27/21          AUD          41.16          AUD          1,767          (81,509 ) 

AstraZeneca PLC

   Goldman Sachs International        73,100          07/27/21          GBP          81.73          GBP          6,347          (542,995 ) 

DBS Group Holdings Ltd.

   Goldman Sachs International        134,200          07/27/21          SGD          30.63          SGD          4,001          (21,750 ) 

Relx PLC

   UBS AG        79,700          07/27/21          EUR          22.19          EUR          1,792          (53,919 ) 

TELUS Corp.

   Goldman Sachs International        97,200          07/27/21          CAD          27.10          CAD          2,702          (67,815 ) 

Wal-Mart de Mexico SAB de CV

   Citibank N.A.        610,000          07/27/21          MXN          65.19          MXN          39,693          (80,984 ) 

Diageo PLC

   Goldman Sachs International        45,500          07/29/21          GBP          35.83          GBP          1,575          (18,824 ) 

Koninklijke Philips Electronics NV

   Credit Suisse International        71,000          07/29/21          EUR          45.91          EUR          2,967          (7,358 ) 

Amadeus IT Group SA

   JPMorgan Chase Bank N.A.        55,800          08/04/21          EUR          65.42          EUR          3,310          (24,737 ) 

Ansell Ltd.

   Morgan Stanley & Co. International PLC        22,100          08/04/21          AUD          40.85          AUD          962          (50,208 ) 

EssilorLuxottica SA

   JPMorgan Chase Bank N.A.        22,000          08/04/21          EUR          151.52          EUR          3,424          (165,138 ) 

Prudential PLC

   Morgan Stanley & Co. International PLC        91,800          08/04/21          GBP          14.67          GBP          1,261          (13,595 ) 

Prudential PLC

   Morgan Stanley & Co. International PLC        60,400          08/04/21          GBP          14.70          GBP          830          (5,573 ) 

Reckitt Benckiser Group PLC

   JPMorgan Chase Bank N.A.        58,100          08/04/21          GBP          65.80          GBP          3,717          (51,291 ) 

Relx PLC

   JPMorgan Chase Bank N.A.        91,000          08/04/21          EUR          22.97          EUR          2,046          (24,138 ) 

Sanofi

   Morgan Stanley & Co. International PLC        46,500          08/04/21          EUR          89.05          EUR          4,109          (88,021 ) 

China Feihe Ltd.

   Goldman Sachs International        1,142,000          08/05/21          HKD          18.13          HKD          19,140          (50,567 ) 

Hasbro, Inc.

   Credit Suisse Securities (USA) LLC        22,300          08/06/21          USD          94.50          USD          2,108          (78,050 ) 

Unilever PLC

   Credit Suisse International        29,700          08/10/21          GBP          42.29          GBP          1,256          (31,958 ) 

Ansell Ltd.

   JPMorgan Chase Bank N.A.        14,300          08/11/21          AUD          42.92          AUD          622          (18,453 ) 

Diageo PLC

   Goldman Sachs International        74,400          08/11/21          GBP          35.41          GBP          2,575          (63,655 ) 

Prudential PLC

   Morgan Stanley & Co. International PLC        91,800          08/11/21          GBP          14.67          GBP          1,261          (17,090 ) 

Relx PLC

   Morgan Stanley & Co. International PLC        91,000          08/11/21          EUR          22.97          EUR          2,046          (28,408 ) 

BAE Systems PLC

   Credit Suisse International        205,100          08/12/21          GBP          5.31          GBP          1,071          (27,237 ) 

China Feihe Ltd.

   UBS AG        695,000          08/12/21          HKD          18.39          HKD          11,648          (29,475 ) 

Ferguson PLC

   UBS AG        24,500          08/12/21          GBP          102.92          GBP          2,462          (37,679 ) 

Novo Nordisk A/S, Class B

   Morgan Stanley & Co. International PLC        19,400          08/12/21          DKK          531.21          DKK          10,193          (34,402 ) 

Taiwan Semiconductor Manufacturing Co. Ltd.

   UBS AG        456,000          08/12/21          USD          606.90          USD          271,320          (303,336 ) 

AstraZeneca PLC

   Goldman Sachs International        18,400          08/18/21          GBP          88.32          GBP          1,598          (41,193 ) 

Ferguson PLC

   Morgan Stanley & Co. International PLC        15,300          08/18/21          GBP          102.18          GBP          1,538          (39,261 ) 

Prudential PLC

   UBS AG        101,900          08/18/21          GBP          14.59          GBP          1,400          (27,936 ) 

Relx PLC

   Morgan Stanley & Co. International PLC        34,000          08/18/21          EUR          22.93          EUR          764          (12,435 ) 
                                     

 

 

 
                                      $   (4,112,369 ) 
                                     

 

 

 

Balances Reported in the Statements of Assets and Liabilities for Options Written

 

Description    Swap
Premiums
Paid
       Swap
Premiums
Received
       Unrealized
Appreciation
       Unrealized
Depreciation
       Value  

Options Written

   $ N/A        $ N/A        $ 1,969,521        $ (3,160,572 )       $   (8,541,611)  

 

 

66  

2 0 2 1   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S


Schedule of Investments (unaudited) (continued)

June 30, 2021

  

BlackRock Enhanced Global Dividend Trust (BOE)

    

 

Derivative Financial Instruments Categorized by Risk Exposure    

As of period end, the fair values of derivative financial instruments located in the Statements of Assets and Liabilities were as follows:

 

     Commodity
Contracts
    Credit
Contracts
    Equity
Contracts
    Foreign
Currency
Exchange
Contracts
    Interest
Rate
Contracts
    Other
Contracts
    Total  

Liabilities — Derivative Financial Instruments

             

Options written

             

Options written at value

  $ —     $ —     $   8,541,611     $ —     $ —     $ —     $   8,541,611  
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

For the six months ended June 30, 2021, the effect of derivative financial instruments in the Statements of Operations was as follows:

 

     Commodity
Contracts
    Credit
Contracts
    Equity
Contracts
    Foreign
Currency
Exchange
Contracts
    Interest
Rate
Contracts
    Other
Contracts
    Total  

Net Realized Gain (Loss) from

             

Options written

  $ —     $ —     $ (7,271,190 )    $ —     $ —     $ —     $ (7,271,190 ) 
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net Change in Unrealized Appreciation (Depreciation) on

             

Options written

  $ —     $ —     $   (1,024,212 )    $ —     $ —     $ —     $   (1,024,212 ) 
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Average Quarterly Balances of Outstanding Derivative Financial Instruments

 

Options

        

Average value of option contracts written

   $ 8,838,128  

For more information about the Trust’s investment risks regarding derivative financial instruments, refer to the Notes to Financial Statements.

Derivative Financial Instruments — Offsetting as of Period End

The Trust’s derivative assets and liabilities (by type) were as follows:

 

      Assets        Liabilities  

Derivative Financial Instruments

       

Options

   $ —        $ 8,541,611  
  

 

 

      

 

 

 

Total derivative assets and liabilities in the Statements of Assets and Liabilities

     —          8,541,611  
  

 

 

      

 

 

 

Derivatives not subject to a Master Netting Agreement or similar agreement (“MNA”)

     —          (4,429,242 ) 
  

 

 

      

 

 

 

Total derivative assets and liabilities subject to an MNA

   $ —        $ 4,112,369  
  

 

 

      

 

 

 

The following table presents the Trust’s derivative liabilities by counterparty net of amounts available for offset under an MNA and net of the related collateral pledged by the Trust:

 

Counterparty     



Derivative
Liabilities
Subject to
an MNA by
Counterparty
 
 

 
 
      

Derivatives
Available
for Offset
 
 
 
      

Non-Cash
Collateral
Pledged
 
 
(a)  
    

Cash
Collateral
Pledged
 
 
(a)  
    

Net Amount
of Derivative
Liabilities
 
 
(b) 

Barclays Bank PLC

   $ 217,354        $ —        $ (217,354 )     $ —      $ —  

Citibank N.A.

     138,266          —          —          (138,266 )       —  

Credit Suisse International

     731,948          —          —        (260,000 )       471,948  

Credit Suisse Securities (USA) LLC

     78,050          —          —        —        78,050  

Goldman Sachs International

     962,093          —          (942,093 )       (20,000 )       —  

JPMorgan Chase Bank N.A.

     524,131          —          (524,131 )       —        —  

Morgan Stanley & Co. International PLC

     508,125          —          (508,125 )       —        —  

UBS AG

     952,402          —          (879,534 )       (72,868 )       —  
  

 

 

      

 

 

      

 

 

    

 

 

    

 

 

 
   $ 4,112,369        $ —        $   (3,071,237 )     $ (491,134 )     $ 549,998  
  

 

 

      

 

 

      

 

 

    

 

 

    

 

 

 

 

  (a) 

Excess of collateral pledged to the individual counterparty is not shown for financial reporting purposes.

 
  (b) 

Net amount represents the net amount payable due to counterparty in the event of default. Net amount may be offset further by the options written receivable/payable on the Statements of Assets and Liabilities.

 

 

 

S C H E D U L E   O F   I N V E S T M E N T S

  67


Schedule of Investments (unaudited) (continued)

June 30, 2021

  

BlackRock Enhanced Global Dividend Trust (BOE)

    

 

Fair Value Hierarchy as of Period End

Various inputs are used in determining the fair value of financial instruments. For a description of the input levels and information about the Trust’s policy regarding valuation of financial instruments, refer to the Notes to Financial Statements.

The following table summarizes the Trust’s financial instruments categorized in the fair value hierarchy. The breakdown of the Trust’s financial instruments into major categories is disclosed in the Schedule of Investments above.

 

      Level 1        Level 2        Level 3        Total  

Assets

                 

Investments

                 

Long-Term Investments

                 

Common Stocks

                 

Australia

   $ —        $ 6,659,424        $ 3        $ 6,659,427  

Canada

     25,187,639          —          —          25,187,639  

China

     —          23,301,089          —          23,301,089  

Denmark

     —          16,280,487          —          16,280,487  

France

     —          82,227,574          —          82,227,574  

India

     —          —          596,065          596,065  

Ireland

     8,605,064          —          —          8,605,064  

Mexico

     8,851,906          —          —          8,851,906  

Netherlands

     —          10,527,852          —          10,527,852  

Singapore

     —          9,007,220          —          9,007,220  

Spain

     —          13,217,832          —          13,217,832  

Taiwan

     —          28,064,051          —          28,064,051  

United Kingdom

     —          172,605,299          —          172,605,299  

United States

     442,319,286          —          —          442,319,286  

Short-Term Securities

                 

Money Market Funds

     5,226,715          —          —          5,226,715  
  

 

 

      

 

 

      

 

 

      

 

 

 
   $   490,190,610        $   361,890,828        $   596,068        $   852,677,506  
  

 

 

      

 

 

      

 

 

      

 

 

 

Derivative Financial Instruments(a)

                 

Liabilities

                 

Equity Contracts

   $ (4,191,259 )       $ (4,350,352 )       $ —        $ (8,541,611 ) 
  

 

 

      

 

 

      

 

 

      

 

 

 

 

  (a) 

Derivative financial instruments are options written. Options written are shown at value.

 

See notes to financial statements.

 

 

68  

2 0 2 1   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S


Schedule of Investments (unaudited)

June 30, 2021

  

BlackRock Enhanced International Dividend Trust (BGY)

(Percentages shown are based on Net Assets)

 

Security   Shares     Value  

Common Stocks

   
Australia — 2.1%            

Ansell Ltd.

    455,152     $ 14,847,245  
   

 

 

 
Canada — 4.5%            

TELUS Corp.

    1,412,703       31,682,110  
   

 

 

 
China — 5.2%            

China Feihe Ltd.(a)

    10,214,000       22,021,613  

Enn Energy Holdings Ltd.

    792,700       15,065,841  
   

 

 

 
      37,087,454  
Denmark — 3.6%            

Novo Nordisk A/S, Class B

    310,268       25,972,103  
   

 

 

 
France — 17.3%            

Air Liquide SA

    61,686       10,816,638  

EssilorLuxottica SA

    155,966       28,812,102  

LVMH Moet Hennessy Louis Vuitton SE

    30,632       24,096,870  

Sanofi

    346,582       36,412,798  

Schneider Electric SE

    149,011       23,490,771  
   

 

 

 
      123,629,179  
India — 3.3%            

HDFC Bank Ltd.

    1,113,144       22,483,116  

Jasper Infotech Private Ltd., Series I, (Acquired 05/07/14,
Cost: $3,948,600)(b)(c)

    5,300       892,414  
   

 

 

 
      23,375,530  
Mexico — 2.4%            

Wal-Mart de Mexico SAB de CV

    5,117,558       16,705,102  
   

 

 

 
Netherlands — 2.6%            

Koninklijke Philips NV(d)

    379,536       18,837,950  
   

 

 

 
Singapore — 4.3%            

DBS Group Holdings Ltd.

    633,200       14,086,990  

United Overseas Bank Ltd.

    849,800       16,364,935  
   

 

 

 
      30,451,925  
Spain — 5.2%            

Amadeus IT Group SA(d)

    315,811       22,263,604  

Bankinter SA

    2,971,923       14,951,876  
   

 

 

 
      37,215,480  
Taiwan — 5.0%            

Taiwan Semiconductor Manufacturing Co. Ltd.

    1,668,000       35,925,431  
   

 

 

 
United Kingdom — 34.5%            

AstraZeneca PLC

    250,844       30,137,433  

BAE Systems PLC

    2,834,604       20,482,898  

Diageo PLC

    666,193       31,929,620  

Ferguson PLC

    236,520       32,906,357  

Prudential PLC

    1,552,742       29,542,109  

Reckitt Benckiser Group PLC

    410,312       36,251,127  

RELX PLC

    1,301,982       34,722,997  

Unilever PLC

    515,592       30,127,867  
   

 

 

 
        246,100,408  
Security   Shares     Value  
United States(e) — 9.1%            

Estee Lauder Cos., Inc., Class A

    83,761     $ 26,642,699  

Otis Worldwide Corp.

    206,671       16,899,488  

Visa, Inc., Class A

    92,155       21,547,682  
   

 

 

 
      65,089,869  
   

 

 

 
Total Common Stocks — 99.1%
    (Cost: $573,564,419)
        706,919,786  
   

 

 

 

Preferred Securities

   
Preferred Stocks — 0.3%            
China — 0.3%            

Xiaoju Kuaizhi, Inc., Series A-17, (Acquired 07/28/15, Cost: $1,053,166)(c)

    38,400       2,063,309  
   

 

 

 
Total Preferred Securities — 0.3%
    (Cost: $1,053,166)
    2,063,309  
   

 

 

 
Total Long-Term Investments — 99.4%
    (Cost: $574,617,585)
    708,983,095  
   

 

 

 

Short-Term Securities

   
Money Market Funds — 0.4%  

BlackRock Liquidity Funds, T-Fund, Institutional Class, 0.01%(f)(g)

    3,006,927       3,006,927  
   

 

 

 
Total Short-Term Securities — 0.4%
    (Cost: $3,006,927)
    3,006,927  
   

 

 

 
Total Investments Before Options Written — 99.8%
    (Cost: $577,624,512)
    711,990,022  
   

 

 

 
Options Written — (1.0)%
    (Premiums Received: $(5,591,310))
    (7,406,017)  
   

 

 

 
Total Investments, Net of Options Written — 98.8%
    (Cost: $572,033,202)
    704,584,005  

Other Assets Less Liabilities — 1.2%

 

    8,438,777  
   

 

 

 

Net Assets — 100.0%

 

  $   713,022,782  
   

 

 

 

 

(a) 

Security exempt from registration pursuant to Rule 144A under the Securities Act of 1933, as amended. These securities may be resold in transactions exempt from registration to qualified institutional investors.

(b) 

Security is valued using significant unobservable inputs and is classified as Level 3 in the fair value hierarchy.

(c) 

Restricted security as to resale, excluding 144A securities. The Trust held restricted securities with a current value of $3,848,137, representing 0.4% of its net assets as of period end, and an original cost of $8,950,366.

(d) 

Non-income producing security.

(e) 

All or a portion of the security has been pledged as collateral in connection with outstanding OTC derivatives.

(f) 

Affiliate of the Trust.

(g) 

Annualized 7-day yield as of period end.

 

 

 

S C H E D U L E   O F   I N V E S T M E N T S

  69


Schedule of Investments (unaudited) (continued)

June 30, 2021

  

BlackRock Enhanced International Dividend Trust (BGY)

    

 

Affiliates

Investments in issuers considered to be affiliate(s) of the Trust during the six-months ended June 30, 2021 for purposes of
Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

 

Affiliated Issuer   Value at
12/31/20
    Purchases
at Cost
    Proceeds
from Sales
    Net
Realized
Gain (Loss)
    Change in
Unrealized
Appreciation
(Depreciation)
    Value at
06/30/21
    Shares
Held at
06/30/21
    Income     Capital Gain
Distributions
from
Underlying
Funds
 

BlackRock Liquidity Funds, T-Fund, Institutional Class

  $   287,381     $   2,719,546 (a)    $ —     $ —     $ —     $   3,006,927       3,006,927     $ 604     $ —  
       

 

 

   

 

 

   

 

 

     

 

 

   

 

 

 

 

  (a) 

Represents net amount purchased (sold).

 

Derivative Financial Instruments Outstanding as of Period End

Exchange-Traded Options Written

 

Description    Number of
Contracts
       Expiration
Date
       Exercise Price       

Notional

Amount (000)

       Value  

Call

                                

Visa, Inc., Class A

     72          07/09/21          USD          235.00          USD          1,684        $ (14,040 ) 

Estee Lauder Cos., Inc., Class A

     196          07/16/21          USD          300.00          USD          6,234          (371,420 ) 

Otis Worldwide Corp.

     206          07/16/21          USD          80.00          USD          1,684          (48,410 ) 

Visa, Inc., Class A

     32          07/16/21          USD          235.00          USD          748          (9,600 ) 

Visa, Inc., Class A

     69          07/23/21          USD          235.00          USD          1,613          (31,223 ) 

Visa, Inc., Class A

     97          07/30/21          USD          240.00          USD          2,268          (31,525 ) 

Estee Lauder Cos., Inc., Class A

     180          08/13/21          USD          310.00          USD          5,725          (244,788 ) 

Otis Worldwide Corp.

     270          08/20/21          USD          85.00          USD          2,208          (40,500 ) 

TELUS Corp.

     2,622          08/20/21          CAD          28.00          CAD          7,289          (83,550 ) 

Visa, Inc., Class A

     52          08/20/21          USD          235.00          USD          1,216          (34,970 ) 

Otis Worldwide Corp.

     10          09/17/21          USD          85.00          USD          82          (1,975 ) 
                                

 

 

 
                                 $   (912,001 ) 
                                

 

 

 

OTC Options Written

 

Description    Counterparty      Number of
Contracts
       Expiration
Date
       Exercise Price       

Notional

Amount (000)

       Value  

Call

                                     

AstraZeneca PLC

   UBS AG        500          07/07/21          GBP          82.62          GBP          3        $ (2,929 ) 

BAE Systems PLC

   Credit Suisse International        364,000          07/07/21          GBP          5.33          GBP          1,901          (9,973 ) 

LVMH Moet Hennessy Louis Vuitton SE

   Barclays Bank PLC        14,900          07/07/21          EUR          661.37          EUR          9,885            (145,094 ) 

TELUS Corp.

   Credit Suisse International        153,600          07/07/21          CAD          26.52          CAD          4,270          (159,043 ) 

Reckitt Benckiser Group PLC

   Morgan Stanley & Co. International PLC        78,000          07/08/21          GBP          65.56          GBP          4,982          (13,358 ) 

Relx PLC

   UBS AG        2,400          07/08/21          EUR          22.02          EUR          54          (1,549 ) 

Schneider Electric SE

   Morgan Stanley & Co. International PLC        71,700          07/08/21          EUR          131.90          EUR          9,532          (184,335 ) 

United Overseas Bank Ltd.

   Goldman Sachs International        75,500          07/08/21          SGD          25.93          SGD          1,955          (12,522 ) 

Otis Worldwide Corp.

   Barclays Bank PLC        65,000          07/13/21          USD          77.25          USD          5,315          (306,734 ) 

TELUS Corp.

   Goldman Sachs International        127,100          07/13/21          CAD          26.00          CAD          3,533          (184,977 ) 

Air Liquide SA

   UBS AG        13,800          07/14/21          EUR          141.36          EUR          2,041          (109,092 ) 

Bankinter SA

   UBS AG        502,350          07/14/21          EUR          4.78          EUR          2,131          (336 ) 

China Feihe Ltd.

   JPMorgan Chase Bank N.A.        1,434,000          07/14/21          HKD          22.46          HKD          24,005          (4 ) 

Diageo PLC

   Credit Suisse International        131,400          07/14/21          GBP          35.05          GBP          686          (59,380 ) 

Enn Energy Holdings Ltd.

   JPMorgan Chase Bank N.A.        202,500          07/14/21          HKD          146.22          HKD          29,882          (110,288 ) 

Novo Nordisk A/S, Class B

   UBS AG        77,800          07/14/21          DKK          496.74          DKK          40,842          (370,300 ) 

Reckitt Benckiser Group PLC

   Barclays Bank PLC        52,400          07/14/21          GBP          65.21          GBP          3,347          (23,330 ) 

Relx PLC

   Barclays Bank PLC        105,600          07/14/21          EUR          21.72          EUR          2,375          (104,091 ) 

Unilever PLC

   Credit Suisse International        54,600          07/14/21          GBP          43.54          GBP          2,306          (5,055 ) 

Wal-Mart de Mexico SAB de CV

   Citibank N.A.        1,030,000          07/14/21          MXN          65.19          MXN          67,022          (96,722 ) 

Ansell Ltd.

   UBS AG        2,600          07/15/21          AUD          40.95          AUD          113          (5,256 ) 

BAE Systems PLC

   UBS AG        355,400          07/15/21          GBP          5.35          GBP          1,857          (18,558 ) 

DBS Group Holdings Ltd.

   UBS AG        38,400          07/15/21          SGD          30.07          SGD          1,149          (8,886 ) 

Ferguson PLC

   Morgan Stanley & Co. International PLC        38,300          07/15/21          GBP          98.05          GBP          3,852          (164,016 ) 

Koninklijke Philips Electronics NV

   Morgan Stanley & Co. International PLC        90,400          07/15/21          EUR          46.62          EUR          3,784          (509 ) 

United Overseas Bank Ltd.

   JPMorgan Chase Bank N.A.        73,400          07/19/21          SGD          26.93          SGD          1,901          (2,444 ) 

 

 

70  

2 0 2 1   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S


Schedule of Investments (unaudited) (continued)

June 30, 2021

  

BlackRock Enhanced International Dividend Trust (BGY)

    

 

OTC Options Written (continued)

 

Description    Counterparty      Number of
Contracts
       Expiration
Date
       Exercise Price       

Notional

Amount (000)

       Value  

Call (continued)

                                     

Air Liquide SA

   Credit Suisse International        13,900          07/20/21          EUR          142.57          EUR          2,056        $ (96,918 ) 

Amadeus IT Group SA

   UBS AG        39,031          07/20/21          EUR          65.57          EUR          2,321          (9,273 ) 

Ansell Ltd.

   JPMorgan Chase Bank N.A.        121,700          07/20/21          AUD          39.17          AUD          5,294          (398,348 ) 

BAE Systems PLC

   Goldman Sachs International        355,400          07/20/21          GBP          5.34          GBP          1,857          (26,613 ) 

China Feihe Ltd.

   Goldman Sachs International        1,076,000          07/20/21          HKD          20.29          HKD          18,012          (1,950 ) 

Enn Energy Holdings Ltd.

   JPMorgan Chase Bank N.A.        154,300          07/20/21          HKD          146.98          HKD          22,769          (88,862 ) 

EssilorLuxottica SA

   Credit Suisse International        37,800          07/20/21          EUR          148.52          EUR          5,889          (375,760 ) 

Novo Nordisk A/S, Class B

   Credit Suisse International        13,500          07/20/21          DKK          496.00          DKK          7,087          (67,098 ) 

Sanofi

   UBS AG        81,500          07/20/21          EUR          88.44          EUR          7,221          (127,858 ) 

Unilever PLC

   Credit Suisse International        30,300          07/20/21          GBP          43.15          GBP          1,280          (8,156 ) 

Ansell Ltd.

   UBS AG        75,400          07/27/21          AUD          41.16          AUD          3,280          (151,375 ) 

AstraZeneca PLC

   Goldman Sachs International        112,400          07/27/21          GBP          81.73          GBP          9,762          (834,918 ) 

Bankinter SA

   UBS AG        502,350          07/27/21          EUR          4.78          EUR          2,131          (2,951 ) 

DBS Group Holdings Ltd.

   Goldman Sachs International        246,600          07/27/21          SGD          30.63          SGD          7,377          (39,968 ) 

Relx PLC

   UBS AG        128,700          07/27/21          EUR          22.19          EUR          2,895          (87,068 ) 

Taiwan Semiconductor Manufacturing Co. Ltd.

   UBS AG        122,000          07/27/21          USD          609.95          USD          73,213          (53,948 ) 

TELUS Corp.

   Goldman Sachs International        126,800          07/27/21          CAD          27.10          CAD          3,525          (88,466 ) 

Wal-Mart de Mexico SAB de CV

   Citibank N.A.        1,030,000          07/27/21          MXN          65.19          MXN          67,022          (136,743 ) 

Diageo PLC

   Goldman Sachs International        168,400          07/29/21          GBP          35.83          GBP          5,828          (69,671 ) 

Koninklijke Philips Electronics NV

   Credit Suisse International        78,000          07/29/21          EUR          45.91          EUR          3,265          (8,084 ) 

Ansell Ltd.

   Morgan Stanley & Co. International PLC        10,900          08/04/21          AUD          40.85          AUD          474          (24,763 ) 

EssilorLuxottica SA

   JPMorgan Chase Bank N.A.        37,700          08/04/21          EUR          151.52          EUR          5,873          (282,986 ) 

Prudential PLC

   Morgan Stanley & Co. International PLC        169,200          08/04/21          GBP          14.67          GBP          2,327          (25,057 ) 

Reckitt Benckiser Group PLC

   JPMorgan Chase Bank N.A.        45,400          08/04/21          GBP          65.80          GBP          2,900          (40,079 ) 

Relx PLC

   JPMorgan Chase Bank N.A.        107,000          08/04/21          EUR          22.97          EUR          2,407          (28,382 ) 

Sanofi

   Morgan Stanley & Co. International PLC        39,900          08/04/21          EUR          89.05          EUR          3,535          (75,528 ) 

United Overseas Bank Ltd.

   Goldman Sachs International        233,600          08/04/21          SGD          25.74          SGD          6,049          (93,052 ) 

Amadeus IT Group SA

   UBS AG        71,600          08/05/21          EUR          65.78          EUR          4,257          (35,887 ) 

China Feihe Ltd.

   Goldman Sachs International        1,465,000          08/05/21          HKD          18.13          HKD          24,524          (64,870 ) 

Air Liquide SA

   Morgan Stanley & Co. International PLC        6,200          08/10/21          EUR          149.38          EUR          917          (17,040 ) 

Koninklijke Philips Electronics NV

   Morgan Stanley & Co. International PLC        2,400          08/10/21          EUR          42.66          EUR          100          (2,353 ) 

Unilever PLC

   Credit Suisse International        95,600          08/10/21          GBP          42.29          GBP          4,038          (102,870 ) 

Ansell Ltd.

   JPMorgan Chase Bank N.A.        39,700          08/11/21          AUD          42.92          AUD          1,727          (51,229 ) 

Prudential PLC

   Morgan Stanley & Co. International PLC        169,200          08/11/21          GBP          14.67          GBP          2,327          (31,499 ) 

Relx PLC

   Morgan Stanley & Co. International PLC        107,000          08/11/21          EUR          22.97          EUR          2,407          (33,402 ) 

BAE Systems PLC

   Credit Suisse International        200,800          08/12/21          GBP          5.31          GBP          1,049          (26,666 ) 

China Feihe Ltd.

   UBS AG        621,000          08/12/21          HKD          18.39          HKD          10,396          (26,336 ) 

Ferguson PLC

   UBS AG        44,500          08/12/21          GBP          102.92          GBP          4,476          (68,438 ) 

Novo Nordisk A/S, Class B

   Credit Suisse International        48,400          08/12/21          DKK          527.02          DKK          25,408          (121,140 ) 

Taiwan Semiconductor Manufacturing Co. Ltd.

   UBS AG        461,000          08/12/21          USD          606.90          USD          276,648          (306,662 ) 

AstraZeneca PLC

   Goldman Sachs International        25,000          08/18/21          GBP          88.32          GBP          2,171          (55,968 ) 

Enn Energy Holdings Ltd.

   JPMorgan Chase Bank N.A.        79,100          08/18/21          HKD          152.03          HKD          11,672          (40,799 ) 

Ferguson PLC

   Morgan Stanley & Co. International PLC        23,600          08/18/21          GBP          102.18          GBP          2,374          (60,560 ) 

Prudential PLC

   UBS AG        205,100          08/18/21          GBP          14.59          GBP          2,821          (56,229 ) 

Relx PLC

   Morgan Stanley & Co. International PLC        135,100          08/18/21          EUR          22.93          EUR          3,039          (49,412 ) 
                                     

 

 

 
                                      $   (6,494,016 ) 
                                     

 

 

 

Balances Reported in the Statements of Assets and Liabilities for Options Written

 

Description    Swap
Premiums
Paid
     Swap
Premiums
Received
     Unrealized
Appreciation
     Unrealized
Depreciation
     Value  

Options Written

   $ N/A      $ N/A      $ 1,443,712      $ (3,258,418 )     $ (7,406,017 ) 

 

 

S C H E D U L E   O F   I N V E S T M E N T S

  71


Schedule of Investments (unaudited) (continued)

June 30, 2021

  

BlackRock Enhanced International Dividend Trust (BGY)

    

 

Derivative Financial Instruments Categorized by Risk Exposure

As of period end, the fair values of derivative financial instruments located in the Statements of Assets and Liabilities were as follows:

 

     Commodity
Contracts
    Credit
Contracts
    Equity
Contracts
    Foreign
Currency
Exchange
Contracts
    Interest
Rate
Contracts
    Other
Contracts
    Total  

Liabilities — Derivative Financial Instruments

             

Options written

             

Options written at value

  $ —     $ —     $   7,406,017     $ —     $ —     $ —     $   7,406,017  
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

For the six months ended June 30, 2021, the effect of derivative financial instruments in the Statements of Operations was as follows:

 

     Commodity
Contracts
    Credit
Contracts
    Equity
Contracts
    Foreign
Currency
Exchange
Contracts
    Interest
Rate
Contracts
    Other
Contracts
    Total  

Net Realized Gain (Loss) from

             

Options written

  $ —     $ —     $ (7,980,801 )    $ —     $ —     $ —     $ (7,980,801 ) 
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net Change in Unrealized Appreciation (Depreciation) on

             

Options written

  $ —     $ —     $   (1,130,084 )    $ —     $ —     $ —     $   (1,130,084 ) 
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Average Quarterly Balances of Outstanding Derivative Financial Instruments

 

Options

        

Average notional value of swaption contracts written

   $ 7,774,924  

For more information about the Trust’s investment risks regarding derivative financial instruments, refer to the Notes to Financial Statements.

Derivative Financial Instruments — Offsetting as of Period End

The Trust’s derivative assets and liabilities (by type) were as follows:

 

      Assets        Liabilities  

Derivative Financial Instruments

       

Options

   $ —        $ 7,406,017  
  

 

 

      

 

 

 

Total derivative assets and liabilities in the Statements of Assets and Liabilities

     —          7,406,017  
  

 

 

      

 

 

 

Derivatives not subject to a Master Netting Agreement or similar agreement (“MNA”)

     —          (912,001 ) 
  

 

 

      

 

 

 

Total derivative assets and liabilities subject to an MNA

   $ —        $   6,494,016  
  

 

 

      

 

 

 

The following table presents the Trust’s derivative liabilities by counterparty net of amounts available for offset under an MNA and net of the related collateral pledged by the Trust:

 

Counterparty     



Derivative
Liabilities
Subject to
an MNA by
Counterparty
 
 

 
 
      

Derivatives
Available
for Offset
 
 
 
      

Non-Cash
Collateral
Pledged
 
 
(a)  
    

Cash
Collateral
Pledged
 
 
(a)  
    

Net Amount
of Derivative
Liabilities
 
 
(b) 

Barclays Bank PLC

   $ 579,249        $ —        $ —      $ (579,249 )     $ —  

Citibank N.A.

     233,465          —          —        (178,000 )       55,465  

Credit Suisse International

     1,040,143          —          (1,040,143 )       —        —  

Goldman Sachs International

     1,472,975          —          —        —        1,472,975  

JPMorgan Chase Bank N.A.

     1,043,421          —          (1,043,421 )       —        —  

Morgan Stanley & Co. International PLC

     681,832          —          (360,832 )       (321,000 )       —  

UBS AG

     1,442,931          —          —        —        1,442,931  
  

 

 

      

 

 

      

 

 

    

 

 

    

 

 

 
   $ 6,494,016        $ —        $   (2,444,396 )     $   (1,078,249 )     $ 2,971,371  
  

 

 

      

 

 

      

 

 

    

 

 

    

 

 

 

 

  (a) 

Excess of collateral pledged to the individual counterparty is not shown for financial reporting purposes.

 
  (b) 

Net amount represents the net amount payable due to counterparty in the event of default. Net amount may be offset further by the options written receivable/payable on the Statements of Assets and Liabilities.

 

 

 

72  

2 0 2 1   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S


Schedule of Investments (unaudited) (continued)

June 30, 2021

  

BlackRock Enhanced International Dividend Trust (BGY)

    

 

Fair Value Hierarchy as of Period End

Various inputs are used in determining the fair value of financial instruments. For a description of the input levels and information about the Trust’s policy regarding valuation of financial instruments, refer to the Notes to Financial Statements.

The following table summarizes the Trust’s financial instruments categorized in the fair value hierarchy. The breakdown of the Trust’s financial instruments into major categories is disclosed in the Schedule of Investments above.

 

      Level 1        Level 2        Level 3        Total  

Assets

                 

Investments

                 

Long-Term Investments

                 

Common Stocks

                 

Australia

   $ —        $ 14,847,245        $ —        $ 14,847,245  

Canada

     31,682,110          —          —          31,682,110  

China

     —          37,087,454          —          37,087,454  

Denmark

     —          25,972,103          —          25,972,103  

France

     —          123,629,179          —          123,629,179  

India

     —          22,483,116          892,414          23,375,530  

Mexico

     16,705,102          —          —          16,705,102  

Netherlands

     —          18,837,950          —          18,837,950  

Singapore

     —          30,451,925          —          30,451,925  

Spain

     —          37,215,480          —          37,215,480  

Taiwan

     —          35,925,431          —          35,925,431  

United Kingdom

     —          246,100,408          —          246,100,408  

United States

     65,089,869          —          —          65,089,869  

Preferred Securities

                 

Preferred Stocks

     —          2,063,309          —          2,063,309  

Short-Term Securities

                 

Money Market Funds

     3,006,927          —          —          3,006,927  
  

 

 

      

 

 

      

 

 

      

 

 

 
   $   116,484,008        $   594,613,600        $   892,414        $   711,990,022  
  

 

 

      

 

 

      

 

 

      

 

 

 

Derivative Financial Instruments(a)

                 

Liabilities

                 

Equity Contracts

   $ (667,213 )       $ (6,738,804 )       $ —        $ (7,406,017 ) 
  

 

 

      

 

 

      

 

 

      

 

 

 

 

  (a) 

Derivative financial instruments are options written. Options written are shown at value.

 

See notes to financial statements.

 

 

S C H E D U L E   O F  I N V E S T M E N T S

  73


Schedule of Investments (unaudited) 

June 30, 2021

  

BlackRock Health Sciences Trust (BME)

(Percentages shown are based on Net Assets)

 

Security   Shares     Value  

Common Stocks

   
Biotechnology — 20.7%            

AbbVie, Inc.

    49,530     $ 5,579,059  

Acceleron Pharma, Inc.(a)(b)

    38,325       4,809,404  

Acerta Pharma BV, Series B, (Acquired 05/06/15, Cost: $986,402)(c)(d)

    17,146,440       2,415,419  

Acumen Pharmaceuticals, Inc., (Acquired 11/20/20, Cost: $580,000)(d)

    152,651       2,289,765  

Agios Pharmaceuticals, Inc.(a)(b)

    21,625       1,191,754  

Allakos, Inc.(a)(b)

    22,275       1,901,617  

Allogene Therapeutics, Inc.(a)(b)

    30,786       802,899  

Alnylam Pharmaceuticals, Inc.(a)(b)

    34,003       5,764,189  

Ambrx Biopharma, Inc., (Acquired 06/22/21, Cost: $500,001)(d)

    303,869       811,128  

Amgen, Inc.(a)

    62,397       15,209,269  

Annexon, Inc., (Acquired 06/26/20, Cost: $190,006)(d)

    15,164       341,342  

Apellis Pharmaceuticals, Inc.(a)(b)

    15,300       966,960  

Arcutis Biotherapeutics, Inc.(a)(b)

    42,854       1,169,486  

Arena Pharmaceuticals, Inc.(a)(b)

    14,984       1,021,909  

Argenx SE, ADR(a)(b)

    4,800       1,445,136  

Biogen, Inc.(b)

    25,065       8,679,257  

Biohaven Pharmaceutical Holding
Co. Ltd.(a)(b)

    7,120       691,210  

BioMarin Pharmaceutical, Inc.(a)(b)

    14,814       1,236,080  

Blueprint Medicines Corp.(a)(b)

    9,623       846,439  

Bridgebio Pharma, Inc.(a)(b)

    13,427       818,510  

Cerevel Therapeutics Holdings, Inc.(b)

    12,589       322,530  

Connect Biopharma Holdings Ltd.(b)(e)

    12,117       236,645  

Connect Biopharma Holdings Ltd., (Acquired 12/01/20, Cost: $250,023)(d)

    22,809       435,932  

Cytokinetics, Inc.(a)(b)

    16,280       322,181  

Decibel Therapeutics, Inc.(b)

    25,174       216,496  

Decibel Therapeutics, Inc., (Acquired 11/02/20, Cost: $198,658)(d)

    21,710       184,528  

Design Therapeutics, Inc.(b)

    13,967       277,804  

Dicerna Pharmaceuticals, Inc.(a)(b)

    14,790       551,963  

Enanta Pharmaceuticals, Inc.(b)

    5,480       241,175  

Everest Medicines Ltd.(b)(f)

    30,500       303,191  

Exact Sciences Corp.(a)(b)

    14,000       1,740,340  

Forma Therapeutics Holdings, Inc.(b)

    11,947       297,361  

Genmab A/S(b)

    14,763       6,049,028  

Genmab A/S, ADR(a)(b)

    51,161       2,088,904  

Gilead Sciences, Inc.(a)

    206,984         14,252,918  

Global Blood Therapeutics, Inc.(a)(b)

    25,084       878,442  

Horizon Therapeutics PLC(a)(b)

    19,295       1,806,784  

Ideaya Biosciences, Inc.(b)

    15,835       332,377  

Immunocore Holdings PLC, ADR(b)

    9,668       377,535  

Incyte Corp.(b)

    23,637       1,988,581  

Kronos Bio, Inc., (Acquired 10/09/20, Cost: $260,000), 8/20/2020(d)

    16,099       385,571  

Krystal Biotech, Inc.(a)(b)

    3,730       253,640  

Mersana Therapeutics, Inc.(b)

    57,220       777,048  

Mirati Therapeutics, Inc.(a)(b)

    14,516       2,344,769  

Monte Rosa Therapeutics, Inc.(b)

    28,575       648,652  

Natera, Inc.(b)

    13,740       1,559,902  

Neurocrine Biosciences, Inc.(b)

    18,372       1,787,963  

Prothena Corp. PLC(a)(b)

    21,064       1,082,900  

PTC Therapeutics, Inc.(b)

    4,745       200,571  

Rapt Therapeutics, Inc.(a)(b)

    8,660       275,301  

Regeneron Pharmaceuticals, Inc.(b)

    11,420       6,378,527  

Relay Therapeutics, Inc.(b)

    10,918       399,490  

Remegen Co. Ltd., Class H(b)(f)

    54,500       831,226  
Security   Shares     Value  
Biotechnology (continued)            

Sarepta Therapeutics, Inc.(a)(b)

    8,718     $ 677,737  

Seagen, Inc.(a)(b)

    65,708       10,373,979  

Seres Therapeutics, Inc.(b)

    11,900       283,815  

Sigilon Therapeutics, Inc.(b)

    19,555       209,825  

Talaris Therapeutics, Inc.(b)

    23,939       351,664  

Taysha Gene Therapies, Inc.(b)

    30,936       655,843  

TCR2 Therapeutics, Inc.(a)(b)

    10,160       166,726  

Translate Bio, Inc.(a)(b)

    15,460       425,768  

Vertex Pharmaceuticals, Inc.(a)(b)

    21,723       4,380,008  
   

 

 

 
        125,346,472  
Diversified Financial Services(b) — 0.3%  

BCTG Acquisition Corp.

    8,720       99,147  

Health Assurance Acquisition Corp., Class A

    90,235       903,252  

Health Sciences Acquisitions Corp.

    13,696       139,699  

Helix Acquisition Corp., Class A

    11,715       121,016  

MedTech Acquisition Corp., Class A

    42,753       417,269  

Therapeutics Acquisition Corp., Class A

    27,000       277,560  
   

 

 

 
      1,957,943  
Health Care Equipment & Supplies — 27.0%  

Abbott Laboratories(a)

    267,322       30,990,639  

ABIOMED, Inc.(b)

    10,709       3,342,386  

Alcon, Inc.(a)

    103,355       7,261,722  

Baxter International, Inc.(a)

    36,592       2,945,656  

Becton Dickinson and Co.(a)

    12,471       3,032,823  

Boston Scientific Corp.(a)(b)

    327,442       14,001,420  

Butterfly Network, Inc.(a)(b)(e)

    35,345       511,796  

DENTSPLY SIRONA, Inc.(a)

    52,685       3,332,853  

Edwards Lifesciences Corp.(a)(b)

    103,085       10,676,513  

Intuitive Surgical, Inc.(a)(b)

    16,663       15,323,961  

Kangji Medical Holdings Ltd.(e)

    264,936       440,339  

Masimo Corp.(a)(b)

    22,110       5,360,570  

Medtronic PLC(a)

    168,996       20,977,474  

Nevro Corp.(a)(b)

    13,928       2,309,123  

Novocure Ltd.(a)(b)

    8,970       1,989,725  

ResMed, Inc.(a)

    28,437       7,010,289  

Straumann Holding AG, Registered Shares

    1,690       2,695,624  

Stryker Corp.(a)

    51,491       13,373,757  

Teleflex, Inc.(a)

    19,140       7,690,261  

Zimmer Biomet Holdings, Inc.(a)

    63,022       10,135,198  
   

 

 

 
      163,402,129  
Health Care Providers & Services — 20.4%  

Agiliti, Inc.(b)

    75,106       1,642,568  

Agilon Health, Inc.(a)(b)

    41,052       1,665,480  

Alignment Healthcare, Inc.(a)(b)

    50,071       1,170,159  

Amedisys, Inc.(a)(b)

    19,757       4,839,082  

AmerisourceBergen Corp.(a)

    14,280       1,634,917  

Anthem, Inc.(a)

    30,827       11,769,749  

Cano Health, Inc., (Acquired 06/03/21, Cost: $1,485,000)(d)

    148,500       1,780,379  

Cardinal Health, Inc.(a)

    81,660       4,661,970  

CareMax, Inc., (Acquired 06/08/21, Cost: $257,350)(d)

    25,735       322,944  

CareMax, Inc.(b)

    21,007       270,990  

Centene Corp.(a)(b)

    99,507       7,257,046  

Cigna Corp.(a)

    59,034       13,995,190  

Encompass Health Corp.(a)

    40,167       3,134,231  

Guardant Health, Inc.(b)

    7,365       914,659  

Henry Schein, Inc.(a)(b)

    41,035       3,044,387  

Humana, Inc.(a)

    35,650       15,782,968  

Innovage Holding Corp.(b)

    13,434       286,279  

LHC Group, Inc.(a)(b)

    20,224       4,050,058  
 

 

 

74  

2 0 2 1   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S


Schedule of Investments (unaudited) (continued)

June 30, 2021

  

BlackRock Health Sciences Trust (BME)

(Percentages shown are based on Net Assets)

 

Security   Shares     Value  
Health Care Providers & Services (continued)  

LifeStance Health Group, Inc.(b)

    73,455     $ 2,046,456  

McKesson Corp.(a)

    6,180       1,181,863  

Oak Street Health, Inc.(a)(b)

    54,700       3,203,779  

Privia Health Group, Inc.(b)

    23,774       1,054,852  

UnitedHealth Group, Inc.(a)

    94,809       37,965,316  
   

 

 

 
        123,675,322  
Health Care Technology — 0.6%  

Teladoc Health, Inc.(a)(b)

    21,980       3,655,054  
   

 

 

 
Internet & Direct Marketing Retail — 0.4%  

JD Health International, Inc.(b)(f)

    163,250       2,331,701  
   

 

 

 
Life Sciences Tools & Services — 9.5%  

Agilent Technologies, Inc.(a)

    13,960       2,063,428  

Avantor, Inc.(a)(b)

    111,649       3,964,656  

Illumina, Inc.(a)(b)

    14,027       6,637,717  

IQVIA Holdings, Inc.(a)(b)

    31,163       7,551,418  

Nautilus Biotechnology, Inc.(b)

    16,560       167,256  

Thermo Fisher Scientific, Inc.(a)(g)

    53,083       26,778,781  

WuXi AppTec Co. Ltd., Class H(f)

    232,542       5,427,894  

Wuxi Biologics Cayman, Inc.(b)(f)

    280,500       5,136,034  
   

 

 

 
      57,727,184  
Pharmaceuticals — 19.8%            

Bristol-Myers Squibb Co.(a)

    157,283       10,509,650  

Eisai Co. Ltd.

    16,500       1,621,574  

Elanco Animal Health, Inc.(b)

    65,535       2,273,409  

Eli Lilly & Co.(a)

    117,763       27,028,964  

Hansoh Pharmaceutical Group Co. Ltd.(f)

    882,438       3,855,934  

Hua Medicine(b)(f)

    735,105       443,406  

Johnson & Johnson

    151,324       24,929,116  

Merck & Co., Inc.(a)

    73,837       5,742,304  

Nektar Therapeutics(a)(b)

    24,513       420,643  

Pfizer, Inc.(a)

    508,101       19,897,235  

Roche Holding AG

    7,972       3,004,151  

Sanofi

    68,800       7,228,305  

Sanofi, ADR

    54,625       2,876,553  

Zoetis, Inc.(a)

    54,489       10,154,570  
   

 

 

 
      119,985,814  
   

 

 

 

Total Common Stocks — 98.7%
(Cost: $354,850,749)

 

    598,081,619  
   

 

 

 
     Benefical
Interest (000)
        

Other Interests(h)

 

Pharmaceuticals — 0.1%            

Afferent Pharmaceuticals, Inc.(c)

  $ 190       273,830  
   

 

 

 

Total Other Interests — 0.1%
(Cost: $ — )

 

    273,830  
   

 

 

 
Security   Shares     Value  

Preferred Securities

   
Preferred Stocks — 0.6%(c)(d)  
Biotechnology — 0.2%            

Cellarity, Inc., Series B, (Acquired 01/15/21, Cost: $265,002)

    44,167     $ 251,752  

Affinvax, Inc., Series C, (Acquired 01/06/21, Cost: $199,992)

    6,331       199,992  

Goldfinch Bio, Inc., Series B, (Acquired 06/26/20, Cost: $149,465)

    126,665       163,398  

Imago Biosciences, Inc., (Acquired 11/12/20, Cost: $235,002)

    194,570       235,430  

Neurogene, Inc., Series B, (Acquired 12/14/20, Cost: $156,340)

    64,074       156,341  
   

 

 

 
      1,006,913  
Health Care Equipment & Supplies — 0.3%  

Exo Imaging, Inc., Series C, (Acquired 06/24/21, Cost: $595,999)

    101,741       595,999  

Nucleix Ltd., Series AA, (Acquired 03/25/21, Cost: $1,070,001)

    367,395       1,070,001  

Quanta Dialysis Technologies Ltd., Series D, (Acquired 06/18/21, Cost: $515,759)

    4,243,029       516,371  
   

 

 

 
      2,182,371  
Pharmaceuticals — 0.1%            

Insitro, Inc., Series C, (Acquired 03/10/21, Cost: $560,000)

    30,616       560,000  
   

 

 

 

Total Preferred Stocks — 0.6%

 

    3,749,284  
   

 

 

 

Total Preferred Securities — 0.6%
(Cost: $3,747,560)

 

    3,749,284  
   

 

 

 

Warrants

   
Biotechnology — 0.0%            

Cerevel Therapeutics Holdings, Inc. (Expires 10/27/2025)(b)

    4,196       59,835  
   

 

 

 
Diversified Financial Services(b) — 0.0%  

Health Assurance Acquisition Corp. (Expires 11/12/2025)

    22,558       40,379  

MedTech Acquisition Corp. (Expires 12/18/2025)

    14,251       14,147  
   

 

 

 
      54,526  
Health Care Equipment & Supplies — 0.0%  

Butterfly Network, Inc. (Expires 05/27/2025)(b)

    11,781       56,902  
   

 

 

 
Health Care Providers & Services — 0.0%  

CareMax, Inc. (Expires 06/08/2026)(b)

    4,201       19,829  
   

 

 

 
Pharmaceuticals — 0.0%            

Nuvation Bio, Inc. (Expires 07/07/2027)(b)

    4,050       10,530  
   

 

 

 

Total Warrants — 0.0%
(Cost: $134,776)

 

    201,622  
   

 

 

 

Total Long-Term Investments — 99.4%
(Cost: $358,733,085)

 

      602,306,355  
   

 

 

 
 

 

 

S C H E D U L E   O F   I N V E S T M E N T S

  75


Schedule of Investments  (unaudited) (continued)

June 30, 2021

  

BlackRock Health Sciences Trust (BME)

(Percentages shown are based on Net Assets)

 

Security   Shares     Value  

Short-Term Securities

 

Money Market Funds — 1.7%  

BlackRock Liquidity Funds, T-Fund, Institutional Class, 0.01%(i)(j)

    9,977,621     $ 9,977,621  

SL Liquidity Series, LLC, Money Market Series, 0.13%(i)(j)(k)

    431,108       431,237  
   

 

 

 

Total Short-Term Securities — 1.7%
(Cost: $10,408,858)

 

    10,408,858  
   

 

 

 

Total Investments Before Options Written — 101.1%
(Cost: $369,141,943)

 

    612,715,213  
   

 

 

 

Options Written — (1.0)%
(Premiums Received: $(5,172,885))

 

    (6,019,812 ) 
   

 

 

 

Total Investments, Net of Options Written — 100.1%
(Cost: $363,969,058)

 

    606,695,401  

Liabilities in Excess of Other Assets — (0.1)%

 

    (561,466 ) 
   

 

 

 

Net Assets — 100.0%

 

  $   606,133,935  
   

 

 

 

 

(a) 

All or a portion of the security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written.

(b) 

Non-income producing security.

(c) 

Security is valued using significant unobservable inputs and is classified as Level 3 in the fair value hierarchy.

(d) 

Restricted security as to resale, excluding 144A securities. The Trust held restricted securities with a current value of $12,716,292, representing 2.1% of its net assets as of period end, and an original cost of $8,455,000.

(e) 

All or a portion of this security is on loan.

(f) 

Security exempt from registration pursuant to Rule 144A under the Securities Act of 1933, as amended. These securities may be resold in transactions exempt from registration to qualified institutional investors.

(g) 

All or a portion of the security has been pledged as collateral in connection with outstanding OTC derivatives.

(h) 

Other interests represent beneficial interests in liquidation trusts and other reorganization or private entities.

(i) 

Affiliate of the Trust.

(j) 

Annualized 7-day yield as of period end.

(k) 

All or a portion of this security was purchased with the cash collateral from loaned securities.

 

For Trust compliance purposes, the Trust’s industry classifications refer to one or more of the industry sub-classifications used by one or more widely recognized market indexes or rating group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.

Affiliates

Investments in issuers considered to be affiliate(s) of the Trust during the six-months ended June 30, 2021 for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

 

Affiliated Issuer    Value at
12/31/20
     Purchases
at Cost
     Proceeds
from Sales
    Net
Realized
Gain (Loss)
     Change in
Unrealized
Appreciation
(Depreciation)
     Value at
06/30/21
     Shares
Held at
06/30/21
     Income      Capital Gain
Distributions
from
Underlying
Funds
 

BlackRock Liquidity Funds, T-Fund, Institutional Class

   $ 13,774,637      $ —      $ (3,797,016 )(a)    $ —      $ —      $ 9,977,621        9,977,621      $ 1,036      $ —  

SL Liquidity Series, LLC, Money Market Series

     102,701        328,545 (a)       —       (9 )       —        431,237        431,108        6,520 (b)       —  
          

 

 

    

 

 

    

 

 

       

 

 

    

 

 

 
           $ (9 )     $ —      $ 10,408,858         $ 7,556      $ —  
          

 

 

    

 

 

    

 

 

       

 

 

    

 

 

 

 

  (a) 

Represents net amount purchased (sold).

 
  (b) 

All or a portion represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of fees and collateral investment expenses, and other payments to and from borrowers of securities.

 

Derivative Financial Instruments Outstanding as of Period End

Exchange-Traded Options Written

 

Description    Number of
Contracts
     Expiration
Date
     Exercise Price     

Notional

Amount (000)

     Value  

Call

                    

Abbott Laboratories

     219        07/02/21        USD        119.00        USD        2,539      $ (3,285 ) 

Amgen, Inc.

     59        07/02/21        USD        252.50        USD        1,438        (620 ) 

Anthem, Inc.

     52        07/02/21        USD        397.50        USD        1,985        (1,820 ) 

Centene Corp.

     72        07/02/21        USD        72.50        USD        525        (10,980 ) 

Cigna Corp.

     32        07/02/21        USD        270.00        USD        759        (320 ) 

Humana, Inc.

     43        07/02/21        USD        450.00        USD        1,904        (2,580 ) 

Intuitive Surgical, Inc.

     9        07/02/21        USD        815.00        USD        828        (94,500 ) 

Nektar Therapeutics

     93        07/02/21        USD        19.00        USD        160        (1,395 ) 

Sarepta Therapeutics, Inc.

     4        07/02/21        USD        84.00        USD        31        (30 ) 

AmerisourceBergen Corp.

     27        07/09/21        USD        119.00        USD        309        (1,553 ) 

Baxter International, Inc.

     150        07/09/21        USD        84.50        USD        1,208        (15,000 ) 

Cigna Corp.

     38        07/09/21        USD        262.50        USD        901        (3,420 ) 

Edwards Lifesciences Corp.

     245        07/09/21        USD        95.50        USD        2,537        (197,225 ) 

Eli Lilly & Co.

     45        07/09/21        USD        205.00        USD        1,033        (110,250 ) 

 

 

76  

2 0 2 1   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S


Schedule of Investments (unaudited) (continued)

June 30, 2021

  

BlackRock Health Sciences Trust (BME)

    

 

Exchange-Traded Options Written (continued)

 

Description    Number of
Contracts
     Expiration
Date
     Exercise Price     

Notional

Amount (000)

     Value  

Call (continued)

                    

Exact Sciences Corp.

     17        07/09/21        USD        120.00        USD        211      $ (9,775 ) 

Humana, Inc.

     16        07/09/21        USD        437.50        USD        708        (13,280 ) 

Intuitive Surgical, Inc.

     9        07/09/21        USD        885.00        USD        828        (35,055 ) 

McKesson Corp.

     12        07/09/21        USD        197.50        USD        229        (840 ) 

Medtronic PLC

     116        07/09/21        USD        130.00        USD        1,440        (1,334 ) 

Pfizer, Inc.

     415        07/09/21        USD        40.00        USD        1,625        (4,565 ) 

Teladoc Health, Inc.

     39        07/09/21        USD        165.00        USD        649        (19,792 ) 

UnitedHealth Group, Inc.

     70        07/09/21        USD        405.00        USD        2,803        (17,150 ) 

Vertex Pharmaceuticals, Inc.

     82        07/09/21        USD        217.50        USD        1,653        (11,890 ) 

ABIOMED, Inc.

     40        07/16/21        USD        310.00        USD        1,248        (38,400 ) 

Agilon Health, Inc.

     77        07/16/21        USD        35.00        USD        312        (45,815 ) 

Agios Pharmaceuticals, Inc.

     46        07/16/21        USD        65.00        USD        254        (1,380 ) 

Alignment Healthcare, Inc.

     89        07/16/21        USD        30.00        USD        208        (4,450 ) 

Allakos, Inc.

     42        07/16/21        USD        115.00        USD        359        (21,000 ) 

Allogene Therapeutics, Inc.

     116        07/16/21        USD        30.00        USD        303        (3,770 ) 

Alnylam Pharmaceuticals, Inc.

     57        07/16/21        USD        150.00        USD        966        (124,260 ) 

Amedisys, Inc.

     3        07/16/21        USD        270.00        USD        73        (330 ) 

Amgen, Inc.

     54        07/16/21        USD        250.00        USD        1,316        (6,345 ) 

Anthem, Inc.

     51        07/16/21        USD        390.00        USD        1,947        (11,857 ) 

Apellis Pharmaceuticals, Inc.

     41        07/16/21        USD        55.00        USD        259        (35,875 ) 

Arcutis Biotherapeutics, Inc.

     43        07/16/21        USD        30.00        USD        117        (2,043 ) 

Arena Pharmaceuticals, Inc.

     56        07/16/21        USD        65.00        USD        382        (23,380 ) 

Argenx SE, ADR

     12        07/16/21        USD        290.00        USD        361        (20,760 ) 

Avantor, Inc.

     180        07/16/21        USD        32.50        USD        639        (56,700 ) 

Becton Dickinson and Co.

     49        07/16/21        USD        250.00        USD        1,192        (5,390 ) 

Biohaven Pharmaceutical Holding Co. Ltd.

     3        07/16/21        USD        95.00        USD        29        (1,860 ) 

BioMarin Pharmaceutical, Inc.

     56        07/16/21        USD        85.00        USD        467        (6,720 ) 

Blueprint Medicines Corp.

     36        07/16/21        USD        100.00        USD        317        (2,880 ) 

Boston Scientific Corp.

     137        07/16/21        USD        43.00        USD        586        (9,179 ) 

Boston Scientific Corp.

     137        07/16/21        USD        44.00        USD        586        (5,001 ) 

Bristol-Myers Squibb Co.

     102        07/16/21        USD        67.50        USD        682        (4,437 ) 

Butterfly Network, Inc.

     69        07/16/21        USD        15.00        USD        100        (3,968 ) 

Centene Corp.

     103        07/16/21        USD        75.00        USD        751        (6,438 ) 

Cytokinetics, Inc.

     29        07/16/21        USD        28.00        USD        57        (4,350 ) 

DENTSPLY SIRONA, Inc.

     85        07/16/21        USD        70.00        USD        538        (3,400 ) 

Dicerna Pharmaceuticals, Inc.

     27        07/16/21        USD        30.00        USD        101        (20,520 ) 

Elanco Animal Health, Inc.

     249        07/16/21        USD        37.00        USD        864        (4,358 ) 

Enanta Pharmaceuticals, Inc.

     20        07/16/21        USD        50.00        USD        88        (1,100 ) 

Encompass Health Corp.

     72        07/16/21        USD        90.00        USD        562        (1,800 ) 

Encompass Health Corp.

     80        07/16/21        USD        85.00        USD        624        (2,400 ) 

Exact Sciences Corp.

     11        07/16/21        USD        130.00        USD        137        (2,530 ) 

Genmab A/S

     63        07/16/21        USD        40.00        USD        257        (15,750 ) 

Gilead Sciences, Inc.

     179        07/16/21        USD        72.50        USD        1,233        (2,417 ) 

Global Blood Therapeutics, Inc.

     52        07/16/21        USD        40.00        USD        182        (1,430 ) 

Global Blood Therapeutics, Inc.

     13        07/16/21        USD        45.00        USD        46        (98 ) 

Henry Schein, Inc.

     155        07/16/21        USD        82.50        USD        1,150        (26,350 ) 

Horizon Pharma PLC

     73        07/16/21        USD        100.00        USD        684        (8,213 ) 

Intuitive Surgical, Inc.

     19        07/16/21        USD        870.00        USD        1,747        (102,980 ) 

IQVIA Holdings, Inc.

     75        07/16/21        USD        250.00        USD        1,817        (9,375 ) 

Krystal Biotech, Inc.

     14        07/16/21        USD        75.00        USD        95        (3,325 ) 

LHC Group, Inc.

     29        07/16/21        USD        210.00        USD        581        (4,133 ) 

Masimo Corp.

     55        07/16/21        USD        218.00        USD        1,333        (133,431 ) 

McKesson Corp.

     6        07/16/21        USD        200.00        USD        115        (510 ) 

Medtronic PLC

     125        07/16/21        USD        130.00        USD        1,552        (2,688 ) 

Mirati Therapeutics, Inc.

     28        07/16/21        USD        175.00        USD        452        (3,780 ) 

Nevro Corp.

     28        07/16/21        USD        155.00        USD        464        (34,160 ) 

Novocure Ltd.

     34        07/16/21        USD        200.00        USD        754        (80,750 ) 

Oak Street Health, Inc.

     155        07/16/21        USD        70.00        USD        908        (2,325 ) 

Pfizer, Inc.

     416        07/16/21        USD        41.00        USD        1,629        (3,744 ) 

Prothena Corp. PLC

     21        07/16/21        USD        26.00        USD        108        (54,390 ) 

Prothena Corp. PLC

     59        07/16/21        USD        55.00        USD        303        (15,782 ) 

PTC Therapeutics, Inc.

     9        07/16/21        USD        50.00        USD        38        (135 ) 

 

 

S C H E D U L E   O F  I N V E S T M E N T S

  77


Schedule of Investments (unaudited) (continued)

June 30, 2021

  

BlackRock Health Sciences Trust (BME)

    

 

Exchange-Traded Options Written (continued)

 

Description    Number of
Contracts
     Expiration
Date
     Exercise Price     

Notional

Amount (000)

     Value  

Call (continued)

                    

Rapt Therapeutics, Inc.

     7        07/16/21        USD        25.00        USD        22      $ (4,935 ) 

Regeneron Pharmaceuticals, Inc.

     22        07/16/21        USD        540.00        USD        1,229        (54,450 ) 

ResMed, Inc.

     62        07/16/21        USD        200.00        USD        1,528        (289,850 ) 

Sarepta Therapeutics, Inc.

     2        07/16/21        USD        90.00        USD        16        (100 ) 

Sarepta Therapeutics, Inc.

     27        07/16/21        USD        95.00        USD        210        (1,080 ) 

Seagen, Inc.

     129        07/16/21        USD        160.00        USD        2,037        (38,700 ) 

Stryker Corp.

     110        07/16/21        USD        260.00        USD        2,857        (41,250 ) 

TCR2 Therapeutics, Inc.

     18        07/16/21        USD        22.50        USD        30        (1,350 ) 

Teladoc Health, Inc.

     9        07/16/21        USD        165.00        USD        150        (5,895 ) 

Teleflex, Inc.

     34        07/16/21        USD        420.00        USD        1,366        (15,980 ) 

Translate Bio, Inc.

     29        07/16/21        USD        25.00        USD        80        (9,425 ) 

UnitedHealth Group, Inc.

     45        07/16/21        USD        410.00        USD        1,802        (16,537 ) 

Zimmer Biomet Holdings, Inc.

     171        07/16/21        USD        170.00        USD        2,750        (5,985 ) 

Zoetis, Inc.

     126        07/16/21        USD        175.00        USD        2,348        (138,600 ) 

Arcutis Biotherapeutics, Inc.

     63        07/21/21        USD        30.00        USD        172        (3,584 ) 

Abbott Laboratories

     384        07/23/21        USD        111.00        USD        4,452        (239,040 ) 

AbbVie, Inc.

     94        07/23/21        USD        118.00        USD        1,059        (2,726 ) 

Amgen, Inc.

     53        07/23/21        USD        245.00        USD        1,292        (20,405 ) 

Bristol-Myers Squibb Co.

     43        07/23/21        USD        67.00        USD        287        (3,419 ) 

Cardinal Health, Inc.

     40        07/23/21        USD        60.50        USD        228        (2,100 ) 

Centene Corp.

     128        07/23/21        USD        72.00        USD        934        (30,400 ) 

Cigna Corp.

     74        07/23/21        USD        245.00        USD        1,754        (14,615 ) 

Edwards Lifesciences Corp.

     148        07/23/21        USD        102.00        USD        1,533        (47,360 ) 

Exact Sciences Corp.

     25        07/23/21        USD        120.00        USD        311        (20,500 ) 

Humana, Inc.

     37        07/23/21        USD        447.50        USD        1,638        (25,530 ) 

Illumina, Inc.

     31        07/23/21        USD        450.00        USD        1,467        (88,660 ) 

McKesson Corp.

     6        07/23/21        USD        200.00        USD        115        (1,065 ) 

Merck & Co., Inc.

     140        07/23/21        USD        78.00        USD        1,089        (16,240 ) 

Pfizer, Inc.

     857        07/23/21        USD        40.00        USD        3,356        (29,138 ) 

Teladoc Health, Inc.

     23        07/23/21        USD        167.50        USD        382        (14,662 ) 

Global Blood Therapeutics, Inc.

     30        07/29/21        USD        43.00        USD        105        (1,471 ) 

Stryker Corp.

     85        07/29/21        USD        262.78        USD        2,208        (33,532 ) 

Abbott Laboratories

     174        07/30/21        USD        115.00        USD        2,017        (58,290 ) 

AmerisourceBergen Corp.

     27        07/30/21        USD        120.00        USD        309        (2,970 ) 

Anthem, Inc.

     14        07/30/21        USD        392.50        USD        535        (7,980 ) 

Becton Dickinson and Co.

     48        07/30/21        USD        255.00        USD        1,167        (7,080 ) 

Boston Scientific Corp

     781        07/30/21        USD        43.50        USD        3,340        (71,071 ) 

Bristol-Myers Squibb Co.

     139        07/30/21        USD        67.00        USD        929        (17,305 ) 

Cardinal Health, Inc.

     146        07/30/21        USD        59.50        USD        834        (8,395 ) 

Centene Corp.

     75        07/30/21        USD        72.50        USD        547        (20,625 ) 

Cigna Corp.

     80        07/30/21        USD        237.50        USD        1,897        (43,200 ) 

Eli Lilly & Co.

     195        07/30/21        USD        225.00        USD        4,476        (168,187 ) 

Gilead Sciences, Inc.

     178        07/30/21        USD        68.50        USD        1,226        (44,589 ) 

Humana, Inc.

     39        07/30/21        USD        435.00        USD        1,727        (70,785 ) 

Illumina, Inc.

     22        07/30/21        USD        465.00        USD        1,041        (47,190 ) 

Intuitive Surgical, Inc.

     14        07/30/21        USD        900.00        USD        1,287        (55,930 ) 

Johnson & Johnson

     273        07/30/21        USD        165.00        USD        4,497        (77,941 ) 

Medtronic PLC

     141        07/30/21        USD        127.00        USD        1,750        (18,400 ) 

Merck & Co., Inc.

     140        07/30/21        USD        77.50        USD        1,089        (25,970 ) 

Pfizer, Inc.

     242        07/30/21        USD        40.50        USD        948        (9,317 ) 

Regeneron Pharmaceuticals, Inc.

     21        07/30/21        USD        560.00        USD        1,173        (38,010 ) 

UnitedHealth Group, Inc.

     194        07/30/21        USD        412.50        USD        7,769        (94,090 ) 

AbbVie, Inc.

     94        08/06/21        USD        114.00        USD        1,059        (17,813 ) 

Bristol-Myers Squibb Co.

     170        08/06/21        USD        67.00        USD        1,136        (24,055 ) 

Bristol-Myers Squibb Co.

     21        08/06/21        USD        68.00        USD        140        (2,174 ) 

Intuitive Surgical, Inc.

     12        08/06/21        USD        925.00        USD        1,104        (33,960 ) 

Johnson & Johnson

     302        08/06/21        USD        165.00        USD        4,975        (98,905 ) 

Medtronic PLC

     118        08/06/21        USD        124.00        USD        1,465        (33,689 ) 

UnitedHealth Group, Inc.

     51        08/06/21        USD        405.00        USD        2,042        (45,772 ) 

Bridgebio Pharma, Inc.

     39        08/10/21        USD        64.86        USD        238        (9,318 ) 

Amedisys, Inc.

     72        08/13/21        USD        267.00        USD        1,763        (37,690 ) 

Abbott Laboratories

     140        08/20/21        USD        115.00        USD        1,623        (57,750 ) 

 

 

78  

2 0 2 1   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S


Schedule of Investments (unaudited) (continued)

June 30, 2021

  

BlackRock Health Sciences Trust (BME)

    

 

Exchange-Traded Options Written (continued)

 

Description    Number of
Contracts
     Expiration
Date
     Exercise Price     

Notional

Amount (000)

     Value  

Call (continued)

                    

Acceleron Pharma, Inc.

     145        08/20/21        USD        140.00        USD        1,820      $ (44,950 ) 

Agilent Technologies, Inc.

     55        08/20/21        USD        145.00        USD        813        (37,125 ) 

Agilon Health, Inc.

     78        08/20/21        USD        39.50        USD        316        (26,550 ) 

Agios Pharmaceuticals, Inc.

     36        08/20/21        USD        65.00        USD        198        (2,970 ) 

Alcon AG

     128        08/20/21        USD        72.50        USD        899        (21,120 ) 

Alignment Healthcare, Inc.

     6        08/20/21        USD        30.00        USD        14        (390 ) 

Alignment Healthcare, Inc.

     95        08/20/21        USD        35.00        USD        222        (7,125 ) 

Allakos, Inc.

     42        08/20/21        USD        105.00        USD        359        (9,030 ) 

Alnylam Pharmaceuticals, Inc.

     72        08/20/21        USD        170.00        USD        1,221        (100,080 ) 

Amgen, Inc.

     71        08/20/21        USD        255.00        USD        1,731        (20,661 ) 

Apellis Pharmaceuticals, Inc.

     17        08/20/21        USD        63.50        USD        107        (8,759 ) 

Arcutis Biotherapeutics, Inc.

     21        08/20/21        USD        30.00        USD        57        (5,303 ) 

Argenx SE, ADR

     6        08/20/21        USD        320.00        USD        181        (7,230 ) 

Avantor, Inc.

     247        08/20/21        USD        35.00        USD        877        (51,870 ) 

Biohaven Pharmaceutical Holding Co. Ltd.

     24        08/20/21        USD        105.25        USD        233        (12,547 ) 

Boston Scientific Corp.

     351        08/20/21        USD        42.00        USD        1,501        (71,428 ) 

Bridgebio Pharma, Inc.

     12        08/20/21        USD        65.00        USD        73        (3,330 ) 

Bristol-Myers Squibb Co.

     122        08/20/21        USD        67.50        USD        815        (17,446 ) 

Cardinal Health, Inc.

     124        08/20/21        USD        60.00        USD        708        (13,950 ) 

Cytokinetics, Inc.

     31        08/20/21        USD        30.00        USD        61        (7,053 ) 

DENTSPLY SIRONA, Inc.

     135        08/20/21        USD        67.50        USD        854        (15,862 ) 

Dicerna Pharmaceuticals, Inc.

     29        08/20/21        USD        37.75        USD        108        (7,558 ) 

Eli Lilly & Co.

     207        08/20/21        USD        240.00        USD        4,751        (97,807 ) 

Genmab A/S

     88        08/20/21        USD        45.00        USD        359        (7,260 ) 

Gilead Sciences, Inc.

     429        08/20/21        USD        70.00        USD        2,954        (80,008 ) 

Incyte Corp.

     89        08/20/21        USD        85.00        USD        749        (40,495 ) 

IQVIA Holdings, Inc.

     43        08/20/21        USD        250.00        USD        1,042        (24,940 ) 

LHC Group, Inc.

     29        08/20/21        USD        210.01        USD        581        (13,317 ) 

Masimo Corp.

     29        08/20/21        USD        245.00        USD        703        (27,695 ) 

Medtronic PLC

     142        08/20/21        USD        130.00        USD        1,763        (16,046 ) 

Mirati Therapeutics, Inc.

     27        08/20/21        USD        180.00        USD        436        (12,082 ) 

Neurocrine Biosciences, Inc.

     69        08/20/21        USD        115.00        USD        672        (9,660 ) 

Nevro Corp.

     24        08/20/21        USD        175.00        USD        398        (15,000 ) 

Rapt Therapeutics, Inc.

     25        08/20/21        USD        35.00        USD        79        (7,063 ) 

ResMed, Inc.

     51        08/20/21        USD        240.00        USD        1,257        (76,245 ) 

Sanofi, ADR

     109        08/20/21        USD        53.28        USD        574        (12,863 ) 

Seagen, Inc.

     120        08/20/21        USD        170.00        USD        1,895        (54,600 ) 

Teleflex, Inc.

     38        08/20/21        USD        430.00        USD        1,527        (24,890 ) 

Thermo Fisher Scientific, Inc.

     83        08/20/21        USD        500.00        USD        4,187        (173,470 ) 

Translate Bio, Inc.

     29        08/20/21        USD        25.00        USD        80        (15,805 ) 

Zoetis, Inc.

     81        08/20/21        USD        185.00        USD        1,510        (53,865 ) 

LHC Group, Inc.

     18        09/17/21        USD        220.00        USD        360        (8,910 ) 
                    

 

 

 
                       (5,276,514 ) 
                    

 

 

 

Put

                    

Vertex Pharmaceuticals, Inc.

     79        07/16/21        USD        190.00        USD        1,593        (3,753 ) 
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 
                     $ (5,280,267 ) 
                    

 

 

 

OTC Options Written

 

Description   Counterparty    Number of
Contracts
     Expiration
Date
     Exercise Price      Notional
Amount (000)
     Value  

Call

                      

Mersana Therapeutics, Inc.

  Morgan Stanley & Co. International PLC      4,100        07/02/21        USD        15.42        USD        56      $ —  

Hansoh Pharmaceutical Group Co. Ltd.

  JPMorgan Chase Bank N.A.      82,000        07/07/21        HKD        35.52        HKD        2,782        (2,482 ) 

Sanofi

  Barclays Bank PLC      11,300        07/07/21        EUR        88.17        EUR        1,001        (14,028 ) 

Agiliti, Inc.

  Citibank N.A.      28,500        07/14/21        USD        22.05        USD        623        (27,478 ) 

Arcutis Biotherapeutics, Inc.

  JPMorgan Chase Bank N.A.      3,500        07/14/21        USD        33.00        USD        96        (219 ) 

Privia Health Group, Inc.

  Citibank N.A.      9,000        07/14/21        USD        41.74        USD        399        (35,911 ) 

Alcon AG

  Credit Suisse International      13,200        07/15/21        USD        71.76        USD        927        (5,836 ) 

Genmab A/S

  Morgan Stanley & Co. International PLC      1,400        07/15/21        DKK        2,504.07        DKK        3,597        (22,730 ) 

 

 

S C H E D U L E   O F  I N V E S T M E N T S

  79


Schedule of Investments (unaudited) (continued)

June 30, 2021

  

BlackRock Health Sciences Trust (BME)

    

 

OTC Options Written (continued)

 

Description   Counterparty    Number of
Contracts
     Expiration
Date
     Exercise Price      Notional
Amount (000)
     Value  

Call (continued)

                      

Straumann Holding AG, Registered Shares

  UBS AG      1,000        07/15/21        CHF        1,446.27        CHF        1,476      $ (46,571 ) 

Mersana Therapeutics, Inc.

  Morgan Stanley & Co. International PLC      4,100        07/16/21        USD        15.42        USD        56        (295 ) 

Genmab A/S

  Morgan Stanley & Co. International PLC      1,400        07/20/21        DKK        2,504.07        DKK        3,597        (24,620 ) 

Hansoh Pharmaceutical Group Co. Ltd.

  JPMorgan Chase Bank N.A.      86,000        07/20/21        HKD        35.86        HKD        2,918        (6,091 ) 

Sanofi

  UBS AG      8,300        07/20/21        EUR        88.44        EUR        735        (13,021 ) 

Wuxi Apptec Ltd., Class H

  Citibank N.A.      21,600        07/27/21        HKD        173.36        HKD        3,915        (35,968 ) 

Wuxi Biologics Cayman Inc.

  Goldman Sachs International      106,000        07/27/21        HKD        124.28        HKD        15,070        (258,174 ) 

Alcon AG

  Credit Suisse International      13,200        07/28/21        USD        72.46        USD        927        (10,802 ) 

Hansoh Pharmaceutical Group Co. Ltd.

  JPMorgan Chase Bank N.A.      34,000        07/29/21        HKD        33.72        HKD        1,154        (7,022 ) 

Zimmer Biomet Holdings, Inc.

  Barclays Bank PLC      6,800        08/03/21        USD        161.28        USD        1,094        (32,779 ) 

Hansoh Pharmaceutical Group Co. Ltd.

  Morgan Stanley & Co. International PLC      52,000        08/04/21        HKD        34.65        HKD        1,764        (8,819 ) 

Sanofi

  Morgan Stanley & Co. International PLC      6,600        08/04/21        EUR        89.05        EUR        585        (12,493 ) 

Eisai Co. Ltd.

  Goldman Sachs International      6,300        08/05/21        JPY        12,740.00        JPY        68,784        (552 ) 

Roche Holding AG

  JPMorgan Chase Bank N.A.      2,000        08/05/21        CHF        348.20        CHF        697        (16,154 ) 

TCR2 Therapeutics, Inc.

  Barclays Bank PLC      2,000        08/05/21        USD        20.34        USD        33        (1,113 ) 

Teladoc Health, Inc.

  Morgan Stanley & Co. LLC      1,200        08/06/21        USD        177.50        USD        200        (7,650 ) 

Sanofi, ADR

  Barclays Bank PLC      9,800        08/09/21        USD        53.00        USD        516        (10,852 ) 

Genmab A/S

  Citibank N.A.      4,300        08/10/21        USD        41.88        USD        176        (5,063 ) 

Hansoh Pharmaceutical Group Co. Ltd.

  JPMorgan Chase Bank N.A.      80,000        08/11/21        HKD        36.70        HKD        2,714        (8,152 ) 

Wuxi Apptec Ltd., Class H

  JPMorgan Chase Bank N.A.      48,000        08/11/21        HKD        188.75        HKD        8,699        (48,964 ) 

Oak Street Health, Inc.

  Citibank N.A.      5,200        08/12/21        USD        66.58        USD        305        (6,033 ) 

Roche Holding AG

  Barclays Bank PLC      1,100        08/12/21        CHF        354.03        CHF        384        (6,642 ) 

Genmab A/S

  Morgan Stanley & Co. International PLC      1,400        08/18/21        DKK        2,620.83        DKK        3,597        (15,686 ) 

Wuxi Apptec Ltd., Class H

  JPMorgan Chase Bank N.A.      18,700        08/18/21        HKD        193.99        HKD        3,389        (12,445 ) 

Guardant Health, Inc.

  JPMorgan Chase Bank N.A.      2,700        08/20/21        USD        126.56        USD        335        (17,857 ) 

Genmab A/S

  Morgan Stanley & Co. International PLC      1,400        08/25/21        DKK        2,620.67        DKK        3,597        (17,043 ) 
                      

 

 

 
                       $ (739,545 ) 
                      

 

 

 

Balances Reported in the Statements of Assets and Liabilities for Options Written

 

Description   Swap
Premiums
Paid
     Swap
Premiums
Received
     Unrealized
Appreciation
     Unrealized
Depreciation
     Value  

Options Written

  $  N/A      $  N/A      $ 1,258,466        $(2,105,394)        $(6,019,812)  

Derivative Financial Instruments Categorized by Risk Exposure

As of period end, the fair values of derivative financial instruments located in the Statements of Assets and Liabilities were as follows:

 

      Commodity
Contracts
   Credit
Contracts
     Equity
Contracts
     Foreign
Currency
Exchange
Contracts
    Interest
Rate
Contracts
     Other
Contracts
    Total  

Liabilities — Derivative Financial Instruments

                  

Options written

                  

Options written at value

   $             —    $ —      $ 6,019,812      $ —     $ —      $ —     $ 6,019,812  
  

 

  

 

 

    

 

 

    

 

 

   

 

 

    

 

 

   

 

 

 

For the six months ended June 30, 2021, the effect of derivative financial instruments in the Statements of Operations was as follows:

 

     Commodity
Contracts
     Credit
Contracts
     Equity
Contracts
    Foreign
Currency
Exchange
Contracts
     Interest
Rate
Contracts
     Other
Contracts
     Total  

Net Realized Gain (Loss) from

                  

Options written

  $ —      $ —      $ (3,095,078 )    $ —      $ —      $ —      $ (3,095,078 ) 
 

 

 

    

 

 

    

 

 

   

 

 

    

 

 

    

 

 

    

 

 

 

Net Change in Unrealized Appreciation (Depreciation) on

                  

Options written

  $ —      $ —      $ 465,819     $ —      $ —      $ —      $ 465,819  
 

 

 

    

 

 

    

 

 

   

 

 

    

 

 

    

 

 

    

 

 

 

 

 

80  

2 0 2 1   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S


Schedule of Investments (unaudited) (continued)

June 30, 2021

  

BlackRock Health Sciences Trust (BME)

    

 

Average Quarterly Balances of Outstanding Derivative Financial Instruments

 

Options

       

Average value of option contracts written

  $ 6,000,547  

For more information about the Trust’s investment risks regarding derivative financial instruments, refer to the Notes to Financial Statements.

Derivative Financial Instruments — Offsetting as of Period End

The Trust’s derivative assets and liabilities (by type) were as follows:

 

     Assets      Liabilities  

Derivative Financial Instruments

    

Options

  $ —      $ 6,019,812  
 

 

 

    

 

 

 

Total derivative assets and liabilities in the Statements of Assets and Liabilities

    —        6,019,812  
 

 

 

    

 

 

 

Derivatives not subject to a Master Netting Agreement or similar agreement (“MNA”)

    —        (5,280,267 ) 
 

 

 

    

 

 

 

Total derivative assets and liabilities subject to an MNA

  $ —      $ 739,545  
 

 

 

    

 

 

 

The following table presents the Trust’s derivative liabilities by counterparty net of amounts available for offset under an MNA and net of the related collateral pledged by the Trust:

 

Counterparty

   



Derivative
Liabilities
Subject to
an MNA by
Counterparty
 
 
 
 
 
    

Derivatives
Available
for Offset
 
 
 
    

Non-Cash
Collateral
Pledged
 
 
(a)  
   

Cash
Collateral
Pledged
 
 
(a)  
   

Net Amount
of Derivative
Liabilities
 
 
(b) 

Barclays Bank PLC

  $ 65,414      $ —      $ —     $ —     $ 65,414  

Citibank N.A.

    110,453        —        —       (110,453 )      —  

Credit Suisse International

    16,638        —        —       —       16,638  

Goldman Sachs International

    258,726        —        (258,726 )      —       —  

JPMorgan Chase Bank N.A.

    119,386        —        (119,386 )      —       —  

Morgan Stanley & Co. International PLC

    101,686        —        —       —       101,686  

Morgan Stanley & Co. LLC

    7,650        —        —       —       7,650  

UBS AG

    59,592        —        —       —       59,592  
 

 

 

    

 

 

    

 

 

   

 

 

   

 

 

 

  $ 739,545      $ —      $ (378,112 )    $ (110,453 )    $ 250,980  
 

 

 

    

 

 

    

 

 

   

 

 

   

 

 

 

 

  (a) 

Excess of collateral pledged to the individual counterparty is not shown for financial reporting purposes.

 
  (b) 

Net amount represents the net amount payable due to counterparty in the event of default. Net amount may be offset further by the options written receivable/payable on the Statements of Assets and Liabilities.

 

Fair Value Hierarchy as of Period End

Various inputs are used in determining the fair value of financial instruments. For a description of the input levels and information about the Trust’s policy regarding valuation of financial instruments, refer to the Notes to Financial Statements.

The following table summarizes the Trust’s financial instruments categorized in the fair value hierarchy. The breakdown of the Trust’s financial instruments into major categories is disclosed in the Schedule of Investments above.

 

      Level 1        Level 2        Level 3        Total  

Assets

                 

Investments

                 

Long-Term Investments

                 

Common Stocks

                 

Biotechnology

   $ 111,299,342        $ 11,631,711        $ 2,415,419        $ 125,346,472  

Diversified Financial Services

     1,957,943          —          —          1,957,943  

Health Care Equipment & Supplies

     160,266,166          3,135,963          —          163,402,129  

Health Care Providers & Services

     121,571,999          2,103,323          —          123,675,322  

Health Care Technology

     3,655,054          —          —          3,655,054  

Internet & Direct Marketing Retail

     —          2,331,701          —          2,331,701  

Life Sciences Tools & Services

     47,163,256          10,563,928          —          57,727,184  

Pharmaceuticals

     103,832,444          16,153,370          —          119,985,814  

Other Interests

     —          —          273,830          273,830  

 

 

S C H E D U L E   O F  I N V E S T M E N T S

  81


Schedule of Investments (unaudited) (continued)

June 30, 2021

  

BlackRock Health Sciences Trust (BME)

    

 

Fair Value Hierarchy as of Period End (continued)

 

      Level 1        Level 2        Level 3        Total  

Preferred Securities

                 

Preferred Stocks

   $ —        $ —        $ 3,749,284        $ 3,749,284  

Warrants

     201,622          —          —          201,622  

Short-Term Securities

                 

Money Market Funds

     9,977,621          —          —          9,977,621  
  

 

 

      

 

 

      

 

 

      

 

 

 
   $ 559,925,447        $ 45,919,996        $ 6,438,533          612,283,976  
  

 

 

      

 

 

      

 

 

      

 

 

 

Investments Valued at NAV(a)

                    431,237  
                 

 

 

 
                  $ 612,715,213  
                 

 

 

 

Derivative Financial Instruments(b)

                 

Liabilities

                 

Equity Contracts

   $ (4,979,647 )       $ (1,040,165 )       $ —        $ (6,019,812 ) 
  

 

 

      

 

 

      

 

 

      

 

 

 

 

  (a) 

Certain investments of the Trust were fair valued using NAV per share as no quoted market value is available and therefore have been excluded from the fair value hierarchy.

 
  (b) 

Derivative financial instruments are options written. Options written are shown at value.

 

A reconciliation of Level 3 financial instruments is presented when the Trust had a significant amount of Level 3 investments at the beginning and/or end of the period in relation to net assets. The following table is a reconciliation of Level 3 investments for which significant unobservable inputs were used in determining fair value:

 

     Common
Stocks
    Other
Interests
     Preferred
Stocks
    Total  

Assets

        

Opening balance, as of December 31, 2020

  $ 2,699,612     $ 254,814      $ 1,417,773     $ 4,372,199  

Transfers into Level 3

    —       —        —       —  

Transfers out of Level 3

    (132,438 )      —        (598,024 )      (730,462 ) 

Other(a)

    (235,430 )      —        235,430       —  

Accrued discounts/premiums

    —       —        —       —  

Net realized gain (loss)

    —       —        —       —  

Net change in unrealized appreciation (depreciation)(b)(c)

    83,675       19,016        (12,647 )      90,044  

Purchases

    —       —        3,206,753       3,206,753  

Sales

    —       —        (500,001 )      (500,001 ) 
 

 

 

   

 

 

    

 

 

   

 

 

 

Closing balance, as of June 30, 2021

  $ 2,415,419     $ 273,830      $ 3,749,284     $ 6,438,533  
 

 

 

   

 

 

    

 

 

   

 

 

 

Net change in unrealized appreciation (depreciation) on investments still held at June 30, 2021(c)

  $ 83,675     $ 19,016      $ (12,638 )    $ 90,053  
 

 

 

   

 

 

    

 

 

   

 

 

 

 

  (a) 

Certain Level 3 investments were re-classified between Common Stocks and Preferred Stocks.

 
  (b) 

Included in the related net change in unrealized appreciation (depreciation) in the Statements of Operations.

 
  (c) 

Any difference between net change in unrealized appreciation (depreciation) and net change in unrealized appreciation (depreciation) on investments still held at June 30, 2021 is generally due to investments no longer held or categorized as Level 3 at period end.

 

The following table summarizes the valuation approaches used and unobservable inputs utilized by the BlackRock Global Valuation Methodologies Committee (the “Global Valuation Committee”) to determine the value of certain of the Trust’s Level 3 financial instruments as of period end.

 

      Value       
Valuation
Approach
 
 
    

Unobservable

Inputs

 

 

    


Range of
Unobservable
Inputs
Utilized
 
 
 
(a)  
   



Weighted
Average of
Unobservable
Inputs Based
on Fair Value
 
 
 
 
 

Assets

            

Common Stocks

  $   2,415,419        Income       

Discount Rate

       1%       —  

Other Interests

    273,830        Income       

Discount Rate

       1% -2%       1%  

Preferred Stocks(b)

    3,749,284        Market       

Market Adjustment Multiple

       0.95x - 1.10x       1.00x  
         

Volatility

       82%       —  
         

Time to Exit

       3.0       —  

 

 

82  

2 0 2 1   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S


Schedule of Investments (unaudited) (continued)

June 30, 2021

  

BlackRock Health Sciences Trust (BME)

    

 

      Value       
Valuation
Approach
 
 
    

Unobservable

Inputs

 

 

    


Range of
Unobservable
Inputs
Utilized
 
 
 
(a)  
   



Weighted
Average of
Unobservable
Inputs Based
on Fair Value
 
 
 
 
 
          Recent Transactions        —       —  
 

 

 

            
  $ 6,438,533             
 

 

 

            

 

  (a) 

A significant change in unobservable input would have resulted in a correlated (inverse) significant change to value.

 
  (b) 

For the period end June 30, 2021, the valuation technique for investments classified as Preferred Stocks amounting to $795,430 changed to Current Value approach. The investments were previously valued utilizing Transaction Price approach. The change was due to consideration of the information that was available at the time the investments were valued.

 

See notes to financial statements.

 

 

S C H E D U L E   O F  I N V E S T M E N T S

  83


Schedule of Investments (unaudited)

June 30, 2021

  

BlackRock Health Sciences Trust II (BMEZ)

(Percentages shown are based on Net Assets)

 

Security   Shares     Value  
Common Stocks            
Biotechnology — 36.0%            

Acceleron Pharma, Inc.(a)(b)

    306,307     $     38,438,465  

Acumen Pharmaceuticals, Inc., (Acquired 11/20/20, Cost: $5,420,000)(c)

    1,426,503       21,397,545  

Agios Pharmaceuticals, Inc.(a)(b)

    430,220       23,709,424  

Akeso, Inc.(b)(d)

    2,608,000       21,033,573  

Akouos, Inc.(b)

    296,671       3,723,221  

Allakos, Inc.(a)(b)

    226,456       19,332,549  

Alnylam Pharmaceuticals, Inc.(a)(b)

    270,206       45,805,321  

ALX Oncology Holdings, Inc.(b)

    73,436       4,015,480  

Ambrx Biopharma, Inc., (Acquired 06/22/21, Cost: $14,580,000)(c)

    8,860,794       23,652,410  

Annexon, Inc.(b)

    115,174       2,592,567  

Annexon, Inc., (Acquired 06/26/20, Cost: $4,170,549)(c)

    332,856       7,492,589  

Antengene Corp. Ltd., (Acquired 11/18/20, Cost: $7,091,948)(c)

    5,019,274       12,373,157  

Apellis Pharmaceuticals, Inc.(b)

    165,816       10,479,571  

Applied Molecular Transport, Inc.(b)

    161,287       7,377,267  

Arcutis Biotherapeutics, Inc.(b)

    477,143       13,021,232  

Arena Pharmaceuticals, Inc.(a)(b)

    129,202       8,811,576  

Argenx SE, ADR(a)(b)

    117,843       35,478,992  

Arrowhead Pharmaceuticals, Inc.(b)

    83,508       6,916,133  

Avidity Biosciences, Inc.(b)

    288,706       7,133,925  

Beam Therapeutics, Inc.(b)

    36,988       4,760,725  

BioAtla, Inc.(b)

    142,704       6,047,796  

Biohaven Pharmaceutical Holding Co. Ltd.(b)

    119,802       11,630,378  

BioMarin Pharmaceutical, Inc.(b)

    106,412       8,879,017  

Biomea Fusion, Inc.(b)(e)

    521,404       8,139,116  

Blueprint Medicines Corp.(b)

    73,928       6,502,707  

Bridgebio Pharma, Inc.(b)

    217,158       13,237,952  

C4 Therapeutics, Inc.(b)

    377,822       14,296,785  

CareDx, Inc.(b)

    220,971       20,223,266  

Cerevel Therapeutics Holdings, Inc.(b)

    204,554       5,240,674  

Connect Biopharma Holdings Ltd.(b)(e)

    73,308       1,431,705  

Connect Biopharma Holdings Ltd., (Acquired 12/01/20, Cost: $14,579,981)(c)

    1,330,134       25,421,887  

Cytokinetics, Inc.(b)

    285,386       5,647,789  

Decibel Therapeutics, Inc., (Acquired 11/02/20, Cost: $5,826,938)(c)

    636,792       5,412,520  

Decibel Therapeutics, Inc.(b)

    161,538       1,389,227  

Deciphera Pharmaceuticals, Inc.(b)

    80,050       2,930,631  

Design Therapeutics, Inc., (Acquired 01/25/21, Cost: $10,000,003)(c)

    936,636       18,194,997  

Dicerna Pharmaceuticals, Inc.(b)

    391,382       14,606,376  

Enanta Pharmaceuticals, Inc.(b)

    69,510       3,059,135  

Everest Medicines Ltd., (Acquired 05/29/20, Cost: $11,209,200)(c)

    3,113,667       30,979,068  

Everest Medicines Ltd.(b)(d)(e)

    446,500       4,438,522  

Fate Therapeutics, Inc.(b)

    56,308       4,886,971  

Forma Therapeutics Holdings, Inc.(b)

    528,851       13,163,101  

Fusion Pharmaceuticals, Inc.(b)

    425,054       3,434,436  

Genetron Holdings Ltd., ADR(b)

    944,676       19,025,775  

Genmab A/S(b)

    212,666       87,138,294  

Genmab A/S, ADR(a)(b)

    753,955       30,783,983  

Global Blood Therapeutics, Inc.(b)

    394,678       13,821,624  

Gracell Biotechnologies, Inc., ADR(b)

    845,451       10,990,863  

Gritstone bio, Inc.(b)

    320,160       2,923,061  

HBM Holdings Ltd.(b)(d)

    7,553,000       9,620,860  

Horizon Therapeutics PLC(b)

    228,802       21,425,019  

Ideaya Biosciences, Inc.(b)

    317,801       6,670,643  
Security   Shares     Value  

Biotechnology (continued)

   

Immunocore Holdings PLC, ADR(b)

    61,703     $ 2,409,502  

Immunocore Ltd., (Acquired 12/21/20, Cost: $5,861,799)(c)

    321,900       12,447,985  

Insmed, Inc.(b)

    129,404       3,682,838  

Kadmon Holdings, Inc.(b)

    2,455,865       9,504,198  

Keros Therapeutics, Inc.(b)

    206,755       8,780,885  

Kinnate Biopharma, Inc.(b)

    304,595       7,090,972  

Kodiak Sciences, Inc.(b)

    89,926       8,363,118  

Kronos Bio, Inc., (Acquired 10/09/20, Cost: $4,591,000), 8/20/2020(c)

    284,272       6,808,314  

Krystal Biotech, Inc.(b)

    113,540       7,720,720  

Kymera Therapeutics, Inc.(b)

    738,191       35,802,264  

Mersana Therapeutics, Inc.(b)

    1,518,223       20,617,468  

Mirati Therapeutics, Inc.(a)(b)

    97,655       15,774,212  

Monte Rosa Therapeutics, Inc., (Acquired 03/11/21, Cost: $7,999,998)(c)

    764,573       16,516,943  

Morphic Holding, Inc.(b)

    97,810       5,613,316  

Natera, Inc.(b)

    174,875       19,853,559  

Nkarta, Inc.(b)

    143,310       4,541,494  

Olema Pharmaceuticals, Inc.(b)

    636,734       17,815,817  

ORIC Pharmaceuticals, Inc.(b)

    191,303       3,384,150  

PMV Pharmaceuticals, Inc.(b)

    472,036       16,124,750  

Praxis Precision Medicines, Inc.(b)

    16,198       296,099  

Prometheus Biosciences, Inc.(b)

    316,988       7,785,225  

Prothena Corp. PLC(b)

    353,623       18,179,758  

PTC Therapeutics, Inc.(b)

    211,663       8,946,995  

Rapt Therapeutics, Inc.(b)

    184,017       5,849,900  

Relay Therapeutics, Inc.(b)

    59,826       2,189,033  

Remegen Co. Ltd., Class H(b)(d)

    534,000       8,144,493  

Revolution Medicines, Inc.(b)

    100,563       3,191,870  

Rubius Therapeutics, Inc.(b)

    165,785       4,046,812  

Sarepta Therapeutics, Inc.(a)(b)

    70,856       5,508,345  

Seagen, Inc.(a)(b)(f)

    531,710       83,946,375  

Seres Therapeutics, Inc.(b)

    348,666       8,315,684  

Sigilon Therapeutics, Inc.(b)

    581,839       6,243,132  

Stoke Therapeutics, Inc.(b)

    134,172       4,516,230  

Talaris Therapeutics, Inc., (Acquired 09/30/20, Cost: $7,369,358)(c)

    748,614       10,612,240  

Taysha Gene Therapies, Inc.(b)

    448,538       9,509,006  

TCR2 Therapeutics, Inc.(b)

    222,535       3,651,799  

Translate Bio, Inc.(b)

    186,305       5,130,840  

United Therapeutics Corp.(a)(b)

    57,411       10,300,108  

Voyager Therapeutics, Inc.(b)

    255,970       1,057,156  

Zai Lab Ltd., ADR(b)

    189,238       33,493,234  

Zentalis Pharmaceuticals, Inc.(b)

    221,186       11,767,095  

Zymeworks, Inc.(b)

    245,566       8,518,685  
   

 

 

 
      1,233,192,519  
Diversified Financial Services(b) — 1.4%  

BCTG Acquisition Corp.

    167,744       1,907,249  

Eucrates Biomedical Acquisition Corp.(g)

    897,657       8,837,433  

Health Assurance Acquisition Corp., Class A

    1,361,273       13,626,343  

Health Sciences Acquisitions Corp.

    233,344       2,380,109  

Helix Acquisition Corp., Class A

    216,150       2,232,829  

Lifesci Acquisition II Corp.(g)

    728,200       7,282,000  

MedTech Acquisition Corp., Class A

    917,284       8,952,692  

Therapeutics Acquisition Corp., Class A

    407,000       4,183,960  
   

 

 

 
      49,402,615  
Electronic Equipment, Instruments & Components — 0.3%  

908 Devices, Inc.(b)(e)

    282,484       10,946,255  
   

 

 

 
Health Care Equipment & Supplies — 23.9%  

ABIOMED, Inc.(a)(b)

    78,093       24,373,606  
 

 

 

84  

2 0 2 1   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S


Schedule of Investments (unaudited) (continued)

June 30, 2021

  

BlackRock Health Sciences Trust II (BMEZ)

(Percentages shown are based on Net Assets)

 

Security   Shares     Value  
Health Care Equipment & Supplies (continued)  

Alcon, Inc.

    758,750     $ 53,309,775  

Angelalign Technology, Inc.(b)(d)

    15,400       794,565  

Butterfly Network, Inc.(b)(e)

    485,650       7,032,212  

Cardiovascular Systems, Inc.(b)

    164,491       7,015,541  

ConvaTec Group PLC(d)

    4,546,400       15,131,418  

Cooper Cos., Inc.

    60,705       24,055,570  

Demant A/S(b)

    480,791       27,094,698  

DexCom, Inc.(a)(b)

    58,156       24,832,612  

Edwards Lifesciences Corp.(b)

    274,041       28,382,426  

GN Store Nord A/S

    301,475       26,363,955  

Hill-Rom Holdings, Inc.(a)

    142,465       16,182,599  

Insulet Corp.(b)

    139,019       38,162,106  

Intuitive Surgical, Inc.(b)(f)

    72,553       66,722,641  

Kangji Medical Holdings Ltd.(e)

    4,870,919       8,095,749  

Masimo Corp.(b)

    214,664       52,045,287  

Nevro Corp.(a)(b)

    243,330       40,341,681  

Novocure Ltd.(b)

    25,885       5,741,811  

NuVasive, Inc.(b)

    133,755       9,065,914  

Penumbra, Inc.(a)(b)

    61,955       16,979,387  

Pulmonx Corp.(b)

    108,476       4,785,961  

ResMed, Inc.(a)

    204,886       50,508,497  

Shenzhen Mindray Bio-Medical Electronics Co. Ltd., Class A

    287,653       21,308,656  

SI-BONE, Inc.(b)

    155,808       4,903,278  

Silk Road Medical, Inc.(b)

    211,418       10,118,465  

Sonova Holding AG, Registered Shares

    79,726       30,029,170  

STERIS PLC

    135,782       28,011,827  

Straumann Holding AG, Registered Shares

    36,658       58,471,113  

Tandem Diabetes Care, Inc.(a)(b)

    147,331       14,350,039  

Teleflex, Inc.

    140,510       56,455,513  

Zimmer Biomet Holdings, Inc.

    300,735       48,364,203  
   

 

 

 
      819,030,275  
Health Care Providers & Services — 15.0%            

Addus HomeCare Corp.(b)

    43,339       3,780,894  

Agilon Health, Inc.(b)

    282,683       11,468,449  

Alignment Healthcare, Inc.(b)

    349,917       8,177,560  

Amedisys, Inc.(a)(b)(f)

    224,896       55,083,777  

Amplifon SpA

    629,668       31,133,122  

Cano Health, Inc., (Acquired 06/03/21, Cost: $21,741,890)(c)

    2,174,189       26,066,532  

Cardinal Health, Inc.

    433,660       24,757,650  

CareMax, Inc., (Acquired 06/08/21, Cost: $14,077,000)(c)

    1,407,700       17,664,992  

CareMax, Inc.(b)

    319,040       4,115,616  

Centene Corp.(a)(b)

    423,582       30,891,835  

Chemed Corp.

    23,666       11,229,517  

Encompass Health Corp.(a)

    403,202       31,461,852  

Guardant Health, Inc.(b)

    140,410       17,437,518  

Humana, Inc.

    87,998       38,958,475  

Innovage Holding Corp.(b)

    83,873       1,787,334  

Jinxin Fertility Group Ltd.(d)

    19,001,100       47,890,775  

LHC Group, Inc.(a)(b)

    241,129       48,288,494  

LifeStance Health Group, Inc.(b)

    417,013       11,617,982  

Oak Street Health, Inc.(b)(f)

    1,236,532       72,423,679  

Privia Health Group, Inc.(b)

    137,329       6,093,288  

Rede D’Or Sao Luiz SA(d)

    869,415       12,066,371  
   

 

 

 
      512,395,712  
Security   Shares      Value  
Health Care Technology(b) — 1.5%             

Certara, Inc.

    504,495      $ 14,292,343  

Doximity, Inc., Class A

    98,503        5,732,875  

Teladoc Health, Inc.

    190,098        31,611,396  
    

 

 

 
       51,636,614  
Internet & Direct Marketing Retail — 0.7%  

JD Health International, Inc.(b)(d)

    1,667,600        23,818,340  
    

 

 

 
Life Sciences Tools & Services — 10.5%  

Avantor, Inc.(b)

    746,918        26,523,058  

Berkeley Lights, Inc.(a)(b)

    330,537        14,811,363  

Bruker Corp.

    216,025        16,413,580  

Charles River Laboratories International, Inc.(a)(b)

    88,682        32,805,246  

Gerresheimer AG

    152,221        16,836,762  

Illumina, Inc.(a)(b)

    34,293        16,227,791  

IQVIA Holdings, Inc.(a)(b)

    140,247        33,984,653  

Joinn Laboratories China Co. Ltd., Class H(d)

    395,220        6,349,420  

Lonza Group AG, Registered Shares

    34,812        24,680,193  

Nautilus Biotechnology, Inc.(b)

    324,000        3,272,400  

Olink Holding AB, ADR(b)

    30,344        1,044,441  

Sotera Health Co.(b)

    1,216,066        29,465,279  

WuXi AppTec Co. Ltd., Class H(d)

    2,794,392        65,225,486  

Wuxi Biologics Cayman, Inc.(b)(d)

    3,867,303        70,811,408  
    

 

 

 
       358,451,080  
Pharmaceuticals — 4.3%             

Antengene Corp. Ltd.(b)(d)

    2,537,500        6,245,150  

Eisai Co. Ltd.

    241,400        23,724,118  

Hansoh Pharmaceutical Group Co.
Ltd.(d)

    9,062,068        39,597,947  

Marinus Pharmaceuticals, Inc.(b)

    330,305        5,925,672  

Merck KGaA

    102,956        19,754,800  

Nektar Therapeutics(b)

    345,460        5,928,094  

Nuvation Bio, Inc.(b)

    206,640        1,923,818  

Relmada Therapeutics, Inc.(b)

    255,648        8,183,292  

UCB SA

    354,931        37,172,502  
    

 

 

 
       148,455,393  
    

 

 

 

Total Common Stocks — 93.6%
(Cost: $2,123,926,266)

       3,207,328,803  
    

 

 

 

Preferred Securities

    

Preferred Stocks — 7.5%(c)(h)

    
Biotechnology — 4.2%             

Cellarity, Inc., Series B, (Acquired 01/15/21, Cost: $14,584,998)

    2,430,833        13,855,748  

Abbisko Cayman Ltd., (Acquired 12/21/20, Cost: $14,841,983)

    1,037,825        14,841,986  

Affinvax, Inc., Series C, (Acquired 01/06/21, Cost: $5,786,041)

    183,164        5,786,041  

Amunix Pharmaceuticals, Inc., Series B, (Acquired 02/26/21, Cost: $9,999,999)

    5,657,068        9,999,999  

Bright Peak Therapeutics AG, Series B, (Acquired 05/14/21, Cost: $8,000,004)

    2,048,132        8,000,004  

Goldfinch Bio, Inc., Series B, (Acquired 06/26/20, Cost: $3,029,231)

    2,567,145        3,311,617  

Imago Biosciences, Inc., (Acquired 11/12/20, Cost: $10,000,009)

    8,279,524        10,018,224  

Immuneering Corp, Series B, (Acquired 12/21/20, Cost: $5,999,982)

    583,758        6,001,032  
 

 

 

S C H E D U L E    O F   I N V E S T M E N T S

  85


Schedule of Investments (unaudited) (continued)

June 30, 2021

  

BlackRock Health Sciences Trust II (BMEZ)

(Percentages shown are based on Net Assets)

 

Security   Shares     Value  
Biotechnology (continued)  

IsoPlexis Corp., Series D, (Acquired 12/30/20, Cost: $14,800,023)

    192,408     $ 15,606,213  

LianBio, Series A, (Acquired 10/28/20, Cost: $5,960,632)

    105,200       6,538,180  

Neurogene, Inc., Series B, (Acquired 12/14/20, Cost: $5,729,950)

    2,348,340       5,729,950  

NiKang Therapeutics, Inc., Series C, (Acquired 05/20/21, Cost: $7,999,996)

    1,394,189       7,999,996  

Numab Therapeutics AG, (Acquired 05/07/21, Cost: $7,770,441)

    815,851       7,565,525  

Omega Therapeutics, Inc., Series C, (Acquired 03/04/21,
Cost: $7,999,998)(g)

    2,666,666       7,999,998  

OnKure, Inc., Series B, (Acquired 03/03/21, Cost: $2,250,000)

    814,244       2,250,000  

Rapid Micro Biosystems, Inc., Series D, (Acquired 03/09/21, Cost: $9,896,004)

    2,748,890       9,896,004  

TScan Therapeutics, Inc., Series C, (Acquired 01/15/21, Cost: $9,999,999)

    7,013,606       9,999,992  
   

 

 

 
      145,400,509  
Health Care Equipment & Supplies — 1.0%  

Exo Imaging, Inc., Series C, (Acquired 06/24/21, Cost: $13,225,003)

    2,257,597       13,225,003  

Nucleix Ltd., Series AA, (Acquired 03/25/21, Cost: $6,929,998)

    2,379,480       6,929,998  

Quanta Dialysis Technologies Ltd., Series D, (Acquired 06/18/21,
Cost: $14,071,890)

    115,766,240       14,088,587  
   

 

 

 
      34,243,588  
Health Care Services — 1.1%  

Adicon Holdings Ltd., (Acquired 12/22/20, Cost: $17,840,000)

    2,139,245,197       19,323,802  

Everly Well, Inc., Series D, (Acquired 11/25/20, Cost: $9,999,986)

    382,775       18,599,037  
   

 

 

 
      37,922,839  
Pharmaceuticals — 0.8%            

Insitro, Inc.

   

Series B, (Acquired 05/21/20, Cost: $5,000,000)

    802,478       14,677,322  

Series C, (Acquired 03/10/21, Cost: $3,600,018)

    196,818       3,600,018  

Vividion Therapeutics, Inc., Series C, (Acquired 02/18/21, Cost: $8,000,000)

    3,809,524       7,619,048  
   

 

 

 
      25,896,388  
Semiconductors & Semiconductor Equipment — 0.4%  

PsiQuantum Corp., Series D, (Acquired 05/21/21, Cost: $14,999,996)

    571,947       15,002,170  
   

 

 

 

Total Preferred Stocks — 7.5%

 

    258,465,494  
   

 

 

 

Total Preferred Securities — 7.5%
(Cost: $238,316,181)

 

    258,465,494  
   

 

 

 

Warrants

   
Biotechnology — 0.0%  

Cerevel Therapeutics Holdings, Inc. (Expires 10/27/2025)(b)

    68,184       972,304  
   

 

 

 
Security   Shares     Value  
Diversified Financial Services(b) — 0.1%  

Eucrates Biomedical Acquisition Corp. (Expires 12/14/2025)

    299,219     $ 308,195  

Health Assurance Acquisition Corp. (Expires 11/12/2025)

    340,318       609,169  

MedTech Acquisition Corp. (Expires 12/18/2025)

    305,761       303,529  
   

 

 

 
      1,220,893  
Health Care Equipment & Supplies — 0.0%  

Butterfly Network, Inc.
(Expires 05/27/2025)(b)

    162,183       783,344  
   

 

 

 
Health Care Providers & Services — 0.0%  

CareMax, Inc. (Expires 06/08/2026)(b)

    63,808       301,174  
   

 

 

 
Pharmaceuticals — 0.0%            

Nuvation Bio, Inc. (Expires 07/07/2027)(b)

    68,880       179,095  
   

 

 

 

Total Warrants — 0.1%
(Cost: $2,676,284)

 

    3,456,810  
   

 

 

 

Total Long-Term Investments — 101.2%
(Cost: $2,364,918,731)

 

    3,469,251,107  
   

 

 

 

Short-Term Securities

 

Money Market Funds — 0.2%  

SL Liquidity Series, LLC, Money Market Series, 0.13%(g)(i)(j)

    6,243,159       6,245,032  
   

 

 

 

Total Short-Term Securities — 0.2%
(Cost: $6,245,032)

 

    6,245,032  
   

 

 

 

Total Investments Before Options Written — 101.4%
(Cost: $2,371,163,763)

 

    3,475,496,139  
   

 

 

 

Options Written — (1.1)%
(Premiums Received: $(26,477,309))

 

    (36,875,732 ) 
   

 

 

 

Total Investments, Net of Options Written — 100.3%
(Cost: $2,344,686,454)

 

    3,438,620,407  

Liabilities in Excess of Other Assets — (0.3)%

 

    (10,590,795 ) 
   

 

 

 

Net Assets — 100.0%

 

  $   3,428,029,612  
   

 

 

 

 

(a) 

All or a portion of the security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written.

(b) 

Non-income producing security.

(c) 

Restricted security as to resale, excluding 144A securities. The Trust held restricted securities with a current value of $493,506,673, representing 14.4% of its net assets as of period end, and an original cost of $372,835,845.

(d) 

Security exempt from registration pursuant to Rule 144A under the Securities Act of 1933, as amended. These securities may be resold in transactions exempt from registration to qualified institutional investors.

(e) 

All or a portion of this security is on loan.

(f) 

All or a portion of the security has been pledged as collateral in connection with outstanding OTC derivatives.

(g) 

Affiliate of the Trust.

(h) 

Security is valued using significant unobservable inputs and is classified as Level 3 in the fair value hierarchy.

(i) 

Annualized 7-day yield as of period end.

(j) 

All or a portion of this security was purchased with the cash collateral from loaned securities.

 

 

 

For Trust compliance purposes, the Trust’s industry classifications refer to one or more of the industry sub-classifications used by one or more widely recognized market indexes or rating group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.

 

 

86  

2 0 2 1   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S


Schedule of Investments (unaudited) (continued)

June 30, 2021

  

BlackRock Health Sciences Trust II (BMEZ)

    

 

Affiliates

Investments in issuers considered to be affiliate(s) of the Trust during the six-months ended June 30, 2021 for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

 

Affiliated Issuer   Value at
12/31/20
    Purchases
at Cost
    Proceeds
from Sales
    Net
Realized
Gain (Loss)
    Change in
Unrealized
Appreciation
(Depreciation)
    Value at
06/30/21
    Shares
Held at
06/30/21
    Income     Capital Gain
Distributions
from
Underlying
Funds
 

BlackRock Liquidity Funds, T-Fund, Institutional
Class(a)

  $ 18,347,773     $ —     $ (18,347,773 )(b)    $ —     $ —     $ —       —     $ 4,302       —  

Eucrates Biomedical Acquisition Corp.

    —       8,555,569       —       —       281,864       8,837,433       897,657       —       —  

Lifesci Acquisition II Corp.

    7,733,484       —       —       —       (451,484 )      7,282,000       728,200       —       —  

Omega Therapeutics, Inc., Series C

    —       7,999,998       —       —       —       7,999,998       2,666,666       —       —  

SL Liquidity Series, LLC, Money Market Series

    9,577,689       —       (3,332,796 )(b)      139       —       6,245,032       6,243,159       116,400 (c)      —  
       

 

 

   

 

 

   

 

 

     

 

 

   

 

 

 
        $ 139     $ (169,620 )    $   30,364,463       $   120,702     $ —  
       

 

 

   

 

 

   

 

 

     

 

 

   

 

 

 

 

  (a) 

As of period end, the entity is no longer an affiliate.

 
  (b) 

Represents net amount purchased (sold).

 
  (c) 

All or a portion represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of fees and collateral investment expenses, and other payments to and from borrowers of securities.

 

Derivative Financial Instruments Outstanding as of Period End

Exchange-Traded Options Written

 

Description    Number of
Contracts
       Expiration
Date
       Exercise Price       

Notional

Amount (000)

       Value  

Call

                                

Centene Corp.

     288          07/02/21          USD          72.50          USD          2,100        $ (43,920 ) 

Humana, Inc.

     85          07/02/21          USD          450.00          USD          3,763          (5,100 ) 

Intuitive Surgical, Inc.

     39          07/02/21          USD          815.00          USD          3,587          (409,500 ) 

Nektar Therapeutics

     536          07/02/21          USD          19.00          USD          920          (8,040 ) 

Sarepta Therapeutics, Inc.

     23          07/02/21          USD          84.00          USD          179          (173 ) 

Edwards Lifesciences Corp.

     293          07/09/21          USD          95.50          USD          3,035          (235,865 ) 

Humana, Inc.

     54          07/09/21          USD          437.50          USD          2,391          (44,820 ) 

Intuitive Surgical, Inc.

     42          07/09/21          USD          885.00          USD          3,862          (163,590 ) 

Teladoc Health, Inc.

     55          07/09/21          USD          165.00          USD          915          (27,913 ) 

ABIOMED, Inc.

     234          07/16/21          USD          310.00          USD          7,303          (224,640 ) 

Addus HomeCare Corp.

     130          07/16/21          USD          90.00          USD          1,134          (10,400 ) 

Agilon Health, Inc.

     424          07/16/21          USD          35.00          USD          1,720          (252,280 ) 

Agios Pharmaceuticals, Inc.

     604          07/16/21          USD          65.00          USD          3,329          (18,120 ) 

Alignment Healthcare, Inc.

     490          07/16/21          USD          30.00          USD          1,145          (24,500 ) 

Allakos, Inc.

     343          07/16/21          USD          115.00          USD          2,928          (171,500 ) 

Alnylam Pharmaceuticals, Inc.

     428          07/16/21          USD          150.00          USD          7,255          (933,040 ) 

Amedisys, Inc.

     346          07/16/21          USD          270.00          USD          8,475          (38,060 ) 

Apellis Pharmaceuticals, Inc.

     239          07/16/21          USD          55.00          USD          1,510          (209,125 ) 

Applied Molecular Transport, Inc.

     220          07/16/21          USD          55.00          USD          1,006          (55,550 ) 

Arcutis Biotherapeutics, Inc.

     107          07/16/21          USD          30.00          USD          292          (5,083 ) 

Arena Pharmaceuticals, Inc.

     387          07/16/21          USD          65.00          USD          2,639          (161,572 ) 

Argenx SE, ADR

     177          07/16/21          USD          290.00          USD          5,329          (306,210 ) 

Arrowhead Pharmaceuticals, Inc.

     130          07/16/21          USD          80.00          USD          1,077          (80,600 ) 

Avantor, Inc.

     1,107          07/16/21          USD          32.50          USD          3,931          (348,705 ) 

Berkeley Lights, Inc.

     391          07/16/21          USD          45.00          USD          1,752          (78,200 ) 

Biohaven Pharmaceutical Holding Co.

     90          07/16/21          USD          80.00          USD          874          (159,300 ) 

Biohaven Pharmaceutical Holding Co. Ltd.

     117          07/16/21          USD          95.00          USD          1,136          (72,540 ) 

BioMarin Pharmaceutical, Inc.

     319          07/16/21          USD          85.00          USD          2,662          (38,280 ) 

Blueprint Medicines Corp.

     221          07/16/21          USD          100.00          USD          1,944          (17,680 ) 

Bruker Corp.

     648          07/16/21          USD          70.00          USD          4,924          (392,040 ) 

Butterfly Network, Inc.

     731          07/16/21          USD          15.00          USD          1,058          (42,033 ) 

Cardiovascular Systems, Inc.

     230          07/16/21          USD          40.00          USD          981          (74,175 ) 

CareDx, Inc.

     182          07/16/21          USD          80.00          USD          1,666          (221,130 ) 

Centene Corp.

     312          07/16/21          USD          75.00          USD          2,275          (19,500 ) 

Certara, Inc.

     93          07/16/21          USD          30.00          USD          263          (8,370 ) 

Charles River Laboratories International, Inc.

     126          07/16/21          USD          330.00          USD          4,661          (509,040 ) 

 

 

S C H E D U L E    O F   I N V E S T M E N T S

  87


Schedule of Investments (unaudited) (continued)

June 30, 2021

  

BlackRock Health Sciences Trust II (BMEZ)

    

 

Exchange-Traded Options Written (continued)

 

Description    Number of
Contracts
       Expiration
Date
       Exercise Price       

Notional

Amount (000)

       Value  

Call (continued)

                                

Chemed Corp.

     70          07/16/21          USD          510.00          USD          3,322        $ (35,000 ) 

Cooper Cos., Inc.

     91          07/16/21          USD          390.00          USD          3,606          (84,630 ) 

Cytokinetics, Inc.

     431          07/16/21          USD          28.00          USD          853          (64,650 ) 

Deciphera Pharmaceuticals, Inc.

     240          07/16/21          USD          40.00          USD          879          (12,600 ) 

DexCom, Inc.

     174          07/16/21          USD          410.00          USD          7,430          (368,880 ) 

Dicerna Pharmaceuticals, Inc.

     549          07/16/21          USD          30.00          USD          2,049          (417,240 ) 

Enanta Pharmaceuticals, Inc.

     208          07/16/21          USD          50.00          USD          915          (11,440 ) 

Encompass Health Corp.

     649          07/16/21          USD          90.00          USD          5,064          (16,225 ) 

Encompass Health Corp.

     560          07/16/21          USD          85.00          USD          4,370          (16,800 ) 

Genmab A/S

     937          07/16/21          USD          40.00          USD          3,826          (234,250 ) 

Global Blood Therapeutics, Inc.

     563          07/16/21          USD          40.00          USD          1,972          (15,483 ) 

Global Blood Therapeutics, Inc.

     267          07/16/21          USD          45.00          USD          935          (2,003 ) 

Guardant Health, Inc.

     250          07/16/21          USD          130.00          USD          3,105          (50,625 ) 

Hill-Rom Holdings, Inc.

     252          07/16/21          USD          115.00          USD          2,862          (28,980 ) 

Horizon Pharma PLC

     486          07/16/21          USD          100.00          USD          4,551          (54,675 ) 

Insmed, Inc.

     194          07/16/21          USD          32.00          USD          552          (6,305 ) 

Insulet Corp.

     117          07/16/21          USD          260.00          USD          3,212          (228,735 ) 

Intuitive Surgical, Inc.

     76          07/16/21          USD          870.00          USD          6,989          (411,920 ) 

IQVIA Holdings, Inc.

     146          07/16/21          USD          250.00          USD          3,538          (18,250 ) 

Kadmon Holdings, Inc.

     17          07/16/21          USD          5.00          USD          7          (298 ) 

Kodiak Sciences, Inc.

     135          07/16/21          USD          90.00          USD          1,256          (93,825 ) 

Krystal Biotech, Inc.

     336          07/16/21          USD          75.00          USD          2,285          (79,800 ) 

Kymera Therapeutics, Inc.

     1,062          07/16/21          USD          55.00          USD          5,151          (191,160 ) 

LHC Group, Inc.

     230          07/16/21          USD          210.00          USD          4,606          (32,775 ) 

Marinus Pharmaceuticals, Inc.

     200          07/16/21          USD          18.00          USD          359          (17,000 ) 

Marinus Pharmaceuticals, Inc.

     460          07/16/21          USD          16.00          USD          825          (123,050 ) 

Masimo Corp.

     475          07/16/21          USD          218.00          USD          11,516          (1,152,357 ) 

Mirati Therapeutics, Inc.

     146          07/16/21          USD          175.00          USD          2,358          (19,710 ) 

Natera, Inc.

     254          07/16/21          USD          110.00          USD          2,884          (171,450 ) 

Natera, Inc.

     270          07/16/21          USD          105.00          USD          3,065          (274,050 ) 

Nevro Corp.

     353          07/16/21          USD          155.00          USD          5,852          (430,660 ) 

Nkarta, Inc.

     243          07/16/21          USD          30.00          USD          770          (121,500 ) 

Novocure Ltd.

     77          07/16/21          USD          200.00          USD          1,708          (182,875 ) 

NuVasive, Inc.

     201          07/16/21          USD          75.00          USD          1,362          (84,420 ) 

Oak Street Health, Inc.

     1,664          07/16/21          USD          70.00          USD          9,746          (24,960 ) 

Penumbra, Inc.

     60          07/16/21          USD          290.00          USD          1,644          (20,100 ) 

PMV Pharmaceuticals, Inc.

     485          07/16/21          USD          40.00          USD          1,657          (138,225 ) 

Prothena Corp. PLC

     279          07/16/21          USD          26.00          USD          1,434          (722,610 ) 

Prothena Corp. PLC

     781          07/16/21          USD          55.00          USD          4,015          (208,917 ) 

PTC Therapeutics, Inc.

     301          07/16/21          USD          50.00          USD          1,272          (4,515 ) 

Rapt Therapeutics, Inc.

     147          07/16/21          USD          25.00          USD          467          (103,635 ) 

Relmada Therapeutics, Inc.

     453          07/16/21          USD          45.00          USD          1,450          (29,445 ) 

ResMed, Inc.

     448          07/16/21          USD          200.00          USD          11,044          (2,094,400 ) 

Revolution Medicines, Inc.

     192          07/16/21          USD          40.00          USD          609          (19,200 ) 

Rubius Therapeutics, Inc.

     497          07/16/21          USD          35.00          USD          1,213          (14,910 ) 

Sarepta Therapeutics, Inc.

     13          07/16/21          USD          90.00          USD          101          (650 ) 

Sarepta Therapeutics, Inc.

     176          07/16/21          USD          95.00          USD          1,368          (7,040 ) 

Seagen, Inc.

     791          07/16/21          USD          160.00          USD          12,488          (237,300 ) 

SI-BONE, Inc.

     167          07/16/21          USD          35.00          USD          526          (16,283 ) 

Silk Road Medical, Inc.

     382          07/16/21          USD          50.00          USD          1,828          (90,725 ) 

STERIS PLC

     199          07/16/21          USD          190.00          USD          4,105          (316,410 ) 

Stoke Therapeutics, Inc.

     92          07/16/21          USD          40.00          USD          310          (46,000 ) 

Tandem Diabetes Care, Inc.

     145          07/16/21          USD          95.00          USD          1,412          (57,275 ) 

TCR2 Therapeutics, Inc.

     342          07/16/21          USD          22.50          USD          561          (25,650 ) 

Teladoc Health, Inc.

     171          07/16/21          USD          165.00          USD          2,844          (112,005 ) 

Teleflex, Inc.

     149          07/16/21          USD          420.00          USD          5,987          (70,030 ) 

Translate Bio, Inc.

     279          07/16/21          USD          25.00          USD          768          (90,675 ) 

United Therapeutics Corp.

     86          07/16/21          USD          195.00          USD          1,543          (9,030 ) 

Zai Lab Ltd.

     197          07/16/21          USD          170.00          USD          3,487          (222,610 ) 

Zentalis Pharmaceuticals, Inc.

     333          07/16/21          USD          60.00          USD          1,772          (166,500 ) 

Zimmer Biomet Holdings, Inc.

     390          07/16/21          USD          170.00          USD          6,272          (13,650 ) 

Zymeworks, Inc.

     396          07/16/21          USD          35.00          USD          1,374          (109,890 ) 

 

 

88  

2 0 2 1   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S


Schedule of Investments (unaudited) (continued)

June 30, 2021

  

BlackRock Health Sciences Trust II (BMEZ)

    

 

Exchange-Traded Options Written (continued)

 

Description    Number of
Contracts
       Expiration
Date
       Exercise Price        Notional
Amount (000)
       Value  

Call (continued)

                                

Arcutis Biotherapeutics, Inc.

     615          07/21/21          USD          30.00          USD          1,678        $ (34,991 ) 

Cardinal Health, Inc.

     432          07/23/21          USD          60.50          USD          2,466          (22,680 ) 

Centene Corp.

     220          07/23/21          USD          72.00          USD          1,604          (52,250 ) 

Edwards Lifesciences Corp.

     104          07/23/21          USD          102.00          USD          1,077          (33,280 ) 

Humana, Inc.

     45          07/23/21          USD          447.50          USD          1,992          (31,050 ) 

Illumina, Inc.

     63          07/23/21          USD          450.00          USD          2,981          (180,180 ) 

Tandem Diabetes Care, Inc.

     106          07/23/21          USD          95.00          USD          1,032          (48,230 ) 

Teladoc Health, Inc.

     231          07/23/21          USD          167.50          USD          3,841          (147,262 ) 

Global Blood Therapeutics, Inc.

     354          07/29/21          USD          43.00          USD          1,240          (17,358 ) 

Cardinal Health, Inc.

     868          07/30/21          USD          59.50          USD          4,955          (49,910 ) 

Centene Corp.

     450          07/30/21          USD          72.50          USD          3,282          (123,750 ) 

Humana, Inc.

     79          07/30/21          USD          435.00          USD          3,497          (143,385 ) 

Illumina, Inc.

     39          07/30/21          USD          465.00          USD          1,846          (83,655 ) 

Intuitive Surgical, Inc.

     31          07/30/21          USD          900.00          USD          2,851          (123,845 ) 

Nektar Therapeutics

     500          07/30/21          USD          18.50          USD          858          (52,500 ) 

Edwards Lifesciences Corp.

     425          08/06/21          USD          106.00          USD          4,402          (113,687 ) 

Intuitive Surgical, Inc.

     29          08/06/21          USD          925.00          USD          2,667          (82,070 ) 

Pulmonx Corp.

     137          08/06/21          USD          43.25          USD          604          (44,405 ) 

Zai Lab Ltd.

     370          08/06/21          USD          169.75          USD          6,549          (561,397 ) 

Bridgebio Pharma, Inc.

     452          08/10/21          USD          64.86          USD          2,755          (107,991 ) 

Amedisys, Inc.

     328          08/13/21          USD          267.00          USD          8,034          (171,697 ) 

Acceleron Pharma, Inc.

     918          08/20/21          USD          140.00          USD          11,520          (284,580 ) 

Agilon Health, Inc.

     424          08/20/21          USD          39.50          USD          1,720          (144,322 ) 

Agios Pharmaceuticals, Inc.

     686          08/20/21          USD          65.00          USD          3,781          (56,595 ) 

Alcon AG

     702          08/20/21          USD          72.50          USD          4,932          (115,830 ) 

Alignment Healthcare, Inc.

     34          08/20/21          USD          30.00          USD          79          (2,210 ) 

Alignment Healthcare, Inc.

     525          08/20/21          USD          35.00          USD          1,227          (39,375 ) 

Allakos, Inc.

     343          08/20/21          USD          105.00          USD          2,928          (73,745 ) 

Alnylam Pharmaceuticals, Inc.

     382          08/20/21          USD          170.00          USD          6,476          (530,980 ) 

Alx Oncology Holdings Inc.

     220          08/20/21          USD          70.00          USD          1,203          (57,200 ) 

Apellis Pharmaceuticals, Inc.

     258          08/20/21          USD          63.50          USD          1,631          (132,938 ) 

Applied Molecular Transport, Inc.

     250          08/20/21          USD          50.00          USD          1,144          (112,500 ) 

Arcutis Biotherapeutics, Inc.

     507          08/20/21          USD          30.00          USD          1,384          (128,017 ) 

Argenx SE, ADR

     177          08/20/21          USD          320.00          USD          5,329          (213,285 ) 

Arrowhead Pharmaceuticals, Inc.

     120          08/20/21          USD          95.00          USD          994          (49,200 ) 

Avantor, Inc.

     1,133          08/20/21          USD          35.00          USD          4,023          (237,930 ) 

Beam Therapeutics, Inc.

     110          08/20/21          USD          95.00          USD          1,416          (421,300 ) 

Berkeley Lights, Inc.

     300          08/20/21          USD          50.00          USD          1,344          (66,750 ) 

Biohaven Pharmaceutical Holding Co. Ltd.

     151          08/20/21          USD          105.25          USD          1,466          (78,941 ) 

Bridgebio Pharma, Inc.

     199          08/20/21          USD          65.00          USD          1,213          (55,222 ) 

C4 Therapeutics, Inc.

     424          08/20/21          USD          40.00          USD          1,604          (167,480 ) 

Cardiovascular Systems, Inc.

     263          08/20/21          USD          45.00          USD          1,122          (49,312 ) 

CareDx, Inc.

     480          08/20/21          USD          92.50          USD          4,393          (377,919 ) 

Certara, Inc.

     116          08/20/21          USD          30.00          USD          329          (17,690 ) 

Charles River Laboratories International, Inc.

     140          08/20/21          USD          360.00          USD          5,179          (306,600 ) 

Cooper Cos., Inc.

     91          08/20/21          USD          400.00          USD          3,606          (84,630 ) 

Cytokinetics, Inc.

     419          08/20/21          USD          30.00          USD          829          (95,322 ) 

Dicerna Pharmaceuticals, Inc.

     621          08/20/21          USD          37.75          USD          2,318          (161,849 ) 

Fate Therapeutics, Inc.

     75          08/20/21          USD          95.00          USD          651          (45,750 ) 

Fate Therapeutics, Inc.

     93          08/20/21          USD          100.00          USD          807          (39,990 ) 

Genmab A/S

     475          08/20/21          USD          45.00          USD          1,939          (39,188 ) 

Hill-Rom Holdings, Inc.

     175          08/20/21          USD          120.00          USD          1,988          (38,938 ) 

Horizon Pharma PLC

     200          08/20/21          USD          95.00          USD          1,873          (112,000 ) 

Insmed, Inc.

     194          08/20/21          USD          33.00          USD          552          (50,925 ) 

Insulet Corp.

     300          08/20/21          USD          300.00          USD          8,235          (282,000 ) 

IQVIA Holdings, Inc.

     274          08/20/21          USD          250.00          USD          6,640          (158,920 ) 

LHC Group, Inc.

     230          08/20/21          USD          210.01          USD          4,606          (105,621 ) 

Masimo Corp.

     168          08/20/21          USD          245.00          USD          4,073          (160,440 ) 

Mirati Therapeutics, Inc.

     146          08/20/21          USD          180.00          USD          2,358          (65,335 ) 

Nevro Corp.

     376          08/20/21          USD          175.00          USD          6,234          (235,000 ) 

Nkarta, Inc.

     25          08/20/21          USD          35.00          USD          79          (10,000 ) 

NuVasive, Inc.

     200          08/20/21          USD          70.25          USD          1,356          (97,677 ) 

 

 

S C H E D U L E    O F   I N V E S T M E N T S

  89


Schedule of Investments (unaudited) (continued)

June 30, 2021

  

BlackRock Health Sciences Trust II (BMEZ)

    

 

Exchange-Traded Options Written (continued)

 

Description    Number of
Contracts
       Expiration
Date
       Exercise Price        Notional
Amount (000)
       Value  

Call (continued)

                                

Oak Street Health, Inc.

     665          08/20/21          USD          60.00          USD          3,895        $ (184,537 ) 

Penumbra, Inc.

     125          08/20/21          USD          310.00          USD          3,426          (90,625 ) 

Pulmonx Corp.

     94          08/20/21          USD          50.00          USD          415          (16,920 ) 

Rapt Therapeutics, Inc.

     405          08/20/21          USD          35.00          USD          1,287          (114,412 ) 

Relmada Therapeutics, Inc.

     300          08/20/21          USD          35.00          USD          960          (144,000 ) 

ResMed, Inc.

     166          08/20/21          USD          240.00          USD          4,092          (248,170 ) 

Revolution Medicines, Inc.

     110          08/20/21          USD          40.00          USD          349          (53,900 ) 

Seagen, Inc.

     800          08/20/21          USD          170.00          USD          12,630          (364,000 ) 

Silk Road Medical, Inc.

     252          08/20/21          USD          55.00          USD          1,206          (57,330 ) 

STERIS PLC

     208          08/20/21          USD          210.00          USD          4,291          (95,680 ) 

Stoke Therapeutics, Inc.

     310          08/20/21          USD          40.00          USD          1,043          (93,000 ) 

Tandem Diabetes Care, Inc.

     190          08/20/21          USD          90.00          USD          1,851          (194,750 ) 

Teleflex, Inc.

     272          08/20/21          USD          430.00          USD          10,929          (178,160 ) 

Translate Bio, Inc.

     279          08/20/21          USD          25.00          USD          768          (152,055 ) 

United Therapeutics Corp.

     86          08/20/21          USD          200.00          USD          1,543          (21,930 ) 

Zentalis Pharmaceuticals, Inc.

     330          08/20/21          USD          60.00          USD          1,756          (87,450 ) 

Zymeworks, Inc.

     340          08/20/21          USD          40.00          USD          1,179          (75,650 ) 

LHC Group, Inc.

     263          09/17/21          USD          220.00          USD          5,267          (130,185 ) 
                                

 

 

 
                                 $   (25,468,688 ) 
                                

 

 

 

OTC Options Written

 

Description    Counterparty      Number of
Contracts
       Expiration
Date
       Exercise Price        Notional
Amount (000)
       Value  

Call

                                     

Mersana Therapeutics, Inc.

   Morgan Stanley & Co. International PLC        96,950          07/02/21          USD          15.42          USD          1,317        $ (1 ) 

Convatec Group PLC

   Barclays Bank PLC        500,000          07/07/21          GBP          2.39          GBP          1,203          (20,065 ) 

GN Store Nord A/S

   UBS AG        48,300          07/07/21          DKK          523.99          DKK          26,489          (194,039 ) 

Hansoh Pharmaceutical Group Co. Ltd.

   JPMorgan Chase Bank N.A.        582,000          07/07/21          HKD          35.52          HKD          19,746          (17,619 ) 

Jinxin Fertility Group Ltd.

   JPMorgan Chase Bank N.A.        1,200,000          07/07/21          HKD          21.32          HKD          23,483          (29,161 ) 

Pulmonx Corp.

   JPMorgan Chase Bank N.A.        9,400          07/07/21          USD          44.80          USD          415          (8,685 ) 

Avidity Biosciences, Inc.

   Credit Suisse International        25,800          07/08/21          USD          21.77          USD          638          (81,373 ) 

Gerresheimer AG

   Credit Suisse International        19,000          07/08/21          EUR          95.89          EUR          1,772          (11,710 ) 

Sonova Holding AG, Registered Shares

   UBS AG        10,200          07/08/21          CHF          315.93          CHF          3,555          (359,261 ) 

Berkeley Lights, Inc.

   Credit Suisse International        30,000          07/09/21          USD          51.00          USD          1,344          (6,216 ) 

Sotera Health Co.

   Credit Suisse International        50,000          07/09/21          USD          22.92          USD          1,212          (72,209 ) 

Amplifon

   UBS AG        25,600          07/14/21          EUR          39.80          EUR          1,067          (66,581 ) 

Arcutis Biotherapeutics, Inc.

   JPMorgan Chase Bank N.A.        20,200          07/14/21          USD          33.00          USD          551          (1,264 ) 

Eisai Ltd.

   JPMorgan Chase Bank N.A.        36,700          07/14/21          JPY          7,073.29          JPY          400,695          (1,272,782 ) 

Lonza Group AG

   Morgan Stanley & Co. International PLC        1,100          07/14/21          CHF          602.55          CHF          722          (64,126 ) 

Privia Health Group, Inc.

   Citibank N.A.        41,100          07/14/21          USD          41.74          USD          1,824          (163,994 ) 

Alcon AG

   Credit Suisse International        78,700          07/15/21          USD          71.76          USD          5,529          (34,794 ) 

Amplifon

   UBS AG        52,000          07/15/21          EUR          39.69          EUR          2,168          (141,431 ) 

Genmab A/S

   Morgan Stanley & Co. International PLC        17,200          07/15/21          DKK          2,504.07          DKK          44,197          (279,256 ) 

Jinxin Fertility Group Ltd.

   JPMorgan Chase Bank N.A.        1,334,000          07/15/21          HKD          23.22          HKD          26,105          (20,969 ) 

Lonza Group AG

   UBS AG        2,900          07/15/21          CHF          601.19          CHF          1,902          (173,495 ) 

Straumann Holding AG, Registered Shares

   UBS AG        4,000          07/15/21          CHF          1,446.27          CHF          5,903          (186,283 ) 

UCB SA

   Credit Suisse International        38,100          07/15/21          EUR          76.73          EUR          3,365          (523,839 ) 

Mersana Therapeutics, Inc.

   Morgan Stanley & Co. International PLC        96,950          07/16/21          USD          15.42          USD          1,317          (6,985 ) 

Avidity Biosciences, Inc.

   JPMorgan Chase Bank N.A.        35,000          07/20/21          USD          24.95          USD          865          (62,085 ) 

Genmab A/S

   Morgan Stanley & Co. International PLC        17,200          07/20/21          DKK          2,504.07          DKK          44,197          (302,472 ) 

Gerresheimer AG

   Morgan Stanley & Co. International PLC        26,600          07/20/21          EUR          92.67          EUR          2,481          (90,744 ) 

Hansoh Pharmaceutical Group Co. Ltd.

   JPMorgan Chase Bank N.A.        484,000          07/20/21          HKD          35.86          HKD          16,421          (34,277 ) 

Merck Kgaa

   Goldman Sachs International        30,800          07/20/21          EUR          158.81          EUR          4,984          (175,486 ) 

Rede Dor Sao Luiz SA

   Credit Suisse International        260,800          07/20/21          USD          70.74          USD          18,003          (69,892 ) 

Jinxin Fertility Group Ltd.

   Goldman Sachs International        1,272,000          07/27/21          HKD          20.31          HKD          24,892          (172,447 ) 

Wuxi Apptec Ltd., Class H

   Citibank N.A.        282,000          07/27/21          HKD          173.36          HKD          51,107          (469,582 ) 

Wuxi Biologics Cayman Inc.

   Goldman Sachs International        710,000          07/27/21          HKD          124.28          HKD          100,938          (1,729,281 ) 

Alcon AG

   Credit Suisse International        78,700          07/28/21          USD          72.46          USD          5,529          (64,402 ) 

Marinus Pharmaceuticals, Inc.

   JPMorgan Chase Bank N.A.        33,000          07/28/21          USD          18.29          USD          592          (56,949 ) 

Hansoh Pharmaceutical Group Co. Ltd.

   JPMorgan Chase Bank N.A.        766,000          07/29/21          HKD          33.72          HKD          25,988          (158,205 ) 

 

 

90  

2 0 2 1   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S


Schedule of Investments (unaudited) (continued)

June 30, 2021

  

BlackRock Health Sciences Trust II (BMEZ)

    

 

OTC Options Written (continued)

 

Description    Counterparty    Number of
Contracts
     Expiration
Date
     Exercise Price     

Notional

Amount (000)

     Value  
Call (continued)                                                    

Lonza Group AG

   UBS AG      6,400        07/29/21        CHF       680.01        CHF       4,198      $ (40,711 ) 

Straumann Holding AG, Registered Shares

   UBS AG      3,300        07/29/21        CHF       1,447.15        CHF       4,870        (190,480 ) 

UCB SA

   Morgan Stanley & Co. International PLC      22,400        07/29/21        EUR       86.75        EUR       1,978        (86,273 ) 

SI-BONE, Inc.

   JPMorgan Chase Bank N.A.      30,000        07/30/21        USD       31.90        USD       944        (39,697 ) 

Zimmer Biomet Holdings, Inc.

   Barclays Bank PLC      51,200        08/03/21        USD       161.29        USD       8,234        (246,810 ) 

Amplifon

   Morgan Stanley & Co. International PLC      111,300        08/04/21        EUR       41.31        EUR       4,641        (227,909 ) 

Convatec Group PLC

   Goldman Sachs International      545,000        08/04/21        GBP       2.43        GBP       1,311        (28,701 ) 

Demant

   Goldman Sachs International      84,200        08/04/21        DKK       356.70        DKK       29,757        (146,246 ) 

Hansoh Pharmaceutical Group Co. Ltd.

   Morgan Stanley & Co. International PLC      452,000        08/04/21        HKD       34.65        HKD       15,335        (76,656 ) 

Jinxin Fertility Group Ltd.

   JPMorgan Chase Bank N.A.      1,100,000        08/04/21        HKD       18.84        HKD       21,526        (271,405 ) 

Sonova Holding AG, Registered Shares

   Morgan Stanley & Co. International PLC      13,700        08/04/21        CHF       345.36        CHF       4,774        (163,921 ) 

Akeso Inc.

   JPMorgan Chase Bank N.A.      560,000        08/05/21        HKD       67.94        HKD       35,067        (176,528 ) 

Eisai Co. Ltd.

   Goldman Sachs International      35,700        08/05/21        JPY       12,740.00        JPY       389,776        (3,127 ) 

Genetron Holdings Ltd., ADR

   Bank of America N.A.      50,000        08/05/21        USD       21.81        USD       1,007        (31,600 ) 

GN Store Nord A/S

   JPMorgan Chase Bank N.A.      42,200        08/05/21        DKK       560.26        DKK       23,143        (82,758 ) 

Morphic Holding, Inc.

   Citibank N.A.      14,700        08/05/21        USD       62.17        USD       844        (21,915 ) 

TCR2 Therapeutics, Inc.

   Barclays Bank PLC      32,500        08/05/21        USD       20.34        USD       533        (18,078 ) 

Teladoc Health, Inc.

   Morgan Stanley & Co. LLC      11,300        08/06/21        USD       177.50        USD       1,879        (72,037 ) 

Avidity Biosciences, Inc.

   Bank of America N.A.      25,800        08/09/21        USD       26.09        USD       638        (28,241 ) 

Genmab A/S

   Citibank N.A.      84,900        08/10/21        USD       41.88        USD       3,466        (99,961 ) 

C4 Therapeutics, Inc.

   JPMorgan Chase Bank N.A.      35,500        08/11/21        USD       41.30        USD       1,343        (39,050 ) 

Convatec Group PLC

   UBS AG      319,000        08/11/21        GBP       2.40        GBP       768        (26,084 ) 

Demant

   UBS AG      60,000        08/11/21        DKK       361.82        DKK       21,205        (94,722 ) 

Hansoh Pharmaceutical Group Co. Ltd.

   JPMorgan Chase Bank N.A.      434,000        08/11/21        HKD       36.70        HKD       14,724        (44,226 ) 

Jinxin Fertility Group Ltd.

   Morgan Stanley & Co. International PLC      794,000        08/11/21        HKD       21.79        HKD       15,538        (88,175 ) 

Morphic Holding, Inc.

   Citibank N.A.      14,700        08/11/21        USD       62.17        USD       844        (25,311 ) 

Straumann Holding AG, Registered Shares

   Morgan Stanley & Co. International PLC      3,600        08/11/21        CHF       1,509.09        CHF       5,313        (118,909 ) 

UCB SA

   JPMorgan Chase Bank N.A.      46,000        08/11/21        EUR       85.82        EUR       4,063        (96,375 ) 

Wuxi Apptec Ltd., Class H

   JPMorgan Chase Bank N.A.      300,000        08/11/21        HKD       188.75        HKD       54,369        (306,024 ) 

Wuxi Biologics Cayman Inc.

   Morgan Stanley & Co. International PLC      450,000        08/11/21        HKD       148.52        HKD       63,975        (395,751 ) 

Akeso Inc.

   JPMorgan Chase Bank N.A.      222,000        08/12/21        HKD       68.11        HKD       13,901        (82,133 ) 

Keros Therapeutics, Inc.

   Citibank N.A.      31,000        08/12/21        USD       45.53        USD       1,317        (62,921 ) 

Oak Street Health, Inc.

   Citibank N.A.      138,000        08/12/21        USD       66.58        USD       8,083        (160,105 ) 

Genetron Holdings Ltd., ADR

   Bank of America N.A.      50,000        08/17/21        USD       21.81        USD       1,007        (67,275 ) 

Genmab A/S

   Morgan Stanley & Co. International PLC      14,600        08/18/21        DKK       2,620.83        DKK       37,516        (163,577 ) 

Wuxi Apptec Ltd., Class H

   JPMorgan Chase Bank N.A.      256,300        08/18/21        HKD       193.99        HKD       46,449        (170,565 ) 

Guardant Health, Inc.

   JPMorgan Chase Bank N.A.      17,100        08/20/21        USD       126.56        USD       2,124        (113,094 ) 

Genmab A/S

   Morgan Stanley & Co. International PLC      14,600        08/25/21        DKK       2,620.67        DKK       37,516        (177,733 ) 
                     

 

 

 
                      $ (11,407,044 ) 
                     

 

 

 

Balances Reported in the Statements of Assets and Liabilities for Options Written

 

Description    Swap
Premiums
Paid
     Swap
Premiums
Received
     Unrealized
Appreciation
     Unrealized
Depreciation
     Value  

Options Written

   $ N/A      $ N/A      $ 5,379,879      $ (15,778,302 )     $ (36,875,732 ) 

Derivative Financial Instruments Categorized by Risk Exposure

As of period end, the fair values of derivative financial instruments located in the Statements of Assets and Liabilities were as follows:

 

      Commodity
Contracts
     Credit
Contracts
     Equity
Contracts
     Foreign
Currency
Exchange
Contracts
     Interest
Rate
Contracts
     Other
Contracts
     Total  

Liabilities — Derivative Financial Instruments

                    

Options written

                    

Options written at value

   $ —      $ —      $ 36,875,732      $ —      $ —      $ —      $ 36,875,732  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

 

 

S C H E D U L E   O F   I N V E S T M E N T S

  91


Schedule of Investments (unaudited) (continued)

June 30, 2021

  

BlackRock Health Sciences Trust II (BMEZ)

    

 

For the six months ended June 30, 2021, the effect of derivative financial instruments in the Statements of Operations was as follows:

 

     Commodity
Contracts
     Credit
Contracts
     Equity
Contracts
    Foreign
Currency
Exchange
Contracts
     Interest
Rate
Contracts
     Other
Contracts
     Total  

Net Realized Gain (Loss) from

                  

Options written

  $ —      $ —      $ (11,593,593 )    $ —      $ —      $ —      $ (11,593,593 ) 
 

 

 

    

 

 

    

 

 

   

 

 

    

 

 

    

 

 

    

 

 

 

Net Change in Unrealized Appreciation (Depreciation) on

                  

Options written

  $ —      $ —      $ 5,317,215     $ —      $ —      $ —      $ 5,317,215  
 

 

 

    

 

 

    

 

 

   

 

 

    

 

 

    

 

 

    

 

 

 

Average Quarterly Balances of Outstanding Derivative Financial Instruments

 

Options

       

Average value of option contracts written

  $ 29,355,573  

For more information about the Trust’s investment risks regarding derivative financial instruments, refer to the Notes to Financial Statements.

Derivative Financial Instruments — Offsetting as of Period End

The Trust’s derivative assets and liabilities (by type) were as follows:

 

     Assets      Liabilities  

Derivative Financial Instruments

    

Options

  $ —      $ 36,875,732  
 

 

 

    

 

 

 

Total derivative assets and liabilities in the Statements of Assets and Liabilities

    —        36,875,732  
 

 

 

    

 

 

 

Derivatives not subject to a Master Netting Agreement or similar agreement (“MNA”)

    —        (25,468,688 ) 
 

 

 

    

 

 

 

Total derivative assets and liabilities subject to an MNA

  $         —      $ 11,407,044  
 

 

 

    

 

 

 

The following table presents the Trust’s derivative liabilities by counterparty net of amounts available for offset under an MNA and net of the related collateral pledged by the Trust:

 

Counterparty    



Derivative
Liabilities
Subject to
an MNA by
Counterparty
 
 
 
 
 
    

Derivatives
Available
for Offset
 
 
 
    

Non-Cash
Collateral
Pledged
 
 
(a)  
   

Cash
Collateral
Pledged
 
 
(a)  
   

Net Amount
of Derivative
Liabilities
 
 
(b) 

Bank of America N.A.

  $ 127,116      $ —      $ —     $ —     $ 127,116  

Barclays Bank PLC

    284,953        —        (284,953 )      —       —  

Citibank N.A.

    1,003,789        —        (1,003,789 )      (20,000 )      (20,000 ) 

Credit Suisse International

    864,435        —        (497,352 )      —       367,083  

Goldman Sachs International

    2,255,288        —        (1,890,887 )      (364,401 )      —  

JPMorgan Chase Bank N.A.

    3,083,851        —        (3,083,851 )      —       —  

Morgan Stanley & Co. International PLC

    2,242,488        —        (2,242,488 )      (16,000 )      (16,000 ) 

Morgan Stanley & Co. LLC

    72,037        —        —       —       72,037  

UBS AG

    1,473,087        —        (777,587 )      —       695,500  
 

 

 

    

 

 

    

 

 

   

 

 

   

 

 

 
  $ 11,407,044      $ —      $ (9,780,907 )    $ (400,401 )    $ 1,225,736  
 

 

 

    

 

 

    

 

 

   

 

 

   

 

 

 

 

  (a) 

Excess of collateral pledged to the individual counterparty is not shown for financial reporting purposes.

 
  (b) 

Net amount represents the net amount payable due to counterparty in the event of default. Net amount may be offset further by the options written receivable/payable on the Statements of Assets and Liabilities.

 

 

 

92  

2 0 2 1   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S


Schedule of Investments (unaudited) (continued)

June 30, 2021

  

BlackRock Health Sciences Trust II (BMEZ)

    

 

Fair Value Hierarchy as of Period End

Various inputs are used in determining the fair value of financial instruments. For a description of the input levels and information about the Trust’s policy regarding valuation of financial instruments, refer to the Notes to Financial Statements.

The following table summarizes the Trust’s financial instruments categorized in the fair value hierarchy. The breakdown of the Trust’s financial instruments into major categories is disclosed in the Schedule of Investments above.

 

      Level 1        Level 2        Level 3        Total  

Assets

                 

Investments

                 

Long-Term Investments

                 

Common Stocks

                 

Biotechnology

   $ 911,507,122        $ 321,685,397        $ —        $ 1,233,192,519  

Diversified Financial Services

     49,402,615          —          —          49,402,615  

Electronic Equipment, Instruments & Components

     10,946,255          —          —          10,946,255  

Health Care Equipment & Supplies

     647,666,934          171,363,341          —          819,030,275  

Health Care Providers & Services

     389,640,291          122,755,421          —          512,395,712  

Health Care Technology

     51,636,614          —          —          51,636,614  

Internet & Direct Marketing Retail

     —          23,818,340          —          23,818,340  

Life Sciences Tools & Services

     174,547,811          183,903,269          —          358,451,080  

Pharmaceuticals

     21,960,876          126,494,517          —          148,455,393  

Preferred Securities

                 

Preferred Stocks

     —          —          258,465,494          258,465,494  

Warrants

     3,456,810          —          —          3,456,810  
  

 

 

      

 

 

      

 

 

      

 

 

 
   $ 2,260,765,328        $   950,020,285        $     258,465,494          3,469,251,107  
  

 

 

      

 

 

      

 

 

      

 

 

 

Investments Valued at NAV(a)

                    6,245,032  
                 

 

 

 
                  $ 3,475,496,139  
                 

 

 

 

Derivative Financial Instruments(b)

                 

Liabilities

                 

Equity Contracts

   $ (22,279,225 )       $ (14,596,507 )       $ —        $ (36,875,732 ) 
  

 

 

      

 

 

      

 

 

      

 

 

 

 

  (a) 

Certain investments of the Trust were fair valued using NAV per share as no quoted market value is available and therefore have been excluded from the fair value hierarchy.

 
  (b) 

Derivative financial instruments are options written. Options written are shown at value.

 

A reconciliation of Level 3 financial instruments is presented when the Trust had a significant amount of Level 3 investments at the beginning and/or end of the period in relation to net assets. The following table is a reconciliation of Level 3 investments for which significant unobservable inputs were used in determining fair value:

 

      Common
Stocks
       Preferred
Stocks
       Total  

Assets

            

Opening balance, as of December 31, 2020

   $ 28,744,832        $ 112,069,329        $ 140,814,161  

Transfers into Level 3

     —          —          —  

Transfers out of Level 3(a)

     (3,884,625 )         (31,063,087 )         (34,947,712 ) 

Other(b)

     (24,860,207 )         24,860,207          —  

Accrued discounts/premiums

     —          —          —  

Net realized gain (loss)

     —          —          —  

Net change in unrealized appreciation (depreciation)(c)(d)

     —          19,664,669          19,664,669  

Purchases

     —          147,514,376          147,514,376  

Sales

     —          (14,580,000 )         (14,580,000 ) 
  

 

 

      

 

 

      

 

 

 

Closing balance, as of June 30, 2021

   $ —        $ 258,465,494        $ 258,465,494  
  

 

 

      

 

 

      

 

 

 

Net change in unrealized appreciation (depreciation) on investments still held at
June 30, 2021(d)

   $ —        $ 19,664,919        $ 19,664,919  
  

 

 

      

 

 

      

 

 

 

 

  (a) 

As of December 31, 2020, the Trust used significant unobservable inputs in determining the value of certain investments. As of June 30, 2021, the Trust used observable inputs in determining the value of the same investments. As a result, investments at beginning of period value were transferred from Level 3 to Level 2 in the disclosure hierarchy.

 
  (b) 

Certain Level 3 investments were re-classified between Common Stocks and Preferred Stocks.

 
  (c) 

Included in the related net change in unrealized appreciation (depreciation) in the Statements of Operations.

 
  (d) 

Any difference between net change in unrealized appreciation (depreciation) and net change in unrealized appreciation (depreciation) on investments still held at June 30, 2021 is generally due to investments no longer held or categorized as Level 3 at period end.

 

The following table summarizes the valuation approaches used and unobservable inputs utilized by the BlackRock Global Valuation Methodologies Committee (the “Global Valuation Committee”) to determine the value of certain of the Trust’s Level 3 financial instruments as of period end. The table does not include Level 3 investments with values

 

 

S C H E D U L E   O F   I N V E S T M E N T S

  93


Schedule of Investments (unaudited) (continued)

June 30, 2021

  

BlackRock Health Sciences Trust II (BMEZ)

    

 

based upon unadjusted third party pricing information in the amount of $6,538,179. A significant change in the third party information could result in a significantly lower or higher value of such Level 3 investments.

 

       Value         
Valuation
Approach
 
 
      
Unobservable
Inputs

 
      


Range of
Unobservable
Inputs
Utilized
 
 
 
(a)  
    



Weighted
Average of
Unobservable
Inputs Based
on Fair Value
 
 
 
 
 

Assets

 

Preferred Stocks(b)

   $ 251,927,315          Market          Revenue Multiple          6.60x        —  
               EBITDA Multiple          11.00x        —  
               Volatility          80% - 82%        81%  
               Time to Exit          2.0 - 3.0        2.6  
               Market Adjustment Multiple          0.95x - 1.10x        0.99x  
               Recent Transactions          —        —  
                             
  

 

 

                   
   $     251,927,315                    
  

 

 

                   

 

  (a) 

A significant change in unobservable input would have resulted in a correlated (inverse) significant change to value.

 
  (b) 

For the period end June 30, 2021, the valuation technique for investments classified as Preferred Stocks amounting to $63,507,814 changed to Current Value approach. The investments were previously valued utilizing Transaction Price approach. The change was due to consideration of the information that was available at the time the investments were valued.

 

See notes to financial statements.

 

 

94  

2 0 2 1   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S


Schedule of Investments (unaudited)

June 30, 2021

  

BlackRock Innovation and Growth Trust (BIGZ)

(Percentages shown are based on Net Assets)

 

Security   Shares      Value  

Common Stocks

    
Aerospace & Defense — 4.4%  

Axon Enterprise, Inc.(a)(b)

    874,632      $   154,634,938  

HEICO Corp.

    405,786        56,574,684  
    

 

 

 
       211,209,622  
Auto Components — 2.4%  

Fox Factory Holding Corp.(b)

    731,101        113,803,182  
    

 

 

 
Beverages — 1.2%  

Celsius Holdings, Inc.(b)

    784,040        59,657,604  
    

 

 

 
Biotechnology(b) — 3.5%  

Halozyme Therapeutics, Inc.

    1,772,429        80,486,001  

Invitae Corp.(c)

    1,279,324        43,151,599  

Natera, Inc.

    389,429        44,211,874  
    

 

 

 
       167,849,474  
Building Products — 1.8%  

AZEK Co., Inc.(b)

    2,075,071        88,107,515  
    

 

 

 
Chemicals — 3.2%  

Amyris, Inc.(a)(b)

    9,353,069        153,109,739  
    

 

 

 
Diversified Consumer Services — 3.8%  

Bright Horizons Family Solutions,
Inc.(b)

    393,799        57,931,771  

Chegg, Inc.(b)(c)

    883,286        73,409,899  

Ideal Image, Class A, (Acquired 05/05/21, Cost: $50,000,000)(d)(e)

    6,224        50,000,000  
    

 

 

 
       181,341,670  
Electrical Equipment — 1.9%  

Shoals Technologies Group, Inc., Class A(b)

    2,604,084        92,444,982  
    

 

 

 
Electronic Equipment, Instruments & Components — 2.2%  

908 Devices, Inc.(b)(f)(g)

    1,687,470        65,389,463  

Halma PLC

    1,072,993        39,974,599  
    

 

 

 
       105,364,062  
Entertainment — 2.1%  

Kahoot! AS(b)

    14,891,946        102,091,465  
    

 

 

 
Equity Real Estate Investment Trusts (REITs) — 1.2%  

Innovative Industrial Properties, Inc.

    143,783        27,465,429  

Rexford Industrial Realty, Inc.

    496,178        28,257,337  
    

 

 

 
       55,722,766  
Food Products(b) — 2.8%  

Freshpet, Inc.(a)

    731,442        119,195,789  

Vital Farms, Inc.

    842,467        16,815,641  
    

 

 

 
       136,011,430  
Health Care Equipment & Supplies(b) — 7.1%  

Eargo, Inc.(f)

    2,065,987        82,453,541  

Inmode Ltd.

    508,987        48,190,889  

Masimo Corp.(c)

    479,358        116,220,347  

Outset Medical, Inc.

    1,196,816        59,816,864  

Pulmonx Corp.

    799,583        35,277,602  
    

 

 

 
       341,959,243  
Health Care Providers & Services — 0.9%  

Guardant Health, Inc.(b)

    357,111        44,349,615  
    

 

 

 
Health Care Technology(b) — 6.8%  

Certara, Inc.

    2,767,607        78,406,306  

Doximity, Inc., Class A

    134,838        7,847,572  
Security   Shares      Value  
Health Care Technology (continued)  

Health Catalyst, Inc.(c)

    1,625,593      $ 90,236,668  

Phreesia, Inc.(a)

    2,414,488        148,008,114  
    

 

 

 
       324,498,660  
Hotels, Restaurants & Leisure — 4.4%  

Penn National Gaming, Inc.(a)(b)(c)

    1,263,250        96,625,992  

Planet Fitness, Inc., Class A(b)(c)

    854,290        64,285,323  

Wingstop, Inc.

    324,890        51,212,411  
    

 

 

 
       212,123,726  
IT Services(b) — 5.9%  

Globant SA

    384,189        84,206,545  

Marqeta, Inc.(g)

    1,351,466        37,935,651  

MongoDB, Inc.

    189,408        68,474,780  

Wix.com Ltd.

    317,829        92,259,402  
    

 

 

 
       282,876,378  
Life Sciences Tools & Services — 8.6%  

10X Genomics, Inc., Class A(b)(c)

    696,579        136,404,100  

Adaptive Biotechnologies Corp.(b)

    115,349        4,713,160  

Bio-Techne Corp.(c)

    272,619        122,749,431  

Olink Holding AB, ADR(b)

    828,793        28,527,055  

Repligen Corp.(b)

    339,630        67,796,941  

Seer, Inc.(b)

    1,551,639        50,862,726  
    

 

 

 
       411,053,413  
Machinery — 1.5%  

Chart Industries, Inc.(b)

    500,362        73,212,968  
    

 

 

 
Personal Products — 1.6%  

Honest Co., Inc.(b)(f)

    4,815,961        77,970,408  
    

 

 

 
Road & Rail — 1.0%  

Saia, Inc.(b)

    231,295        48,453,989  
    

 

 

 
Semiconductors & Semiconductor Equipment — 7.9%  

Brooks Automation, Inc.

    531,986        50,687,626  

Cree, Inc.(b)

    357,706        35,030,148  

Entegris, Inc.(a)(c)

    1,112,238        136,771,907  

Lattice Semiconductor Corp.(b)

    942,144        52,929,650  

Monolithic Power Systems, Inc.(a)

    280,564        104,776,626  
    

 

 

 
       380,195,957  
Software — 16.8%  

8x8, Inc.(b)

    845,242        23,463,918  

Avalara, Inc.(a)(b)

    892,670        144,434,006  

Bill.Com Holdings, Inc.(b)

    487,752        89,346,411  

Blackline, Inc.(b)

    504,593        56,146,063  

Everbridge, Inc.(b)

    159,136        21,655,227  

Five9, Inc.(b)

    602,725        110,533,738  

Lightspeed POS, Inc.(b)

    1,586,916        132,819,083  

nCino Inc.(b)

    1,293,134        77,484,589  

Paylocity Holding Corp.(b)

    602,034        114,868,087  

Q2 Holdings, Inc.(b)

    147,420        15,122,344  

Snorkel Al, Inc., (Acquired 06/30/21, Cost: $2,999,997)(d)(e)

    199,738        3,269,711  

Vonage Holdings Corp.(b)

    1,359,054        19,583,968  
    

 

 

 
       808,727,145  
 

 

 

S C H E D U L E   O F   I N V E S T M E N T S

  95


Schedule of Investments (unaudited) (continued)

June 30, 2021

  

BlackRock Innovation and Growth Trust (BIGZ)

(Percentages shown are based on Net Assets)

 

Security   Shares     Value  
Specialty Retail(b) — 4.5%  

Leslie’s Inc.

    2,632,664     $ 72,371,933  

Vroom Inc.(a)(c)

    3,463,203       144,969,678  
   

 

 

 
      217,341,611  
   

 

 

 

Total Common Stocks — 97.5%
(Cost: $4,671,171,784)

 

    4,689,476,624  
   

 

 

 

Preferred Securities

   
Preferred Stocks — 4.0%(d)(e)            
Aerospace & Defense — 1.1%            

Relativity Space, Inc., Series E, (Acquired 05/27/21, Cost: $50,000,009)

    2,189,612       49,988,842  
   

 

 

 
Capital Markets — 1.1%            

The Production Board LLC, Series A, (Acquired 06/04/21,
Cost: $50,000,001)

    16,666,667       50,000,001  
   

 

 

 
Food Products — 0.8%            

Motif Food Works, Inc., Series B, (Acquired 06/08/21, Cost: $39,999,986)

    1,972,240       39,999,985  
   

 

 

 
Semiconductors & Semiconductor Equipment — 0.8%  

PsiQuantum Corp., Series D, (Acquired 05/21/21, Cost: $39,999,990)

    1,525,192       40,005,786  
   

 

 

 
Software — 0.2%            

Snorkel AI, Inc., Series C, (Acquired 06/30/21, Cost: $10,999,994)

    732,373       10,999,993  
   

 

 

 

Total Preferred Stocks — 4.0%

      190,994,607  
   

 

 

 

Total Preferred Securities — 4.0%
(Cost: $190,999,980)

      190,994,607  
   

 

 

 

Total Long-Term Investments — 101.5%
(Cost: $4,862,171,764)

      4,880,471,231  
   

 

 

 
Security   Shares     Value  

Short-Term Securities

   
Money Market Funds — 0.1%            

BlackRock Liquidity Funds, T-Fund, Institutional Class, 0.01%(f)(h)

    6,081,460     $ 6,081,460  

SL Liquidity Series, LLC, Money Market Series, 0.13%(f)(h)

    796,714       796,953  
   

 

 

 

Total Short-Term Securities — 0.1%
(Cost: $6,878,413)

 

    6,878,413  
   

 

 

 

Total Investments Before Options Written — 101.6%
(Cost: $4,869,050,177)

 

    4,887,349,644  
   

 

 

 

Options Written — (1.4)%
(Premiums Received: $(43,810,527))

 

    (68,185,597 ) 
   

 

 

 

Total Investments, Net of Options Written — 100.2%
(Cost: $4,825,239,650)

 

    4,819,164,047  

Liabilities in Excess of Other Assets — (0.2)%

 

    (8,135,536 ) 
   

 

 

 

Net Assets — 100.0%

 

  $ 4,811,028,511  
   

 

 

 

 

(a) 

All or a portion of the security has been pledged as collateral in connection with outstanding OTC derivatives.

(b) 

Non-income producing security.

(c) 

All or a portion of the security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written.

(d) 

Security is valued using significant unobservable inputs and is classified as Level 3 in the fair value hierarchy.

(e) 

Restricted security as to resale, excluding 144A securities. The Trust held restricted securities with a current value of $244,264,318, representing 5.1% of its net assets as of period end, and an original cost of $243,999,977.

(f) 

Affiliate of the Trust.

(g) 

All or a portion of this security is on loan.

(h)

Annualized 7-day yield as of period end.

 

For Trust compliance purposes, the Trust’s industry classifications refer to one or more of the industry sub-classifications used by one or more widely recognized market indexes or rating group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.

Affiliates

Investments in issuers considered to be affiliate(s) of the Trust during the period ended June 30, 2021 for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

 

Affiliated Issuer  

Value at     

03/29/21(a)

    Purchases
at Cost
    Proceeds
from Sales
    Net
Realized
Gain (Loss)
    Change in
Unrealized
Appreciation
(Depreciation)
    Value at
06/30/21
    Shares
Held at
06/30/21
    Income     Capital Gain
Distributions
from
Underlying
Funds
 

908 Devices, Inc.

  $ —         $ 83,484,668     $ —     $ —     $ (18,095,205 )    $ 65,389,463       1,687,470     $ —     $ —  

BlackRock Liquidity Funds, T-Fund, Institutional Class

    —           6,081,460 (b)       —       —       —       6,081,460       6,081,460       42,766       —  

Eargo, Inc.

    —           99,231,391       —       —       (16,777,850 )      82,453,541       2,065,987       —       —  

Honest Co., Inc.

    —           77,055,376       —       —       915,033       77,970,409       4,815,961       —       —  

iShares Russell 2000 Growth ETF(c)

    —           214,699,815       (212,175,613 )      (2,524,202 )      —       —       —       —       —  

iShares Russell Mid-Cap Growth ETF(c)

    —           211,658,254       (226,065,994 )      14,407,740       —       —       —       —       —  

SL Liquidity Series, LLC, Money Market Series

    —           796,953 (b)       —       —       —       796,953       796,714       61,662 (d)       —  
       

 

 

   

 

 

   

 

 

     

 

 

   

 

 

 
        $ 11,883,538     $ (33,958,022 )    $ 232,691,826       $ 104,428     $ —  
       

 

 

   

 

 

   

 

 

     

 

 

   

 

 

 

 

  (a) 

Commencement of operations.

  (b) 

Represents net amount purchased (sold).

  (c) 

As of period end, the entity is no longer held.

  (d) 

All or a portion of this security was purchased with the cash collateral from loaned securities.

 

 

96  

2 0 2 1   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S


Schedule of Investments (unaudited) (continued)

June 30, 2021

  

BlackRock Innovation and Growth Trust (BIGZ)

    

 

Derivative Financial Instruments Outstanding as of Period End

Exchange-Traded Options Written

 

Description    Number of
Contracts
       Expiration
Date
       Exercise Price       

Notional

Amount (000)

       Value  
Call                                                   

Globant SA

     163          07/01/21        USD     231.00        USD     3,573        $ (18 ) 

MongoDB, Inc.

     202          07/02/21        USD     320.00        USD     7,303          (856,480 ) 

Phreesia, Inc.

     650          07/06/21        USD     50.00        USD     3,985          (746,197 ) 

Guardant Health, Inc.

     451          07/07/21        USD     140.00        USD     5,601          (7,723 ) 

Leslie’s Inc.

     568          07/07/21        USD     30.50        USD     1,561          (5,695 ) 

8x8, Inc.

     679          07/09/21        USD     24.00        USD     1,885          (261,415 ) 

Chegg, Inc.

     474          07/09/21        USD     82.51        USD     3,939          (104,916 ) 

Vonage Holdings Corp.

     2,740          07/12/21        USD     14.15        USD     3,948          (160,991 ) 

Phreesia, Inc.

     850          07/13/21        USD     49.00        USD     5,211          (1,098,319 ) 

Leslie’s Inc.

     568          07/14/21        USD     32.00        USD     1,561          (7,407 ) 

10X Genomics, Inc., Class A

     235          07/16/21        USD     175.00        USD     4,602          (534,625 ) 

10X Genomics, Inc., Class A

     361          07/16/21        USD     200.00        USD     7,069          (176,890 ) 

Adaptive Biotechnologies Corp.

     90          07/16/21        USD     45.00        USD     368          (5,625 ) 

Amyris, Inc.

     1,500          07/16/21        USD     18.50        USD     2,456          (48,750 ) 

Axon Enterprise, Inc.

     871          07/16/21        USD     155.00        USD     15,399          (1,903,135 ) 

AZEK Co., Inc.

     817          07/16/21        USD     45.00        USD     3,469          (20,425 ) 

Bill.Com Holdings, Inc.

     293          07/16/21        USD     165.00        USD     5,367          (588,930 ) 

Bio-Techne Corp.

     207          07/16/21        USD     450.00        USD     9,320          (185,265 ) 

Bio-Techne Corp.

     128          07/16/21        USD     430.00        USD     5,763          (291,200 ) 

Blackline, Inc.

     501          07/16/21        USD     110.00        USD     5,575          (180,360 ) 

Bright Horizons Family Solutions, Inc.

     424          07/16/21        USD     144.01        USD     6,237          (236,219 ) 

Brooks Automation, Inc.

     642          07/16/21        USD     110.00        USD     6,117          (17,655 ) 

Brooks Automation, Inc.

     214          07/16/21        USD     100.00        USD     2,039          (33,170 ) 

Celsius Holdings, Inc.

     840          07/16/21        USD     70.00        USD     6,392          (655,200 ) 

Celsius Holdings, Inc.

     843          07/16/21        USD     65.00        USD     6,414          (1,007,385 ) 

Certara, Inc.

     623          07/16/21        USD     30.00        USD     1,765          (56,070 ) 

Chart Industries, Inc.

     536          07/16/21        USD     160.00        USD     7,843          (76,380 ) 

Chegg, Inc.

     947          07/16/21        USD     95.00        USD     7,871          (14,205 ) 

Chegg, Inc.

     474          07/16/21        USD     85.00        USD     3,939          (80,580 ) 

Eargo Inc.

     1,422          07/16/21        USD     60.00        USD     5,675          (135,090 ) 

Eargo Inc.

     800          07/16/21        USD     50.00        USD     3,193          (60,000 ) 

Everbridge, Inc.

     347          07/16/21        USD     125.00        USD     4,722          (423,340 ) 

Five9, Inc.

     650          07/16/21        USD     185.00        USD     11,920          (295,750 ) 

Fox Factory Holding Corp.

     785          07/16/21        USD     165.00        USD     12,219          (64,762 ) 

Freshpet, Inc.

     353          07/16/21        USD     180.00        USD     5,752          (134,140 ) 

Globant SA

     130          07/16/21        USD     240.00        USD     2,849          (14,950 ) 

Globant SA

     325          07/16/21        USD     232.95        USD     7,123          (55,735 ) 

Guardant Health, Inc.

     290          07/16/21        USD     155.00        USD     3,602          (7,975 ) 

Guardant Health, Inc.

     310          07/16/21        USD     130.00        USD     3,850          (62,775 ) 

Halozyme Therapeutics, Inc.

     1,691          07/16/21        USD     46.00        USD     7,679          (253,650 ) 

Halozyme Therapeutics, Inc.

     613          07/16/21        USD     47.00        USD     2,784          (49,040 ) 

Health Catalyst, Inc.

     970          07/16/21        USD     60.00        USD     5,384          (36,375 ) 

Health Catalyst, Inc.

     1,309          07/16/21        USD     65.00        USD     7,266          (65,450 ) 

HEICO Corp.

     265          07/16/21        USD     145.00        USD     3,695          (23,188 ) 

Honest Co., Inc.

     2,000          07/16/21        USD     17.50        USD     3,238          (70,000 ) 

Honest Co., Inc.

     405          07/16/21        USD     20.00        USD     656          (4,050 ) 

Honest Co., Inc.

     1,000          07/16/21        USD     22.50        USD     1,619          (15,000 ) 

Inmode Ltd.

     546          07/16/21        USD     85.25        USD     5,170          (553,090 ) 

Innovative Industrial Properties, Inc.

     154          07/16/21        USD     195.00        USD     2,942          (46,200 ) 

Invitae Corp.

     1,370          07/16/21        USD     35.25        USD     4,621          (145,567 ) 

Lattice Semiconductor Corp.

     1,000          07/16/21        USD     52.51        USD     5,618          (472,263 ) 

Leslie’s Inc.

     1,000          07/16/21        USD     30.00        USD     2,749          (45,000 ) 

Lightspeed Pos Inc.

     1,000          07/16/21        CAD     110.00        CAD     10,375          (155,292 ) 

Lightspeed Pos Inc.

     710          07/16/21        CAD     115.00        CAD     7,366          (57,277 ) 

Marqeta, Inc.

     4          07/16/21        USD     35.00        USD     11          (60 ) 

Masimo Corp.

     515          07/16/21        USD     231.00        USD     12,486          (666,162 ) 

Monolithic Power Systems, Inc.

     300          07/16/21        USD     340.01        USD     11,204          (1,043,732 ) 

Natera, Inc.

     417          07/16/21        USD     110.00        USD     4,734          (281,475 ) 

Paylocity Holding Corp.

     520          07/16/21        USD     185.00        USD     9,922          (465,400 ) 

Phreesia, Inc.

     1,327          07/16/21        USD     55.00        USD     8,135          (776,295 ) 

 

 

S C H E D U L E   O F   I N V E S T M E N T S

  97


Schedule of Investments (unaudited) (continued)

June 30, 2021

  

BlackRock Innovation and Growth Trust (BIGZ)

    

 

Exchange-Traded Options Written (continued)

 

Description    Number of
Contracts
       Expiration
Date
       Exercise Price       

Notional

Amount (000)

       Value  
Call (continued)                                                   

Phreesia, Inc.

     442          07/16/21        USD     50.00        USD     2,709        $ (545,870 ) 

Phreesia, Inc.

     710          07/16/21        USD     60.00        USD     4,352          (225,425 ) 

Planet Fitness, Inc., Class A

     917          07/16/21        USD     82.50        USD     6,900          (18,340 ) 

Repligen Corp.

     364          07/16/21        USD     185.01        USD     7,266          (573,006 ) 

Saia, Inc.

     230          07/16/21        USD     220.00        USD     4,818          (45,425 ) 

Seer Inc., Class A

     1,530          07/16/21        USD     40.00        USD     5,015          (68,850 ) 

Shoals Technologies Group, Inc., Class A

     2,000          07/16/21        USD     35.00        USD     7,100          (385,000 ) 

Vital Farms, Inc.

     1,521          07/16/21        USD     22.50        USD     3,036          (22,815 ) 

Vonage Holdings Corp.

     2,740          07/16/21        USD     14.25        USD     3,948          (138,743 ) 

Vroom Inc.

     3,416          07/16/21        USD     50.00        USD     14,299          (25,620 ) 

Wingstop, Inc.

     152          07/16/21        USD     145.00        USD     2,396          (199,880 ) 

Wix.Com Ltd.

     500          07/16/21        USD     310.00        USD     14,514          (155,000 ) 

8x8, Inc.

     1,294          07/23/21        USD     27.00        USD     3,592          (262,035 ) 

Amyris, Inc.

     1,000          07/23/21        USD     18.50        USD     1,637          (52,500 ) 

Amyris, Inc.

     1,000          07/23/21        USD     19.00        USD     1,637          (45,000 ) 

Cree, Inc.

     357          07/23/21        USD     102.00        USD     3,496          (83,895 ) 

Masimo Corp.

     510          07/23/21        USD     233.00        USD     12,365          (652,128 ) 

MongoDB, Inc.

     201          07/23/21        USD     400.00        USD     7,267          (111,555 ) 

Monolithic Power Systems, Inc.

     300          07/23/21        USD     360.50        USD     11,204          (576,652 ) 

Innovative Industrial Properties, Inc.

     154          07/27/21        USD     195.23        USD     2,942          (66,412 ) 

10X Genomics, Inc., Class A

     354          07/28/21        USD     205.00        USD     6,932          (187,157 ) 

Bright Horizons Family Solutions, Inc.

     423          07/28/21        USD     151.00        USD     6,223          (122,568 ) 

Brooks Automation, Inc.

     325          07/28/21        USD     101.00        USD     3,097          (72,243 ) 

Five9, Inc.

     650          07/28/21        USD     185.06        USD     11,920          (485,638 ) 

Repligen Corp.

     364          07/28/21        USD     193.50        USD     7,266          (388,012 ) 

Amyris, Inc.

     1,500          07/30/21        USD     19.00        USD     2,456          (123,750 ) 

Cree, Inc.

     383          07/30/21        USD     99.00        USD     3,751          (158,945 ) 

Avalara, Inc.

     139          08/02/21        USD     165.00        USD     2,249          (86,875 ) 

Invitae Corp.

     1,377          08/03/21        USD     29.56        USD     4,645          (678,426 ) 

Shoals Technologies Group, Inc., Class A

     1,000          08/03/21        USD     36.00        USD     3,550          (220,785 ) 

Amyris, Inc.

     1,088          08/06/21        USD     21.50        USD     1,781          (127,840 ) 

Amyris, Inc.

     1,000          08/06/21        USD     19.50        USD     1,637          (120,000 ) 

Cree, Inc.

     376          08/06/21        USD     103.00        USD     3,682          (104,340 ) 

Pulmonx Corp.

     503          08/06/21        USD     43.25        USD     2,219          (163,033 ) 

Vroom Inc.

     3,145          08/06/21        USD     50.01        USD     13,165          (136,830 ) 

Phreesia, Inc.

     760          08/10/21        USD     58.00        USD     4,659          (454,344 ) 

Health Catalyst, Inc.

     889          08/12/21        USD     60.01        USD     4,935          (212,722 ) 

10X Genomics, Inc., Class A

     716          08/20/21        USD     210.00        USD     14,021          (716,000 ) 

8x8, Inc.

     663          08/20/21        USD     30.00        USD     1,840          (79,560 ) 

Adaptive Biotechnologies Corp.

     90          08/20/21        USD     50.00        USD     368          (18,450 ) 

Amyris, Inc.

     2,000          08/20/21        USD     21.00        USD     3,274          (165,000 ) 

Avalara, Inc.

     834          08/20/21        USD     150.00        USD     13,494          (1,446,990 ) 

AZEK Co., Inc.

     907          08/20/21        USD     45.00        USD     3,851          (117,910 ) 

Bill.Com Holdings, Inc.

     610          08/20/21        USD     185.00        USD     11,174          (838,750 ) 

Bio-Techne Corp.

     106          08/20/21        USD     450.00        USD     4,773          (219,950 ) 

Bio-Techne Corp.

     208          08/20/21        USD     460.00        USD     9,365          (335,920 ) 

Blackline, Inc.

     531          08/20/21        USD     115.00        USD     5,908          (265,500 ) 

Bright Horizons Family Solutions, Inc.

     382          08/20/21        USD     155.00        USD     5,620          (156,620 ) 

Brooks Automation, Inc.

     478          08/20/21        USD     100.00        USD     4,554          (231,830 ) 

Celsius Holdings, Inc.

     762          08/20/21        USD     75.00        USD     5,798          (758,190 ) 

Certara, Inc.

     2,201          08/20/21        USD     35.00        USD     6,235          (121,055 ) 

Certara, Inc.

     116          08/20/21        USD     30.00        USD     329          (17,690 ) 

Chart Industries, Inc.

     498          08/20/21        USD     155.00        USD     7,287          (390,930 ) 

Chegg, Inc.

     860          08/20/21        USD     85.00        USD     7,147          (412,800 ) 

Eargo Inc.

     1,403          08/20/21        USD     45.00        USD     5,599          (375,302 ) 

Entegris, Inc.

     1,083          08/20/21        USD     130.00        USD     13,318          (395,295 ) 

Everbridge, Inc.

     150          08/20/21        USD     145.00        USD     2,041          (98,250 ) 

Five9, Inc.

     283          08/20/21        USD     195.00        USD     5,190          (198,100 ) 

Fox Factory Holding Corp.

     711          08/20/21        USD     150.00        USD     11,067          (888,750 ) 

Freshpet, Inc.

     250          08/20/21        USD     185.00        USD     4,074          (68,125 ) 

Freshpet, Inc.

     900          08/20/21        USD     180.00        USD     14,666          (396,000 ) 

Globant SA

     550          08/20/21        USD     240.00        USD     12,055          (299,750 ) 

 

 

98  

2 0 2 1   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S


Schedule of Investments (unaudited) (continued)

June 30, 2021

  

BlackRock Innovation and Growth Trust (BIGZ)

    

 

Exchange-Traded Options Written (continued)

 

Description   Number of
Contracts
     Expiration
Date
     Exercise Price     

Notional

Amount (000)

     Value  

Call (continued)

                   

Health Catalyst, Inc.

    1,229        08/20/21        USD        60.00        USD        6,822      $ (334,902 ) 

HEICO Corp.

    333        08/20/21        USD        150.00        USD        4,643        (51,615 ) 

Honest Co., Inc.

    2,018        08/20/21        USD        20.00        USD        3,267        (116,035 ) 

Honest Co., Inc.

    1,000        08/20/21        USD        25.00        USD        1,619        (17,500 ) 

Honest Co., Inc.

    2,000        08/20/21        USD        17.50        USD        3,238        (220,000 ) 

Inmode Ltd.

    546        08/20/21        USD        95.00        USD        5,170        (371,280 ) 

Innovative Industrial Properties, Inc.

    140        08/20/21        USD        200.00        USD        2,674        (107,800 ) 

Lattice Semiconductor Corp.

    906        08/20/21        USD        55.00        USD        5,090        (434,880 ) 

Leslie’s Inc.

    568        08/20/21        USD        35.00        USD        1,561        (32,660 ) 

Leslie’s Inc.

    4,888        08/20/21        USD        30.00        USD        13,437        (708,760 ) 

Lightspeed Pos Inc.

    1,000        08/20/21        CAD        115.00        CAD        10,375        (417,473 ) 

Lightspeed Pos Inc.

    1,500        08/20/21        CAD        120.00        CAD        15,563        (471,926 ) 

Marqeta, Inc.

    1,046        08/20/21        USD        35.00        USD        2,936        (70,605 ) 

Masimo Corp.

    470        08/20/21        USD        245.00        USD        11,395        (448,850 ) 

MongoDB, Inc.

    184        08/20/21        USD        370.00        USD        6,652        (412,160 ) 

Monolithic Power Systems, Inc.

    275        08/20/21        USD        370.00        USD        10,270        (624,250 ) 

Natera, Inc.

    378        08/20/21        USD        115.00        USD        4,291        (349,650 ) 

nCino Inc.

    1,090        08/20/21        USD        75.00        USD        6,531        (49,050 ) 

Paylocity Holding Corp.

    200        08/20/21        USD        185.00        USD        3,816        (274,000 ) 

Paylocity Holding Corp.

    520        08/20/21        USD        190.00        USD        9,922        (572,000 ) 

Phreesia, Inc.

    816        08/20/21        USD        65.00        USD        5,002        (252,960 ) 

Planet Fitness, Inc., Class A

    849        08/20/21        USD        80.00        USD        6,389        (208,005 ) 

Pulmonx Corp.

    560        08/20/21        USD        50.00        USD        2,471        (100,800 ) 

Q2 Holdings, Inc.

    229        08/20/21        USD        110.00        USD        2,349        (63,548 ) 

Repligen Corp.

    331        08/20/21        USD        210.00        USD        6,607        (231,700 ) 

Saia, Inc.

    197        08/20/21        USD        230.00        USD        4,127        (58,608 ) 

Seer Inc., Class A

    874        08/20/21        USD        40.00        USD        2,865        (170,430 ) 

Seer Inc., Class A

    203        08/20/21        USD        45.00        USD        665        (21,823 ) 

Shoals Technologies Group, Inc., Class A

    2,000        08/20/21        USD        40.00        USD        7,100        (385,000 ) 

Shoals Technologies Group, Inc., Class A

    1,000        08/20/21        USD        45.00        USD        3,550        (105,000 ) 

Vital Farms, Inc.

    553        08/20/21        USD        22.50        USD        1,104        (41,475 ) 

Vroom Inc.

    4,241        08/20/21        USD        45.00        USD        17,753        (922,417 ) 

Wingstop, Inc.

    428        08/20/21        USD        165.00        USD        6,747        (271,780 ) 

Wix.Com Ltd.

    491        08/20/21        USD        330.00        USD        14,253        (395,255 ) 

Q2 Holdings, Inc.

    230        08/24/21        USD        110.01        USD        2,359        (75,900 ) 
                   

 

 

 
                    $   (42,340,786 )
                   

 

 

 

OTC Options Written

 

Description   Counterparty    Number of
Contracts
     Expiration
Date
     Exercise Price     

Notional

Amount (000)

     Value  

Call

                      

Eargo Inc.

  JPMorgan Chase Bank N.A.      92,600        07/06/21        USD        41.27        USD        3,696      $ (98,492 ) 

Outset Medical, Inc.

  Morgan Stanley & Co. International PLC      50,000        07/06/21        USD        44.71        USD        2,499        (265,388 ) 

AZEK Co., Inc.

  Bank of America N.A.      100,000        07/07/21        USD        48.96        USD        4,246        (1,030 ) 

Pulmonx Corp.

  JPMorgan Chase Bank N.A.      56,000        07/07/21        USD        44.80        USD        2,471        (51,741 ) 

Rexford Industrial Realty, Inc.

  Bank of America N.A.      39,900        07/07/21        USD        54.11        USD        2,272        (118,225 ) 

Saia, Inc.

  Bank of America N.A.      24,800        07/07/21        USD        247.66        USD        5,195        (7 ) 

Seer Inc., Class A

  JPMorgan Chase Bank N.A.      76,600        07/07/21        USD        32.78        USD        2,511        (117,909 ) 

Eargo Inc.

  JPMorgan Chase Bank N.A.      92,600        07/08/21        USD        41.27        USD        3,696        (122,025 ) 

Health Catalyst, Inc.

  Citibank N.A.      67,300        07/08/21        USD        55.66        USD        3,736        (98,950 ) 

AZEK Co., Inc.

  Bank of America N.A.      73,500        07/09/21        USD        48.15        USD        3,121        (1,227 ) 

nCino Inc.

  Bank of America N.A.      122,000        07/09/21        USD        61.63        USD        7,310        (118,173 ) 

Axon Enterprise, Inc.

  JPMorgan Chase Bank N.A.      94,000        07/12/21        USD        137.61        USD        16,619        (3,699,241 ) 

Avalara, Inc.

  Citibank N.A.      45,300        07/13/21        USD        136.58        USD        7,330        (1,145,939 ) 

AZEK Co., Inc.

  Barclays Bank PLC      73,500        07/13/21        USD        45.89        USD        3,121        (6,397 ) 

Entegris, Inc.

  Bank of America N.A.      119,300        07/14/21        USD        114.29        USD        14,670        (1,139,524 ) 

Halozyme Therapeutics, Inc.

  JPMorgan Chase Bank N.A.      170,000        07/14/21        USD        45.24        USD        7,720        (298,114 ) 

nCino Inc.

  Citibank N.A.      122,000        07/16/21        USD        56.87        USD        7,310        (493,910 ) 

Rexford Industrial Realty, Inc.

  Bank of America N.A.      39,900        07/16/21        USD        53.75        USD        2,272        (141,424 ) 

Five9, Inc.

  Barclays Bank PLC      29,600        07/21/21        USD        173.92        USD        5,428        (352,715 ) 

 

 

S C H E D U L E   O F   I N V E S T M E N T S

  99


Schedule of Investments (unaudited) (continued)

June 30, 2021

  

BlackRock Innovation and Growth Trust (BIGZ)

    

 

OTC Options Written (continued)

 

Description   Counterparty    Number of
Contracts
     Expiration
Date
     Exercise Price     

Notional

Amount (000)

     Value  

Call (continued)

                      

Planet Fitness, Inc., Class A

  Bank of America N.A.      91,600        07/21/21        USD        86.97        USD        6,893      $ (17,215 ) 

Avalara, Inc.

  Barclays Bank PLC      90,500        07/22/21        USD        133.26        USD        14,643        (2,598,854 ) 

Lattice Semiconductor Corp.

  UBS AG      51,600        07/26/21        USD        52.96        USD        2,899        (217,691 ) 

Wingstop, Inc.

  BNP Paribas S.A.      21,100        07/27/21        USD        155.93        USD        3,326        (134,496 ) 

Bill.Com Holdings, Inc.

  BNP Paribas S.A.      60,900        07/28/21        USD        180.09        USD        11,156        (666,094 ) 

Entegris, Inc.

  Barclays Bank PLC      119,300        07/28/21        USD        108.26        USD        14,670        (1,827,565 ) 

Lightspeed Pos Inc.

  Citibank N.A.      70,900        07/28/21        CAD        112.52        CAD        7,356        (140,390 ) 

Marqeta, Inc.

  UBS AG      39,250        07/28/21        USD        32.49        USD        1,102        (17,819 ) 

Phreesia, Inc.

  Citibank N.A.      50,000        07/28/21        USD        54.90        USD        3,065        (361,428 ) 

Avalara, Inc.

  Citibank N.A.      45,300        07/29/21        USD        137.21        USD        7,330        (1,145,510 ) 

Freshpet, Inc.

  Barclays Bank PLC      27,800        07/29/21        USD        163.99        USD        4,530        (202,470 ) 

Halma PLC

  Morgan Stanley & Co. International PLC      110,000        07/29/21        GBP        29.19        GBP        2,961        (6,656 ) 

Lattice Semiconductor Corp.

  Morgan Stanley & Co. International PLC      51,600        07/30/21        USD        55.28        USD        2,899        (152,405 ) 

Rexford Industrial Realty, Inc.

  Bank of America N.A.      35,000        08/02/21        USD        58.75        USD        1,993        (35,371 ) 

Adaptive Biotechnologies Corp.

  Goldman Sachs International      18,000        08/03/21        USD        43.72        USD        735        (34,453 ) 

Axon Enterprise, Inc.

  Citibank N.A.      93,500        08/03/21        USD        135.06        USD        16,531        (4,048,245 ) 

Certara, Inc.

  Bank of America N.A.      100,000        08/03/21        USD        29.20        USD        2,833        (143,215 ) 

Fox Factory Holding Corp.

  Barclays Bank PLC      39,200        08/03/21        USD        160.99        USD        6,102        (148,270 ) 

Inmode Ltd.

  Citibank N.A.      54,600        08/03/21        USD        81.47        USD        5,170        (792,114 ) 

Paylocity Holding Corp.

  Barclays Bank PLC      63,700        08/03/21        USD        207.28        USD        12,154        (171,005 ) 

Phreesia, Inc.

  Morgan Stanley & Co. International PLC      71,500        08/03/21        USD        63.17        USD        4,383        (150,200 ) 

Halma PLC

  Goldman Sachs International      111,300        08/04/21        GBP        27.77        GBP        2,996        (46,763 ) 

Natera, Inc.

  Citibank N.A.      41,900        08/04/21        USD        97.64        USD        4,757        (745,313 ) 

Invitae Corp.

  Citibank N.A.      127,000        08/05/21        USD        31.98        USD        4,284        (444,706 ) 

nCino Inc.

  Barclays Bank PLC      50,200        08/05/21        USD        61.10        USD        3,008        (130,816 ) 

Phreesia, Inc.

  Morgan Stanley & Co. International PLC      71,500        08/05/21        USD        63.78        USD        4,383        (145,238 ) 

Shoals Technologies Group, Inc., Class A

  Bank of America N.A.      75,000        08/05/21        USD        36.78        USD        2,663        (133,462 ) 

Halozyme Therapeutics, Inc.

  Citibank N.A.      156,100        08/09/21        USD        45.52        USD        7,089        (508,594 ) 

10X Genomics, Inc., Class A

  Citibank N.A.      50,600        08/10/21        USD        215.00        USD        9,908        (361,778 ) 

Bio-Techne Corp.

  Barclays Bank PLC      19,600        08/10/21        USD        462.90        USD        8,825        (220,216 ) 

Fox Factory Holding Corp.

  Barclays Bank PLC      39,200        08/10/21        USD        164.11        USD        6,102        (167,874 ) 

Freshpet, Inc.

  BNP Paribas S.A.      50,000        08/10/21        USD        172.61        USD        8,148        (247,400 ) 

AZEK Co., Inc.

  Citibank N.A.      227,800        08/11/21        USD        42.32        USD        9,672        (485,809 ) 

Blackline, Inc.

  Bank of America N.A.      54,100        08/11/21        USD        114.94        USD        6,020        (219,294 ) 

Halma PLC

  Morgan Stanley & Co. International PLC      111,300        08/11/21        GBP        27.64        GBP        2,996        (61,261 ) 

Eargo Inc.

  JPMorgan Chase Bank N.A.      92,700        08/12/21        USD        42.59        USD        3,700        (212,190 ) 

Wingstop, Inc.

  Barclays Bank PLC      22,200        08/13/21        USD        165.47        USD        3,499        (121,740 ) 

Rexford Industrial Realty, Inc.

  Citibank N.A.      39,900        08/16/21        USD        58.61        USD        2,272        (55,201 ) 

Guardant Health, Inc.

  JPMorgan Chase Bank N.A.      7,000        08/20/21        USD        126.56        USD        869        (46,296 ) 

Leslie’s Inc.

  Barclays Bank PLC      56,900        08/25/21        USD        28.93        USD        1,564        (98,443 ) 

Certara, Inc.

  Citibank N.A.      100,000        08/26/21        USD        30.38        USD        2,833        (110,520 ) 
                      

 

 

 
                       $   (25,844,811 ) 
                      

 

 

 

Balances Reported in the Statements of Assets and Liabilities for Options Written

 

Description   Swap
Premiums
Paid
     Swap
Premiums
Received
     Unrealized
Appreciation
     Unrealized
Depreciation
    Value  

Options Written

  $  N/A      $  N/A      $  8,113,293        $  (32,488,363 )      $  (68,185,597 ) 

 

 

100  

2 0 2 1   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S


Schedule of Investments (unaudited) (continued)

June 30, 2021

  

BlackRock Innovation and Growth Trust (BIGZ)

    

 

Derivative Financial Instruments Categorized by Risk Exposure

As of period end, the fair values of derivative financial instruments located in the Statements of Assets and Liabilities were as follows:

 

      Commodity
Contracts
     Credit
Contracts
     Equity
Contracts
     Foreign
Currency
Exchange
Contracts
     Interest
Rate
Contracts
     Other
Contracts
     Total  

Liabilities — Derivative Financial Instruments

                    

Options written

                    

Options written at value

   $ —      $ —      $   68,185,597      $ —      $ —      $ —      $   68,185,597  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

For the six months ended June 30, 2021, the effect of derivative financial instruments in the Statements of Operations was as follows:

 

      Commodity
Contracts
     Credit
Contracts
     Equity
Contracts
     Foreign
Currency
Exchange
Contracts
     Interest
Rate
Contracts
     Other
Contracts
     Total  

Net Realized Gain (Loss) from

                    

Options written

   $ —      $ —      $ 26,727,084      $ —      $ —      $ —      $ 26,727,084  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Net Change in Unrealized Appreciation (Depreciation) on

                    

Options written

   $ —      $ —      $   (24,375,070 )     $ —      $ —      $ —      $   (24,375,070 ) 
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Average Quarterly Balances of Outstanding Derivative Financial Instruments

 

Options

        

Average value of option contracts written

   $   38,914,087  

For more information about the Trust’s investment risks regarding derivative financial instruments, refer to the Notes to Financial Statements.

Derivative Financial Instruments — Offsetting as of Period End

The Trust’s derivative assets and liabilities (by type) were as follows:

 

      Assets      Liabilities  

Derivative Financial Instruments

     

Options

   $ —      $ 68,185,597  
  

 

 

    

 

 

 

Total derivative assets and liabilities in the Statements of Assets and Liabilities

     —        68,185,597  
  

 

 

    

 

 

 

Derivatives not subject to a Master Netting Agreement or similar agreement (“MNA”)

     —        (42,340,786 ) 
  

 

 

    

 

 

 

Total derivative assets and liabilities subject to an MNA

   $ —      $ 25,844,811  
  

 

 

    

 

 

 

The following table presents the Trust’s derivative liabilities by counterparty net of amounts available for offset under an MNA and net of the related collateral pledged by the Trust:

 

Counterparty     



Derivative
Liabilities
Subject to an
MNA by
Counterparty
 
 
 
 
 
    

Derivatives
Available for
Offset
 
 
 
    

Non-Cash
Collateral
Pledged
 
 
(a)  
    

Cash
Collateral
Pledged
 
 
(a)  
    

Net Amount
of Derivative
Liabilities
 
 
(b) 

Bank of America N.A.

   $ 2,068,167      $ —      $ (2,068,167 )     $ —      $ —  

Barclays Bank PLC

     6,046,365        —        (6,046,365 )       —        —  

BNP Paribas S.A.

     1,047,990        —        —        (1,047,990 )       —  

Citibank N.A.

     10,938,407        —        (10,938,407 )       —        —  

Goldman Sachs International

     81,216        —        —        —        81,216  

JPMorgan Chase Bank N.A.

     4,646,008        —        (4,646,008 )       —        —  

Morgan Stanley & Co. International PLC

     781,148        —        (781,148 )       —        —  

UBS AG

     235,510        —        —        —        235,510  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 
   $ 25,844,811      $ —      $   (24,480,095 )     $   (1,047,990 )     $   316,726  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

 

  (a) 

Excess of collateral pledged to the individual counterparty is not shown for financial reporting purposes.

 
  (b) 

Net amount represents the net amount payable due to counterparty in the event of default. Net amount may be offset further by the options written receivable/payable on the Statements of Assets and Liabilities.

 

 

 

S C H E D U L E   O F   I N V E S T M E N T S

  101


Schedule of Investments (unaudited) (continued)

June 30, 2021

  

BlackRock Innovation and Growth Trust (BIGZ)

    

 

Fair Value Hierarchy as of Period End

Various inputs are used in determining the fair value of financial instruments. For a description of the input levels and information about the Trust’s policy regarding valuation of financial instruments, refer to the Notes to Financial Statements.

The following table summarizes the Trust’s financial instruments categorized in the fair value hierarchy. The breakdown of the Trust’s financial instruments into major categories is disclosed in the Schedule of Investments above.

 

      Level 1        Level 2        Level 3        Total  

Assets

                 

Investments

                 

Long-Term Investments

                 

Common Stocks

                 

Aerospace & Defense

   $ 211,209,622        $ —        $ —        $ 211,209,622  

Auto Components

     113,803,182          —          —          113,803,182  

Beverages

     59,657,604          —          —          59,657,604  

Biotechnology

     167,849,474          —          —          167,849,474  

Building Products

     88,107,515          —          —          88,107,515  

Chemicals

     153,109,739          —          —          153,109,739  

Diversified Consumer Services

     131,341,670          —          50,000,000          181,341,670  

Electrical Equipment

     92,444,982          —          —          92,444,982  

Electronic Equipment, Instruments & Components

     65,389,463          39,974,599          —          105,364,062  

Entertainment

     —          102,091,465          —          102,091,465  

Equity Real Estate Investment Trusts (REITs)

     55,722,766          —          —          55,722,766  

Food Products

     136,011,430          —          —          136,011,430  

Health Care Equipment & Supplies

     341,959,243          —          —          341,959,243  

Health Care Providers & Services

     44,349,615          —          —          44,349,615  

Health Care Technology

     324,498,660          —          —          324,498,660  

Hotels, Restaurants & Leisure

     212,123,726          —          —          212,123,726  

IT Services

     282,876,378          —          —          282,876,378  

Life Sciences Tools & Services

     411,053,413          —          —          411,053,413  

Machinery

     73,212,968          —          —          73,212,968  

Personal Products

     77,970,408          —          —          77,970,408  

Road & Rail

     48,453,989          —          —          48,453,989  

Semiconductors & Semiconductor Equipment

     380,195,957          —          —          380,195,957  

Software

     805,457,434          —          3,269,711          808,727,145  

Specialty Retail

     217,341,611          —          —          217,341,611  

Preferred Securities

                 

Preferred Stocks

     —          —          190,994,607          190,994,607  

Short-Term Securities

                 

Money Market Funds

     6,081,460          —          —          6,081,460  
  

 

 

      

 

 

      

 

 

      

 

 

 
   $   4,500,222,309        $   142,066,064        $   244,264,318          4,886,552,691  
  

 

 

      

 

 

      

 

 

      

 

 

 

Investments Valued at NAV(a)

                    796,953  
                 

 

 

 
                  $   4,887,349,644  
                 

 

 

 

Derivative Financial Instruments(b)

                 

Liabilities

                 

Equity Contracts

   $ (31,745,278 )       $ (36,440,319 )       $ —        $ (68,185,597 ) 
  

 

 

      

 

 

      

 

 

      

 

 

 

 

  (a)

Certain investments of the Trust were fair valued using NAV per share as no quoted market value is available and therefore have been excluded from the fair value hierarchy.

 
  (b)

Derivative financial instruments are options written. Options written are shown at value.

 

A reconciliation of Level 3 financial instruments is presented when the Trust had a significant amount of Level 3 investments at the beginning and/or end of the period in relation to net assets. The following table is a reconciliation of Level 3 investments for which significant unobservable inputs were used in determining fair value:

 

      Common
Stocks
       Preferred
Stocks
       Total  

Assets

            

Opening balance, as of December 31, 2020

   $ —        $ —        $ —  

Transfers into Level 3

     —          —          —  

Transfers out of Level 3

     —          —          —  

Accrued discounts/premiums

     —          —          —  

Net realized gain (loss)

     —          —          —  

Net change in unrealized appreciation (depreciation)(a)(b)

     269,714          (5,372 )         264,342  

 

 

102  

2 0 2 1   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S


Schedule of Investments (unaudited) (continued)

June 30, 2021

  

BlackRock Innovation and Growth Trust (BIGZ)

    

 

      Common
Stocks
       Preferred
Stocks
       Total  

Purchases

   $   52,999,997        $   190,999,979        $   243,999,976  

Sales

     —          —          —  
  

 

 

      

 

 

      

 

 

 

Closing balance, as of June 30, 2021

   $ 53,269,711        $ 190,994,607        $ 244,264,318  
  

 

 

      

 

 

      

 

 

 

Net change in unrealized appreciation (depreciation) on investments still held at June 30, 2021(b)

   $ 269,714        $ (5,372 )       $ 264,342  
  

 

 

      

 

 

      

 

 

 

 

  (a) 

Included in the related net change in unrealized appreciation (depreciation) in the Statements of Operations.

 
  (b) 

Any difference between net change in unrealized appreciation (depreciation) and net change in unrealized appreciation (depreciation) on investments still held at June 30, 2021 is generally due to investments no longer held or categorized as Level 3 at period end.

 

The following table summarizes the valuation approaches used and unobservable inputs utilized by the BlackRock Global Valuation Methodologies Committee (the “Global Valuation Committee”) to determine the value of certain of the Trust’s Level 3 financial instruments as of period end.

 

      Value        Valuation
Approach
       Unobservable
Inputs(a)
 

Assets

 

Common Stocks

   $ 53,269,711          Market          Recent Transactions  

Preferred Stocks

     190,994,607          Market          Recent Transactions  
  

 

 

           
   $   244,264,318            
  

 

 

           

 

  (a) 

A significant change in unobservable input would have resulted in a correlated (inverse) significant change to value.

 

See notes to financial statements.

 

 

S C H E D U L E   O F   I N V E S T M E N T S

  103


Schedule of Investments (unaudited)

June 30, 2021

  

BlackRock Resources & Commodities Strategy Trust (BCX)

(Percentages shown are based on Net Assets)

 

Security   Shares     Value  

Common Stocks

 

Chemicals — 13.0%            

CF Industries Holdings, Inc.(a)(b)

    721,556     $ 37,124,056  

FMC Corp.(b)

    208,193       22,526,483  

Koninklijke DSM NV

    113,246       21,169,423  

Nutrien Ltd.(b)

    534,280       32,382,711  
   

 

 

 
      113,202,673  
Containers & Packaging(b) — 5.8%            

International Paper Co.

    257,868       15,809,887  

Packaging Corp. of America

    146,597       19,852,166  

Westrock Co.

    287,709       15,311,873  
   

 

 

 
      50,973,926  
Electronic Equipment, Instruments & Components — 2.3%  

Trimble, Inc.(b)(c)

    242,807       19,868,897  
   

 

 

 
Food Products — 6.0%            

Bunge Ltd.(b)

    312,261       24,403,197  

Darling Ingredients, Inc.(b)(c)

    135,966       9,177,705  

Hofseth International AS, (Acquired 05/26/21, Cost: $10,198,057)(c)(d)(e)

    18,993,283       9,884,715  

Nestle SA, Registered Shares

    70,298       8,762,439  
   

 

 

 
      52,228,056  
Machinery — 2.1%            

Deere & Co.(b)

    52,807       18,625,557  
   

 

 

 
Metals & Mining — 29.2%            

Anglo American PLC

    1,013,424       40,328,335  

ArcelorMittal SA

    289,221       8,983,204  

BHP Group PLC

    920,299       27,232,527  

First Quantum Minerals Ltd.

    433,164       9,983,459  

Freeport-McMoRan, Inc.(b)

    292,833       10,867,033  

Glencore PLC(c)

    6,693,784       28,730,319  

Kinross Gold Corp.

    2,507,451       15,899,133  

Lundin Mining Corp.

    563,434       5,081,633  

Neo Lithium Corp.(c)

    2,006,082       4,676,974  

Newcrest Mining Ltd.

    224,134       4,250,432  

Newmont Corp.(a)(b)

    378,189       23,969,619  

Polyus PJSC, Registered Shares, GDR

    79,029       7,654,206  

Stelco Holdings, Inc.

    315,041       9,250,962  

Vale SA, ADR(b)

    2,561,920       58,437,395  
   

 

 

 
      255,345,231  
Oil, Gas & Consumable Fuels — 40.3%  

Aker BP ASA

    341,497       10,884,609  

Canadian Natural Resources Ltd.

    826,516       30,004,211  

Chevron Corp.(b)

    449,291       47,058,739  

CNOOC Ltd.

    7,973,000       9,044,839  

ConocoPhillips(b)

    455,735       27,754,261  

Equinor ASA

    720,762       15,257,452  

Exxon Mobil Corp.(b)

    405,921       25,605,497  

Hess Corp.

    124,927       10,908,626  

Kosmos Energy Ltd.(c)

    1,540,084       5,328,691  

LUKOIL PJSC, ADR

    137,359       12,748,614  

Marathon Petroleum Corp.(b)

    174,011       10,513,745  

Pioneer Natural Resources Co.

    94,574       15,370,166  

Royal Dutch Shell PLC, Class B, ADR(b)

    1,082,789       42,044,697  

Suncor Energy, Inc.

    1,152,591       27,606,023  
Security          Shares     Value  
Oil, Gas & Consumable Fuels (continued)  

TotalEnergies SE

      1,065,353     $ 48,262,397  

Valero Energy Corp.(b)

      171,796       13,413,832  
     

 

 

 
        351,806,399  
Paper & Forest Products — 0.0%  

Precious Woods Holding AG, Registered Shares(c)

      20,000       248,581  
     

 

 

 
Total Common Stocks — 98.7%  

(Cost: $630,499,484)

        862,299,320  
     

 

 

 
           

Par

(000)

        

Corporate Bonds

     
Metals & Mining — 0.5%                  

Osisko Gold Royalties Ltd., 4.00%, 12/31/22(f)

    CAD       5,556       4,662,630  
     

 

 

 
Total Corporate Bonds — 0.5%        

(Cost: $4,434,866)

        4,662,630  
     

 

 

 
Total Long-Term Investments — 99.2%  

(Cost: $634,934,350)

        866,961,950  
     

 

 

 
            Shares         

Short-Term Securities

     
Money Market Funds — 1.2%  

BlackRock Liquidity Funds, T-Fund, Institutional Class, 0.01%(g)(h)

      10,298,740       10,298,740  
     

 

 

 
Total Short-Term Securities — 1.2%  

(Cost: $10,298,740)

        10,298,740  
     

 

 

 
Options Purchased — 0.0%  

(Cost: $13,723)

        7,481  
     

 

 

 
Total Investments Before Options Written — 100.4%  

(Cost: $645,246,813)

        877,268,171  
     

 

 

 
Options Written — (0.6)%  

(Premiums Received: $(8,728,329))

 

    (4,916,658 ) 
     

 

 

 
Total Investments, Net of Options Written — 99.8%  

(Cost: $636,518,484)

        872,351,513  
Other Assets Less Liabilities — 0.2%     1,629,112  
     

 

 

 
Net Assets — 100.0%               $  873,980,625  
     

 

 

 

 

(a) 

All or a portion of the security has been pledged as collateral in connection with outstanding OTC derivatives.

(b) 

All or a portion of the security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written.

(c) 

Non-income producing security.

(d) 

Security is valued using significant unobservable inputs and is classified as Level 3 in the fair value hierarchy.

(e) 

Restricted security as to resale, excluding 144A securities. The Trust held restricted securities with a current value of $9,884,715, representing 1.1% of its net assets as of period end, and an original cost of $10,198,057.

(f) 

Convertible security.

(g) 

Affiliate of the Trust.

(h) 

Annualized 7-day yield as of period end.

 

 

For Trust compliance purposes, the Trust’s industry classifications refer to one or more of the industry sub-classifications used by one or more widely recognized market indexes or rating group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.

 

 

104  

2 0 2 1   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S


Schedule of Investments (unaudited) (continued)

June 30, 2021

  

BlackRock Resources & Commodities Strategy Trust (BCX)

    

 

Affiliates

Investments in issuers considered to be affiliate(s) of the Trust during the six-months ended June 30, 2021 for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

 

Affiliated Issuer   Value at
12/31/20
    Purchases
at Cost
    Proceeds
from Sales
    Net
Realized
Gain (Loss)
    Change in
Unrealized
Appreciation
(Depreciation)
    Value at
06/30/21
    Shares
Held at
06/30/21
    Income     Capital Gain
Distributions
from
Underlying
Funds
 

BlackRock Liquidity Funds, T-Fund, Institutional Class

  $   289,665     $   10,009,075 (a)    $ —     $ —     $ —     $   10,298,740       10,298,740     $ 825     $ —  
       

 

 

   

 

 

   

 

 

     

 

 

   

 

 

 

 

  (a) 

Represents net amount purchased (sold).

Derivative Financial Instruments Outstanding as of Period End

Exchange-Traded Options Purchased

 

Description   Number of
Contracts
    Expiration
Date
    Exercise Price    

Notional

Amount (000)

     Value

Call

              

Freeport-McMoRan, Inc.

    365       07/02/21       USD       43.50       USD       1,355      $            1,643

Newmont Corp.

    225       07/02/21       USD       70.50       USD       1,426      675

Kinross Gold Corp.

    1,600       07/16/21       CAD       9.00       CAD       1,258      5,163
              

 

               $            7,481
              

 

Exchange-Traded Options Written

 

Description   Number of
Contracts
    Expiration
Date
    Exercise Price    

Notional

Amount (000)

     Value

Call

              

CF Industries Holdings, Inc.

    675       07/02/21       USD       54.50       USD       3,473      $        (10,125)

Chevron Corp.

    381       07/02/21       USD       110.00       USD       3,991      (1,334)

Deere & Co.

    46       07/02/21       USD       385.00       USD       1,622      (368)

Deere & Co.

    47       07/02/21       USD       375.00       USD       1,658      (658)

Freeport-McMoRan, Inc.

    730       07/02/21       USD       44.50       USD       2,709      (2,190)

Marathon Petroleum Corp.

    221       07/02/21       USD       61.00       USD       1,335      (7,514)

Newmont Corp.

    449       07/02/21       USD       73.50       USD       2,846      (1,347)

Nutrien Ltd.

    211       07/02/21       USD       63.00       USD       1,279      (1,055)

Nutrien Ltd.

    351       07/02/21       USD       62.50       USD       2,127      (3,510)

Valero Energy Corp.

    234       07/02/21       USD       80.00       USD       1,827      (8,073)

CF Industries Holdings, Inc.

    247       07/09/21       USD       57.00       USD       1,271      (4,940)

CF Industries Holdings, Inc.

    248       07/09/21       USD       56.00       USD       1,276      (4,960)

ConocoPhillips

    275       07/09/21       USD       58.00       USD       1,675      (87,312)

Freeport-McMoRan, Inc.

    413       07/09/21       USD       42.00       USD       1,533      (2,685)

Marathon Petroleum Corp.

    222       07/09/21       USD       61.01       USD       1,341      (21,827)

Nutrien Ltd.

    363       07/09/21       USD       65.00       USD       2,200      (3,630)

Suncor Energy, Inc.

    456       07/09/21       CAD       31.00       CAD       1,354      (6,621)

Vale SA, ADR

    1,484       07/09/21       USD       23.50       USD       3,385      (27,454)

Bunge Ltd.

    404       07/16/21       USD       92.50       USD       3,157      (20,200)

Bunge Ltd.

    256       07/16/21       USD       85.00       USD       2,001      (5,120)

CF Industries Holdings, Inc.

    420       07/16/21       USD       55.00       USD       2,161      (14,700)

Chevron Corp.

    334       07/16/21       USD       110.00       USD       3,498      (15,698)

ConocoPhillips

    130       07/16/21       USD       60.00       USD       792      (26,065)

Darling Ingredients, Inc.

    260       07/16/21       USD       75.00       USD       1,755      (10,400)

Deere & Co.

    33       07/16/21       USD       380.00       USD       1,164      (1,997)

Exxon Mobil Corp.

    781       07/16/21       USD       65.00       USD       4,927      (47,641)

First Quantum Minerals Ltd.

    924       07/16/21       CAD       31.00       CAD       2,640      (21,617)

FMC Corp.

    280       07/16/21       USD       120.00       USD       3,030      (14,000)

Freeport-McMoRan, Inc.

    154       07/16/21       USD       45.00       USD       571      (1,155)

Freeport-McMoRan, Inc.

    96       07/16/21       USD       43.00       USD       356      (1,248)

International Paper Co.

    731       07/16/21       USD       65.00       USD       4,482      (5,483)

Kinross Gold Corp.

    3,150       07/16/21       CAD       10.00       CAD       2,476      (7,623)

Lundin Mining Corp.

    1,042       07/16/21       CAD       13.00       CAD       1,165      (4,203)

Marathon Petroleum Corp.

    200       07/16/21       USD       60.00       USD       1,208      (34,600)

 

 

S C H E D U L E   O F   I N V E S T M E N T S

  105


Schedule of Investments (unaudited) (continued)

June 30, 2021

  

BlackRock Resources & Commodities Strategy Trust (BCX)

    

 

Exchange-Traded Options Written (continued)

 

Description    Number of
Contracts
       Expiration
Date
       Exercise Price       

Notional

Amount (000)

       Value  

Call (continued)

                                

Packaging Corp. of America

     266          07/16/21          USD          155.00          USD          3,602        $          (7,980 ) 

Royal Dutch Shell PLC, Class B, ADR

     482          07/16/21          USD          37.50          USD          1,872          (98,810 ) 

Royal Dutch Shell PLC, Class B, ADR

     437          07/16/21          USD          40.00          USD          1,697          (19,665 ) 

Royal Dutch Shell PLC, Class B, ADR

     564          07/16/21          USD          42.50          USD          2,190          (7,050 ) 

Stelco Holdings Inc.

     760          07/16/21          CAD          34.00          CAD          2,766          (174,734 ) 

Suncor Energy, Inc.

     1,706          07/16/21          CAD          29.00          CAD          5,065          (167,903 ) 

Trimble, Inc.

     470          07/16/21          USD          78.00          USD          3,846          (200,038 ) 

Vale SA, ADR

     1,707          07/16/21          USD          23.00          USD          3,894          (92,178 ) 

Vale SA, ADR

     1,385          07/16/21          USD          25.00          USD          3,159          (12,465 ) 

Valero Energy Corp.

     204          07/16/21          USD          85.00          USD          1,593          (8,568 ) 

Westrock Co.

     311          07/16/21          USD          62.50          USD          1,655          (9,330 ) 

Westrock Co.

     754          07/16/21          USD          57.50          USD          4,013          (9,425 ) 

CF Industries Holdings, Inc.

     168          07/23/21          USD          56.00          USD          864          (6,300 ) 

Chevron Corp.

     362          07/23/21          USD          112.00          USD          3,792          (17,557 ) 

ConocoPhillips

     207          07/23/21          USD          60.40          USD          1,261          (49,499 ) 

Exxon Mobil Corp.

     716          07/23/21          USD          64.00          USD          4,517          (88,426 ) 

Freeport-McMoRan, Inc.

     412          07/23/21          USD          42.50          USD          1,529          (15,656 ) 

Vale SA, ADR

     1,635          07/23/21          USD          23.50          USD          3,729          (76,845 ) 

Valero Energy Corp.

     118          07/23/21          USD          83.50          USD          921          (11,623 ) 

CF Industries Holdings, Inc.

     911          07/30/21          USD          53.50          USD          4,687          (100,210 ) 

ConocoPhillips

     221          07/30/21          USD          64.00          USD          1,346          (23,868 ) 

ConocoPhillips

     176          07/30/21          USD          62.00          USD          1,072          (31,504 ) 

Deere & Co.

     69          07/30/21          USD          352.50          USD          2,434          (67,965 ) 

Nutrien Ltd.

     335          07/30/21          USD          64.00          USD          2,030          (25,125 ) 

Vale SA, ADR

     1,635          07/30/21          USD          23.50          USD          3,729          (103,822 ) 

ConocoPhillips

     267          08/06/21          USD          63.00          USD          1,626          (46,058 ) 

International Paper Co.

     223          08/06/21          USD          63.00          USD          1,367          (28,990 ) 

Nutrien Ltd.

     358          08/06/21          USD          62.00          USD          2,170          (45,645 ) 

Bunge Ltd.

     495          08/20/21          USD          85.00          USD          3,868          (64,350 ) 

Canadian Natural Resources Ltd.

     1,495          08/20/21          CAD          47.00          CAD          6,728          (165,227 ) 

Chevron Corp.

     505          08/20/21          USD          110.00          USD          5,289          (102,515 ) 

ConocoPhillips

     205          08/20/21          USD          65.00          USD          1,248          (30,135 ) 

ConocoPhillips

     205          08/20/21          USD          60.00          USD          1,248          (68,675 ) 

Darling Ingredients, Inc.

     243          08/20/21          USD          70.00          USD          1,640          (78,975 ) 

First Quantum Minerals Ltd.

     924          08/20/21          CAD          32.00          CAD          2,640          (65,595 ) 

Lundin Mining Corp.

     1,042          08/20/21          CAD          13.00          CAD          1,165          (9,247 ) 

Nutrien Ltd.

     358          08/20/21          USD          65.00          USD          2,170          (30,430 ) 

Packaging Corp. of America

     276          08/20/21          USD          140.00          USD          3,738          (82,800 ) 

Royal Dutch Shell PLC, Class B, ADR

     1,078          08/20/21          USD          40.00          USD          4,186          (132,055 ) 

Stelco Holdings Inc.

     405          08/20/21          CAD          38.00          CAD          1,474          (74,328 ) 

Suncor Energy, Inc.

     1,493          08/20/21          CAD          31.00          CAD          4,433          (133,088 ) 

Suncor Energy, Inc.

     456          08/20/21          CAD          32.00          CAD          1,354          (28,877 ) 

Trimble, Inc.

     428          08/20/21          USD          80.00          USD          3,502          (203,300 ) 

Vale SA, ADR

     1,635          08/20/21          USD          24.00          USD          3,729          (99,735 ) 

Canadian Natural Resources Ltd.

     1,213          09/17/21          CAD          46.00          CAD          5,459          (219,193 ) 

Royal Dutch Shell PLC, Class B, ADR

     481          09/17/21          USD          40.00          USD          1,868          (73,352 ) 
                                

 

 

 
                                 $   (3,636,469 ) 
                                

 

 

 

OTC Options Written

 

Description    Counterparty    Number of
Contracts
     Expiration
Date
    Exercise Price    

Notional

Amount (000)

     Value  

Call

                     

BHP Group PLC

   Barclays Bank PLC      232,600        07/07/21       GBP        21.95       GBP        4,954      $   (43,614 ) 

Koninklijke Dsm NV

   Credit Suisse International      22,100        07/07/21       EUR        153.23       EUR        3,479        (123,325 ) 

LUKOIL PJSC, ADR

   Morgan Stanley & Co. International PLC      8,700        07/08/21       USD        81.31       USD        806        (97,729 ) 

TotalEnergies SE

   Goldman Sachs International      106,500        07/08/21       EUR        39.62       EUR        4,064        (16,961 ) 

Kinross Gold Corp.

   Credit Suisse International      298,000        07/12/21       CAD        9.70       CAD        2,342        (94 ) 

BHP Group PLC

   Credit Suisse International      108,000        07/14/21       GBP        22.19       GBP        2,300        (25,095 ) 

Glencore International PLC

   Morgan Stanley & Co. International PLC      581,600        07/14/21       GBP        3.21       GBP        1,800        (34,060 ) 

Equinor ASA

   Credit Suisse International      215,900        07/15/21       NOK        193.36       NOK        39,333        (15,644 ) 

 

 

106  

2 0 2 1   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S


Schedule of Investments (unaudited) (continued)

June 30, 2021

  

BlackRock Resources & Commodities Strategy Trust (BCX)

    

 

OTC Options Written (continued)

 

Description    Counterparty   Number of
Contracts
    Expiration
Date
    Exercise Price     Notional
Amount (000)
    Value  

Call (continued)

                

Aker BP

   Morgan Stanley & Co. International PLC     86,300       07/20/21       NOK       279.54       NOK       23,681     $ (66,427 ) 

LUKOIL PJSC, ADR

   Credit Suisse International     37,900       07/20/21       USD       93.25       USD       3,510       (21,523 ) 

Public Joint Stock Polyus GDR

   Credit Suisse International     14,500       07/27/21       USD       108.56       USD       1,403       (2,367 ) 

Anglo American PLC

   Morgan Stanley & Co. International PLC     187,000       07/28/21       GBP       32.27       GBP       5,372       (33,955 ) 

Glencore International PLC

   UBS AG     460,000       07/28/21       GBP       3.43       GBP       1,423       (14,494 ) 

Royal Dutch Shell PLC, Class B, ADR

   Barclays Bank PLC     96,400       07/28/21       USD       38.45       USD       3,743       (183,219 ) 

Equinor ASA

   HSBC Bank PLC     50,700       07/29/21       NOK       193.02       NOK       9,237       (9,307 ) 

TotalEnergies SE

   Goldman Sachs International     79,200       07/29/21       EUR       41.73       EUR       3,022       (13,652 ) 

FMC Corp.

   Citibank N.a.     49,000       08/03/21       USD       121.12       USD       5,302       (11,904 ) 

Aker BP ASA

   Goldman Sachs International     40,100       08/04/21       NOK       286.13       NOK       11,003       (25,510 ) 

Public Joint Stock Polyus, GDR

   Credit Suisse International     14,800       08/04/21       USD       102.15       USD       1,432       (17,249 ) 

Koninklijke Dsm NV

   Credit Suisse International     19,800       08/05/21       EUR       159.07       EUR       3,117       (74,817 ) 

Newcrest Mining Ltd.

   JPMorgan Chase Bank N.A.     83,000       08/05/21       AUD       26.51       AUD       2,098       (29,842 ) 

Nestle SA, Registered Shares

   Citibank N.a.     13,000       08/06/21       CHF       116.30       CHF       1,498       (17,845 ) 

Anglo American PLC

   Morgan Stanley & Co. International PLC     187,000       08/10/21       GBP       32.59       GBP       5,372       (41,765 ) 

LUKOIL PJSC, ADR

   Goldman Sachs International     4,300       08/10/21       USD       94.01       USD       398       (6,170 ) 

Glencore International PLC

   Credit Suisse International     880,000       08/11/21       GBP       3.22       GBP       2,723       (108,420 ) 

TotalEnergies SE

   Goldman Sachs International     130,900       08/11/21       EUR       40.66       EUR       4,994       (54,125 ) 

Glencore International PLC

   UBS AG     555,100       08/18/21       GBP       3.23       GBP       1,718       (70,352 ) 

TotalEnergies SE

   Credit Suisse International     77,500       08/18/21       EUR       38.74       EUR       2,957       (99,053 ) 

Nestle SA, Registered Shares

   Citibank N.a.     13,000       08/26/21       CHF       116.30       CHF       1,498       (21,671 ) 
                

 

 

 
                 $ (1,280,189 ) 
                

 

 

 

Balances Reported in the Statements of Assets and Liabilities for Options Written

 

Description    Swap
Premiums
Paid
     Swap
Premiums
Received
     Unrealized
Appreciation
     Unrealized
Depreciation
    

Value

Options Written

   $ N/A      $ N/A      $ 4,483,569      $ (671,898 )     $(4,916,658)

Derivative Financial Instruments Categorized by Risk Exposure

As of period end, the fair values of derivative financial instruments located in the Statements of Assets and Liabilities were as follows:

 

      Commodity
Contracts
   Credit
Contracts
     Equity
Contracts
     Foreign
Currency
Exchange
Contracts
    Interest
Rate
Contracts
     Other
Contracts
    Total  

Assets — Derivative Financial Instruments

                  

Options purchased

                  

Investments at value — unaffiliated(a)

   $             —    $ —      $ 7,481      $ —     $ —      $ —     $ 7,481  
  

 

  

 

 

    

 

 

    

 

 

   

 

 

    

 

 

   

 

 

 

Liabilities — Derivative Financial Instruments

                  

Options written

                  

Options written at value

   $             —    $ —      $ 4,916,658      $ —     $ —      $ —     $ 4,916,658  
  

 

  

 

 

    

 

 

    

 

 

   

 

 

    

 

 

   

 

 

 

 

  (a) 

Includes options purchased at value as reported in the Schedule of Investments.

 

 

S C H E D U L E   O F   I N V E S T M E N T S

  107


Schedule of Investments (unaudited) (continued)

June 30, 2021

  

BlackRock Resources & Commodities Strategy Trust (BCX)

    

 

For the six months ended June 30, 2021, the effect of derivative financial instruments in the Statements of Operations was as follows:

 

      Commodity
Contracts
       Credit
Contracts
       Equity
Contracts
       Foreign
Currency
Exchange
Contracts
       Interest
Rate
Contracts
       Other
Contracts
       Total  

Net Realized Gain (Loss) from

                                

Options purchased(a)

   $  —        $ —        $ (8,055 )       $  —        $  —        $  —        $ (8,055 ) 

Options written

     —          —          (26,931,614 )         —          —          —          (26,931,614 ) 
  

 

 

      

 

 

      

 

 

      

 

 

      

 

 

      

 

 

      

 

 

 
   $ —        $ —        $ (26,939,669 )       $ —        $ —        $ —        $  (26,939,669 ) 
  

 

 

      

 

 

      

 

 

      

 

 

      

 

 

      

 

 

      

 

 

 

Net Change in Unrealized Appreciation (Depreciation) on

                                

Options purchased(b)

   $ —        $ —        $ (6,242 )       $ —        $ —        $ —        $ (6,242 ) 

Options written

     —          —          10,636,050          —          —          —          10,636,050  
  

 

 

      

 

 

      

 

 

      

 

 

      

 

 

      

 

 

      

 

 

 
   $ —        $ —        $ 10,629,808        $ —        $ —        $ —        $ 10,629,808  
  

 

 

      

 

 

      

 

 

      

 

 

      

 

 

      

 

 

      

 

 

 

 

  (a)

Options purchased are included in net realized gain (loss) from investments — unaffiliated.

 
  (b)

Options purchased are included in net change in unrealized appreciation (depreciation) on investments — unaffiliated.

 

Average Quarterly Balances of Outstanding Derivative Financial Instruments

 

Options

        

Average value of option contracts purchased

   $ 3,740  

Average value of option contracts written

   $ 5,392,499  

For more information about the Trust’s investment risks regarding derivative financial instruments, refer to the Notes to Financial Statements.

Derivative Financial Instruments — Offsetting as of Period End

The Trust’s derivative assets and liabilities (by type) were as follows:

 

      Assets        Liabilities  

Derivative Financial Instruments

       

Options

   $ 7,481        $ 4,916,658  
  

 

 

      

 

 

 

Total derivative assets and liabilities in the Statements of Assets and Liabilities

     7,481          4,916,658  
  

 

 

      

 

 

 

Derivatives not subject to a Master Netting Agreement or similar agreement (“MNA”)

     (7,481 )         (3,636,469 ) 
  

 

 

      

 

 

 

Total derivative assets and liabilities subject to an MNA

   $ —        $ 1,280,189  
  

 

 

      

 

 

 

The following table presents the Trust’s derivative liabilities by counterparty net of amounts available for offset under an MNA and net of the related collateral pledged by the Trust:

 

Counterparty     



Derivative
Liabilities
Subject to
an MNA by
Counterparty
 
 
 
 
 
      

Derivatives
Available
for Offset
 
 
 
      

Non-Cash
Collateral
Pledged
 
 
(a)  
    

Cash
Collateral
Pledged
 
 
 
      

Net Amount
of Derivative
Liabilities
 
 
(b)  

Barclays Bank PLC

   $ 226,833        $ —        $ (226,833 )     $ —        $ —  

Citibank N.a.

     51,420          —          —        —          51,420  

Credit Suisse International

     487,587          —          (483,784 )       —          3,803  

Goldman Sachs International

     116,418          —          (116,418 )       —          —  

HSBC Bank PLC

     9,307          —          —        —          9,307  

JPMorgan Chase Bank N.A.

     29,842          —          —        —          29,842  

Morgan Stanley & Co. International PLC

     273,936          —          (273,936 )       —          —  

UBS AG

     84,846          —          (84,846 )       —          —  
  

 

 

      

 

 

      

 

 

    

 

 

      

 

 

 
   $ 1,280,189        $ —        $  (1,185,817 )     $ —        $ 94,372  
  

 

 

      

 

 

      

 

 

    

 

 

      

 

 

 

 

  (a)

Excess of collateral pledged to the individual counterparty is not shown for financial reporting purposes.

 
  (b)

Net amount represents the net amount payable due to counterparty in the event of default. Net amount may be offset further by the options written receivable/payable on the Statements of Assets and Liabilities.

 

 

 

108  

2 0 2 1   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S


Schedule of Investments (unaudited) (continued)

June 30, 2021

  

BlackRock Resources & Commodities Strategy Trust (BCX)

    

 

Fair Value Hierarchy as of Period End

Various inputs are used in determining the fair value of financial instruments. For a description of the input levels and information about the Trust’s policy regarding valuation of financial instruments, refer to the Notes to Financial Statements.

The following table summarizes the Trust’s financial instruments categorized in the fair value hierarchy. The breakdown of the Trust’s financial instruments into major categories is disclosed in the Schedule of Investments above.

 

      Level 1        Level 2        Level 3        Total  

Assets

                 

Investments

                 

Long-Term Investments

                 

Common Stocks

                 

Chemicals

   $ 92,033,250        $ 21,169,423        $ —        $ 113,202,673  

Containers & Packaging

     50,973,926          —          —          50,973,926  

Electronic Equipment, Instruments & Components

     19,868,897          —          —          19,868,897  

Food Products

     33,580,902          8,762,439          9,884,715          52,228,056  

Machinery

     18,625,557          —          —          18,625,557  

Metals & Mining

     147,149,412          108,195,819          —          255,345,231  

Oil, Gas & Consumable Fuels

     255,608,488          96,197,911          —          351,806,399  

Paper & Forest Products

     —          248,581          —          248,581  

Corporate Bonds

     4,662,630          —          —          4,662,630  

Short-Term Securities

                 

Money Market Funds

     10,298,740          —          —          10,298,740  

Options Purchased

                 

Equity Contracts

     7,481          —          —          7,481  
  

 

 

      

 

 

      

 

 

      

 

 

 
   $   632,809,283        $   234,574,173        $   9,884,715        $   877,268,171  
  

 

 

      

 

 

      

 

 

      

 

 

 

Derivative Financial Instruments(a)

                 

Liabilities

                 

Equity Contracts

   $ (3,365,105 )       $ (1,551,553 )       $ —        $ (4,916,658 ) 
  

 

 

      

 

 

      

 

 

      

 

 

 

 

  (a)

Derivative financial instruments are options written. Options written are shown at value.

 

A reconciliation of Level 3 financial instruments is presented when the Trust had a significant amount of Level 3 investments at the beginning and/or end of the period in relation to net assets. The following table is a reconciliation of Level 3 investments for which significant unobservable inputs were used in determining fair value:

 

      Common
Stocks
 

Assets

  

Opening balance, as of December 31, 2020

   $ —  

Transfers into Level 3

     —  

Transfers out of Level 3

     —  

Accrued discounts/premiums

     —  

Net realized gain (loss)

     —  

Net change in unrealized appreciation (depreciation)(a)(b)

     (313,341 ) 

Purchases

     10,198,056  

Sales

     —  
  

 

 

 

Closing balance, as of June 30, 2021

   $ 9,884,715  
  

 

 

 

Net change in unrealized appreciation (depreciation) on investments still held at June 30, 2021(b)

   $ (313,341 ) 
  

 

 

 

 

  (a)

Included in the related net change in unrealized appreciation (depreciation) in the Statements of Operations.

 
  (b)

Any difference between net change in unrealized appreciation (depreciation) and net change in unrealized appreciation (depreciation) on investments still held at June 30, 2021 is generally due to investments no longer held or categorized as Level 3 at period end.

 

 

 

S C H E D U L E   O F   I N V E S T M E N T S

  109


Schedule of Investments (unaudited) (continued)

June 30, 2021

  

BlackRock Resources & Commodities Strategy Trust (BCX)

    

 

The following table summarizes the valuation approaches used and unobservable inputs utilized by the BlackRock Global Valuation Methodologies Committee (the “Global Valuation Committee”) to determine the value of certain of the Trust’s Level 3 financial instruments as of period end.

 

      Value        Valuation
Approach
       Unobservable
Inputs(a)
 

Assets

            

Common Stocks

   $  9,884,715          Market          Recent Transactions  

    

            
  

 

 

           
   $   9,884,715            
  

 

 

           

 

  (a) 

A significant change in unobservable input would have resulted in a correlated (inverse) significant change to value.

 

See notes to financial statements.

 

 

110  

2 0 2 1   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S


Consolidated Schedule of Investments (unaudited)

June 30, 2021

  

BlackRock Science and Technology Trust (BST)

(Percentages shown are based on Net Assets)

 

Security          Shares     Value  

Common Stocks

     
Auto Components — 0.4%                  

Magna International, Inc.(a)

      67,573     $ 6,259,963  
     

 

 

 
Automobiles(a)(b) — 1.5%                  

Arrival Group

      180,232       2,824,235  

Tesla, Inc.

      27,934       18,986,740  
     

 

 

 
        21,810,975  
Banks — 2.6%                  

Klarna Holdings AB, (Acquired 08/07/19, Cost: $7,971,978)(c)(d)

      26,430       36,386,841  
     

 

 

 
Diversified Consumer Services — 1.0%                  

Chegg, Inc.(a)(b)

      120,357       10,002,870  

Think & Learn Private Ltd., (Acquired 09/30/20, Cost: $1,524,948)(c)(d)

      997       3,823,582  
     

 

 

 
        13,826,452  
Diversified Financial Services — 0.4%                  

TransferWise, (Acquired 06/03/19, Cost: $2,471,478)(c)(d)

      27,945       5,482,530  
     

 

 

 
Electrical Equipment — 0.4%                  

Shoals Technologies Group, Inc., Class A(a)(b)

      150,565       5,345,057  
     

 

 

 
Electronic Equipment, Instruments & Components — 0.9%  

Samsung SDI Co. Ltd.

      21,808       13,502,156  
     

 

 

 
Entertainment(a) — 3.0%                  

Activision Blizzard, Inc.

      117,192       11,184,804  

NetEase, Inc., ADR

      84,512       9,740,008  

Roku, Inc.(b)

      45,378       20,839,847  
     

 

 

 
        41,764,659  
Hotels, Restaurants & Leisure — 0.2%                  

Airbnb, Inc., Class A(a)(b)

      20,734       3,175,205  
     

 

 

 
Interactive Media & Services — 11.5%                  

Alphabet, Inc., Class A(a)(b)

      15,765       38,494,819  

Facebook, Inc., Class A(a)(b)

      67,998       23,643,584  

Kakao Corp.

      278,085       40,278,538  

Kanzhun Ltd., ADR(b)

      119,306       4,730,483  

Snap, Inc., Class A(a)(b)

      293,698       20,012,582  

Tencent Holdings Ltd.

      174,700       13,153,595  

Yandex NV, Class A(a)(b)

      162,287       11,481,805  

ZoomInfo Technologies, Inc., Class A(a)(b)

      208,111       10,857,151  
     

 

 

 
        162,652,557  
Internet & Direct Marketing Retail — 5.5%                  

Amazon.com, Inc.(a)(b)

      10,760       37,016,122  

Delivery Hero SE(b)(e)

      86,031       11,366,942  

Ensogo Ltd.(b)(c)

      173,282       1  

Jasper Infotech Private Ltd., Series I, (Acquired 08/18/15, Cost: $1,998,435)(c)(d)

      1,054       177,472  

JD Health International, Inc.(b)(e)

      750,550       10,720,110  

MercadoLibre, Inc.(a)(b)

      11,762       18,322,726  
     

 

 

 
        77,603,373  
IT Services — 18.8%                  

Adyen NV(b)(e)

      4,937       12,107,150  

Amadeus IT Group SA(b)

      95,320       6,719,737  

Automattic, Inc., Series E, (Acquired 02/03/21, Cost: $7,999,945)(c)(d)

      94,117       8,805,587  

Fiserv, Inc.(a)(b)

      87,585       9,361,961  

GMO Payment Gateway, Inc.

      75,700       9,831,434  

Marqeta, Inc.(a)(b)(f)

      333,858       9,371,394  

Mastercard, Inc., Class A(a)

      79,169       28,903,810  
Security          Shares     Value  
IT Services (continued)                  

MongoDB, Inc.(a)(b)

      29,473     $ 10,655,079  

Okta, Inc.(a)(b)

      64,894       15,878,264  

PayPal Holdings, Inc.(a)(b)

      114,305       33,317,621  

Shopify, Inc., Class A(a)(b)

      14,378       21,005,970  

Snowflake, Inc., Class A(a)(b)

      8,644       2,090,119  

Square, Inc., Class A(a)(b)

      114,135       27,826,113  

StoneCo Ltd., Class A(a)(b)

      158,853       10,652,682  

TRAX Ltd., Series D, (Acquired 02/18/21, Cost: $1,999,989)(c)(d)

      38,361       2,149,367  

TRAX Ltd., Series E, (Acquired 09/12/19, Cost: $4,000,013)(c)(d)

      106,667       5,976,552  

Twilio, Inc., Class A(a)(b)

      67,607       26,647,975  

Visa, Inc., Class A(a)

      104,136       24,349,080  
     

 

 

 
                265,649,895  
Professional Services — 0.5%                  

Recruit Holdings Co. Ltd.

      153,900       7,547,066  
     

 

 

 
Road & Rail(a)(b) — 2.1%                  

Lyft, Inc., Class A

      195,882       11,846,943  

TuSimple Holdings, Inc., Class A

      110,935       7,903,010  

Uber Technologies, Inc.

      192,560       9,651,107  
     

 

 

 
        29,401,060  
Semiconductors & Semiconductor Equipment — 16.0%        

Advanced Micro Devices, Inc.(a)(b)

      237,397       22,298,700  

Alphawave IP Group PLC(b)

      1,436,993       7,156,053  

Analog Devices, Inc.(a)

      41,879       7,209,889  

ASML Holding NV

      40,661       28,069,072  

Cree, Inc.(a)(b)

      120,809       11,830,825  

Lam Research Corp.(a)

      42,040       27,355,428  

Marvell Technology, Inc.(a)

      554,334       32,334,302  

Monolithic Power Systems, Inc.(a)

      35,343       13,198,843  

Qualcomm, Inc.(a)

      58,681       8,387,275  

Renesas Electronics Corp.(b)

      1,128,300       12,177,011  

Skyworks Solutions, Inc.(a)

      53,944       10,343,762  

SOITEC(b)

      73,604       16,253,414  

STMicroelectronics NV

      267,921       9,743,366  

Taiwan Semiconductor Manufacturing Co. Ltd., ADR(a)

      159,103       19,117,817  
     

 

 

 
        225,475,757  
Software — 20.2%                  

Adobe, Inc.(a)(b)

      38,188       22,364,420  

Atlassian Corp. PLC, Class A(a)(b)

      45,693       11,736,704  

Autodesk, Inc.(a)(b)

      44,736       13,058,438  

Avalara, Inc.(a)(b)

      78,563       12,711,493  

C3.AI, Inc., Class A(a)(b)

      245,379       15,343,549  

Cadence Design Systems, Inc.(a)(b)

      88,624       12,125,536  

Coupa Software, Inc.(a)(b)

      40,074       10,503,796  

Crowdstrike Holdings, Inc., Class A(a)(b)

      52,434       13,177,189  

Databricks, Inc., (Acquired 07/24/20, Cost: $960,476)(c)(d)

      19,999       3,547,223  

DataRobot, Inc., Series F, (Acquired 03/01/21, Cost: $583,274)(c)(d)

      38,789       661,740  

Elastic NV(a)(b)

      55,431       8,079,623  

Intuit, Inc.(a)

      29,270       14,347,276  

Linklogis, Inc., (Acquired 03/31/21, Cost: $2,624,480)(d)

      1,149,000       2,509,638  

Microsoft Corp.(a)

      200,749       54,382,904  

Online Ventures Pty Ltd., Series C, (Acquired 01/21/20, Cost: $6,160,136)(c)(d)

      53,642       7,874,390  

Paycom Software, Inc.(a)(b)

      22,949       8,341,273  

salesforce.com, Inc.(a)(b)

      53,000       12,946,310  
 

 

 

C O N S O L I D A T E D   S C H E D U L E   O F   I N V E S T M E N T S

  111


Consolidated Schedule of Investments (unaudited) (continued)

June 30, 2021

  

BlackRock Science and Technology Trust (BST)

(Percentages shown are based on Net Assets)

 

Security   Shares     Value  
Software (continued)  

ServiceNow, Inc.(a)(b)

    31,214     $ 17,153,654  

Snorkel Al, Inc., (Acquired 06/30/21, Cost: $997,636)(c)(d)

    66,422       1,087,328  

Unity Software, Inc.(a)(b)

    84,780       9,311,387  

Xero Ltd.(b)

    113,877       11,713,354  

Zoom Video Communications, Inc.,
Class A(a)(b)

    17,056       6,601,184  

Zscaler, Inc.(a)(b)

    72,005       15,557,400  
   

 

 

 
      285,135,809  
Specialty Retail — 0.2%  

Cazoo Ltd., (Acquired 10/08/20, Cost: $1,414,228)(c)(d)

    102,926       3,005,590  
   

 

 

 
Technology Hardware, Storage & Peripherals — 3.9%  

Apple, Inc.(a)

    402,442       55,118,456  
   

 

 

 

Total Common Stocks — 89.1% (Cost: $419,687,793)

      1,259,143,401  
   

 

 

 

Preferred Securities

 

Preferred Stocks — 12.6%(d)

 

Automobiles — 0.9%  

Arrival Ltd., (Acquired 03/23/21, Cost: $6,054,719)

    835,013       12,782,973  
   

 

 

 
Diversified Consumer Services — 0.3%  

Think & Learn Private Ltd., Series F, (Acquired 09/30/20, Cost: $3,052,975)(c)

    1,054       4,042,181  
   

 

 

 
Diversified Financial Services(c) — 0.4%  

TransferWise

   

Series A, (Acquired 06/03/19, Cost: $1,004,242)

    11,355       2,227,737  

Series B, (Acquired 06/03/19, Cost: $288,407)

    3,261       639,776  

Series C, (Acquired 06/03/19, Cost: $161,315)

    1,824       357,850  

Series D, (Acquired 06/03/19, Cost: $44,579)

    504       98,880  

Series E, (Acquired 06/03/19, Cost: $4,688)

    53       10,398  

TransferWise (Seed Preferred), (Acquired 06/03/19, Cost: $849,295)

    9,603       1,884,013  
   

 

 

 
      5,218,654  
Electronic Equipment, Instruments & Components(c) — 0.4%  

Credo Technology Group Holding Ltd.

   

Series D, (Acquired 03/20/20, Cost: $5,000,001)

    1,001,382       5,818,029  

Series D+, (Acquired 01/22/20, Cost: $404,498)

    69,679       404,835  
   

 

 

 
      6,222,864  
Food Products — 0.3%  

Farmer’s Business Network, Inc., Series F, (Acquired 07/31/20, Cost: $2,999,886)(c)

    90,750       3,874,117  
   

 

 

 
Interactive Media & Services — 1.1%  

ByteDance Ltd., Series E-1, (Acquired 11/11/20, Cost: $9,999,959)(c)

    91,262       15,481,232  
   

 

 

 
IT Services — 1.6%  

Ant Group Co., Ltd, Series C, (Acquired 05/18/18, Cost: $6,492,863)(c)

    1,157,373       7,546,072  

Deep Instinct Ltd., Series D-2, (Acquired 03/19/21, Cost: $2,999,391)(c)

    493,493       3,107,590  
Security   Shares     Value  
IT Services (continued)  

Trumid Holdings LLC(c)(g)

   

Class J-A, (Acquired 07/24/20, Cost: $2,499,716)

    5,038     $ 2,947,280  

Class J-B, (Acquired 07/24/20, Cost: $1,499,830)

    5,038       2,947,280  

Xiaoju Kuaizhi, Inc., Series A-17, (Acquired 07/28/15, Cost: $3,016,964)

    110,003       5,910,681  
   

 

 

 
      22,458,903  
Road & Rail — 0.4%  

FlixMobility GmbH, Series F, (Acquired 07/26/19, Cost: $5,482,937)(c)

    275       6,573,473  
   

 

 

 
Semiconductors & Semiconductor Equipment(c) — 3.1%  

Innovium, Inc.

   

Series E, (Acquired 08/21/19, Cost: $3,000,003)

    353,478       3,609,011  

Series F, (Acquired 06/10/20, Cost: $2,999,996)

    296,062       3,339,579  

Psiquantum Corp., Series C, (Acquired 09/09/19, Cost: $3,200,234)

    690,003       14,103,661  

PsiQuantum Corp., Series D, (Acquired 05/21/21, Cost: $5,000,025)

    190,650       5,000,750  

SambaNova Systems, Inc., Series C, (Acquired 02/20/20, Cost: $9,972,126)

    187,300       17,797,246  
   

 

 

 
      43,850,247  
Software(c) — 3.5%  

Avidxchange, Inc., (Acquired 07/29/20, Cost: $2,022,088)

    41,257       2,534,005  

Databricks, Inc.

   

Series F, (Acquired 10/22/19, Cost: $3,999,999)

    93,135       16,519,355  

Series G, (Acquired 02/01/21, Cost: $4,500,001)

    25,371       4,500,054  

DataRobot, Inc., Series F, (Acquired 10/27/20, Cost: $2,999,996)

    228,276       3,894,389  

GitLab, Inc., Series E, (Acquired 09/10/19, Cost: $2,915,501)

    156,500       6,989,290  

Snorkel AI, Inc., Series C, (Acquired 06/30/21, Cost: $4,999,985)

    332,896       4,999,984  

Unqork, Inc.

   

Series B, (Acquired 09/19/19, Cost: $3,198,417)

    7,027       8,298,325  

Series C, (Acquired 09/18/20, Cost: $1,303,260)

    1,190       1,405,295  
   

 

 

 
      49,140,697  
Specialty Retail(c) — 0.6%  

Cazoo Ltd.

   

Series A, (Acquired 10/08/20, Cost: $46,195)

    3,362       98,175  

Series B, (Acquired 10/08/20, Cost: $808,325)

    58,829       1,717,893  

Series C, (Acquired 10/08/20, Cost: $16,392)

    1,193       34,837  

Series D, (Acquired 10/08/20, Cost: $2,887,649)

    210,160       6,136,980  
   

 

 

 
      7,987,885  
   

 

 

 

Total Preferred Stocks — 12.6%

      177,633,226  
   

 

 

 

Total Preferred Securities — 12.6% (Cost: $105,726,457)

      177,633,226  
   

 

 

 
 

 

 

112  

2 0 2 1   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S


Consolidated Schedule of Investments (unaudited) (continued)

June 30, 2021

  

BlackRock Science and Technology Trust (BST)

(Percentages shown are based on Net Assets)

 

Security   Shares     Value  

Warrants

   
IT Services — 0.0%            

TRAX Ltd., (Acquired 09/12/19, Cost: $0)(c)(d)

    17,065     $ 170,650  
   

 

 

 

Total Warrants — 0.0%
(Cost: $ — )

 

    170,650  
   

 

 

 

Total Long-Term Investments — 101.7%
(Cost: $525,414,250)

 

    1,436,947,277  
   

 

 

 

Short-Term Securities

   

Money Market Funds — 0.3%

   

SL Liquidity Series, LLC, Money Market Series, 0.13%(h)(i)(j)

    3,871,586       3,872,747  
   

 

 

 

Total Short-Term Securities — 0.3%
(Cost: $3,872,747)

 

    3,872,747  
   

 

 

 

Total Investments Before Options Written — 102.0%
(Cost: $529,286,997)

 

    1,440,820,024  
   

 

 

 

Options Written — (1.7)%
(Premiums Received: $(11,659,670))

 

    (23,673,717 ) 
   

 

 

 

Total Investments, Net of Options Written — 100.3%
(Cost: $517,627,327)

 

    1,417,146,307  

Liabilities in Excess of Other Assets — (0.3)%

 

    (4,067,350 ) 
   

 

 

 

Net Assets — 100.0%

 

  $  1,413,078,957  
   

 

 

 
(a) 

All or a portion of the security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written.

(b) 

Non-income producing security.

(c) 

Security is valued using significant unobservable inputs and is classified as Level 3 in the fair value hierarchy.

(d) 

Restricted security as to resale, excluding 144A securities. The Trust held restricted securities with a current value of $259,291,716, representing 18.4% of its net assets as of period end, and an original cost of $146,433,473.

(e) 

Security exempt from registration pursuant to Rule 144A under the Securities Act of 1933, as amended. These securities may be resold in transactions exempt from registration to qualified institutional investors.

(f) 

All or a portion of this security is on loan.

(g) 

All or a portion of the security is held by a wholly-owned subsidiary. See Note 1 of the Notes to Consolidated Financial Statements for details on the wholly-owned subsidiary.

(h) 

Affiliate of the Trust.

(i) 

Annualized 7-day yield as of period end.

(j) 

All or a portion of this security was purchased with the cash collateral from loaned securities.

 

For Trust compliance purposes, the Trust’s industry classifications refer to one or more of the industry sub-classifications used by one or more widely recognized market indexes or rating group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.

Affiliates

Investments in issuers considered to be affiliate(s) of the Trust during the six-months ended June 30, 2021 for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

 

Affiliated Issuer   Value at
12/31/20
    Purchases
at Cost
    Proceeds
from Sales
    Net
Realized
Gain (Loss)
    Change in
Unrealized
Appreciation
(Depreciation)
    Value at
06/30/21
    Shares
Held at
06/30/21
    Income     Capital Gain
Distributions
from
Underlying
Funds
 

BlackRock Liquidity Funds, T-Fund, Institutional
Class(a)

  $  9,266,737     $ —     $  (9,266,737 )(b)    $ —     $ —     $ —       —     $ 1,770     $ —  

SL Liquidity Series, LLC, Money Market Series

    —       3,872,747 (b)      —       —       —       3,872,747       3,871,586       41,953 (c)      —  
       

 

 

   

 

 

   

 

 

     

 

 

   

 

 

 
        $ —     $ —     $  3,872,747       $  43,723     $ —  
       

 

 

   

 

 

   

 

 

     

 

 

   

 

 

 

 

  (a) 

As of period end, the entity is no longer held.

  (b) 

Represents net amount purchased (sold).

  (c) 

All or a portion represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of fees and collateral investment expenses, and other payments to and from borrowers of securities.

Derivative Financial Instruments Outstanding as of Period End

Exchange-Traded Options Written

 

Description    Number of
Contracts
     Expiration
Date
     Exercise Price     

Notional

Amount (000)

     Value  

Call

                    

Activision Blizzard, Inc.

     155        07/02/21        USD        96.50        USD        1,479      $ (5,425 ) 

Alphabet, Inc., Class A

     14        07/02/21        USD        2,280.00        USD        3,419            (227,570 ) 

Amazon.com, Inc.

     7        07/02/21        USD        3,350.00        USD        2,408        (66,290 ) 

Atlassian Corp. PLC, Class A

     4        07/02/21        USD        225.00        USD        103        (12,780 ) 

Cree, Inc.

     211        07/02/21        USD        100.00        USD        2,066        (10,550 ) 

 

 

C O N S O L I D A T E D   S C H E D U L E    O F   I N V E S T M E N T S

  113


Consolidated Schedule of Investments (unaudited) (continued)

June 30, 2021

  

BlackRock Science and Technology Trust (BST)

    

 

Exchange-Traded Options Written (continued)

 

Description    Number of
Contracts
     Expiration
Date
     Exercise Price     

Notional

Amount (000)

     Value  

Call (continued)

                    

Crowdstrike Holdings, Inc., Class A

     41        07/02/21        USD        232.50        USD        1,030      $ (77,592 ) 

Lam Research Corp.

     38        07/02/21        USD        605.00        USD        2,473            (177,270 ) 

Lyft, Inc., Class A

     47        07/02/21        USD        60.00        USD        284        (5,123 ) 

Mastercard, Inc., Class A

     38        07/02/21        USD        380.00        USD        1,387        (627 ) 

MongoDB, Inc.

     8        07/02/21        USD        320.00        USD        289        (33,920 ) 

NetEase, Inc., ADR

     135        07/02/21        USD        125.00        USD        1,556        (58,050 ) 

Snap, Inc., Class A

     23        07/02/21        USD        65.00        USD        157        (7,705 ) 

Snowflake, Inc., Class A

     15        07/02/21        USD        250.00        USD        363        (1,200 ) 

Taiwan Semiconductor Manufacturing Co. Ltd., ADR

     277        07/02/21        USD        119.00        USD        3,328        (44,043 ) 

Yandex NV, Class A

     122        07/02/21        USD        68.50        USD        863        (26,840 ) 

Zscaler, Inc.

     68        07/02/21        USD        200.00        USD        1,469        (110,500 ) 

Airbnb, Inc., Class A

     17        07/09/21        USD        150.00        USD        260        (9,605 ) 

Alphabet, Inc., Class A

     6        07/09/21        USD        2,400.00        USD        1,465        (30,960 ) 

Analog Devices, Inc.

     73        07/09/21        USD        167.50        USD        1,257        (38,325 ) 

Apple, Inc.

     29        07/09/21        USD        129.00        USD        397        (22,983 ) 

Autodesk, Inc.

     47        07/09/21        USD        295.00        USD        1,372        (13,724 ) 

Chegg, Inc.

     105        07/09/21        USD        82.51        USD        873        (23,241 ) 

Coupa Software, Inc.

     36        07/09/21        USD        252.50        USD        944        (45,540 ) 

Cree, Inc.

     113        07/09/21        USD        108.00        USD        1,107        (2,543 ) 

Fiserv, Inc.

     109        07/09/21        USD        117.00        USD        1,165        (1,199 ) 

Mastercard, Inc., Class A

     39        07/09/21        USD        380.00        USD        1,424        (2,126 ) 

MercadoLibre, Inc.

     9        07/09/21        USD        1,420.00        USD        1,402        (127,485 ) 

Microsoft Corp.

     88        07/09/21        USD        252.50        USD        2,384        (163,680 ) 

MongoDB, Inc.

     12        07/09/21        USD        322.50        USD        434        (48,720 ) 

Okta, Inc.

     15        07/09/21        USD        240.00        USD        367        (11,700 ) 

Qualcomm, Inc.

     97        07/09/21        USD        137.00        USD        1,386        (65,232 ) 

Roku, Inc.

     53        07/09/21        USD        365.00        USD        2,434        (501,115 ) 

ServiceNow, Inc.

     42        07/09/21        USD        490.00        USD        2,308        (253,890 ) 

Shopify, Inc., Class A

     25        07/09/21        USD        1,290.00        USD        3,652        (432,625 ) 

Skyworks Solutions, Inc.

     107        07/09/21        USD        177.50        USD        2,052        (152,475 ) 

Snap, Inc., Class A

     173        07/09/21        USD        62.00        USD        1,179        (111,585 ) 

Square, Inc., Class A

     40        07/09/21        USD        240.00        USD        975        (31,400 ) 

Square, Inc., Class A

     41        07/09/21        USD        250.00        USD        1,000        (13,735 ) 

Stoneco Ltd., Class A

     152        07/09/21        USD        70.00        USD        1,019        (7,980 ) 

Taiwan Semiconductor Manufacturing Co. Ltd., ADR

     22        07/09/21        USD        120.00        USD        264        (4,125 ) 

Tesla, Inc.

     6        07/09/21        USD        690.00        USD        408        (10,770 ) 

Tesla, Inc.

     7        07/09/21        USD        640.00        USD        476        (35,263 ) 

Twilio, Inc., Class A

     78        07/09/21        USD        365.00        USD        3,074        (256,230 ) 

Twilio, Inc., Class A

     27        07/09/21        USD        357.50        USD        1,064        (107,392 ) 

Uber Technologies, Inc.

     174        07/09/21        USD        54.00        USD        872        (3,045 ) 

Visa, Inc., Class A

     51        07/09/21        USD        235.00        USD        1,192        (9,945 ) 

Yandex NV, Class A

     123        07/09/21        USD        69.00        USD        870        (26,445 ) 

Activision Blizzard, Inc.

     95        07/16/21        USD        100.00        USD        907        (4,750 ) 

Adobe, Inc.

     30        07/16/21        USD        505.00        USD        1,757        (244,500 ) 

Advanced Micro Devices, Inc.

     160        07/16/21        USD        82.50        USD        1,503        (184,800 ) 

Airbnb, Inc., Class A

     22        07/16/21        USD        150.00        USD        337        (15,400 ) 

Amazon.com, Inc.

     17        07/16/21        USD        3,450.00        USD        5,848        (86,275 ) 

Apple, Inc.

     92        07/16/21        USD        135.00        USD        1,260        (29,670 ) 

Arrival SA

     315        07/16/21        USD        20.00        USD        494        (5,513 ) 

Atlassian Corp. PLC, Class A

     34        07/16/21        USD        250.00        USD        873        (38,420 ) 

Autodesk, Inc.

     34        07/16/21        USD        300.00        USD        992        (9,384 ) 

C3.AI, Inc., Class A

     72        07/16/21        USD        65.00        USD        450        (15,660 ) 

C3.AI, Inc., Class A

     172        07/16/21        USD        70.00        USD        1,076        (17,630 ) 

Chegg, Inc.

     104        07/16/21        USD        85.00        USD        864        (17,680 ) 

Crowdstrike Holdings, Inc., Class A

     37        07/16/21        USD        240.00        USD        930        (55,962 ) 

Elastic NV

     96        07/16/21        USD        125.00        USD        1,399        (207,840 ) 

Fiserv, Inc.

     91        07/16/21        USD        120.00        USD        973        (501 ) 

Intuit, Inc.

     26        07/16/21        USD        440.00        USD        1,274        (132,340 ) 

Lam Research Corp.

     67        07/16/21        USD        640.00        USD        4,360        (159,460 ) 

Lyft, Inc., Class A

     188        07/16/21        USD        57.50        USD        1,137        (71,910 ) 

Magna International, Inc.

     236        07/16/21        USD        97.50        USD        2,186        (13,570 ) 

Marqeta, Inc.

     1        07/16/21        USD        35.00        USD        3        (15 ) 

 

 

114  

2 0 2 1   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S


Consolidated Schedule of Investments (unaudited) (continued)

June 30, 2021

  

BlackRock Science and Technology Trust (BST)

    

 

Exchange-Traded Options Written (continued)

 

Description    Number of
Contracts
     Expiration
Date
     Exercise Price     

Notional

Amount (000)

     Value  

Call (continued)

                    

Mastercard, Inc., Class A

     40        07/16/21        USD        380.00        USD        1,460      $ (5,460 ) 

MercadoLibre, Inc.

     11        07/16/21        USD        1,450.00        USD        1,714            (131,725 ) 

Microsoft Corp.

     120        07/16/21        USD        255.00        USD        3,251        (195,000 ) 

Monolithic Power Systems, Inc.

     123        07/16/21        USD        331.00        USD        4,593        (536,380 ) 

Paycom Software, Inc.

     41        07/16/21        USD        360.00        USD        1,490        (46,330 ) 

PayPal Holdings, Inc.

     112        07/16/21        USD        260.00        USD        3,265        (359,520 ) 

Qualcomm, Inc.

     17        07/16/21        USD        135.00        USD        243        (14,493 ) 

Roku, Inc.

     20        07/16/21        USD        335.00        USD        919        (249,200 ) 

Shoals Technologies Group, Inc., Class A

     263        07/16/21        USD        25.00        USD        934        (276,150 ) 

Shopify, Inc., Class A

     9        07/16/21        USD        1,140.00        USD        1,315        (290,475 ) 

Skyworks Solutions, Inc.

     81        07/16/21        USD        180.00        USD        1,553        (98,617 ) 

Snap, Inc., Class A

     210        07/16/21        USD        60.00        USD        1,431        (180,600 ) 

Snowflake, Inc., Class A

     15        07/16/21        USD        260.00        USD        363        (4,088 ) 

Square, Inc., Class A

     103        07/16/21        USD        240.00        USD        2,511        (103,515 ) 

Stoneco Ltd., Class A

     204        07/16/21        USD        67.50        USD        1,368        (39,270 ) 

Taiwan Semiconductor Manufacturing Co. Ltd., ADR

     175        07/16/21        USD        120.00        USD        2,103        (53,812 ) 

Tesla, Inc.

     23        07/16/21        USD        730.00        USD        1,563        (26,623 ) 

Tesla, Inc.

     1        07/16/21        USD        650.00        USD        68        (4,773 ) 

Tesla, Inc.

     4        07/16/21        USD        630.00        USD        272        (25,340 ) 

Twilio, Inc., Class A

     70        07/16/21        USD        330.00        USD        2,759        (454,825 ) 

Uber Technologies, Inc.

     171        07/16/21        USD        52.50        USD        857        (12,141 ) 

Unity Software, Inc.

     147        07/16/21        USD        105.00        USD        1,615        (101,430 ) 

Visa, Inc., Class A

     23        07/16/21        USD        235.00        USD        538        (6,900 ) 

Zoom Video Communications, Inc., Class A

     32        07/16/21        USD        350.00        USD        1,238        (124,160 ) 

ZoomInfo Technologies, Inc., Class A

     346        07/16/21        USD        45.00        USD        1,805        (250,850 ) 

Zscaler, Inc.

     67        07/16/21        USD        210.00        USD        1,448        (63,650 ) 

Adobe, Inc.

     26        07/23/21        USD        520.00        USD        1,523        (173,550 ) 

Advanced Micro Devices, Inc.

     178        07/23/21        USD        83.50        USD        1,672        (194,910 ) 

Advanced Micro Devices, Inc.

     178        07/23/21        USD        86.50        USD        1,672        (156,195 ) 

Airbnb, Inc., Class A

     33        07/23/21        USD        162.50        USD        505        (10,560 ) 

Amazon.com, Inc.

     9        07/23/21        USD        3,300.00        USD        3,096        (150,300 ) 

Amazon.com, Inc.

     4        07/23/21        USD        3,450.00        USD        1,376        (27,000 ) 

Analog Devices, Inc.

     73        07/23/21        USD        167.50        USD        1,257        (51,830 ) 

Apple, Inc.

     42        07/23/21        USD        128.00        USD        575        (39,060 ) 

Autodesk, Inc.

     38        07/23/21        USD        287.50        USD        1,109        (36,480 ) 

Coupa Software, Inc.

     65        07/23/21        USD        250.00        USD        1,704        (121,550 ) 

Cree, Inc.

     100        07/23/21        USD        102.00        USD        979        (23,500 ) 

Crowdstrike Holdings, Inc., Class A

     26        07/23/21        USD        232.50        USD        653        (57,135 ) 

Facebook, Inc., Class A

     65        07/23/21        USD        337.50        USD        2,260        (97,175 ) 

Lam Research Corp.

     42        07/23/21        USD        670.00        USD        2,733        (58,170 ) 

Lyft, Inc., Class A

     219        07/23/21        USD        61.00        USD        1,325        (49,932 ) 

Marvell Technology Inc.

     300        07/23/21        USD        51.00        USD        1,750        (215,250 ) 

Mastercard, Inc., Class A

     41        07/23/21        USD        375.00        USD        1,497        (15,252 ) 

MercadoLibre, Inc.

     10        07/23/21        USD        1,410.00        USD        1,558        (160,750 ) 

Microsoft Corp.

     43        07/23/21        USD        270.00        USD        1,165        (27,198 ) 

MongoDB, Inc.

     13        07/23/21        USD        340.00        USD        470        (38,675 ) 

MongoDB, Inc.

     8        07/23/21        USD        400.00        USD        289        (4,440 ) 

NetEase, Inc., ADR

     160        07/23/21        USD        120.00        USD        1,844        (38,000 ) 

Okta, Inc.

     56        07/23/21        USD        230.00        USD        1,370        (102,340 ) 

PayPal Holdings, Inc.

     71        07/23/21        USD        275.00        USD        2,070        (135,432 ) 

Qualcomm, Inc.

     98        07/23/21        USD        138.00        USD        1,401        (52,920 ) 

Roku, Inc.

     11        07/23/21        USD        365.00        USD        505        (104,967 ) 

Roku, Inc.

     53        07/23/21        USD        375.00        USD        2,434        (455,005 ) 

salesforce.com, Inc.

     105        07/23/21        USD        247.50        USD        2,565        (44,625 ) 

ServiceNow, Inc.

     45        07/23/21        USD        485.00        USD        2,473        (299,475 ) 

Shopify, Inc., Class A

     18        07/23/21        USD        1,570.00        USD        2,630        (39,780 ) 

Snap, Inc., Class A

     165        07/23/21        USD        64.50        USD        1,124        (107,662 ) 

Square, Inc., Class A

     102        07/23/21        USD        237.50        USD        2,487        (135,915 ) 

Square, Inc., Class A

     116        07/23/21        USD        255.00        USD        2,828        (63,220 ) 

Stoneco Ltd., Class A

     80        07/23/21        USD        68.00        USD        536        (17,400 ) 

Tesla, Inc.

     21        07/23/21        USD        680.00        USD        1,427        (79,852 ) 

Twilio, Inc., Class A

     21        07/23/21        USD        347.50        USD        828        (108,412 ) 

 

 

C O N S O L I D A T E D   S C H E D U L E   O F   I N V E S T M E N T S

  115


Consolidated Schedule of Investments (unaudited) (continued)

June 30, 2021

  

BlackRock Science and Technology Trust (BST)

    

 

Exchange-Traded Options Written (continued)

 

Description    Number of
Contracts
     Expiration
Date
     Exercise Price     

Notional

Amount (000)

     Value  

Call (continued)

                    

Twilio, Inc., Class A

     53        07/23/21        USD        380.00        USD        2,089      $     (136,607 ) 

Uber Technologies, Inc.

     117        07/23/21        USD        53.50        USD        586        (8,600 ) 

Visa, Inc., Class A

     70        07/23/21        USD        235.00        USD        1,637        (31,675 ) 

Yandex NV, Class A

     230        07/23/21        USD        69.50        USD        1,627        (60,375 ) 

Activision Blizzard, Inc.

     77        07/30/21        USD        97.00        USD        735        (15,131 ) 

Adobe, Inc.

     28        07/30/21        USD        570.00        USD        1,640        (69,160 ) 

Arrival SA

     315        07/30/21        USD        22.50        USD        494        (7,088 ) 

Atlassian Corp. PLC, Class A

     37        07/30/21        USD        275.00        USD        950        (24,790 ) 

Autodesk, Inc.

     37        07/30/21        USD        295.00        USD        1,080        (26,733 ) 

Cree, Inc.

     120        07/30/21        USD        99.00        USD        1,175        (49,800 ) 

Crowdstrike Holdings, Inc., Class A

     40        07/30/21        USD        232.50        USD        1,005        (95,100 ) 

Fiserv, Inc.

     106        07/30/21        USD        111.00        USD        1,133        (11,819 ) 

Intuit, Inc.

     21        07/30/21        USD        477.50        USD        1,029        (41,895 ) 

Intuit, Inc.

     55        07/30/21        USD        480.00        USD        2,696        (98,725 ) 

Lyft, Inc., Class A

     73        07/30/21        USD        60.50        USD        442        (22,192 ) 

Marvell Technology Inc.

     410        07/30/21        USD        52.00        USD        2,392        (276,750 ) 

MercadoLibre, Inc.

     10        07/30/21        USD        1,520.00        USD        1,558        (85,600 ) 

Microsoft Corp.

     43        07/30/21        USD        265.00        USD        1,165        (43,215 ) 

MongoDB, Inc.

     54        07/30/21        USD        350.00        USD        1,952        (139,320 ) 

Okta, Inc.

     78        07/30/21        USD        250.00        USD        1,909        (61,815 ) 

Roku, Inc.

     21        07/30/21        USD        445.00        USD        964        (73,132 ) 

Shopify, Inc., Class A

     9        07/30/21        USD        1,290.00        USD        1,315        (170,685 ) 

Snap, Inc., Class A

     251        07/30/21        USD        65.00        USD        1,710        (166,287 ) 

Square, Inc., Class A

     112        07/30/21        USD        255.00        USD        2,731        (77,280 ) 

Tesla, Inc.

     23        07/30/21        USD        690.00        USD        1,563        (93,725 ) 

Tesla, Inc.

     23        07/30/21        USD        665.00        USD        1,563        (123,395 ) 

Twilio, Inc., Class A

     70        07/30/21        USD        340.00        USD        2,759        (418,075 ) 

Visa, Inc., Class A

     41        07/30/21        USD        240.00        USD        959        (13,325 ) 

Zoom Video Communications, Inc., Class A

     61        07/30/21        USD        395.00        USD        2,361        (85,705 ) 

ZoomInfo Technologies, Inc., Class A

     382        07/30/21        USD        50.25        USD        1,993        (141,696 ) 

Zscaler, Inc.

     66        07/30/21        USD        210.00        USD        1,426        (82,005 ) 

Shoals Technologies Group, Inc., Class A

     263        08/03/21        USD        31.25        USD        934        (140,499 ) 

Advanced Micro Devices, Inc.

     191        08/06/21        USD        91.00        USD        1,794        (129,880 ) 

Apple, Inc.

     160        08/06/21        USD        136.00        USD        2,191        (76,800 ) 

Apple, Inc.

     210        08/06/21        USD        137.00        USD        2,876        (87,150 ) 

Apple, Inc.

     49        08/06/21        USD        140.00        USD        671        (13,622 ) 

Coupa Software, Inc.

     39        08/06/21        USD        265.00        USD        1,022        (48,750 ) 

Cree, Inc.

     120        08/06/21        USD        103.00        USD        1,175        (33,300 ) 

Facebook, Inc., Class A

     20        08/06/21        USD        362.50        USD        695        (16,700 ) 

Lyft, Inc., Class A

     47        08/06/21        USD        64.50        USD        284        (9,753 ) 

Marvell Technology Inc.

     161        08/06/21        USD        59.00        USD        939        (32,683 ) 

MercadoLibre, Inc.

     24        08/06/21        USD        1,600.00        USD        3,739        (150,000 ) 

Microsoft Corp.

     55        08/06/21        USD        277.50        USD        1,490        (22,825 ) 

Okta, Inc.

     78        08/06/21        USD        255.00        USD        1,909        (55,575 ) 

PayPal Holdings, Inc.

     73        08/06/21        USD        302.50        USD        2,128        (55,662 ) 

Shopify, Inc., Class A

     18        08/06/21        USD        1,500.00        USD        2,630        (125,190 ) 

Square, Inc., Class A

     113        08/06/21        USD        267.50        USD        2,755        (73,732 ) 

Stoneco Ltd., Class A

     119        08/06/21        USD        73.00        USD        798        (18,445 ) 

Taiwan Semiconductor Manufacturing Co. Ltd., ADR

     82        08/06/21        USD        122.00        USD        985        (28,700 ) 

Uber Technologies, Inc.

     260        08/06/21        USD        51.50        USD        1,303        (73,580 ) 

Marvell Technology Inc.

     481        08/13/21        USD        54.95        USD        2,806        (220,659 ) 

Activision Blizzard, Inc.

     83        08/20/21        USD        100.00        USD        792        (19,754 ) 

Adobe, Inc.

     26        08/20/21        USD        530.00        USD        1,523        (155,870 ) 

Advanced Micro Devices, Inc.

     123        08/20/21        USD        90.00        USD        1,155        (97,477 ) 

Alphabet, Inc., Class A

     11        08/20/21        USD        2,440.00        USD        2,686        (101,200 ) 

Apple, Inc.

     222        08/20/21        USD        135.00        USD        3,041        (129,315 ) 

Atlassian Corp. PLC, Class A

     84        08/20/21        USD        270.00        USD        2,158        (90,720 ) 

Avalara, Inc.

     124        08/20/21        USD        150.00        USD        2,006        (215,140 ) 

C3.AI, Inc., Class A

     259        08/20/21        USD        75.00        USD        1,620        (56,980 ) 

Cadence Design Systems, Inc.

     310        08/20/21        USD        140.00        USD        4,241        (151,900 ) 

Chegg, Inc.

     212        08/20/21        USD        85.00        USD        1,762        (101,760 ) 

Crowdstrike Holdings, Inc., Class A

     39        08/20/21        USD        260.00        USD        980        (46,313 ) 

 

 

116  

2 0 2 1   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S


Consolidated Schedule of Investments (unaudited) (continued)

June 30, 2021

  

BlackRock Science and Technology Trust (BST)

    

 

Exchange-Traded Options Written (continued)

 

Description    Number of
Contracts
     Expiration
Date
     Exercise Price     

Notional

Amount (000)

     Value  

Call (continued)

                    

Elastic NV

     98        08/20/21        USD        150.00        USD        1,428      $ (69,580 ) 

Lyft, Inc., Class A

     111        08/20/21        USD        60.00        USD        671        (51,615 ) 

Marqeta, Inc.

     291        08/20/21        USD        35.00        USD        817        (19,643 ) 

Marvell Technology Inc.

     596        08/20/21        USD        52.50        USD        3,476        (394,850 ) 

Microsoft Corp.

     52        08/20/21        USD        260.00        USD        1,409        (78,910 ) 

MongoDB, Inc.

     8        08/20/21        USD        370.00        USD        289        (17,920 ) 

Paycom Software, Inc.

     39        08/20/21        USD        380.00        USD        1,418        (56,745 ) 

PayPal Holdings, Inc.

     72        08/20/21        USD        290.00        USD        2,099        (106,200 ) 

ServiceNow, Inc.

     22        08/20/21        USD        550.00        USD        1,209        (61,490 ) 

Snap, Inc., Class A

     793        08/20/21        USD        65.00        USD        5,404        (602,680 ) 

Tesla, Inc.

     45        08/20/21        USD        690.00        USD        3,059        (231,862 ) 

TuSimple Holdings, Inc.

     217        08/20/21        USD        45.00        USD        1,546        (607,600 ) 

TuSimple Holdings, Inc.

     203        08/20/21        USD        60.00        USD        1,446        (347,130 ) 

Twilio, Inc., Class A

     53        08/20/21        USD        380.00        USD        2,089        (197,690 ) 

Unity Software, Inc.

     140        08/20/21        USD        105.00        USD        1,538        (150,500 ) 

Visa, Inc., Class A

     23        08/20/21        USD        235.00        USD        538        (15,468 ) 

Yandex NV, Class A

     93        08/20/21        USD        70.00        USD        658        (34,875 ) 

Zscaler, Inc.

     51        08/20/21        USD        220.00        USD        1,102        (52,403 ) 

Adobe, Inc.

     23        09/17/21        USD        580.00        USD        1,347        (68,712 ) 
                    

 

 

 
                     $  (20,388,599 ) 
                    

 

 

 

OTC Options Written

 

Description   Counterparty   Number of
Contracts
    Expiration
Date
    Exercise Price    

Notional

Amount (000)

    Value  

Call

               

Adyen NV

  UBS AG     1,800       07/07/21       EUR       1,963.56       EUR       3,723     $ (241,995 ) 

Soitec SA

  UBS AG     3,900       07/07/21       EUR       171.15       EUR       726       (69,777 ) 

Gmo Payment Gateway Inc.

  Goldman Sachs International     14,000       07/08/21       JPY       13,423.22       JPY       201,996       (132,531 ) 

Xero Ltd.

  JPMorgan Chase Bank N.A.     18,300       07/08/21       AUD       126.36       AUD       2,510       (153,994 ) 

Avalara, Inc.

  Citibank N.A.     7,500       07/13/21       USD       136.58       USD       1,214       (189,725 ) 

Recruit Holdings Ltd.

  JPMorgan Chase Bank N.A.     23,300       07/14/21       JPY       5,624.15       JPY       127,451       (14,353 ) 

STMicroelectronics NV

  Credit Suisse International     27,400       07/14/21       EUR       31.49       EUR       840       (9,897 ) 

TuSimple Holdings, Inc.

  Jane Street Execution Services, LLC     16,700       07/16/21       USD       45.00       USD       1,190       (459,250 ) 

ASML Holding NV

  Goldman Sachs International     14,200       07/20/21       EUR       567.63       EUR       8,267       (381,645 ) 

Delivery Hero SE

  Morgan Stanley & Co. International PLC     24,700       07/20/21       EUR       116.23       EUR       2,752       (55,180 ) 

Renesas Electronics Corp.

  Goldman Sachs International     221,100       07/20/21       JPY       1,237.60       JPY       265,094       (48,530 ) 

Soitec SA

  UBS AG     6,500       07/20/21       EUR       171.44       EUR       1,210       (116,953 ) 

Gmo Payment Gateway Inc.

  Goldman Sachs International     12,000       07/27/21       JPY       13,409.10       JPY       173,140       (133,201 ) 

Recruit Holdings Ltd.

  JPMorgan Chase Bank N.A.     23,300       07/27/21       JPY       5,624.15       JPY       127,451       (24,488 ) 

STMicroelectronics NV

  Credit Suisse International     26,100       07/27/21       EUR       31.12       EUR       800       (23,284 ) 

Tencent Holdings Ltd.

  Goldman Sachs International     61,800       07/27/21       HKD       620.41       HKD       36,128       (41,021 ) 

Marqeta, Inc.

  UBS AG     10,950       07/28/21       USD       32.49       USD       307       (4,971 ) 

Avalara, Inc.

  Citibank N.A.     7,500       07/29/21       USD       137.21       USD       1,214       (189,654 ) 

Soitec SA

  UBS AG     6,500       07/29/21       EUR       195.80       EUR       1,210       (10,393 ) 

Xero Ltd.

  Goldman Sachs International     21,500       08/04/21       AUD       143.27       AUD       2,949       (74,434 ) 

Kakao Corp.

  Morgan Stanley & Co. International PLC     42,600       08/05/21       USD       164,850.00       USD       6,948,675       (320,479 ) 

Facebook, Inc., Class A

  Morgan Stanley & Co. LLC     5,000       08/06/21       USD       355.00       USD       1,739       (55,750 ) 

PayPal Holdings, Inc.

  Citigroup Global Markets, Inc.     7,200       08/06/21       USD       307.50       USD       2,099       (43,020 ) 

Salesforce.com, Inc.

  Morgan Stanley & Co. LLC     8,000       08/06/21       USD       252.50       USD       1,954       (32,600 ) 

Delivery Hero SE

  Goldman Sachs International     5,500       08/10/21       EUR       116.97       EUR       613       (20,342 ) 

Samsung Sdi Ltd.

  JPMorgan Chase Bank N.A.     7,600       08/11/21       USD       710,700.00       USD       5,299,039       (168,162 ) 

Amadeus IT Group SA

  Barclays Bank PLC     33,300       08/12/21       EUR       60.45       EUR       1,980       (76,333 ) 

Kakao Corp.

  UBS AG     13,000       08/12/21       USD       169,060.00       USD       2,120,488       (88,090 ) 

Soitec SA

  Barclays Bank PLC     4,400       08/12/21       EUR       195.06       EUR       819       (22,446 ) 

Soitec SA

  UBS AG     4,400       08/18/21       EUR       195.06       EUR       819       (25,011 ) 

C3.AI, Inc., Class A

  Morgan Stanley & Co. International PLC     9,600       08/20/21       USD       61.87       USD       600       (57,609 ) 
               

 

 

 
                $   (3,285,118 ) 
               

 

 

 

 

 

C O N S O L I D A T E D   S C H E D U L E   O F   I N V E S T M E N T S

  117


Consolidated Schedule of Investments (unaudited) (continued)

June 30, 2021

  

BlackRock Science and Technology Trust (BST)

    

 

Balances Reported in the Consolidated Statements of Assets and Liabilities for Options Written

 

Description    Swap
Premiums
Paid
     Swap
Premiums
Received
     Unrealized
Appreciation
     Unrealized
Depreciation
     Value  

Options Written

   $ N/A      $ N/A      $ 1,241,158      $  (13,255,205 )     $  (23,673,717 ) 

Derivative Financial Instruments Categorized by Risk Exposure

As of period end, the fair values of derivative financial instruments located in the Consolidated Statements of Assets and Liabilities were as follows:

 

      Commodity
Contracts
     Credit
Contracts
     Equity
Contracts
     Foreign
Currency
Exchange
Contracts
     Interest
Rate
Contracts
     Other
Contracts
     Total  

Liabilities — Derivative Financial Instruments

 

           

Options written

                    

Options written at value

   $ —      $ —      $  23,673,717      $ —      $ —      $ —      $  23,673,717  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

For the six months ended June 30, 2021, the effect of derivative financial instruments in the Consolidated Statements of Operations was as follows:

 

      Commodity
Contracts
     Credit
Contracts
     Equity
Contracts
     Foreign
Currency
Exchange
Contracts
     Interest
Rate
Contracts
     Other
Contracts
     Total  

Net Realized Gain (Loss) from

                    

Options purchased(a)

   $ —      $ —      $ (998 )     $ —      $ —      $ —      $ (998 ) 

Options written

     —        —        (1,568,383 )       —        —        —        (1,568,383 ) 
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 
   $ —      $ —      $ (1,569,381 )     $ —      $ —      $ —      $ (1,569,381 ) 
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Net Change in Unrealized Appreciation (Depreciation) on

                    

Options written

   $ —      $ —      $  (4,020,080 )     $ —      $ —      $ —      $  (4,020,080 ) 
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

 

  (a) 

Options purchased are included in net realized gain (loss) from investments — unaffiliated.

 

Average Quarterly Balances of Outstanding Derivative Financial Instruments

 

 

 

Options

  

Average value of option contracts purchased

   $ —( a)  

Average value of option contracts written

   $ 15,757,681  

 

 

 

  (a) 

Derivative not held at any quarter-end. The risk exposure table serves as an indicator of activity during the period.

 

For more information about the Trust’s investment risks regarding derivative financial instruments, refer to the Notes to Consolidated Financial Statements.

Derivative Financial Instruments — Offsetting as of Period End

The Trust’s derivative assets and liabilities (by type) were as follows:

 

      Assets      Liabilities  

Derivative Financial Instruments

     

Options

   $ —      $ 23,673,717  
  

 

 

    

 

 

 

Total derivative assets and liabilities in the Consolidated Statements of Assets and Liabilities

     —        23,673,717  
  

 

 

    

 

 

 

Derivatives not subject to a Master Netting Agreement or similar agreement (“MNA”)

     —        (20,388,599 ) 
  

 

 

    

 

 

 

Total derivative assets and liabilities subject to an MNA

   $     —      $ 3,285,118  
  

 

 

    

 

 

 

 

 

118  

2 0 2 1   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S


Consolidated Schedule of Investments (unaudited) (continued)

June 30, 2021

  

BlackRock Science and Technology Trust (BST)

    

 

The following table presents the Trust’s derivative liabilities by counterparty net of amounts available for offset under an MNA and net of the related collateral pledged by the Trust:

 

Counterparty    



Derivative

Liabilities
Subject to

an MNA by
Counterparty


 
 

 
 

    

Derivatives
Available

for Offset

 
 

 

    

Non-Cash
Collateral
Pledged
 
 
 
    

Cash
Collateral
Pledged
 
 
(a)  
   

Net Amount

of Derivative

Liabilities

 

 

(b)  

Barclays Bank PLC

  $ 98,779      $ —      $ —      $ —     $ 98,779  

Citibank N.A.

    379,379        —        —        (280,000 )      99,379  

Citigroup Global Markets, Inc.

    43,020        —        —        —       43,020  

Credit Suisse International

    33,181        —        —        —       33,181  

Goldman Sachs International

    831,704        —        —        (830,000 )      1,704  

Jane Street Execution Services, LLC

    459,250        —        —        —       459,250  

JPMorgan Chase Bank N.A.

    360,997        —        —        (280,000 )      80,997  

Morgan Stanley & Co. International PLC

    433,268        —        —        (190,000 )      243,268  

Morgan Stanley & Co. LLC

    88,350        —        —        —       88,350  

UBS AG

    557,190        —        —        (557,190 )      —  
 

 

 

    

 

 

    

 

 

    

 

 

   

 

 

 
  $ 3,285,118      $ —      $ —      $   (2,137,190 )    $   1,147,928  
 

 

 

    

 

 

    

 

 

    

 

 

   

 

 

 

 

  (a) 

Excess of collateral pledged to the individual counterparty is not shown for financial reporting purposes.

 
  (b) 

Net amount represents the net amount payable due to counterparty in the event of default. Net amount may be offset further by the options written receivable/payable on the Consolidated Statements of Assets and Liabilities.

 

Fair Value Hierarchy as of Period End

Various inputs are used in determining the fair value of financial instruments. For a description of the input levels and information about the Trust’s policy regarding valuation of financial instruments, refer to the Notes to Consolidated Financial Statements.

The following table summarizes the Trust’s financial instruments categorized in the fair value hierarchy. The breakdown of the Trust’s financial instruments into major categories is disclosed in the Consolidated Schedule of Investments above.

 

      Level 1        Level 2        Level 3        Total  

Assets

                 

Investments

                 

Long-Term Investments

                 

Common Stocks

                 

Auto Components

   $ 6,259,963        $ —        $ —        $ 6,259,963  

Automobiles

     21,810,975          —          —          21,810,975  

Banks

     —          —          36,386,841          36,386,841  

Diversified Consumer Services

     10,002,870          —          3,823,582          13,826,452  

Diversified Financial Services

     —          —          5,482,530          5,482,530  

Electrical Equipment

     5,345,057          —          —          5,345,057  

Electronic Equipment, Instruments & Components

     —          13,502,156          —          13,502,156  

Entertainment

     41,764,659          —          —          41,764,659  

Hotels, Restaurants & Leisure

     3,175,205          —          —          3,175,205  

Interactive Media & Services

     109,220,424          53,432,133          —          162,652,557  

Internet & Direct Marketing Retail

     55,338,848          22,087,052          177,473          77,603,373  

IT Services

     220,060,068          28,658,321          16,931,506          265,649,895  

Professional Services

     —          7,547,066          —          7,547,066  

Road & Rail

     29,401,060          —          —          29,401,060  

Semiconductors & Semiconductor Equipment

     159,232,894          66,242,863          —          225,475,757  

Software

     257,742,136          14,222,992          13,170,681          285,135,809  

Specialty Retail

     —          —          3,005,590          3,005,590  

Technology Hardware, Storage & Peripherals

     55,118,456          —          —          55,118,456  

Preferred Securities

                 

Preferred Stocks

     —          18,693,654          158,939,572          177,633,226  

Warrants

     —          —          170,650          170,650  
  

 

 

      

 

 

      

 

 

      

 

 

 
   $   974,472,615        $   224,386,237        $   238,088,425          1,436,947,277  
  

 

 

      

 

 

      

 

 

      

 

 

 

Investments Valued at NAV(a)

                    3,872,747  
                 

 

 

 
                  $   1,440,820,024  
                 

 

 

 

 

 

C O N S O L I D A T E D   S C H E D U L E   O F   I N V E S T M E N T S

  119


Consolidated Schedule of Investments (unaudited) (continued)

June 30, 2021

  

BlackRock Science and Technology Trust (BST)

    

 

Fair Value Hierarchy as of Period End (continued)

 

      Level 1        Level 2        Level 3        Total  

Derivative Financial Instruments(b)

                 

Liabilities

                 

Equity Contracts

   $     (19,326,124 )       $     (4,347,593 )       $             —        $     (23,673,717 ) 
  

 

 

      

 

 

      

 

 

      

 

 

 

 

  (a) 

Certain investments of the Trust were fair valued using NAV per share as no quoted market value is available and therefore have been excluded from the fair value hierarchy.

 
  (b) 

Derivative financial instruments are options written. Options written are shown at value.

 

A reconciliation of Level 3 financial instruments is presented when the Trust had a significant amount of Level 3 investments at the beginning and/or end of the period in relation to net assets. The following table is a reconciliation of Level 3 investments for which significant unobservable inputs were used in determining fair value:

 

 

 
     Common
Stocks
    

Preferred

Stocks

     Warrants      Total  

 

 

Assets

           

Opening balance, as of December 31, 2020

   $ 37,043,595      $ 124,970,280      $ 189,763      $ 162,203,638  

Transfers into Level 3

     —        —        —        —  

Transfers out of Level 3

     —        (6,192,069 )       —        (6,192,069 ) 

Accrued discounts/premiums

     —        —        —        —  

Net realized gain (loss)

     —        4,698,014        —        4,698,014  

Net change in unrealized appreciation (depreciation)(a)(b)

     30,353,763        31,659,557        (19,113 )       61,994,207  

Purchases

     11,580,845        17,499,405        —        29,080,250  

Sales

     —        (13,695,615 )       —        (13,695,615 ) 
  

 

 

    

 

 

    

 

 

    

 

 

 

Closing balance, as of June 30, 2021

   $ 78,978,203      $ 158,939,572      $ 170,650      $   238,088,425  
  

 

 

    

 

 

    

 

 

    

 

 

 

Net change in unrealized appreciation (depreciation) on investments still held at June 30, 2021(b)

   $   30,353,763      $   45,977,870      $   (19,113 )     $ 76,312,520  
  

 

 

    

 

 

    

 

 

    

 

 

 

 

  (a)

Included in the related net change in unrealized appreciation (depreciation) in the Consolidated Statements of Operations.

 
  (b) 

Any difference between net change in unrealized appreciation (depreciation) and net change in unrealized appreciation (depreciation) on investments still held at June 30, 2021 is generally due to investments no longer held or categorized as Level 3 at period end.

 

The following table summarizes the valuation approaches used and unobservable inputs utilized by the BlackRock Global Valuation Methodologies Committee (the “Global Valuation Committee”) to determine the value of certain of the Trust’s Level 3 financial instruments as of period end.

 

       Value         
Valuation
Approach
 
 
     Unobservable

Inputs

      

Range of
Unobservable
Inputs

Utilized

 
 
 

(a)  

    



Weighted
Average of
Unobservable
Inputs Based
on Fair Value
 
 
 
 
 

Assets

 

Common Stocks(b)

   $ 78,978,203          Market        Revenue Multiple        5.95x - 46.84x        23.06x  
             Volatility        37% - 37%        37%  
             Time to Exit        0.3 - 0.3        0.3  
             Recent Transactions        —        —  
                         

Preferred Stocks(c)(d)

     158,939,572          Income        Discount Rate        17% - 28%        24%  
             Exit Multiple        8.75x        —  
          Market        Revenue Multiple        5.00x - 46.84x        19.34x  
             EBITDA Multiple        18.25x        —  
             Volatility        42% - 50%        47%  
             Time to Exit        3.0 - 4.0        3.7  
             Recent Transactions        —        —  
                         

Warrants(e)

     170,650          Market        Revenue Multiple        11.00x        —  
             Volatility        37%        —  

 

 

120  

2 0 2 1   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S


Consolidated Schedule of Investments (unaudited) (continued)

June 30, 2021

  

BlackRock Science and Technology Trust (BST)

    

 

       Value         
Valuation
Approach
 
 
      
Unobservable
Inputs
 
 
      


Range of
Unobservable
Inputs
Utilized
 
 
 
(a)  
    



Weighted
Average of
Unobservable
Inputs Based
on Fair Value
 
 
 
 
 
               Time to Exit                        0.3        —  
                             
  

 

 

                   
   $   238,088,425                    
  

 

 

                   

 

  (a) 

A significant change in unobservable input would have resulted in a correlated (inverse) significant change to value.

 
  (b) 

For the period end June 30, 2021, the valuation technique for investments classified as Common Stocks amounting to $8,982,142 changed to Current Value Method. The investments were previously valued utilizing Transaction Price approach. The change was due to consideration of the information that was available at the time the investments were valued.

 
  (c) 

For the period end June 30, 2021, the valuation technique for investments classified as Preferred Stocks amounting to $27,363,505 changed to Current Value Method. The investments were previously valued utilizing Transaction Price Approach. The change was due to consideration of the information that was available at the time the investments were valued.

 
  (d) 

For the period end June 30, 2021, the valuation technique for investments classified as Preferred Stocks amounting to $24,370,719 changed to Transaction Price approach. The investments were previously valued utilizing Current Value Method. The change was due to consideration of the information that was available at the time the investments were valued.

 
  (e) 

For the period end June 30, 2021, the valuation technique for investments classified as Warrants amounting to $170,650 changed to Current Value Method. The investments were previously valued utilizing Transaction Price Approach. The change was due to consideration of the information that was available at the time the investments were valued.

 

See notes to financial statements.

 

 

C O N S O L I D A T E D   S C H E D U L E   O F   I N V E S T M E N T S

  121


Consolidated Schedule of Investments (unaudited)

June 30, 2021

  

BlackRock Science and Technology Trust II (BSTZ)

(Percentages shown are based on Net Assets)

 

Security   Shares     Value  

Common Stocks

 

Automobiles — 1.8%

   

Tesla, Inc.(a)(b)

    90,783     $ 61,705,205  
   

 

 

 
Banks — 3.6%            

Klarna Holdings AB, (Acquired 08/07/19, Cost: $23,354,997)(c)(d)

    86,839       119,553,420  
   

 

 

 
Capital Markets — 0.4%  

ASTRA SPACE PIPE, (Acquired 06/30/21, Cost: $12,000,000)(d)

    1,200,000       12,000,000  
   

 

 

 
Diversified Consumer Services — 1.4%  

Chegg, Inc.(b)

    356,167       29,601,039  

Think & Learn Private Ltd., (Acquired 09/30/20, Cost: $7,113,729)(c)(d)

    4,651       17,836,989  
   

 

 

 
      47,438,028  
Diversified Telecommunication Services — 0.5%  

Bandwidth, Inc., Class A(b)

    133,349       18,391,494  
   

 

 

 
Electrical Equipment — 0.4%  

Shoals Technologies Group, Inc., Class A(b)

    363,842       12,916,391  
   

 

 

 
Electronic Equipment, Instruments & Components — 1.3%  

Samsung SDI Co. Ltd.

    73,213       45,328,932  
   

 

 

 
Entertainment — 3.9%  

HYBE Co. Ltd.(b)

    121,331       31,494,024  

NCSoft Corp.

    18,037       13,124,127  

Roku, Inc.(a)(b)

    102,250       46,958,312  

Take-Two Interactive Software, Inc.(b)

    101,063       17,890,172  

Zynga, Inc., Class A(b)

    2,029,687       21,575,573  
   

 

 

 
      131,042,208  
Interactive Media & Services — 6.8%  

Eventbrite, Inc., Class A(b)

    748,770       14,226,630  

Kakao Corp.

    762,481       110,439,684  

Kanzhun Ltd., ADR(b)

    277,944       11,020,480  

Snap, Inc., Class A(a)(b)

    991,722       67,575,937  

ZoomInfo Technologies, Inc., Class A(b)

    496,010       25,876,842  
   

 

 

 
      229,139,573  
Internet & Direct Marketing Retail(b) — 5.2%  

Delivery Hero SE(e)

    238,229       31,476,272  

Farfetch Ltd., Class A

    980,722       49,389,160  

MercadoLibre, Inc.(a)

    26,258       40,904,450  

Ozon Holdings PLC, ADR

    578,440       33,908,153  

Shop Apotheke Europe NV(e)

    105,812       19,879,493  
   

 

 

 
        175,557,528  
IT Services — 17.1%  

Adyen NV(b)(e)

    14,925       36,601,017  

Automattic, Inc., Series E, (Acquired 02/03/21, Cost: $34,000,000)(c)(d)

    400,000       37,424,000  

Dlocal Ltd.(b)

    433,216       22,756,837  

Endava PLC, ADR(b)

    336,360       38,136,497  

GMO Payment Gateway, Inc.

    225,400       29,273,518  

Grid Dynamics Holdings, Inc.(b)

    1,174,694       17,655,651  

Locaweb Servicos de Internet SA(e)

    11,963,124       65,085,475  

MongoDB, Inc.(b)

    78,008       28,201,452  

Okta, Inc.(b)

    140,162       34,294,838  

Pagseguro Digital Ltd., Class A(b)

    401,729       22,464,686  

Shift4 Payments, Inc., Class A(b)

    281,545       26,386,397  

Square, Inc., Class A(a)(b)

    285,008       69,484,950  

StoneCo Ltd., Class A(b)

    399,645       26,800,194  
Security   Shares     Value  
IT Services (continued)            

TRAX Ltd., Series D, (Acquired 02/18/21, Cost: $9,999,998)(c)(d)

    191,806     $ 10,746,890  

TRAX Ltd., Series E, (Acquired 09/12/19, Cost: $10,999,987)(c)(d)

    293,333       16,435,448  

Twilio, Inc., Class A(b)

    166,734       65,719,873  

Wix.com Ltd.(b)

    85,274       24,753,337  
   

 

 

 
        572,221,060  
Multi-line Retail — 0.9%  

Magazine Luiza SA

    7,310,568       31,086,596  
   

 

 

 
Professional Services — 0.4%  

CoStar Group, Inc.(a)(b)

    180,430       14,943,212  
   

 

 

 
Road & Rail(b) — 1.4%            

Lyft, Inc., Class A(a)

    474,493       28,697,337  

TuSimple Holdings, Inc., Class A(f)

    254,443       18,126,519  
   

 

 

 
      46,823,856  
Semiconductors & Semiconductor Equipment — 13.2%  

Alphawave IP Group PLC(b)

    3,372,993       16,797,100  

ASM International NV

    55,019       18,146,753  

BE Semiconductor Industries NV

    285,445       24,324,983  

Cohu, Inc.(b)

    37,692       1,386,689  

Cree, Inc.(b)

    330,702       32,385,647  

Lasertec Corp.

    316,800       61,277,035  

Lattice Semiconductor Corp.(b)

    507,451       28,508,597  

MACOM Technology Solutions Holdings, Inc.(b)

    320,382       20,530,079  

Marvell Technology, Inc.(a)

    1,299,467       75,797,910  

Monolithic Power Systems, Inc.(a)

    91,900       34,320,055  

Qorvo, Inc.(b)

    162,668       31,825,994  

Silergy Corp.

    418,000       56,732,389  

SOITEC(b)

    180,977       39,963,782  
   

 

 

 
      441,997,013  
Software — 22.9%            

Altium Ltd.

    922,809       25,404,048  

Atlassian Corp. PLC, Class A(b)

    98,985       25,425,287  

Avalara, Inc.(b)

    176,638       28,580,028  

C3.AI, Inc., Class A(b)(f)

    863,208       53,976,396  

Cloudflare, Inc., Class A(b)

    252,090       26,681,206  

Confluent, Inc., Class A(b)

    179,725       8,536,937  

Coupa Software, Inc.(b)

    78,392       20,547,327  

Crowdstrike Holdings, Inc., Class A(b)

    147,993       37,192,121  

Databricks, Inc., (Acquired 07/24/20, Cost: $5,501,686)(c)(d)

    114,553       20,318,266  

DataRobot, Inc., Series F, (Acquired 03/01/21, Cost: $1,384,813)(c)(d)

    92,093       1,571,107  

Elastic NV(b)

    170,979       24,921,899  

Five9, Inc.(b)

    198,189       36,345,881  

Freee KK(b)

    362,400       33,084,781  

Kingdee International Software Group Co. Ltd.

    6,627,000       22,444,736  

Legalzoom.com, Inc.

    637,753       24,138,951  

Lightspeed POS, Inc.(b)

    651,145       54,498,462  

Linklogis, Inc., (Acquired 03/31/21, Cost: $8,528,989)(d)

    3,734,000       8,155,778  

Ming Yuan Cloud Group Holdings Ltd.

    4,909,000       24,296,860  

Online Ventures Pty Ltd., Series C, (Acquired 01/21/20, Cost: $20,875,811)(c)(d)

    181,785       26,685,172  

Procore Technologies, Inc.(b)

    62,091       5,895,540  

Rakus Co. Ltd.

    1,236,700       33,615,791  

Snorkel Al, Inc., (Acquired 10/13/20, Cost: $2,017,593)(c)(d)

    500,250       8,189,092  

Snyk Ltd. , (Acquired 11/02/20, Cost: $9,287,400)(c)(d)

    1,267,643       11,472,169  
 

 

 

122  

2 0 2 1   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S


Consolidated Schedule of Investments (unaudited) (continued)

June 30, 2021

  

BlackRock Science and Technology Trust II (BSTZ)

(Percentages shown are based on Net Assets)

 

Security   Shares     Value  
Software (continued)            

Synopsys, Inc.(b)

    110,015     $ 30,341,037  

Trade Desk, Inc., Class A(a)(b)

    280,680       21,713,405  

TUYA, Inc., ADR(b)

    312,386       7,653,457  

Unity Software, Inc.(b)

    242,016       26,580,617  

Weimob, Inc.(b)(e)(f)

    10,787,000       23,804,090  

Xero Ltd.(b)

    259,099       26,650,846  

Zendesk, Inc.(b)

    201,382       29,067,478  

Zscaler, Inc.(a)(b)

    185,686       40,119,317  
   

 

 

 
      767,908,082  
Specialty Retail — 0.4%  

Cazoo Ltd., (Acquired 10/08/20, Cost: $5,656,927)(c)(d)

    411,705       12,022,388  
   

 

 

 

Total Common Stocks — 81.6%
(Cost: $1,168,661,046)

 

    2,740,074,986  
   

 

 

 

Preferred Securities

 

Preferred Stocks — 19.2%(d)

 

Automobiles — 1.3%            

Arrival Ltd., (Acquired 03/23/21, Cost: $20,182,401)

    2,783,376       42,609,920  
   

 

 

 
Communications Equipment — 0.5%  

Astranis Space Technologies Corp., Series C, (Acquired 03/19/21, Cost: $17,000,010)(c)

    775,515       16,999,289  
   

 

 

 
Diversified Consumer Services — 0.6%  

Think & Learn Private Ltd., Series F, (Acquired 09/30/20, Cost: $14,251,080)(c)

    4,920       18,868,627  
   

 

 

 
Electronic Equipment, Instruments & Components(c) — 0.7%  

Credo Technology Group Holding Ltd.

 

Series D, (Acquired 03/20/20, Cost: $19,999,997)

    4,005,527       23,272,112  

Series D+, (Acquired 01/22/20, Cost: $1,617,982)

    278,714       1,619,328  
   

 

 

 
      24,891,440  
Food Products(c) — 1.0%  

Farmer’s Business Network, Inc., Series F, (Acquired 07/31/20, Cost: $11,961,002)

    361,834       15,446,694  

GrubMarket, Inc. , Series D, (Acquired 07/23/20, Cost: $8,000,001)

    1,762,969       17,382,874  
   

 

 

 
      32,829,568  
Interactive Media & Services(c) — 1.8%  

ByteDance Ltd., Series E-1, (Acquired 11/11/20, Cost: $35,000,075)

    319,419       54,184,650  

ResearchGate GmbH, Series D, (Acquired 09/24/20, Cost: $6,999,988)

    424,688       6,998,858  
   

 

 

 
      61,183,508  
IT Services(c) — 1.1%  

Deep Instinct Ltd., Series D-2, (Acquired 03/19/21, Cost: $12,000,008)

    1,974,374       12,432,890  

Trumid Holdings LLC(g)

 

Class J-A, (Acquired 07/24/20, Cost: $9,999,857)

    20,154       11,790,292  

Class J-B, (Acquired 07/24/20, Cost: $5,999,914)

    20,154       11,790,291  
   

 

 

 
      36,013,473  
Road & Rail — 0.6%            

FlixMobility GmbH, Series F, (Acquired 07/26/19, Cost: $16,947,253)(c)

    850       20,318,006  
   

 

 

 
Security   Shares     Value  
Semiconductors & Semiconductor Equipment(c) — 4.9%  

Cnex Labs, Inc.

   

Series E, (Acquired 02/06/20, Cost: $7,000,000)

    329,675     $ 4,971,499  

Series F, (Acquired 02/24/21, Cost: $4,999,999)

    730,332       5,061,201  

Innovium, Inc.

   

Series E, (Acquired 08/21/19, Cost: $8,999,992)

    1,060,432       10,827,011  

Series F, (Acquired 06/10/20, Cost: $6,999,998)

    690,812       7,792,359  

Mythic AI, Inc., Series C, (Acquired 01/26/21, Cost: $7,000,000)

    1,018,908       7,295,381  

Psiquantum Corp., Series C, (Acquired 09/09/19, Cost: $9,101,310)

    1,962,335       40,110,128  

PsiQuantum Corp., Series D, (Acquired 05/21/21, Cost: $19,999,969)

    762,595       20,002,867  

SambaNova Systems, Inc.

   

(Acquired 04/09/21, Cost: $6,999,979)

    73,670       7,000,123  

Series C, (Acquired 02/20/20, Cost: $33,904,162)

    636,800       60,508,736  
   

 

 

 
      163,569,305  
Software(c) — 5.8%            

Avidxchange, Inc., (Acquired 07/29/20, Cost: $7,474,330)

    152,500       9,366,550  

Databricks, Inc.

   

Series F, (Acquired 10/22/19, Cost: $13,200,019)

    307,346       54,513,960  

Series G, (Acquired 02/01/21, Cost: $18,500,004)

    104,303       18,500,223  

DataRobot, Inc., Series F, (Acquired 10/27/20, Cost: $11,499,999)

    875,059       14,928,506  

GitLab, Inc., Series E, (Acquired 09/10/19, Cost: $11,670,984)

    626,482       27,978,686  

Rapyd Financial Network Ltd., Series E, (Acquired 03/31/21, Cost: $13,999,978)

    190,705       14,497,394  

Snorkel Al, Inc., Series B, (Acquired 10/13/20, Cost: $999,996)

    247,943       4,058,827  

Snyk Ltd. , (Acquired 11/02/20, Cost: $13,212,590)

    2,663,936       24,108,621  

Unqork, Inc.

   

Series B, (Acquired 09/19/19, Cost: $6,801,016)

    14,942       17,645,307  

Series C, (Acquired 09/18/20, Cost: $7,994,787)

    7,300       8,620,716  
   

 

 

 
      194,218,790  
Specialty Retail(c) — 0.9%            

Cazoo Ltd.

   

Series A, (Acquired 10/08/20, Cost: $184,683)

    13,441       392,497  

Series B, (Acquired 10/08/20, Cost: $3,233,326)

    235,318       6,871,630  

Series C, (Acquired 10/08/20, Cost: $65,637)

    4,777       139,495  

Series D, (Acquired 10/08/20, Cost: $11,550,639)

    840,643       24,548,005  
   

 

 

 
      31,951,627  
   

 

 

 

Total Preferred Stocks — 19.2%

 

    643,453,553  
   

 

 

 

Total Preferred Securities — 19.2%
(Cost: $405,352,965)

 

    643,453,553  
   

 

 

 

Warrants

   

IT Services — 0.0%

   

TRAX Ltd., (Acquired 09/12/19, Cost: $0)(c)(d)

    46,928       469,280  
   

 

 

 

Total Warrants — 0.0%
(Cost: $ — )

      469,280  
   

 

 

 

Total Long-Term Investments — 100.8%
(Cost: $1,574,014,011)

 

    3,383,997,819  
   

 

 

 
 

 

 

C O N S O L I D A T E D   S C H E D U L E   O F   I N V E S T M E N T S

  123


Consolidated Schedule of Investments (unaudited) (continued)

June 30, 2021

  

BlackRock Science and Technology Trust II (BSTZ)

(Percentages shown are based on Net Assets)

 

Security   Shares     Value  

Short-Term Securities

   

Money Market Funds — 1.1%

 

BlackRock Liquidity Funds, T-Fund, Institutional Class, 0.01%(h)(i)

    32,067,890     $ 32,067,890  

SL Liquidity Series, LLC, Money Market Series, 0.13%(h)(i)

    4,330,795       4,332,095  
   

 

 

 

Total Short-Term Securities — 1.1%
(Cost: $36,399,985)

 

    36,399,985  
   

 

 

 

Total Investments Before Options Written — 101.9%
(Cost: $1,610,413,996)

 

    3,420,397,804  
   

 

 

 

Options Written — (1.7)%
(Premiums Received: $(27,008,924))

 

    (58,192,357 ) 
   

 

 

 

Total Investments, Net of Options
Written — 100.2%
(Cost: $1,583,405,072)

 

    3,362,205,447  

Liabilities in Excess of Other Assets — (0.2)%

 

    (6,552,493 ) 
   

 

 

 

Net Assets — 100.0%

 

  $   3,355,652,954  
   

 

 

 

 

(a) 

All or a portion of the security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written.

(b) 

Non-income producing security.

(c) 

Security is valued using significant unobservable inputs and is classified as Level 3 in the fair value hierarchy.

(d) 

Restricted security as to resale, excluding 144A securities. The Trust held restricted securities with a current value of $946,333,552, representing 28.2% of its net assets as of period end, and an original cost of $556,074,895.

(e) 

Security exempt from registration pursuant to Rule 144A under the Securities Act of 1933, as amended. These securities may be resold in transactions exempt from registration to qualified institutional investors.

(f) 

All or a portion of this security is on loan.

(g) 

All or a portion of the security is held by a wholly-owned subsidiary. See Note 1 of the Notes to Consolidated Financial Statements for details on the wholly-owned subsidiary.

(h) 

Affiliate of the Trust.

(i) 

Annualized 7-day yield as of period end.

 

 

For Trust compliance purposes, the Trust’s industry classifications refer to one or more of the industry sub-classifications used by one or more widely recognized market indexes or rating group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.

Affiliates

Investments in issuers considered to be affiliate(s) of the Trust during the six-months ended June 30, 2021 for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

 

Affiliated Issuer   Value at
12/31/20
    Purchases
at Cost
    Proceeds
from Sales
    Net
Realized
Gain (Loss)
    Change in
Unrealized
Appreciation
(Depreciation)
    Value at
06/30/21
    Shares
Held at
06/30/21
    Income     Capital Gain
Distributions
from
Underlying
Funds
 

BlackRock Liquidity Funds, T-Fund, Institutional Class

  $   21,688,765     $   10,379,125 (a)    $ —     $ —     $ —     $   32,067,890       32,067,890     $ 4,758     $ —  

SL Liquidity Series, LLC, Money Market Series

    —       4,331,452 (a)       —       643       —       4,332,095       4,330,796       180,510 (b)      —  
       

 

 

   

 

 

   

 

 

     

 

 

   

 

 

 
        $ 643     $ —     $ 36,399,985       $   185,268     $ —  
       

 

 

   

 

 

   

 

 

     

 

 

   

 

 

 

 

  (a) 

Represents net amount purchased (sold).

 
  (b) 

All or a portion of this security was purchased with the cash collateral from loaned securities.

 

Derivative Financial Instruments Outstanding as of Period End

Exchange-Traded Options Written

 

Description    Number of
Contracts
       Expiration
Date
       Exercise Price        Notional
Amount (000)
       Value  

Call

                                

Atlassian Corp. PLC, Class A

     163          07/02/21          USD          225.00          USD          4,187        $ (520,785 ) 

Cree, Inc.

     573          07/02/21          USD          100.00          USD          5,611          (28,650 ) 

Crowdstrike Holdings, Inc., Class A

     84          07/02/21          USD          232.50          USD          2,111          (158,970 ) 

Lyft, Inc., Class A

     108          07/02/21          USD          60.00          USD          653          (11,772 ) 

MongoDB, Inc.

     22          07/02/21          USD          320.00          USD          795          (93,280 ) 

Snap, Inc., Class A

     241          07/02/21          USD          65.00          USD          1,642          (80,735 ) 

Zscaler, Inc.

     164          07/02/21          USD          200.00          USD          3,543            (266,500 ) 

Zynga, Inc., Class A

     889          07/02/21          USD          11.00          USD          945          (2,223 ) 

Chegg, Inc.

     300          07/09/21          USD          82.51          USD          2,493          (66,403 ) 

Coupa Software, Inc.

     75          07/09/21          USD          252.50          USD          1,966          (94,875 ) 

Cree, Inc.

     201          07/09/21          USD          108.00          USD          1,968          (4,523 ) 

MercadoLibre, Inc.

     16          07/09/21          USD          1,420.00          USD          2,492          (226,640 ) 

MongoDB, Inc.

     50          07/09/21          USD          322.50          USD          1,808          (203,000 ) 

Okta, Inc.

     170          07/09/21          USD          240.00          USD          4,160          (132,600 ) 

 

 

124  

2 0 2 1   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S


Consolidated Schedule of Investments (unaudited) (continued)

June 30, 2021

  

BlackRock Science and Technology Trust II (BSTZ)

    

 

Exchange-Traded Options Written (continued)

 

Description    Number of
Contracts
       Expiration
Date
       Exercise Price        Notional
Amount (000)
       Value  

Call (continued)

                                

Roku, Inc.

     59          07/09/21          USD          365.00          USD          2,710        $ (557,845 ) 

Snap, Inc., Class A

     401          07/09/21          USD          62.00          USD          2,732          (258,645 ) 

Square, Inc., Class A

     113          07/09/21          USD          240.00          USD          2,755          (88,705 ) 

Square, Inc., Class A

     112          07/09/21          USD          250.00          USD          2,731          (37,520 ) 

Stoneco Ltd., Class A

     201          07/09/21          USD          70.00          USD          1,348          (10,553 ) 

Tesla, Inc.

     22          07/09/21          USD          690.00          USD          1,495          (39,490 ) 

Tesla, Inc.

     27          07/09/21          USD          640.00          USD          1,835          (136,012 ) 

Twilio, Inc., Class A

     108          07/09/21          USD          365.00          USD          4,257          (354,780 ) 

Twilio, Inc., Class A

     103          07/09/21          USD          357.50          USD          4,060          (409,682 ) 

Zynga, Inc., Class A

     377          07/09/21          USD          11.50          USD          401          (2,262 ) 

Zynga, Inc., Class A

     377          07/09/21          USD          11.00          USD          401          (4,713 ) 

Atlassian Corp. PLC, Class A

     34          07/16/21          USD          250.00          USD          873          (38,420 ) 

Bandwidth, Inc., Class A

     220          07/16/21          USD          130.00          USD          3,034          (216,700 ) 

C3.AI, Inc., Class A

     198          07/16/21          USD          65.00          USD          1,238          (43,065 ) 

C3.AI, Inc., Class A

     528          07/16/21          USD          70.00          USD          3,302          (54,120 ) 

Chegg, Inc.

     301          07/16/21          USD          85.00          USD          2,502          (51,170 ) 

Cloudflare, Inc., Class A

     424          07/16/21          USD          75.00          USD          4,488          (1,313,340 ) 

Crowdstrike Holdings, Inc., Class A

     70          07/16/21          USD          240.00          USD          1,759          (105,875 ) 

Dlocal Ltd., Class A

     300          07/16/21          USD          50.00          USD          1,576          (135,000 ) 

Elastic NV

     256          07/16/21          USD          125.00          USD          3,731          (554,240 ) 

Eventbrite, Inc., Class A

     1,079          07/16/21          USD          22.50          USD          2,050          (8,093 ) 

Eventbrite, Inc., Class A

     1,167          07/16/21          USD          20.00          USD          2,217          (46,680 ) 

Farfetch Ltd., Class A

     423          07/16/21          USD          46.00          USD          2,130          (214,672 ) 

Five9, Inc.

     422          07/16/21          USD          180.00          USD          7,739          (305,950 ) 

Grid Dynamics Holdings, Inc.

     1,175          07/16/21          USD          17.50          USD          1,766          (23,500 ) 

Lightspeed Pos Inc.

     975          07/16/21          CAD          96.00          CAD          10,116          (721,654 ) 

Lyft, Inc., Class A

     225          07/16/21          USD          57.50          USD          1,361          (86,063 ) 

MACOM Technology Solutions Holdings, Inc.

     466          07/16/21          USD          65.00          USD          2,986          (74,560 ) 

MercadoLibre, Inc.

     23          07/16/21          USD          1,450.00          USD          3,583          (275,425 ) 

Monolithic Power Systems, Inc.

     130          07/16/21          USD          331.00          USD          4,855          (566,905 ) 

Ozon Holdings PLC

     867          07/16/21          USD          60.00          USD          5,082          (95,370 ) 

Pagseguro Digital Ltd., Class A

     310          07/16/21          USD          52.50          USD          1,734          (131,750 ) 

Pagseguro Digital Ltd., Class A

     450          07/16/21          USD          45.50          USD          2,516          (471,991 ) 

Procore Technologies, Inc.

     186          07/16/21          USD          90.00          USD          1,766          (115,320 ) 

Qorvo, Inc.

     248          07/16/21          USD          185.00          USD          4,852          (296,360 ) 

Roku, Inc.

     80          07/16/21          USD          335.00          USD          3,674          (996,800 ) 

Shift4 Payments, Inc., Class A

     400          07/16/21          USD          110.00          USD          3,749          (9,000 ) 

Shoals Technologies Group, Inc., Class A

     567          07/16/21          USD          25.00          USD          2,013          (595,350 ) 

Snap, Inc., Class A

     1,063          07/16/21          USD          60.00          USD          7,243          (914,180 ) 

Square, Inc., Class A

     100          07/16/21          USD          220.00          USD          2,438          (250,000 ) 

Square, Inc., Class A

     157          07/16/21          USD          240.00          USD          3,828          (157,785 ) 

Stoneco Ltd., Class A

     492          07/16/21          USD          67.50          USD          3,299          (94,710 ) 

Synopsys, Inc.

     190          07/16/21          USD          250.00          USD          5,240          (499,700 ) 

Tesla, Inc.

     89          07/16/21          USD          730.00          USD          6,049          (103,017 ) 

Tesla, Inc.

     22          07/16/21          USD          650.00          USD          1,495          (104,995 ) 

Tesla, Inc.

     47          07/16/21          USD          630.00          USD          3,195          (297,745 ) 

Twilio, Inc., Class A

     205          07/16/21          USD          330.00          USD          8,080          (1,331,987 ) 

Unity Software, Inc.

     313          07/16/21          USD          105.00          USD          3,438          (215,970 ) 

Wix.Com Ltd.

     113          07/16/21          USD          240.00          USD          3,280          (564,435 ) 

Zendesk, Inc.

     304          07/16/21          USD          145.00          USD          4,388          (101,840 ) 

ZoomInfo Technologies, Inc., Class A

     769          07/16/21          USD          45.00          USD          4,012          (557,525 ) 

Zscaler, Inc.

     165          07/16/21          USD          210.00          USD          3,565          (156,750 ) 

Zynga, Inc., Class A

     2,073          07/16/21          USD          11.00          USD          2,204          (40,424 ) 

Cloudflare, Inc., Class A

     322          07/23/21          USD          97.00          USD          3,408          (330,855 ) 

Coupa Software, Inc.

     81          07/23/21          USD          250.00          USD          2,123          (151,470 ) 

Cree, Inc.

     218          07/23/21          USD          102.00          USD          2,135          (51,230 ) 

Crowdstrike Holdings, Inc., Class A

     91          07/23/21          USD          232.50          USD          2,287          (199,972 ) 

Lyft, Inc., Class A

     515          07/23/21          USD          61.00          USD          3,115          (117,420 ) 

Marvell Technology Inc.

     638          07/23/21          USD          51.00          USD          3,721          (457,765 ) 

MercadoLibre, Inc.

     23          07/23/21          USD          1,410.00          USD          3,583          (369,725 ) 

MongoDB, Inc.

     40          07/23/21          USD          340.00          USD          1,446          (119,000 ) 

MongoDB, Inc.

     23          07/23/21          USD          400.00          USD          831          (12,765 ) 

 

 

C O N S O L I D A T E D   S C H E D U L E  O F  I N V E S T M E N T S

  125


Consolidated Schedule of Investments (unaudited) (continued)

June 30, 2021

  

BlackRock Science and Technology Trust II (BSTZ)

    

 

Exchange-Traded Options Written (continued)

 

Description    Number of
Contracts
       Expiration
Date
       Exercise Price        Notional
Amount (000)
       Value  

Call (continued)

                                

Okta, Inc.

     80          07/23/21          USD          230.00          USD          1,957        $ (146,200 ) 

Roku, Inc.

     29          07/23/21          USD          365.00          USD          1,332          (276,732 ) 

Roku, Inc.

     59          07/23/21          USD          375.00          USD          2,710          (506,515 ) 

Snap, Inc., Class A

     1,020          07/23/21          USD          64.50          USD          6,950          (665,550 ) 

Square, Inc., Class A

     158          07/23/21          USD          237.50          USD          3,852          (210,535 ) 

Square, Inc., Class A

     359          07/23/21          USD          255.00          USD          8,752          (195,655 ) 

Stoneco Ltd., Class A

     104          07/23/21          USD          68.00          USD          697          (22,620 ) 

Tesla, Inc.

     34          07/23/21          USD          680.00          USD          2,311          (129,285 ) 

Twilio, Inc., Class A

     57          07/23/21          USD          347.50          USD          2,247          (294,262 ) 

Twilio, Inc., Class A

     120          07/23/21          USD          380.00          USD          4,730          (309,300 ) 

Farfetch Ltd., Class A

     500          07/26/21          USD          45.00          USD          2,518          (309,339 ) 

Atlassian Corp. PLC, Class A

     34          07/30/21          USD          275.00          USD          873          (22,780 ) 

Cloudflare, Inc., Class A

     450          07/30/21          USD          102.00          USD          4,763          (357,750 ) 

Cree, Inc.

     413          07/30/21          USD          99.00          USD          4,045          (171,395 ) 

Crowdstrike Holdings, Inc., Class A

     99          07/30/21          USD          232.50          USD          2,488          (235,372 ) 

Farfetch Ltd., Class A

     820          07/30/21          USD          52.00          USD          4,130          (202,764 ) 

Lyft, Inc., Class A

     249          07/30/21          USD          60.50          USD          1,506          (75,696 ) 

Marvell Technology Inc.

     810          07/30/21          USD          52.00          USD          4,725          (546,750 ) 

MercadoLibre, Inc.

     16          07/30/21          USD          1,520.00          USD          2,492          (136,960 ) 

MongoDB, Inc.

     77          07/30/21          USD          350.00          USD          2,784          (198,660 ) 

Okta, Inc.

     85          07/30/21          USD          250.00          USD          2,080          (67,363 ) 

Roku, Inc.

     79          07/30/21          USD          445.00          USD          3,628          (275,117 ) 

Snap, Inc., Class A

     1,324          07/30/21          USD          65.00          USD          9,022          (877,150 ) 

Square, Inc., Class A

     358          07/30/21          USD          255.00          USD          8,728          (247,020 ) 

Synopsys, Inc.

     140          07/30/21          USD          277.50          USD          3,861          (89,600 ) 

Tesla, Inc.

     89          07/30/21          USD          690.00          USD          6,049          (362,675 ) 

Tesla, Inc.

     89          07/30/21          USD          665.00          USD          6,049          (477,485 ) 

Twilio, Inc., Class A

     205          07/30/21          USD          340.00          USD          8,080          (1,224,362 ) 

ZoomInfo Technologies, Inc., Class A

     718          07/30/21          USD          50.25          USD          3,746          (266,330 ) 

Zscaler, Inc.

     139          07/30/21          USD          210.00          USD          3,003          (172,707 ) 

Zynga, Inc., Class A

     304          07/30/21          USD          11.00          USD          323          (10,184 ) 

Shoals Technologies Group, Inc., Class A

     524          08/03/21          USD          31.25          USD          1,860          (279,930 ) 

Coupa Software, Inc.

     79          08/06/21          USD          265.00          USD          2,071          (98,750 ) 

Cree, Inc.

     414          08/06/21          USD          103.00          USD          4,054          (114,885 ) 

Farfetch Ltd., Class A

     420          08/06/21          USD          44.50          USD          2,115          (291,170 ) 

Lyft, Inc., Class A

     109          08/06/21          USD          64.50          USD          659          (22,618 ) 

Marvell Technology Inc.

     354          08/06/21          USD          59.00          USD          2,065          (71,862 ) 

MercadoLibre, Inc.

     66          08/06/21          USD          1,600.00          USD          10,281          (412,500 ) 

Okta, Inc.

     85          08/06/21          USD          255.00          USD          2,080          (60,563 ) 

Square, Inc., Class A

     210          08/06/21          USD          267.50          USD          5,120          (137,025 ) 

Stoneco Ltd., Class A

     401          08/06/21          USD          73.00          USD          2,689          (62,155 ) 

Zendesk, Inc.

     300          08/06/21          USD          146.00          USD          4,330          (145,017 ) 

Marvell Technology Inc.

     884          08/13/21          USD          54.95          USD          5,156          (405,535 ) 

Ozon Holdings PLC

     868          08/13/21          USD          61.00          USD          5,088          (156,993 ) 

Wix.Com Ltd.

     140          08/16/21          USD          303.00          USD          4,064          (203,535 ) 

Atlassian Corp. PLC, Class A

     65          08/20/21          USD          270.00          USD          1,670          (70,200 ) 

Avalara, Inc.

     212          08/20/21          USD          150.00          USD          3,430          (367,820 ) 

Bandwidth, Inc., Class A

     180          08/20/21          USD          135.00          USD          2,483          (194,400 ) 

C3.AI, Inc., Class A

     808          08/20/21          USD          75.00          USD          5,052          (177,760 ) 

Chegg, Inc.

     468          08/20/21          USD          85.00          USD          3,890          (224,640 ) 

Cloudflare, Inc., Class A

     190          08/20/21          USD          85.00          USD          2,011          (424,175 ) 

Crowdstrike Holdings, Inc., Class A

     99          08/20/21          USD          260.00          USD          2,488          (117,563 ) 

Dlocal Ltd., Class A

     500          08/20/21          USD          60.00          USD          2,627          (140,000 ) 

Elastic NV

     256          08/20/21          USD          150.00          USD          3,731          (181,760 ) 

Farfetch Ltd., Class A

     798          08/20/21          USD          55.00          USD          4,019          (253,365 ) 

Five9, Inc.

     86          08/20/21          USD          195.00          USD          1,577          (60,200 ) 

Grid Dynamics Holdings, Inc.

     1,175          08/20/21          USD          20.00          USD          1,766          (52,875 ) 

Lattice Semiconductor Corp.

     744          08/20/21          USD          55.00          USD          4,180          (357,120 ) 

Lightspeed Pos Inc.

     978          08/20/21          CAD          105.00          CAD          10,147          (674,564 ) 

Lyft, Inc., Class A

     216          08/20/21          USD          60.00          USD          1,306          (100,440 ) 

MACOM Technology Solutions Holdings, Inc.

     397          08/20/21          USD          60.00          USD          2,544          (285,840 ) 

MACOM Technology Solutions Holdings, Inc.

     100          08/20/21          USD          70.00          USD          641          (25,750 ) 

 

 

126  

2 0 2 1   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S


Consolidated Schedule of Investments (unaudited) (continued)

June 30, 2021

  

BlackRock Science and Technology Trust II (BSTZ)

    

 

Exchange-Traded Options Written (continued)

 

Description    Number of
Contracts
       Expiration
Date
       Exercise Price        Notional
Amount (000)
       Value  

Call (continued)

                                

Marvell Technology Inc.

     1,246          08/20/21          USD          52.50          USD          7,268        $ (825,475 ) 

MongoDB, Inc.

     22          08/20/21          USD          370.00          USD          795          (49,280 ) 

Monolithic Power Systems, Inc.

     145          08/20/21          USD          370.00          USD          5,415          (329,150 ) 

Pagseguro Digital Ltd., Class A

     250          08/20/21          USD          47.50          USD          1,398          (232,500 ) 

Pagseguro Digital Ltd., Class A

     195          08/20/21          USD          60.00          USD          1,090          (41,438 ) 

Qorvo, Inc.

     240          08/20/21          USD          195.00          USD          4,696          (265,200 ) 

Shift4 Payments, Inc., Class A

     444          08/20/21          USD          105.00          USD          4,161          (166,500 ) 

Snap, Inc., Class A

     1,460          08/20/21          USD          65.00          USD          9,948          (1,109,600 ) 

Tesla, Inc.

     82          08/20/21          USD          690.00          USD          5,574          (422,505 ) 

TuSimple Holdings, Inc.

     534          08/20/21          USD          45.00          USD          3,804          (1,495,200 ) 

TuSimple Holdings, Inc.

     400          08/20/21          USD          60.00          USD          2,850          (684,000 ) 

Twilio, Inc., Class A

     120          08/20/21          USD          380.00          USD          4,730          (447,600 ) 

Unity Software, Inc.

     410          08/20/21          USD          105.00          USD          4,503          (440,750 ) 

Zscaler, Inc.

     89          08/20/21          USD          220.00          USD          1,923          (91,448 ) 

Zynga, Inc., Class A

     376          08/20/21          USD          12.00          USD          400          (11,468 ) 

Zynga, Inc., Class A

     1,700          08/20/21          USD          11.00          USD          1,807          (92,650 ) 
                                

 

 

 
                                 $   (40,499,688 ) 
                                

 

 

 

OTC Options Written

 

Description    Counterparty   Number of
Contracts
    Expiration
Date
    Exercise Price    

Notional

Amount (000)

    Value  

Call

                

Adyen NV

   UBS AG     4,500       07/07/21       EUR       1,963.56       EUR       9,272     $ (604,987 ) 

Soitec SA

   UBS AG     6,050       07/07/21       EUR       171.15       EUR       1,125       (108,244 ) 

BE Semiconductor Industries NV

   Goldman Sachs International     46,300       07/08/21       EUR       63.52       EUR       3,312       (463,723 ) 

Delivery Hero AG

   Morgan Stanley & Co. International PLC     58,100       07/08/21       EUR       116.89       EUR       6,472       (48,071 ) 

Gmo Payment Gateway Inc.

   Goldman Sachs International     31,400       07/08/21       JPY       13,423.22       JPY       454,358       (297,247 ) 

Silergy Corp.

   UBS AG     49,000       07/08/21       USD       3,734.30       USD       185,710       (274,342 ) 

Xero Ltd

   JPMorgan Chase Bank N.A.     3,200       07/08/21       AUD       126.36       AUD       439       (26,928 ) 

Endava PLC

   Bank of America N.A.     16,600       07/09/21       USD       89.75       USD       1,882       (392,296 ) 

Trade Desk, Inc., Class A

   Morgan Stanley & Co. LLC     36,000       07/09/21       USD       61.50       USD       2,785       (579,600 ) 

Avalara, Inc

   Citibank N.A.     15,900       07/13/21       USD       136.58       USD       2,573       (402,217 ) 

Freee KK

   JPMorgan Chase Bank N.A.     59,600       07/14/21       JPY       8,705.52       JPY       608,516       (802,677 ) 

Ming Yuan Cloud Group Holdings Ltd.

   JPMorgan Chase Bank N.A.     737,000       07/14/21       HKD       41.18       HKD       28,411       (70,489 ) 

Altium Ltd.

   Goldman Sachs International     100,000       07/15/21       AUD       28.90       AUD       3,669       (586,173 ) 

Endava PLC

   Credit Suisse International     16,200       07/15/21       USD       94.77       USD       1,837       (301,555 ) 

Samsung Sdi Ltd.

   JPMorgan Chase Bank N.A.     11,600       07/15/21       USD       634,811.95       USD       8,096,800       (664,054 ) 

Weimob Inc.

   JPMorgan Chase Bank N.A.     469,000       07/15/21       HKD       19.26       HKD       8,029       (22,133 ) 

CoStar Group, Inc.

   J.P. Morgan Securities LLC     26,000       07/16/21       USD       86.00       USD       2,153       (23,400 ) 

Trade Desk, Inc., Class A

   Morgan Stanley & Co. LLC     51,000       07/16/21       USD       59.00       USD       3,945       (946,050 ) 

TuSimple Holdings, Inc.

   Jane Street Execution Services, LLC     40,900       07/16/21       USD       45.00       USD       2,914       (1,124,750 ) 

Endava PLC

   Bank of America N.A.     27,300       07/20/21       USD       107.02       USD       3,095       (192,464 ) 

Locaweb Servicos de Internet SA

   Morgan Stanley & Co. International PLC     1,202,600       07/20/21       USD       25.74       USD       32,542       (500,618 ) 

Magazine Luiza SA

   Morgan Stanley & Co. International PLC     2,216,200       07/20/21       USD       21.85       USD       46,873       (214,351 ) 

Ncsoft Corp.

   Morgan Stanley & Co. International PLC     5,400       07/20/21       USD       873,650.29       USD       4,428,000       (26,725 ) 

Rakus Ltd.

   JPMorgan Chase Bank N.A.     146,300       07/20/21       JPY       2,122.91       JPY       444,021       (1,181,231 ) 

Shop Apotheke Europe NV

   Morgan Stanley & Co. International PLC     18,500       07/20/21       EUR       160.50       EUR       2,930       (145,860 ) 

Soitec SA

   UBS AG     10,500       07/20/21       EUR       171.44       EUR       1,952       (188,925 ) 

Five9, Inc.

   Barclays Bank PLC     8,600       07/21/21       USD       173.92       USD       1,577       (102,478 ) 

Lattice Semiconductor Corp.

   UBS AG     38,900       07/26/21       USD       52.96       USD       2,185       (164,112 ) 

Asm International NV

   Goldman Sachs International     16,500       07/27/21       EUR       273.55       EUR       4,571       (231,713 ) 

BE Semiconductor Industries NV

   Credit Suisse International     39,300       07/27/21       EUR       74.53       EUR       2,812       (56,684 ) 

Gmo Payment Gateway Inc.

   Goldman Sachs International     36,200       07/27/21       JPY       13,409.10       JPY       523,814       (401,823 ) 

Weimob Inc.

   Citibank N.A.     3,300,000       07/27/21       HKD       17.92       HKD       56,496       (452,020 ) 

Xero Ltd.

   UBS AG     35,500       07/27/21       AUD       134.26       AUD       4,867       (205,758 ) 

Endava PLC

   UBS AG     22,000       07/28/21       USD       115.83       USD       2,494       (51,401 ) 

Avalara, Inc.

   Citibank N.A.     15,900       07/29/21       USD       137.21       USD       2,573       (402,067 ) 

Soitec SA

   UBS AG     10,500       07/29/21       EUR       195.80       EUR       1,952       (16,790 ) 

Weimob Inc.

   Morgan Stanley & Co. International PLC     2,164,000       07/29/21       HKD       18.67       HKD       37,048       (239,717 ) 

Lattice Semiconductor Corp.

   Morgan Stanley & Co. International PLC     38,900       07/30/21       USD       55.28       USD       2,185       (114,895 ) 

 

 

C O N S O L I D A T E D   S C H E D U L E  O F  I N V E S T M E N T S

  127


Consolidated Schedule of Investments (unaudited) (continued)

June 30, 2021

  

BlackRock Science and Technology Trust II (BSTZ)

    

 

OTC Options Written (continued)

 

             
Description    Counterparty   Number of
Contracts
    Expiration
Date
    Exercise Price     Notional
Amount (000)
    Value  

Call (continued)

                

TUYA, Inc., ADR

   JPMorgan Chase Bank N.A.     50,000       08/03/21       USD       25.16       USD       1,225     $ (166,500 ) 

Endava PLC

   Credit Suisse International     18,800       08/04/21       USD       105.45       USD       2,132       (167,642 ) 

Shop Apotheke Europe NV

   Goldman Sachs International     13,900       08/04/21       EUR       176.01       EUR       2,202       (63,138 ) 

Silergy Corp.

   Morgan Stanley & Co. International PLC     76,000       08/04/21       USD       3,639.60       USD       288,040       (934,552 ) 

Xero Ltd.

   Goldman Sachs International     39,000       08/04/21       AUD       143.27       AUD       5,347       (135,019 ) 

Altium Ltd.

   Goldman Sachs International     176,800       08/05/21       AUD       37.61       AUD       6,487       (169,528 ) 

Freee KK

   JPMorgan Chase Bank N.A.     41,100       08/05/21       JPY       10,594.50       JPY       419,631       (215,803 ) 

Kakao Corp.

   Morgan Stanley & Co. International PLC     50,200       08/05/21       USD       164,850.00       USD       8,182,600       (377,654 ) 

Kingdee International Software Group

   JPMorgan Chase Bank N.A.     1,284,000       08/05/21       HKD       29.53       HKD       33,833       (152,479 ) 

Lasertec Corp.

   JPMorgan Chase Bank N.A.     68,000       08/05/21       JPY       23,278.50       JPY       1,468,120       (451,971 ) 

Rakus Ltd.

   JPMorgan Chase Bank N.A.     112,300       08/05/21       JPY       2,857.76       JPY       340,831       (273,601 ) 

Delivery Hero SE

   Goldman Sachs International     13,400       08/10/21       EUR       116.97       EUR       1,493       (49,561 ) 

Freee KK

   JPMorgan Chase Bank N.A.     41,100       08/10/21       JPY       10,594.50       JPY       419,631       (235,126 ) 

Lasertec Corp.

   UBS AG     23,800       08/10/21       JPY       23,101.30       JPY       513,842       (110,859 ) 

Rakus Ltd.

   Goldman Sachs International     112,300       08/10/21       JPY       2,857.76       JPY       340,831       (285,827 ) 

Samsung Sdi Ltd.

   JPMorgan Chase Bank N.A.     10,300       08/11/21       USD       710,700.00       USD       7,189,400       (227,904 ) 

Shop Apotheke Europe NV

   Morgan Stanley & Co. International PLC     13,900       08/11/21       EUR       176.01       EUR       2,202       (74,652 ) 

Kakao Corp.

   UBS AG     26,500       08/12/21       USD       169,060.00       USD       4,319,500       (179,569 ) 

Kingdee International Software Group

   Citibank N.A.     786,000       08/12/21       HKD       28.71       HKD       20,711       (121,864 ) 

Ming Yuan Cloud Group Holdings Ltd.

   JPMorgan Chase Bank N.A.     736,000       08/12/21       HKD       43.49       HKD       28,373       (131,708 ) 

Soitec SA

   Barclays Bank PLC     13,600       08/12/21       EUR       195.06       EUR       2,528       (69,377 ) 

Shop Apotheke Europe NV

   Goldman Sachs International     13,900       08/16/21       EUR       176.01       EUR       2,202       (64,892 ) 

Freee KK

   UBS AG     57,500       08/18/21       JPY       10,924.70       JPY       587,075       (118,847 ) 

Soitec SA

   UBS AG     13,600       08/18/21       EUR       195.06       EUR       2,528       (77,306 ) 

C3.AI, Inc., Class A

   Morgan Stanley & Co. International PLC     24,400       08/20/21       USD       61.87       USD       1,526       (146,422 ) 

CoStar Group, Inc.

   J.P. Morgan Securities LLC     28,000       08/20/21       USD       95.00       USD       2,319       (62,300 ) 
                

 

 

 
                 $  (17,692,669 ) 
                

 

 

 

Balances Reported in the Consolidated Statements of Assets and Liabilities for Options Written

 

           
Description    Swap
Premiums
Paid
       Swap
Premiums
Received
       Unrealized
Appreciation
       Unrealized
Depreciation
       Value  

Options Written

   $ N/A        $ N/A        $ 2,368,288          $ (33,551,721 )         $ (58,192,357 ) 

Derivative Financial Instruments Categorized by Risk Exposure

As of period end, the fair values of derivative financial instruments located in the Consolidated Statements of Assets and Liabilities were as follows:

 

               
     Commodity
Contracts
    Credit
Contracts
    Equity
Contracts
    Foreign
Currency
Exchange
Contracts
    Interest
Rate
Contracts
    Other
Contracts
    Total  

Liabilities — Derivative Financial Instruments

             

Options written

             

Options written at value

  $ —     $ —     $  58,192,357     $ —     $ —     $ —     $  58,192,357  
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

For the six months ended June 30, 2021, the effect of derivative financial instruments in the Consolidated Statements of Operations was as follows:

 

               
      Commodity
Contracts
     Credit
Contracts
     Equity
Contracts
     Foreign
Currency
Exchange
Contracts
     Interest
Rate
Contracts
     Other
Contracts
     Total  

Net Realized Gain (Loss) from

                    

Options written

   $ —      $ —      $  (18,711,994 )     $ —      $ —      $ —      $  (18,711,994 ) 
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Net Change in Unrealized Appreciation (Depreciation) on

                    

Options written

   $ —      $ —      $ (4,652,312 )     $ —      $ —      $ —      $ (4,652,312 ) 
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

 

 

128  

2 0 2 1   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S


Consolidated Schedule of Investments (unaudited) (continued)

June 30, 2021

  

BlackRock Science and Technology Trust II (BSTZ)

    

 

Average Quarterly Balances of Outstanding Derivative Financial Instruments

 

   

Options

  

Average value of option contracts written

   $ 36,847,856  

For more information about the Trust’s investment risks regarding derivative financial instruments, refer to the Notes to Consolidated Financial Statements.

Derivative Financial Instruments — Offsetting as of Period End

The Trust’s derivative assets and liabilities (by type) were as follows:

 

     
      Assets      Liabilities  

Derivative Financial Instruments

     

Options

   $ —      $ 58,192,357  
  

 

 

    

 

 

 

Total derivative assets and liabilities in the Consolidated Statements of Assets and Liabilities

     —        58,192,357  
  

 

 

    

 

 

 

Derivatives not subject to a Master Netting Agreement or similar agreement (“MNA”)

     —        (40,499,688 ) 
  

 

 

    

 

 

 

Total derivative assets and liabilities subject to an MNA

   $ —      $ 17,692,669  
  

 

 

    

 

 

 

The following table presents the Trust’s derivative liabilities by counterparty net of amounts available for offset under an MNA and net of the related collateral pledged by the Trust:

 

           
Counterparty     



Derivative
Liabilities
Subject to
an MNA by
Counterparty
 
 
 
 
 
    

Derivatives
Available
for Offset
 
 
 
    

Non-Cash
Collateral
Pledged
 
 
 
    

Cash
Collateral
Pledged
 
 
(a)  
    

Net Amount
of Derivative
Liabilities
 
 
(b)  

Bank of America N.A.

   $ 584,760      $ —      $ —      $ (584,760 )     $ —  

Barclays Bank PLC

     171,855        —        —        —        171,855  

Citibank N.A.

     1,378,168        —        —        (1,378,168 )       —  

Credit Suisse International

     525,881        —        —        (525,881 )       —  

Goldman Sachs International

     2,748,644        —        —        (2,748,644 )       —  

J.P. Morgan Securities LLC

     85,700        —        —        —        85,700  

Jane Street Execution Services, LLC

     1,124,750        —        —        —        1,124,750  

JPMorgan Chase Bank N.A.

     4,622,604        —        —        (3,790,000 )       832,604  

Morgan Stanley & Co. International PLC

     2,823,517        —        —        (2,530,000 )       293,517  

Morgan Stanley & Co. LLC

     1,525,650        —        —        —        1,525,650  

UBS AG

     2,101,140        —        —        (2,101,140 )       —  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 
   $ 17,692,669      $ —      $ —      $  (13,658,593 )     $ 4,034,076  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

 

  (a) 

Excess of collateral pledged to the individual counterparty is not shown for financial reporting purposes.

 
  (b) 

Net amount represents the net amount payable due to counterparty in the event of default. Net amount may be offset further by the options written receivable/payable on the Consolidated Statements of Assets and Liabilities.

 

Fair Value Hierarchy as of Period End

Various inputs are used in determining the fair value of financial instruments. For a description of the input levels and information about the Trust’s policy regarding valuation of financial instruments, refer to the Notes to Consolidated Financial Statements.

The following table summarizes the Trust’s financial instruments categorized in the fair value hierarchy. The breakdown of the Trust’s financial instruments into major categories is disclosed in the Consolidated Schedule of Investments above.

 

         
      Level 1      Level 2      Level 3      Total  

Assets

           

Investments

           

Long-Term Investments

           

Common Stocks

           

Automobiles

   $  61,705,205      $ —      $ —      $ 61,705,205  

Banks

     —        —        119,553,420        119,553,420  

Capital Markets

     —        12,000,000        —        12,000,000  

Diversified Consumer Services

     29,601,039        —        17,836,989        47,438,028  

Diversified Telecommunication Services

     18,391,494        —        —        18,391,494  

Electrical Equipment

     12,916,391        —        —        12,916,391  

Electronic Equipment, Instruments & Components

     —        45,328,932        —        45,328,932  

Entertainment

     86,424,057        44,618,151        —        131,042,208  

 

 

 

C O N S O L I D A T E D   S C H E D U L E   O F   I N V E S T M E N T S

  129


Consolidated Schedule of Investments (unaudited) (continued)

June 30, 2021

  

BlackRock Science and Technology Trust II (BSTZ)

    

 

Fair Value Hierarchy as of Period End (continued)

 

         
      Level 1        Level 2        Level 3        Total  

Common Stocks (continued)

                 

Interactive Media & Services

   $ 118,699,889        $ 110,439,684        $ —        $ 229,139,573  

Internet & Direct Marketing Retail

     124,201,763          51,355,765          —          175,557,528  

IT Services

     441,740,187          65,874,535          64,606,338          572,221,060  

Multi-line Retail

     31,086,596          —          —          31,086,596  

Professional Services

     14,943,212          —          —          14,943,212  

Road & Rail

     46,823,856          —          —          46,823,856  

Semiconductors & Semiconductor Equipment

     241,552,071          200,444,942          —          441,997,013  

Software

     502,215,346          197,456,930          68,235,806          767,908,082  

Specialty Retail

     —          —          12,022,388          12,022,388  

Preferred Securities

                 

Preferred Stocks

     —          42,609,920          600,843,633          643,453,553  

Warrants

     —          —          469,280          469,280  

Short-Term Securities

                 

Money Market Funds

     32,067,890          —          —          32,067,890  
  

 

 

      

 

 

      

 

 

      

 

 

 
   $  1,762,368,996        $  770,128,859        $  883,567,854          3,416,065,709  
  

 

 

      

 

 

      

 

 

      

 

 

 

Investments Valued at NAV

                    4,332,095  
                 

 

 

 
                  $  3,420,397,804  
                 

 

 

 

Derivative Financial Instruments(a)

                 

Liabilities

                 

Equity Contracts

   $ (37,133,776 )       $ (21,058,581 )       $ —        $ (58,192,357 ) 
  

 

 

      

 

 

      

 

 

      

 

 

 

 

  (a)

Derivative financial instruments are options written. Options written are shown at value.

 

A reconciliation of Level 3 financial instruments is presented when the Trust had a significant amount of Level 3 investments at the beginning and/or end of the period in relation to net assets. The following table is a reconciliation of Level 3 investments for which significant unobservable inputs were used in determining fair value:

 

         
     

Common

Stocks

    

Preferred

Stocks

     Warrants      Total  

Assets

           

Opening balance, as of December 31, 2020

   $ 116,083,688      $ 401,750,866      $ 521,839      $ 518,356,393  

Transfers into Level 3

     —        —        —        —  

Transfers out of Level 3

     —        —        —        —  

Accrued discounts/premiums

     —        —        —        —  

Net realized gain (loss)

     —        18,754,001        —        18,754,001  

Net change in unrealized appreciation (depreciation)(a)(b)

     113,286,445        130,584,824        (52,559 )       243,818,710  

Purchases

     52,884,808        100,499,946        —        153,384,754  

Sales

     —        (50,746,004 )       —        (50,746,004 ) 
  

 

 

    

 

 

    

 

 

    

 

 

 

Closing balance, as of June 30, 2021

   $ 282,254,941      $ 600,843,633      $ 469,280      $ 883,567,854  
  

 

 

    

 

 

    

 

 

    

 

 

 

Net change in unrealized appreciation (depreciation) on investments still held at June 30, 2021(b)

   $ 113,286,445      $ 178,307,965      $ (52,559 )     $ 291,541,851  
  

 

 

    

 

 

    

 

 

    

 

 

 

 

  (a) 

Included in the related net change in unrealized appreciation (depreciation) in the Consolidated Statements of Operations.

 
  (b)

Any difference between net change in unrealized appreciation (depreciation) and net change in unrealized appreciation (depreciation) on investments still held at June 30, 2021 is generally due to investments no longer held or categorized as Level 3 at period end.

 

The following table summarizes the valuation approaches used and unobservable inputs utilized by the BlackRock Global Valuation Methodologies Committee (the “Global Valuation Committee”) to determine the value of certain of the Trust’s Level 3 financial instruments as of period end.

 

           
       Value         
Valuation
Approach
 
 
      
Unobservable
Inputs
 
 
      


Range of
Unobservable
Inputs
Utilized
 
 
 
(a)  
    



Weighted
Average of
Unobservable
Inputs Based
on Fair Value
 
 
 
 
 

Assets

                    

Common Stocks(b)

   $ 282,254,941          Market          Revenue Multiple          5.95x - 46.84x        24.46x  
               Volatility          37% - 37%        37%  
               Time to Exit          0.3 - 0.3        0.3  
              
Recent
Transactions
 
 
       —        —  

Preferred Stocks(c)(d)

     600,843,633          Income          Discount Rate          28%        —  
 

 

 

130  

2 0 2 1   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S


Consolidated Schedule of Investments (unaudited) (continued)

June 30, 2021

  

BlackRock Science and Technology Trust II (BSTZ)

    

 

           
       Value         
Valuation
Approach
 
 
      

Unobservable

Inputs

 

 

      

Range of
Unobservable
Inputs

Utilized

 
 
 

(a)  

    



Weighted
Average of
Unobservable
Inputs Based
on Fair Value
 
 
 
 
 
          Market          Revenue Multiple          2.00x - 46.84x        20.98x  
               Volatility          42% - 50%        48%  
               Time to Exit          2.6 - 4.0        3.5  
               Recent Transactions          —        —  

Warrants(e)

     469,280          Market          Revenue Multiple          11.00x        —  
               Volatility          37%        —  
               Time to Exit          0.3        —  
                    
  

 

 

                   
   $  883,567,854                    
  

 

 

                   

 

  (a) 

A significant change in unobservable input would have resulted in a correlated (inverse) significant change to value.

 
  (b) 

For the period end June 30, 2021, the valuation technique for investments classified as Common Stocks amounting to $28,457,836 changed to Current Value Method. The investments were previously valued utilizing Transaction Price approach. The change was due to consideration of the information that was available at the time the investments were valued.

 
  (c) 

For the period end June 30, 2021, the valuation technique for investments classified as Preferred Stocks amounting to $101,064,783 changed to Current Value Method. The investments were previously valued utilizing Transaction Price Approach. The change was due to consideration of the information that was available at the time the investments were valued.

 
  (d) 

For the period end June 30, 2021, the valuation technique for investments classified as Preferred Stocks amounting to $80,826,742 changed to Transaction Price approach. The investments were previously valued utilizing Current Value Method. The change was due to consideration of the information that was available at the time the investments were valued.

 
  (e) 

For the period end June 30, 2021, the valuation technique for investments classified as Warrants amounting to $469,280 changed to Current Value Method. The investments were previously valued utilizing Transaction Price Approach. The change was due to consideration of the information that was available at the time the investments were valued.

 

See notes to financial statements.

 

 

C O N S O L I D A T E D   S C H E D U L E   O F   I N V E S T M E N T S

  131


Schedule of Investments (unaudited)

June 30, 2021

  

BlackRock Utilities, Infrastructure & Power Opportunities Trust (BUI)

(Percentages shown are based on Net Assets)

 

Security   Shares     Value  
Common Stocks            
Building Products — 9.0%            

A O Smith Corp.(a)

    76,870     $ 5,539,252  

Johnson Controls International PLC(a)

    223,309       15,325,697  

Kingspan Group PLC

    113,065       10,686,137  

Trane Technologies PLC(a)

    76,350       14,059,089  
   

 

 

 
      45,610,175  
Chemicals — 4.4%            

Air Liquide SA

    35,489       6,222,995  

LG Chem Ltd.

    3,500       2,642,814  

Linde PLC(b)

    27,272       7,885,153  

Sika AG, Registered Shares

    16,890       5,533,800  
   

 

 

 
      22,284,762  
Commercial Services & Supplies(a) — 4.8%  

Waste Connections, Inc.

    84,800       10,127,664  

Waste Management, Inc.

    101,500       14,221,165  
   

 

 

 
      24,348,829  
Construction & Engineering — 4.0%            

Quanta Services, Inc.(a)

    78,710       7,128,764  

Vinci SA

    122,600       13,105,674  
   

 

 

 
      20,234,438  
Electric Utilities — 28.9%            

American Electric Power Co., Inc.(a)

    116,350       9,842,047  

Duke Energy Corp.(a)

    107,868       10,648,729  

Edison International(a)

    183,100       10,586,842  

EDP - Energias de Portugal SA

    1,337,600       7,089,685  

Enel SpA

    2,776,325       25,800,023  

Exelon Corp.(a)

    226,358       10,029,923  

FirstEnergy Corp.(a)

    185,300       6,895,013  

Iberdrola SA

    1,525,611       18,604,300  

Neoenergia SA

    1,423,250       4,970,416  

NextEra Energy, Inc.(a)(c)

    500,480       36,675,174  

Xcel Energy, Inc.(a)

    76,740       5,055,631  
   

 

 

 
        146,197,783  
Electrical Equipment — 9.3%            

Ballard Power Systems, Inc.(b)

    24,783       449,068  

Eaton Corp. PLC(a)

    50,690       7,511,244  

Prysmian SpA

    156,850       5,628,727  

Schneider Electric SE

    76,282       12,025,441  

Sunrun, Inc.(a)(b)

    59,250       3,304,965  

Vestas Wind Systems A/S

    367,200       14,347,243  

Xinjiang Goldwind Science & Technology Co. Ltd., Class H

    2,357,600       3,683,596  
   

 

 

 
      46,950,284  
Electronic Equipment, Instruments & Components — 2.5%  

Hexagon AB, B Shares

    368,900       5,465,760  

Rogers Corp.(a)(b)

    21,246       4,266,197  

Samsung SDI Co. Ltd.

    4,650       2,878,990  
   

 

 

 
      12,610,947  
Independent Power and Renewable Electricity Producers — 7.3%  

AES Corp.(a)

    360,590       9,400,581  

China Longyuan Power Group Corp. Ltd., Class H

    5,366,000       9,238,699  

EDP Renovaveis SA

    507,942       11,768,791  

Scatec ASA(d)

    109,450       2,900,810  

Sunnova Energy International, Inc.(a)(b)

    87,450       3,293,367  
   

 

 

 
      36,602,248  
Security   Shares     Value  
Machinery — 2.7%            

Atlas Copco AB, B Shares

    261,000     $ 13,745,936  
   

 

 

 
Multi-Utilities — 12.9%            

CMS Energy Corp.(a)

    162,960       9,627,677  

Dominion Energy, Inc.(a)(c)

    168,148       12,370,648  

National Grid PLC

    919,024       11,689,682  

Public Service Enterprise Group, Inc.(a)

    193,392       11,553,238  

RWE AG

    401,350       14,551,819  

Sempra Energy(a)

    42,350       5,610,528  
   

 

 

 
      65,403,592  
Oil, Gas & Consumable Fuels — 8.6%            

Enterprise Products Partners LP(a)

    220,813       5,328,218  

Kinder Morgan, Inc.(a)

    714,050       13,017,132  

TC Energy Corp.

    246,250       12,185,362  

Williams Cos., Inc.(a)

    480,755       12,764,045  
   

 

 

 
      43,294,757  
Semiconductors & Semiconductor Equipment — 4.3%  

Canadian Solar, Inc.(b)

    63,290       2,837,924  

First Solar, Inc.(a)(b)

    33,284       3,012,535  

Infineon Technologies AG

    129,750       5,218,968  

Maxim Integrated Products, Inc.(a)

    51,640       5,440,790  

ON Semiconductor Corp.(a)(b)

    130,180       4,983,290  
   

 

 

 
      21,493,507  
   

 

 

 

Total Long-Term Investments — 98.7%
(Cost: $324,593,340)

      498,777,258  
   

 

 

 

Short-Term Securities

   
Money Market Funds — 1.6%            

BlackRock Liquidity Funds, T-Fund, Institutional Class, 0.01%(e)(f)

    7,971,532       7,971,532  
   

 

 

 

Total Short-Term Securities — 1.6%
(Cost: $7,971,532)

 

    7,971,532  
   

 

 

 

Total Investments Before Options Written — 100.3%
(Cost: $332,564,872)

 

    506,748,790  
   

 

 

 

Options Written — (0.6)%
(Premiums Received: $(3,762,877))

      (2,784,872 ) 
   

 

 

 

Total Investments, Net of Options Written — 99.7%
(Cost: $328,801,995)

 

    503,963,918  
Other Assets Less Liabilities — 0.3%         1,334,612  
   

 

 

 
Net Assets — 100.0%         $ 505,298,530  
   

 

 

 

 

(a) 

All or a portion of the security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written.

(b) 

Non-income producing security.

(c) 

All or a portion of the security has been pledged as collateral in connection with outstanding OTC derivatives.

(d) 

Security exempt from registration pursuant to Rule 144A under the Securities Act of 1933, as amended. These securities may be resold in transactions exempt from registration to qualified institutional investors.

(e) 

Affiliate of the Trust.

(f) 

Annualized 7-day yield as of period end.

 

 

For Trust compliance purposes, the Trust’s industry classifications refer to one or more of the industry sub-classifications used by one or more widely recognized market indexes or rating group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.

 

 

132  

2 0 2 1   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S


Schedule of Investments (unaudited) (continued)

June 30, 2021

  

BlackRock Utilities, Infrastructure & Power Opportunities Trust (BUI)

 

Affiliates

Investments in issuers considered to be affiliate(s) of the Trust during the six-months ended June 30, 2021 for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

 

Affiliated
Issuer
   Value at
12/31/20
     Purchases
at Cost
     Proceeds
from Sales
     Net
Realized
Gain (Loss)
     Change in
Unrealized
Appreciation
(Depreciation)
     Value at
06/30/21
     Shares
Held at
06/30/21
     Income      Capital Gain
Distributions
from
Underlying
Funds
 

BlackRock Liquidity Funds, T-Fund, Institutional Class

   $ 8,385,590      $ —      $ (414,058) (a)     $ —      $ —      $ 7,971,532        7,971,532      $ 840      $ —  

SL Liquidity Series, LLC, Money Market Series(b)

     —        —        (17) (a)        17        —        —        —        12,630 (c)       —  
           

 

 

    

 

 

    

 

 

       

 

 

    

 

 

 
            $ 17      $ —      $  7,971,532         $  13,470      $ —  
           

 

 

    

 

 

    

 

 

       

 

 

    

 

 

 

 

  (a) 

Represents net amount purchased (sold).

 
  (b) 

As of period end, the entity is no longer held.

 
  (c) 

All or a portion represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of fees and collateral investment expenses, and other payments to and from borrowers of securities.

 

Derivative Financial Instruments Outstanding as of Period End

Exchange-Traded Options Written

 

Description    Number of
Contracts
     Expiration
Date
     Exercise Price      Notional
Amount (000)
     Value  

Call

                    

Eaton Corporation PLC

     74        07/02/21        USD        147.00        USD        1,097      $ (12,580)  

ON Semiconductor Corp.

     180        07/02/21        USD        41.00        USD        689        (1,800)  

Eaton Corporation PLC

     103        07/09/21        USD        147.00        USD        1,526        (24,978)  

Enterprise Products Partners LP

     442        07/09/21        USD        24.00        USD        1,067        (15,912)  

Johnson Controls International PLC

     390        07/09/21        USD        67.50        USD        2,677        (77,025)  

Kinder Morgan, Inc.

     599        07/09/21        USD        18.50        USD        1,092        (6,889)  

Kinder Morgan, Inc.

     426        07/13/21        USD        18.10        USD        777        (17,140)  

A O Smith Corp.

     269        07/16/21        USD        70.00        USD        1,938        (67,922)  

AES Corp.

     437        07/16/21        USD        26.00        USD        1,139        (26,220)  

American Electric Power Co., Inc.

     407        07/16/21        USD        85.00        USD        3,443        (35,612)  

CMS Energy Corp.

     251        07/16/21        USD        65.00        USD        1,483        (1,255)  

Dominion Energy, Inc.

     270        07/16/21        USD        77.50        USD        1,986        (2,025)  

Duke Energy Corp.

     179        07/16/21        USD        102.05        USD        1,767        (3,491)  

Edison International

     186        07/16/21        USD        60.00        USD        1,075        (1,395)  

Enterprise Products Partners LP

     80        07/16/21        USD        23.75        USD        193        (5,314)  

Exelon Corp.

     293        07/16/21        USD        46.00        USD        1,298        (5,860)  

Exelon Corp.

     235        07/16/21        USD        47.00        USD        1,041        (2,350)  

FirstEnergy Corp.

     648        07/16/21        USD        39.00        USD        2,411        (6,480)  

Kinder Morgan, Inc.

     408        07/16/21        USD        19.00        USD        744        (3,468)  

NextEra Energy, Inc.

     861        07/16/21        USD        75.00        USD        6,309        (45,202)  

Public Service Enterprise Group, Inc.

     233        07/16/21        USD        62.25        USD        1,392        (2,500)  

Quanta Services, Inc.

     168        07/16/21        USD        95.00        USD        1,522        (7,980)  

Rogers Corp.

     37        07/16/21        USD        190.00        USD        743        (44,585)  

Sempra Energy

     79        07/16/21        USD        140.00        USD        1,047        (1,185)  

Sempra Energy

     69        07/16/21        USD        145.00        USD        914        (345)  

Sunnova Energy International, Inc.

     306        07/16/21        USD        35.00        USD        1,152        (113,220)  

Sunrun, Inc.

     207        07/16/21        USD        55.00        USD        1,155        (74,520)  

TC Energy Corp.

     455        07/16/21        CAD        62.00        CAD        2,791        (17,619)  

Trane Technologies PLC

     122        07/16/21        USD        190.00        USD        2,247        (10,980)  

Waste Connections, Inc.

     112        07/16/21        USD        125.01        USD        1,338        (2,555)  

Waste Management, Inc.

     173        07/16/21        USD        145.00        USD        2,424        (5,623)  

Xcel Energy, Inc.

     143        07/16/21        USD        70.00        USD        942        (1,430)  

Enterprise Products Partners LP

     250        07/23/21        USD        25.50        USD        603        (2,125)  

First Solar, Inc.

     35        07/23/21        USD        83.00        USD        317        (29,312)  

Johnson Controls International PLC

     391        07/23/21        USD        67.50        USD        2,683        (85,042)  

Williams Cos., Inc.

     1,267        07/23/21        USD        28.50        USD        3,364        (12,670)  

Kinder Morgan, Inc.

     533        07/30/21        USD        19.00        USD        972        (10,660)  

ON Semiconductor Corp.

     275        07/30/21        USD        39.50        USD        1,053        (26,812)  

Kinder Morgan, Inc.

     533        08/06/21        USD        18.50        USD        972        (23,186)  

Edison International

     454        08/13/21        USD        59.00        USD        2,625        (28,322)  

 

 

S C H E D U L E   O F   I N V E S T M E N T S

  133


Schedule of Investments (unaudited) (continued)

June 30, 2021

  

BlackRock Utilities, Infrastructure & Power Opportunities Trust (BUI)

 

Exchange-Traded Options Written (continued)

 

Description    Number of
Contracts
       Expiration
Date
       Exercise Price        Notional
Amount (000)
       Value  
Call (continued)                                                   

AES Corp.

     825          08/20/21        USD     26.00        USD     2,151        $ (88,687 ) 

CMS Energy Corp.

     319          08/20/21        USD     62.00        USD     1,885          (17,353 ) 

Dominion Energy, Inc.

     318          08/20/21        USD     77.50        USD     2,340          (17,490 ) 

Duke Energy Corp.

     198          08/20/21        USD     105.00        USD     1,955          (9,405 ) 

Exelon Corp.

     244          08/20/21        USD     47.00        USD     1,081          (8,540 ) 

Exelon Corp.

     20          08/20/21        USD     47.25        USD     89          (775 ) 

First Solar, Inc.

     80          08/20/21        USD     85.00        USD     724          (74,000 ) 

Maxim Integrated Products, Inc.

     180          08/20/21        USD     105.00        USD     1,896          (84,600 ) 

NextEra Energy, Inc.

     890          08/20/21        USD     75.00        USD     6,522          (142,400 ) 

Public Service Enterprise Group, Inc.

     443          08/20/21        USD     61.28        USD     2,646          (43,225 ) 

Quanta Services, Inc.

     107          08/20/21        USD     95.00        USD     969          (25,145 ) 

Rogers Corp.

     37          08/20/21        USD     200.00        USD     743          (47,545 ) 

TC Energy Corp.

     406          08/20/21        CAD     64.00        CAD     2,490          (19,652 ) 

Trane Technologies PLC

     145          08/20/21        USD     190.00        USD     2,670          (58,000 ) 

Waste Connections, Inc.

     184          08/20/21        USD     124.95        USD     2,198          (14,592 ) 

Waste Management, Inc.

     182          08/20/21        USD     140.00        USD     2,550          (71,890 ) 

Williams Cos., Inc.

     415          08/20/21        USD     27.00        USD     1,102          (31,125 ) 
                          

 

 

 
                           $  (1,618,013 ) 
                          

 

 

 

OTC Options Written

 

Description    Counterparty    Number of
Contracts
     Expiration
Date
     Exercise Price      Notional
Amount (000)
     Value  

Call

                                                                 

Enel SpA

   Credit Suisse International      437,000        07/07/21        EUR       8.20        EUR       3,425      $ (685)  

Infineon Technologies AG

   Credit Suisse International      28,600        07/07/21        EUR       33.71        EUR       970        (23,124 ) 

Kingspan Group PLC

   UBS AG      39,500        07/07/21        EUR       79.96        EUR       3,148        (43,517 ) 

Vinci SA

   UBS AG      24,800        07/07/21        EUR       95.61        EUR       2,236        (1,135 ) 

EDP Renovaveis SA

   Credit Suisse International      81,900        07/08/21        EUR       19.89        EUR       1,600        (25,612 ) 

Prysmian SpA

   Credit Suisse International      54,800        07/08/21        EUR       29.17        EUR       1,658        (77,152 ) 

Schneider Electric SE

   Morgan Stanley & Co. International PLC      17,100        07/08/21        EUR       131.89        EUR       2,273        (43,963 ) 

Vestas Wind Systems

   Morgan Stanley & Co. International PLC      37,800        07/08/21        DKK       237.68        DKK       9,262        (62,373 ) 

Xcel Energy, Inc.

   Barclays Bank PLC      12,500        07/13/21        USD       71.00        USD       824        (107 ) 

Atlas Copco, Class B

   UBS AG      1,500        07/14/21        SEK       444.16        SEK       676        (2,118 ) 

Hexagon, Class B

   Credit Suisse International      53,200        07/14/21        SEK       124.32        SEK       6,746        (21,379 ) 

Iberdrola SA

   Credit Suisse International      48,600        07/14/21        EUR       10.89        EUR       500        (98 ) 

Linde PLC

   Credit Suisse International      4,800        07/14/21        EUR       249.21        EUR       1,170        (5,325 ) 

Neoenergia SA

   Credit Suisse International      249,100        07/14/21        USD       19.40        USD       4,327        (60 ) 

RWE AG

   Goldman Sachs International      18,100        07/14/21        EUR       31.42        EUR       553        (4,792 ) 

Sika AG, Registered Shares

   UBS AG      3,400        07/14/21        CHF       297.57        CHF       1,031        (27,414 ) 

Atlas Copco, Class B

   Credit Suisse International      32,300        07/15/21        SEK       442.46        SEK       14,558        (50,870 ) 

Enel SpA

   Goldman Sachs International      276,700        07/15/21        EUR       8.10        EUR       2,169        (5,366 ) 

Iberdrola SA

   Credit Suisse International      242,700        07/15/21        EUR       10.77        EUR       2,496        (2,073 ) 

Infineon Technologies AG

   Credit Suisse International      16,800        07/15/21        EUR       33.76        EUR       570        (17,276 ) 

RWE AG

   Goldman Sachs International      40,500        07/15/21        EUR       31.56        EUR       1,238        (9,050 ) 

Samsung Sdi Ltd.

   JPMorgan Chase Bank N.A.      1,500        07/15/21        USD       634,811.95        USD       1,045,863        (85,869 ) 

Vestas Wind Systems

   Morgan Stanley & Co. International PLC      80,000        07/15/21        DKK       247.48        DKK       19,602        (80,464 ) 

Atlas Copco, Class B

   Credit Suisse International      57,500        07/20/21        SEK       438.82        SEK       25,917        (113,211 ) 

EDP Renovaveis SA

   Goldman Sachs International      61,300        07/20/21        EUR       19.84        EUR       1,198        (38,123 ) 

EDP-Energias de Portugal SA

   Goldman Sachs International      260,100        07/20/21        EUR       4.56        EUR       1,163        (19,316 ) 

RWE AG

   Credit Suisse International      81,800        07/20/21        EUR       31.00        EUR       2,501        (42,556 ) 

Schneider Electric SE

   UBS AG      9,500        07/20/21        EUR       133.32        EUR       1,263        (26,703 ) 

Neoenergia SA

   Credit Suisse International      249,100        07/21/21        USD       19.40        USD       4,327        (309 ) 

LG Chem Ltd.

   UBS AG      1,000        07/27/21        USD       843,586.66        USD       850,344        (33,004 ) 

Linde PLC

   Goldman Sachs International      4,700        07/27/21        EUR       247.34        EUR       1,146        (13,466 ) 

Air Liquide SA

   Credit Suisse International      12,400        07/29/21        EUR       147.20        EUR       1,834        (39,857 ) 

EDP Renovaveis SA

   Credit Suisse International      34,500        07/29/21        EUR       19.89        EUR       674        (25,940 ) 

Enel SpA

   Credit Suisse International      258,000        07/29/21        EUR       8.18        EUR       2,022        (917 ) 

National Grid PLC

   Credit Suisse International      186,700        07/29/21        GBP       9.53        GBP       1,717        (9,739 ) 

Sika AG, Registered Shares

   UBS AG      2,600        07/29/21        CHF       303.85        CHF       788        (16,394 ) 

Hexagon, Class B

   JPMorgan Chase Bank N.A.      75,600        08/04/21        SEK       127.99        SEK       9,586        (25,067 ) 

 

 

134  

2 0 2 1   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S


Schedule of Investments (unaudited) (continued)

June 30, 2021

   BlackRock Utilities, Infrastructure & Power Opportunities Trust (BUI)

 

OTC Options Written (continued)

 

Description    Counterparty   Number of
Contracts
    Expiration
Date
    Exercise Price
    Notional
Amount (000)
    Value  

Call (continued)

                

Vinci SA

   Goldman Sachs International     18,100       08/04/21       EUR       95.06       EUR       1,632     $ (15,701 ) 

Xinjiang Goldwind Science And Technology Ltd.

   Citibank N.A.     425,000       08/04/21       HKD       13.36       HKD       5,156       (8,065 ) 

EDP-Energias de Portugal SA

   Goldman Sachs International     208,000       08/05/21       EUR       4.66       EUR       930       (15,901 ) 

National Grid PLC

   Credit Suisse International     135,000       08/11/21       GBP       9.34       GBP       1,241       (27,306 ) 

Xinjiang Goldwind Science And Technology Ltd.

   JPMorgan Chase Bank N.A.     400,000       08/11/21       HKD       13.64       HKD       4,852       (7,780 ) 

Scatec ASA

   Credit Suisse International     38,300       08/12/21       NOK       258.83       NOK       8,740       (27,561 ) 

Iberdrola SA

   Credit Suisse International     242,600       08/18/21       EUR       10.04       EUR       2,495       (70,121 ) 
                

 

 

 
                 $  (1,166,859 ) 
                

 

 

 

Balances Reported in the Statements of Assets and Liabilities for Options Written

 

Description    Swap
Premiums
Paid
     Swap
Premiums
Received
     Unrealized
Appreciation
     Unrealized
Depreciation
     Value  

Options Written

   $ N/A      $ N/A      $ 1,527,419      $ (549,414)      $  (2,784,872)  

Derivative Financial Instruments Categorized by Risk Exposure

As of period end, the fair values of derivative financial instruments located in the Statements of Assets and Liabilities were as follows:

 

     Commodity
Contracts
    Credit
Contracts
    Equity
Contracts
    Foreign
Currency
Exchange
Contracts
    Interest
Rate
Contracts
    Other
Contracts
    Total  

Liabilities — Derivative Financial Instruments

             

Options written

             

Options written at value

  $ —     $ —     $    2,784,872     $ —     $ —     $ —     $    2,784,872  
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

For the six months ended June 30, 2021, the effect of derivative financial instruments in the Statements of Operations was as follows:

 

     Commodity
Contracts
    Credit
Contracts
    Equity
Contracts
    Foreign
Currency
Exchange
Contracts
    Interest
Rate
Contracts
    Other
Contracts
    Total  

Net Realized Gain (Loss) from

             

Options written

  $ —     $ —     $  (6,184,734)     $ —     $ —     $ —     $  (6,184,734)  
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net Change in Unrealized Appreciation (Depreciation) on

             

Options written

  $ —     $ —     $ 2,740,627     $ —     $ —     $ —     $ 2,740,627  
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Average Quarterly Balances of Outstanding Derivative Financial Instruments

 

Options

       

Average value of option contracts written

  $ 4,294,068  

For more information about the Trust’s investment risks regarding derivative financial instruments, refer to the Notes to Financial Statements.

 

 

S C H E D U L E   O F   I N V E S T M E N T S

  135


Schedule of Investments (unaudited) (continued)

June 30, 2021

   BlackRock Utilities, Infrastructure & Power Opportunities Trust (BUI)

 

Derivative Financial Instruments — Offsetting as of Period End

The Trust’s derivative assets and liabilities (by type) were as follows:

 

      Assets        Liabilities  

Derivative Financial Instruments

       

Options

   $ —        $ 2,784,872  
  

 

 

      

 

 

 

Total derivative assets and liabilities in the Statements of Assets and Liabilities

     —          2,784,872  
  

 

 

      

 

 

 

Derivatives not subject to a Master Netting Agreement or similar agreement (“MNA”)

     —          (1,618,013 ) 
  

 

 

      

 

 

 

Total derivative assets and liabilities subject to an MNA

   $         —        $ 1,166,859  
  

 

 

      

 

 

 

The following table presents the Trust’s derivative liabilities by counterparty net of amounts available for offset under an MNA and net of the related collateral pledged by the Trust:

 

Counterparty     


Derivative

Liabilities
Subject to

an MNA by

Counterparty

 

 
 

 

 

      

Derivatives
Available
for Offset
 
 
 
      

Non-Cash
Collateral
Pledged
 
 
(a)  
    

Cash
Collateral
Pledged
 
 
(a)  
    


Net Amount

of Derivative
Liabilities

 

 
(b)  

Barclays Bank PLC

   $ 107        $ —        $ —      $ (107 )     $ —  

Citibank N.A.

     8,065          —          —        —        8,065  

Credit Suisse International

     581,171          —          (182,942 )       —        398,229  

Goldman Sachs International

     121,715          —          —        (121,715 )       —  

JPMorgan Chase Bank N.A.

     118,716          —          (107,910 )       —        10,806  

Morgan Stanley & Co. International PLC

     186,800          —          (186,800 )       —        —  

UBS AG

     150,285          —          —        (33,500 )       116,785  
  

 

 

      

 

 

      

 

 

    

 

 

    

 

 

 
   $ 1,166,859        $ —        $ (477,652 )     $ (155,322 )     $ 533,885  
  

 

 

      

 

 

      

 

 

    

 

 

    

 

 

 

 

  (a) 

Excess of collateral pledged to the individual counterparty is not shown for financial reporting purposes.

 
  (b) 

Net amount represents the net amount payable due to counterparty in the event of default. Net amount may be offset further by the options written receivable/payable on the Statements of Assets and Liabilities.

 

Fair Value Hierarchy as of Period End

Various inputs are used in determining the fair value of financial instruments. For a description of the input levels and information about the Trust’s policy regarding valuation of financial instruments, refer to the Notes to Financial Statements.

The following table summarizes the Trust’s financial instruments categorized in the fair value hierarchy. The breakdown of the Trust’s financial instruments into major categories is disclosed in the Schedule of Investments above.

 

      Level 1        Level 2        Level 3        Total  

Assets

                 

Investments

                 

Long-Term Investments

                 

Common Stocks

                 

Building Products

   $ 34,924,038        $ 10,686,137        $ —        $ 45,610,175  

Chemicals

     —          22,284,762          —          22,284,762  

Commercial Services & Supplies

     24,348,829          —          —          24,348,829  

Construction & Engineering

     7,128,764          13,105,674          —          20,234,438  

Electric Utilities

     101,793,460          44,404,323          —          146,197,783  

Electrical Equipment

     11,265,277          35,685,007          —          46,950,284  

Electronic Equipment, Instruments & Components

     9,731,957          2,878,990          —          12,610,947  

Independent Power and Renewable Electricity Producers

     24,462,739          12,139,509          —          36,602,248  

Machinery

     —          13,745,936          —          13,745,936  

Multi-Utilities

     39,162,091          26,241,501          —          65,403,592  

Oil, Gas & Consumable Fuels

     43,294,757          —          —          43,294,757  

Semiconductors & Semiconductor Equipment

     16,274,539          5,218,968          —          21,493,507  

Short-Term Securities

                 

Money Market Funds

     7,971,532          —          —          7,971,532  
  

 

 

      

 

 

      

 

 

      

 

 

 
   $   320,357,983        $   186,390,807        $               —        $   506,748,790  
  

 

 

      

 

 

      

 

 

      

 

 

 

 

 

136  

2 0 2 1   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S


Schedule of Investments (unaudited) (continued)

June 30, 2021

   BlackRock Utilities, Infrastructure & Power Opportunities Trust (BUI)

 

Fair Value Hierarchy as of Period End (continued)

 

      Level 1        Level 2        Level 3        Total  

Derivative Financial Instruments(a)

                 

Liabilities

                                                                                                  

Equity Contracts

   $ (1,482,746 )       $ (1,302,126 )       $             —        $ (2,784,872 ) 
  

 

 

      

 

 

      

 

 

      

 

 

 

 

  (a) 

Derivative financial instruments are options written. Options written are shown at value.

 

See notes to financial statements.

 

 

S C H E D U L E   O F   I N V E S T M E N T S

  137


 

Statements of Assets and Liabilities (unaudited) 

June 30, 2021

 

     BGR     CII      BDJ      BOE  

ASSETS

         

Investments, at value — unaffiliated(a)

  $ 297,155,117     $  945,129,794      $  1,904,510,771      $  847,450,791  

Investments, at value — affiliated(b)

    2,837,978       12,748,208        48,566,704        5,226,715  

Cash

    —       345,228        214,318        58,596  

Cash pledged:

         

Collateral — exchange-traded options written

    —       —        —        4,880,000  

Collateral — OTC derivatives

    —       420,000        —        657,630  

Foreign currency, at value(c)

    18,448       —        1,988        —  

Receivables:

         

Investments sold

    570,168       —        7,750,461        —  

Options written

    139,914       164,228        901,746        1,205,287  

Dividends — unaffiliated

    750,942       839,951        1,910,792        1,984,137  

Dividends — affiliated

    25       126        302        40  
 

 

 

   

 

 

    

 

 

    

 

 

 

Total assets

    301,472,592       959,647,535        1,963,857,082        861,463,196  
 

 

 

   

 

 

    

 

 

    

 

 

 

LIABILITIES

         

Bank overdraft

    9,230       —        —        —  

Foreign bank overdraft(d)

    —       —        —        536,438  

Options written, at value(e)

    2,803,335       11,763,153        13,785,732        8,541,611  

Payables:

         

Investments purchased

    901,653       —        3,347,641        —  

Income dividend distributions

    57,746       218,327        318,166        147,027  

Investment advisory fees

    241,905       658,681        1,291,384        579,943  

Trustees’ and Officer’s fees

    585,667       286,709        1,246,528        859,373  

Options written

    138,426       324,089        581,097        436,966  

Other accrued expenses

    229,178       238,679        531,700        392,291  
 

 

 

   

 

 

    

 

 

    

 

 

 

Total liabilities

    4,967,140       13,489,638        21,102,248        11,493,649  
 

 

 

   

 

 

    

 

 

    

 

 

 

NET ASSETS

  $ 296,505,452     $ 946,157,897      $ 1,942,754,834      $ 849,969,547  
 

 

 

   

 

 

    

 

 

    

 

 

 

NET ASSETS CONSIST OF

         

Paid-in capital(f)(g)(h)

  $ 547,187,771     $ 561,321,996      $ 1,309,268,867      $ 718,537,151  

Accumumlated earnings (loss)

    (250,682,319 )      384,835,901        633,485,967        131,432,396  
 

 

 

   

 

 

    

 

 

    

 

 

 

NET ASSETS

  $ 296,505,452     $ 946,157,897      $ 1,942,754,834      $ 849,969,547  
 

 

 

   

 

 

    

 

 

    

 

 

 

Net asset value(f)(g)(h)

  $ 10.19     $ 21.44      $ 10.44      $ 13.28  
 

 

 

   

 

 

    

 

 

    

 

 

 

(a)  Investments, at cost — unaffiliated

  $ 243,962,247     $ 563,386,172      $ 1,357,339,710      $ 700,161,001  

(b)  Investments, at cost — affiliated

  $ 2,837,978     $ 12,748,208      $ 48,566,704      $ 5,226,715  

(c)   Foreign currency, at cost

  $ 18,454     $ —      $ 2,059      $ —  

(d)  Foreign bank overdraft, at cost

  $ —     $ —      $ —      $ 528,864  

(e)  Premiums received

  $ 3,240,569     $ 11,084,600      $ 22,612,707      $ 7,350,560  

(f)   Shares outstanding

    29,108,471       44,121,400        186,003,434        64,025,316  

(g)  Shares authorized

    Unlimited       200 million        Unlimited        Unlimited  

(h)  Par value

  $ 0.001     $ 0.10      $ 0.001      $ 0.001  

See notes to financial statements.

 

 

138  

2 0 2 1   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S


 

Statements of Assets and Liabilities (unaudited) (continued)

June 30, 2021

 

    BGY      BME      BMEZ      BIGZ  

 

 

ASSETS

          

Investments, at value — unaffiliated(a)(b)

  $  708,983,095      $  602,306,355      $  3,445,131,676      $  4,654,657,818  

Investments, at value — affiliated(c)

    3,006,927        10,408,858        30,364,463        232,691,826  

Cash

    —        320,426        —        —  

Cash pledged:

          

Collateral — exchange-traded options written

    7,091,000        —        —        —  

Collateral — OTC derivatives

    1,159,450        265,000        1,231,000        1,050,000  

Foreign currency, at value(d)

    —        —        710        848  

Receivables:

          

Investments sold

    —        303,595        2,989,209        289,987  

Options written

    1,438,533        172,915        952,486        6,299,698  

Securities lending income — affiliated

    —        2,279        40,751        61,662  

Capital shares sold

    —        476,478        —        —  

Dividends — unaffiliated

    2,335,255        471,897        1,087,390        529,235  

Dividends — affiliated

    35        122        239        77  

Deferred offering costs

    —        103,141        —        —  
 

 

 

    

 

 

    

 

 

    

 

 

 

Total assets

    724,014,295        614,831,066        3,481,797,924        4,895,581,151  
 

 

 

    

 

 

    

 

 

    

 

 

 

LIABILITIES

          

Bank overdraft

    —        —        1,558,135        868,091  

Foreign bank overdraft(e)

    551,587        9,492        —        —  

Due to broker

    —        265,000        —        —  

Collateral on securities loaned, at value

    —        431,254        6,245,023        796,953  

Options written, at value(f)

    7,406,017        6,019,812        36,875,732        68,185,597  

Payables:

          

Investments purchased

    —        317,511        —        4,350,820  

Deferred foreign capital gain tax

    491,018        —        —        —  

Income dividend distributions

    167,405        —        3,282,593        —  

Investment advisory fees

    535,641        487,998        3,459,487        4,798,750  

Offering costs

    —        29,000        —        —  

Trustees’ and Officer’s fees

    725,784        28,635        84,474        —  

Options written

    711,259        897,314        1,564,569        5,263,715  

Other accrued expenses

    402,802        211,115        698,299        288,714  
 

 

 

    

 

 

    

 

 

    

 

 

 

Total liabilities

    10,991,513        8,697,131        53,768,312        84,552,640  
 

 

 

    

 

 

    

 

 

    

 

 

 

NET ASSETS

  $ 713,022,782      $ 606,133,935      $ 3,428,029,612      $ 4,811,028,511  
 

 

 

    

 

 

    

 

 

    

 

 

 

NET ASSETS CONSIST OF

          

Paid-in capital(g)(h)(i)

  $ 618,323,885      $ 374,116,054      $ 2,253,396,500      $ 4,866,518,001  

Accumumlated earnings (loss)

    94,698,897        232,017,881        1,174,633,112        (55,489,490 ) 
 

 

 

    

 

 

    

 

 

    

 

 

 

NET ASSETS

  $ 713,022,782      $ 606,133,935      $ 3,428,029,612      $ 4,811,028,511  
 

 

 

    

 

 

    

 

 

    

 

 

 

Net asset value(g)(h)(i)

  $ 6.84      $ 47.73      $ 30.43      $ 19.77  
 

 

 

    

 

 

    

 

 

    

 

 

 

(a)  Investments, at cost — unaffiliated

  $ 574,617,585      $ 358,733,085      $ 2,341,081,164      $ 4,602,400,329  

(b)  Securities loaned, at value

  $ —      $ 429,001      $ 3,791,714      $ 771,115  

(c)   Investments, at cost — affiliated

  $ 3,006,927      $ 10,408,858      $ 30,082,599      $ 266,649,848  

(d)  Foreign currency, at cost

  $ —      $ —      $ 715      $ 849  

(e)  Foreign bank overdraft, at cost

  $ 551,831      $ 9,500      $ —      $ —  

(f)   Premiums received

  $ 5,591,310      $ 5,172,885      $ 26,477,309      $ 43,810,527  

(g)  Shares outstanding

    104,237,971        12,700,462        112,669,825        243,328,558  

(h)  Shares authorized

    Unlimited        Unlimited        Unlimited        Unlimited  

(i)   Par value

  $ 0.001      $ 0.001      $ 0.001      $ 0.001  

See notes to financial statements.

 

 

F I N A N C I A L   S T A T E M E N T S

  139


 

Statements of Assets and Liabilities (unaudited) (continued)

June 30, 2021

 

     BCX     BST(a)      BSTZ(a)      BUI  

ASSETS

         

Investments, at value — unaffiliated(b)(c)

  $ 866,969,431     $  1,436,947,277      $  3,383,997,819      $  498,777,258  

Investments, at value — affiliated(d)

    10,298,740       3,872,747        36,399,985        7,971,532  

Cash

    —       —        —        428,359  

Cash pledged as collateral for OTC derivatives

    —       2,650,000        16,510,000        183,100  

Foreign currency, at value(e)

    89,642       1,593        1,772        —  

Receivables:

         

Investments sold

    —       1,911,523        10,820,331        —  

Options written

    293,386       255,227        799,016        130,960  

Securities lending income — affiliated

    —       17,419        99,555        —  

Capital shares sold

    —       —        —        596,530  

Dividends — unaffiliated

    3,029,754       132,578        149,126        1,141,730  

Dividends — affiliated

    607       90        266        63  

Deferred offering costs

    —       205,452        —        53,151  
 

 

 

   

 

 

    

 

 

    

 

 

 

Total assets

    880,681,560       1,445,993,906        3,448,777,870        509,282,683  
 

 

 

   

 

 

    

 

 

    

 

 

 

LIABILITIES

         

Bank overdraft

    2,502       2,558,708        229,186        —  

Foreign bank overdraft(f)

    —       —        —        20,608  

Collateral on securities loaned, at value

    —       3,872,747        4,331,436        —  

Options written, at value(g)

    4,916,658       23,673,717        58,192,357        2,784,872  

Payables:

         

Investments purchased

    358       —        17,851,602        449,794  

Deferred foreign capital gain tax

    —       511,654        2,046,819        —  

Income dividend distributions

    124,512       —        2,412,628        —  

Investment advisory fees

    732,413       1,061,586        3,278,077        403,631  

Offering costs

    —       31,935        —        34,604  

Trustees’ and Officer’s fees

    346,511       2,661        92,245        112  

Options written

    153,786       750,537        3,679,635        24,190  

Other accrued expenses

    424,195       451,404        1,010,931        266,342  
 

 

 

   

 

 

    

 

 

    

 

 

 

Total liabilities

    6,700,935       32,914,949        93,124,916        3,984,153  
 

 

 

   

 

 

    

 

 

    

 

 

 

NET ASSETS

  $ 873,980,625     $ 1,413,078,957      $ 3,355,652,954      $ 505,298,530  
 

 

 

   

 

 

    

 

 

    

 

 

 

NET ASSETS CONSIST OF

         

Paid-in capital(h)(i)(j)

  $ 1,114,975,900     $ 448,052,506      $ 1,506,840,775      $ 356,412,606  

Accumumlated earnings (loss)

    (240,995,275 )      965,026,451        1,848,812,179        148,885,924  
 

 

 

   

 

 

    

 

 

    

 

 

 

NET ASSETS

  $ 873,980,625     $ 1,413,078,957      $ 3,355,652,954      $ 505,298,530  
 

 

 

   

 

 

    

 

 

    

 

 

 

Net asset value(h)(i)(j)

  $ 9.90     $ 55.94      $ 42.97      $ 24.87  
 

 

 

   

 

 

    

 

 

    

 

 

 

(a)  Consolidated Statement of Assets and Liabilities.

         

(b)  Investments, at cost — unaffiliated

  $ 634,948,073     $ 525,414,250      $ 1,574,014,011      $ 324,593,340  

(c)  Securities loaned, at value

  $ —     $ 3,748,552      $ 4,272,638      $ —  

(d)  Investments, at cost — affiliated

  $ 10,298,740     $ 3,872,747      $ 36,399,985      $ 7,971,532  

(e)  Foreign currency, at cost

  $ 89,671     $ 1,641      $ 1,776      $ —  

(f)  Foreign bank overdraft, at cost

  $ —     $ —      $ —      $ 20,770  

(g)  Premiums received

  $ 8,728,329     $ 11,659,670      $ 27,008,924      $ 3,762,877  

(h)  Shares outstanding

    88,315,994       25,260,448        78,089,962        20,319,397  

(i)  Shares authorized

    Unlimited       Unlimited        Unlimited        Unlimited  

(j)  Par value

  $ 0.001     $ 0.001      $ 0.001      $ 0.001  

See notes to financial statements.

 

 

140  

2 0 2 1   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S


 

Statements of Operations (unaudited) 

Six Months Ended June 30, 2021

 

    BGR     CII     BDJ     BOE  

 

 

INVESTMENT INCOME

       

Dividends — unaffiliated

  $ 5,582,366     $ 5,637,085     $ 23,740,360     $ 11,302,634  

Dividends — affiliated

    245       1,133       1,352       604  

Securities lending income — affiliated — net

    —       —       4,054       —  

Foreign taxes withheld

    (455,501 )      (138,611 )      (1,034,408 )      (457,569 ) 
 

 

 

   

 

 

   

 

 

   

 

 

 

Total investment income

    5,127,110       5,499,607       22,711,358       10,845,669  
 

 

 

   

 

 

   

 

 

   

 

 

 

EXPENSES

       

Investment advisory

    1,643,981       3,810,430       7,456,575       4,058,708  

Trustees and Officer

    77,954       59,729       193,916       132,269  

Professional

    41,945       57,357       99,176       70,138  

Transfer agent

    35,513       42,563       82,558       48,944  

Custodian

    27,700       22,312       61,848       51,986  

Accounting services

    20,242       24,000       46,031       28,903  

Rating agency

    5,238       8,351       13,189       7,927  

Registration

    5,121       7,576       45,602       11,224  

Printing and postage

    3,686       14,235       14,296       2,705  

Miscellaneous

    30,505       24,253       40,601       64,329  
 

 

 

   

 

 

   

 

 

   

 

 

 

Total expenses

    1,891,885       4,070,806       8,053,792       4,477,133  

Less:

       

Fees waived and/or reimbursed by the Manager

    (301,978 )      (2,673 )      (2,923 )      (711,645 ) 
 

 

 

   

 

 

   

 

 

   

 

 

 

Total expenses after fees waived and/or reimbursed

    1,589,907       4,068,133       8,050,869       3,765,488  
 

 

 

   

 

 

   

 

 

   

 

 

 

Net investment income

    3,537,203       1,431,474       14,660,489       7,080,181  
 

 

 

   

 

 

   

 

 

   

 

 

 

REALIZED AND UNREALIZED GAIN (LOSS)

       

Net realized gain (loss) from:

       

Investments — unaffiliated

    (10,206,192 )      57,504,744       153,235,236       72,726,717  

Foreign currency transactions

    (33,037 )      —       27,762       (154,206 ) 

Options written

    (7,788,133 )      (15,068,271 )      (62,390,351 )      (7,271,190 ) 

Payment by affiliate

    25,456       —       —       —  
 

 

 

   

 

 

   

 

 

   

 

 

 
    (18,001,906 )      42,436,473       90,872,647       65,301,321  
 

 

 

   

 

 

   

 

 

   

 

 

 

Net change in unrealized appreciation (depreciation) on:

       

Investments — unaffiliated

    79,385,620       81,934,324       135,349,710       16,842,264  

Foreign currency translations

    (5,478 )      —       (25,698 )      (52,024 ) 

Options written

    270,941       (153,841 )      18,576,411       (1,024,212 ) 
 

 

 

   

 

 

   

 

 

   

 

 

 
    79,651,083       81,780,483       153,900,423       15,766,028  
 

 

 

   

 

 

   

 

 

   

 

 

 

Net realized and unrealized gain

    61,649,177       124,216,956       244,773,070       81,067,349  
 

 

 

   

 

 

   

 

 

   

 

 

 

NET INCREASE IN NET ASSETS RESULTING FROM OPERATIONS

  $ 65,186,380     $  125,648,430     $  259,433,559     $  88,147,530  
 

 

 

   

 

 

   

 

 

   

 

 

 

See notes to financial statements.

 

 

F I N A N C I A L   S T A T E M E N T S

  141


 

Statements of Operations (unaudited) (continued)

Six Months Ended June 30, 2021

 

    BGY     BME     BMEZ     BIGZ(a)  

 

 

INVESTMENT INCOME

       

Dividends — unaffiliated

  $ 10,633,835     $ 3,333,183     $ 4,017,385     $ 815,867  

Dividends — affiliated

    604       1,036       4,302       42,766  

Securities lending income — affiliated — net

    —       6,520       116,400       61,662  

Foreign taxes withheld

    (761,945 )      (78,907 )      (373,532 )      —  
 

 

 

   

 

 

   

 

 

   

 

 

 

Total investment income

    9,872,494       3,261,832       3,764,555       920,295  
 

 

 

   

 

 

   

 

 

   

 

 

 

EXPENSES

       

Investment advisory

    3,458,474       2,820,129       20,934,637       14,497,955  

Trustees and Officer

    111,554       20,126       103,533       22,382  

Professional

    64,880       45,560       143,488       68,317  

Custodian

    54,868       51,204       101,068       76,439  

Transfer agent

    45,216       30,585       66,235       43,315  

Accounting services

    24,000       14,178       132,162       88,925  

Registration

    18,130       5,801       —       —  

Rating agency

    7,327       6,688       20,617       —  

Printing and postage

    3,486       3,861       12,137       2,548  

Offering

    —       61,531       —       —  

Miscellaneous

    93,365       30,518       72,734       38,519  
 

 

 

   

 

 

   

 

 

   

 

 

 

Total expenses

    3,881,300       3,090,181       21,586,611       14,838,400  

Less:

       

Fees waived and/or reimbursed by the Manager

    (347,235 )      (2,530 )      (9,915 )      (362,022 ) 
 

 

 

   

 

 

   

 

 

   

 

 

 

Total expenses after fees waived and/or reimbursed

    3,534,065       3,087,651       21,576,696       14,476,378  
 

 

 

   

 

 

   

 

 

   

 

 

 

Net investment income (loss)

    6,338,429       174,181       (17,812,141 )      (13,556,083 ) 
 

 

 

   

 

 

   

 

 

   

 

 

 

REALIZED AND UNREALIZED GAIN (LOSS)

       

Net realized gain (loss) from:

       

Investments — unaffiliated

    53,327,905 (b)      16,414,021       192,710,231       (50,188,072 ) 

Investments — affiliated

    —       (9 )      139       11,883,538  

Foreign currency transactions

    (181,058 )      4,961       (20,983 )      29,389  

Options written

    (7,980,801 )      (3,095,078 )      (11,593,593 )      26,727,084  
 

 

 

   

 

 

   

 

 

   

 

 

 
    45,166,046       13,323,895       181,095,794       (11,548,061 ) 
 

 

 

   

 

 

   

 

 

   

 

 

 

Net change in unrealized appreciation (depreciation) on:

       

Investments — unaffiliated

    6,918,558 (c)       26,019,338       (115,145,685 )        52,257,489  

Investments — affiliated

    —       —       (169,620 )      (33,958,022 ) 

Foreign currency translations

    (79,464 )      (1,415 )      (11,531 )      (1 ) 

Options written

    (1,130,084 )      465,819       5,317,215       (24,375,070 ) 
 

 

 

   

 

 

   

 

 

   

 

 

 
    5,709,010       26,483,742       (110,009,621 )      (6,075,604 ) 
 

 

 

   

 

 

   

 

 

   

 

 

 

Net realized and unrealized gain (loss)

    50,875,056       39,807,637       71,086,173       (17,623,665 ) 
 

 

 

   

 

 

   

 

 

   

 

 

 

NET INCREASE (DECREASE) IN NET ASSETS RESULTING FROM OPERATIONS

  $  57,213,485     $  39,981,818     $ 53,274,032     $ (31,179,748 ) 
 

 

 

   

 

 

   

 

 

   

 

 

 

(a) The Trust commenced operations on March 29, 2021.

 

     

(b) Net of foreign capital gain tax of

  $ 125,053     $ —     $ —     $ —  

(c) Net of increase in deferred foreign capital gain tax of

  $ (111,595 )    $ —     $ —     $ —  

See notes to financial statements.

 

 

142  

2 0 2 1   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S


 

Statements of Operations (unaudited) (continued)

Six Months Ended June 30, 2021

 

    BCX     BST(a)     BSTZ(a)     BUI  

 

 

INVESTMENT INCOME

       

Dividends — unaffiliated

  $ 16,765,282     $ 1,252,121     $ 1,155,154     $ 4,833,520  

Dividends — affiliated

    825       1,770       4,758       840  

Securities lending income — affiliated — net

    —       41,953       180,510       12,630  

Non-cash dividends — unaffiliated

    —       —       —       282,863  

Foreign taxes withheld

    (905,737 )      (48,230 )      (138,472 )      (446,622 ) 
 

 

 

   

 

 

   

 

 

   

 

 

 

Total investment income

    15,860,370       1,247,614       1,201,950       4,683,231  
 

 

 

   

 

 

   

 

 

   

 

 

 

EXPENSES

       

Investment advisory

    4,151,964       6,639,306       19,406,135       2,372,762  

Trustees and Officer

    69,379       40,582       100,788       13,685  

Professional

    68,278       100,834       190,938       41,441  

Custodian

    51,053       78,201       152,777       39,307  

Transfer agent

    49,097       47,448       59,780       28,466  

Accounting services

    28,826       24,000       109,941       24,000  

Rating agency

    21,611       10,507       19,541       19,832  

Registration

    15,597       4,782       15,086       4,938  

Printing and postage

    2,904       4,022       5,477       3,205  

Offering

    —       29,000       —       29,000  

Miscellaneous

    55,384       116,078       269,385       42,925  
 

 

 

   

 

 

   

 

 

   

 

 

 

Total expenses

    4,514,093       7,094,760       20,329,848       2,619,561  

Less:

       

Fees waived and/or reimbursed by the Manager

    (1,871 )      (335,543 )      (10,015 )      (61,255 ) 
 

 

 

   

 

 

   

 

 

   

 

 

 

Total expenses after fees waived and/or reimbursed

    4,512,222       6,759,217       20,319,833       2,558,306  
 

 

 

   

 

 

   

 

 

   

 

 

 

Net investment income (loss)

    11,348,148       (5,511,603 )      (19,117,883 )      2,124,925  
 

 

 

   

 

 

   

 

 

   

 

 

 

REALIZED AND UNREALIZED GAIN (LOSS)

       

Net realized gain (loss) from:

       

Investments — unaffiliated

    53,030,904       125,846,427       250,799,212       9,890,029  

Investments — affiliated

    —       —       643       17  

Foreign currency transactions

    (55,262 )      (42,068 )      (238,387 )      13,341  

Options written

    (26,931,614 )      (1,568,383 )      (18,711,994 )      (6,184,734 ) 
 

 

 

   

 

 

   

 

 

   

 

 

 
    26,044,028       124,235,976       231,849,474       3,718,653  
 

 

 

   

 

 

   

 

 

   

 

 

 

Net change in unrealized appreciation (depreciation) on:

       

Investments — unaffiliated

    100,547,306       18,177,770 (b)       195,205,311 (b)      24,826,566  

Foreign currency translations

    (14,431 )      (1,166 )      (1,418 )      (27,373 ) 

Options written

    10,636,050       (4,020,080 )      (4,652,312 )      2,740,627  
 

 

 

   

 

 

   

 

 

   

 

 

 
    111,168,925       14,156,524       190,551,581       27,539,820  
 

 

 

   

 

 

   

 

 

   

 

 

 

Net realized and unrealized gain

    137,212,953       138,392,500       422,401,055       31,258,473  
 

 

 

   

 

 

   

 

 

   

 

 

 

NET INCREASE IN NET ASSETS RESULTING FROM OPERATIONS

  $  148,561,101     $  132,880,897     $  403,283,172     $  33,383,398  
 

 

 

   

 

 

   

 

 

   

 

 

 

(a) Consolidated Statement of Operations.

(b) Net of increase in deferred foreign capital gain tax of

       
  $ —     $ (511,654 )    $ (2,046,819 )    $ —  

See notes to financial statements.

 

 

F I N A N C I A L   S T A T E M E N T S

  143


 

Statements of Changes in Net Assets

 

    BGR     CII  
    Six Months Ended
06/30/21
(unaudited)
    Year Ended
12/31/20
    Six Months Ended
06/30/21
(unaudited)
    Year Ended
12/31/20
 

 

 

INCREASE (DECREASE) IN NET ASSETS

       

OPERATIONS

       

Net investment income

  $ 3,537,203     $ 9,391,948     $ 1,431,474     $ 5,811,399  

Net realized gain (loss)

    (18,001,906 )      (88,982,831 )      42,436,473       26,868,142  

Net change in unrealized appreciation (depreciation)

    79,651,083       (33,080,100 )      81,780,483       64,682,735  
 

 

 

   

 

 

   

 

 

   

 

 

 

Net increase (decrease) in net assets resulting from operations

    65,186,380       (112,670,983 )      125,648,430       97,362,276  
 

 

 

   

 

 

   

 

 

   

 

 

 

DISTRIBUTIONS TO SHAREHOLDERS(a)

       

From net investment income

    (6,549,406 )(b)       (9,329,536 )      (23,163,735 )      (46,327,470 ) 

Return of capital

    —       (10,213,545 )      —       —  
 

 

 

   

 

 

   

 

 

   

 

 

 

Decrease in net assets resulting from distributions to shareholders

    (6,549,406 )      (19,543,081 )      (23,163,735 )      (46,327,470 ) 
 

 

 

   

 

 

   

 

 

   

 

 

 

CAPITAL SHARE TRANSACTIONS

       

Redemption of shares resulting from share repurchase program (including transaction costs)

    —       (4,813,281 )      —       —  
 

 

 

   

 

 

   

 

 

   

 

 

 

NET ASSETS

       

Total increase (decrease) in net assets

    58,636,974       (137,027,345 )      102,484,695       51,034,806  

Beginning of period

    237,868,478       374,895,823       843,673,202       792,638,396  
 

 

 

   

 

 

   

 

 

   

 

 

 

End of period

  $  296,505,452     $ 237,868,478     $  946,157,897     $  843,673,202  
 

 

 

   

 

 

   

 

 

   

 

 

 

 

(a) 

Distributions for annual periods determined in accordance with U.S. federal income tax regulations.

(b)

A portion of the distributions from net investment income may be deemed a return of capital or net realized gain at fiscal year-end.

See notes to financial statements.

 

 

144  

2 0 2 1   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S


 

Statements of Changes in Net Assets (continued)

 

    BDJ     BOE  
    Six Months Ended
06/30/21
(unaudited)
    Year Ended
12/31/20
    Six Months Ended
06/30/21
(unaudited)
    Year Ended
12/31/20
 

 

 

INCREASE (DECREASE) IN NET ASSETS

       

OPERATIONS

       

Net investment income

  $ 14,660,489     $ 34,483,661     $ 7,080,181     $ 16,919,404  

Net realized gain (loss)

    90,872,647       25,963,990       65,301,321       (20,345,581 ) 

Net change in unrealized appreciation (depreciation)

    153,900,423       (79,304,070 )      15,766,028       45,992,227  
 

 

 

   

 

 

   

 

 

   

 

 

 

Net increase (decrease) in net assets resulting from operations

    259,433,559       (18,856,419 )      88,147,530       42,566,050  
 

 

 

   

 

 

   

 

 

   

 

 

 

DISTRIBUTIONS TO SHAREHOLDERS(a)

       

From net investment income and net realized gain

    (55,801,030 )      (112,342,324 )      (24,202,739 )      (16,818,451 ) 

Return of capital

    —       —       —       (32,343,267 ) 
 

 

 

   

 

 

   

 

 

   

 

 

 

Decrease in net assets resulting from distributions to shareholders

    (55,801,030 )      (112,342,324 )      (24,202,739 )      (49,161,718 ) 
 

 

 

   

 

 

   

 

 

   

 

 

 

CAPITAL SHARE TRANSACTIONS

       

Redemption of shares resulting from share repurchase program (including transaction costs)

    —       (11,354,242 )      (205,246 )      (14,886,112 ) 
 

 

 

   

 

 

   

 

 

   

 

 

 

NET ASSETS

       

Total increase (decrease) in net assets

    203,632,529       (142,552,985 )      63,739,545       (21,481,780 ) 

Beginning of period

    1,739,122,305       1,881,675,290       786,230,002       807,711,782  
 

 

 

   

 

 

   

 

 

   

 

 

 

End of period

  $  1,942,754,834     $  1,739,122,305     $  849,969,547     $  786,230,002  
 

 

 

   

 

 

   

 

 

   

 

 

 

 

(a) 

Distributions for annual periods determined in accordance with U.S. federal income tax regulations.

See notes to financial statements.

 

 

F I N A N C I A L   S T A T E M E N T S

  145


 

Statements of Changes in Net Assets (continued)

 

    BGY     BME  
    Six Months Ended
06/30/21
(unaudited)
    Year Ended
12/31/20
    Six Months Ended
06/30/21
(unaudited)
    Year Ended
12/31/20
 

 

 

INCREASE (DECREASE) IN NET ASSETS

       

OPERATIONS

       

Net investment income

  $ 6,338,429     $ 12,589,207     $ 174,181     $ 68,856  

Net realized gain (loss)

    45,166,046       (25,760,822 )      13,323,895       21,389,585  

Net change in unrealized appreciation (depreciation)

    5,709,010       56,961,229       26,483,742       58,101,987  
 

 

 

   

 

 

   

 

 

   

 

 

 

Net increase in net assets resulting from operations

    57,213,485       43,789,614       39,981,818       79,560,428  
 

 

 

   

 

 

   

 

 

   

 

 

 

DISTRIBUTIONS TO SHAREHOLDERS(a)

       

From net investment income

    (21,139,460 )      (12,744,924 )      (14,792,005 )      (27,390,801 ) 

Return of capital

    —       (29,856,975 )      —       —  
 

 

 

   

 

 

   

 

 

   

 

 

 

Decrease in net assets resulting from distributions to shareholders

    (21,139,460 )      (42,601,899 )      (14,792,005 )      (27,390,801 ) 
 

 

 

   

 

 

   

 

 

   

 

 

 

CAPITAL SHARE TRANSACTIONS

       

Net proceeds from the issuance of shares

    —       —       34,062,716       45,251,850  

Reinvestment of distributions

    —       —       944,907       1,742,431  

Redemption of shares resulting from share repurchase program (including transaction costs)

    —       (7,486,085 )      —       —  
 

 

 

   

 

 

   

 

 

   

 

 

 

Net increase (decrease) in net assets derived from capital share transactions

    —       (7,486,085 )      35,007,623       46,994,281  
 

 

 

   

 

 

   

 

 

   

 

 

 

NET ASSETS

       

Total increase (decrease) in net assets

    36,074,025       (6,298,370 )      60,197,436       99,163,908  

Beginning of period

    676,948,757       683,247,127       545,936,499       446,772,591  
 

 

 

   

 

 

   

 

 

   

 

 

 

End of period

  $  713,022,782     $  676,948,757     $  606,133,935     $  545,936,499  
 

 

 

   

 

 

   

 

 

   

 

 

 

 

(a) 

Distributions for annual periods determined in accordance with U.S. federal income tax regulations.

See notes to financial statements.

 

 

146  

2 0 2 1   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S


 

Statements of Changes in Net Assets (continued)

 

    BMEZ     BIGZ  
   

Six Months Ended
06/30/21

(unaudited)

 
 

 

   

Period from

01/30/20

to 12/31/20

 

(a) 

 

   

Period from

03/29/21

to 06/30/21

(unaudited)

 

(a) 

 

 

 

 

INCREASE (DECREASE) IN NET ASSETS

     

OPERATIONS

     

Net investment loss

  $ (17,812,141 )    $ (24,489,080 )    $ (13,556,083 ) 

Net realized gain (loss)

    181,095,794       131,179,423       (11,548,061 ) 

Net change in unrealized appreciation (depreciation)

    (110,009,621 )      1,203,954,044       (6,075,604 ) 
 

 

 

   

 

 

   

 

 

 

Net increase (decrease) in net assets resulting from operations

    53,274,032       1,310,644,387       (31,179,748 ) 
 

 

 

   

 

 

   

 

 

 

DISTRIBUTIONS TO SHAREHOLDERS(b)

     

Decrease in net assets resulting from distributions to shareholders

    (87,882,464 )      (101,402,843 )      (24,309,742 )(c)  
 

 

 

   

 

 

   

 

 

 

CAPITAL SHARE TRANSACTIONS

     

Net proceeds from the issuance of shares

    —       2,253,296,500       4,861,848,440  

Reinvestment of distributions

    —       —       4,569,561  
 

 

 

   

 

 

   

 

 

 

Net increase in net assets derived from capital share transactions

    —       2,253,296,500       4,866,418,001  
 

 

 

   

 

 

   

 

 

 

NET ASSETS

     

Total increase (decrease) in net assets

    (34,608,432 )      3,462,538,044       4,810,928,511  

Beginning of period

    3,462,638,044       100,000       100,000  
 

 

 

   

 

 

   

 

 

 

End of period

  $ 3,428,029,612     $  3,462,638,044     $  4,811,028,511  
 

 

 

   

 

 

   

 

 

 

 

(a) 

Commencement of operations.

(b) 

Distributions for annual periods determined in accordance with U.S. federal income tax regulations.

(c) 

A portion of the distributions from net investment income may be deemed a return of capital or net realized gain at fiscal year-end.

See notes to financial statements.

 

 

 

F I N A N C I A L   S T A T E M E N T S

  147


 

Statements of Changes in Net Assets (continued)

 

    BCX     BST  
   

Six Months Ended

06/30/21

(unaudited)

 

 

 

   

Year Ended

12/31/20

 

 

   

Six Months Ended

06/30/21

(unaudited)

(a) 

 

 

   

Year Ended

12/31/20

(a) 

 

 

 

INCREASE (DECREASE) IN NET ASSETS

       

OPERATIONS

       

Net investment income (loss)

  $ 11,348,148     $ 17,695,239     $ (5,511,603 )    $ (6,690,031 ) 

Net realized gain (loss)

    26,044,028       (51,657,513 )      124,235,976       11,596,671  

Net change in unrealized appreciation (depreciation)

    111,168,925       22,570,394       14,156,524       516,296,551  
 

 

 

   

 

 

   

 

 

   

 

 

 

Net increase (decrease) in net assets resulting from operations

    148,561,101       (11,391,880 )      132,880,897       521,203,191  
 

 

 

   

 

 

   

 

 

   

 

 

 

DISTRIBUTIONS TO SHAREHOLDERS(b)

       

From net investment income

    (21,195,839 )(c)      (20,310,556 )      (32,178,242 )      (49,046,315 ) 

Return of capital

    —       (27,173,604 )      —       —  
 

 

 

   

 

 

   

 

 

   

 

 

 

Decrease in net assets resulting from distributions to shareholders

    (21,195,839 )      (47,484,160 )      (32,178,242 )      (49,046,315 ) 
 

 

 

   

 

 

   

 

 

   

 

 

 

CAPITAL SHARE TRANSACTIONS

       

Net proceeds from the issuance of shares

    —       —       12,814,651       80,490,747  

Reinvestment of distributions

    —       —       2,217,548       2,024,962  

Redemption of shares resulting from share repurchase program (including transaction costs)

    —       (17,262,335 )      —       —  
 

 

 

   

 

 

   

 

 

   

 

 

 

Net increase (decrease) in net assets derived from capital share transactions

    —       (17,262,335 )      15,032,199       82,515,709  
 

 

 

   

 

 

   

 

 

   

 

 

 

NET ASSETS

       

Total increase (decrease) in net assets

    127,365,262       (76,138,375 )      115,734,854       554,672,585  

Beginning of period

    746,615,363       822,753,738       1,297,344,103       742,671,518  
 

 

 

   

 

 

   

 

 

   

 

 

 

End of period

  $ 873,980,625     $ 746,615,363     $ 1,413,078,957     $ 1,297,344,103  
 

 

 

   

 

 

   

 

 

   

 

 

 

 

(a) 

Consolidated Statement of Changes in Net Assets.

(b) 

Distributions for annual periods determined in accordance with U.S. federal income tax regulations.

(c) 

A portion of the distributions from net investment income may be deemed a return of capital or net realized gain at fiscal year-end.

See notes to financial statements.

 

 

148  

2 0 2 1   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S


 

Statements of Changes in Net Assets (continued)

 

    BSTZ            BUI  
   

Six Months Ended
06/30/21

(unaudited)

 
 

(a)  

   
Year Ended
12/31/20
 
(a)  
      

Six Months Ended
06/30/21
(unaudited)
 
 
 
   
Year Ended
12/31/20
 
 

 

 

INCREASE (DECREASE) IN NET ASSETS

          

OPERATIONS

          

Net investment income (loss)

  $ (19,117,883 )    $ (23,552,855 )       $ 2,124,925     $ 5,932,846  

Net realized gain

    231,849,474       68,051,628          3,718,653       5,076,772  

Net change in unrealized appreciation (depreciation)

    190,551,581       1,440,501,253          27,539,820       47,279,667  
 

 

 

   

 

 

      

 

 

   

 

 

 

Net increase in net assets resulting from operations

    403,283,172       1,485,000,026          33,383,398       58,289,285  
 

 

 

   

 

 

      

 

 

   

 

 

 

DISTRIBUTIONS TO SHAREHOLDERS(b)

          

From net investment income and net realized gain

    (71,374,226 )      (85,373,164 )         (14,152,749 )(c)      (22,859,592 ) 

Return of capital

    —       (11,848,839 )         —       (3,077,573 ) 
 

 

 

   

 

 

      

 

 

   

 

 

 

Decrease in net assets resulting from distributions to shareholders

    (71,374,226 )      (97,222,003 )         (14,152,749 )      (25,937,165 ) 
 

 

 

   

 

 

      

 

 

   

 

 

 

CAPITAL SHARE TRANSACTIONS

          

Net proceeds from the issuance of shares

    —       —          40,762,313       27,563,701  

Reinvestment of distributions

    —       —          779,595       1,273,042  
 

 

 

   

 

 

      

 

 

   

 

 

 

Net increase in net assets derived from capital share transactions

    —       —          41,541,908       28,836,743  
 

 

 

   

 

 

      

 

 

   

 

 

 

NET ASSETS

          

Total increase in net assets

    331,908,946       1,387,778,023          60,772,557       61,188,863  

Beginning of period

    3,023,744,008       1,635,965,985          444,525,973       383,337,110  
 

 

 

   

 

 

      

 

 

   

 

 

 

End of period

  $ 3,355,652,954     $  3,023,744,008        $ 505,298,530     $  444,525,973  
 

 

 

   

 

 

      

 

 

   

 

 

 

 

(a) 

Consolidated Statement of Changes in Net Assets.

(b) 

Distributions for annual periods determined in accordance with U.S. federal income tax regulations.

(c) 

A portion of the distributions from net investment income may be deemed a return of capital or net realized gain at fiscal year-end.

See notes to financial statements.

 

 

F I N A N C I A L   S T A T E M E N T S

  149


 

Statements of Cash Flows (unaudited)

Six Months Ended June 30, 2021

 

     BGR     CII     BDJ     BOE  

CASH PROVIDED BY (USED FOR) OPERATING ACTIVITIES

       

Net increase in net assets resulting from operations

  $ 65,186,380     $ 125,648,430     $ 259,433,559     $ 88,147,530  

Adjustments to reconcile net increase in net assets resulting from operations to net cash provided by operating activities

       

Proceeds from sales of long-term investments and principal paydowns/payups

    102,832,590       173,710,800       532,883,354       408,519,026  

Purchases of long-term investments

    (92,600,261 )      (134,023,742 )      (390,209,680 )      (375,968,739 ) 

Net proceeds from sales (purchases) of short-term securities

    580,508       (1,134,204 )      (36,550,067 )      (5,226,715 ) 

Premiums paid on closing options written

    (20,665,804 )      (66,015,594 )      (173,031,373 )      (40,795,382 ) 

Premiums received from options written

    12,998,783       49,901,172       105,949,292       31,982,845  

Net realized (gain) loss on investments and options written

    18,502,819       (42,432,039 )      (89,404,982 )      (65,151,399 ) 

Net unrealized appreciation on investments, options written and foreign currency translations

    (79,656,561 )      (81,780,483 )      (153,926,121 )      (15,818,053 ) 

(Increase) Decrease in Assets

       

Receivables

       

Dividends — affiliated

    84       208       (85 )      164  

Dividends — unaffiliated

    (492,030 )      (138,647 )      488,601       398,576  

Prepaid expenses

    7,014       2,923       82,666       —  

Increase (Decrease) in Liabilities

       

Payables

       

Investment advisory fees

    39,773       59,388       127,555       35,462  

Trustees’ and Officer’s fees

    46,327       32,910       118,078       81,908  

Other accrued expenses

    54,971       68,657       148,949       85,062  
 

 

 

   

 

 

   

 

 

   

 

 

 

Net cash provided by operating activities

    6,834,593       23,899,779       56,109,746       26,290,285  
 

 

 

   

 

 

   

 

 

   

 

 

 

CASH PROVIDED BY (USED FOR) FINANCING ACTIVITIES

       

Cash dividends paid to shareholders

    (6,554,032 )      (23,164,551 )      (55,828,845 )      (24,205,149 ) 

Net payments on redemption of capital shares

    (330,212 )      —       —       (559,569 ) 

Increase (decrease) in bank overdraft

    9,230       —       (66,281 )      (836,148 ) 
 

 

 

   

 

 

   

 

 

   

 

 

 

Net cash used for financing activities

    (6,875,014 )      (23,164,551 )      (55,895,126 )      (25,600,866 ) 
 

 

 

   

 

 

   

 

 

   

 

 

 

CASH IMPACT FROM FOREIGN EXCHANGE FLUCTUATIONS

       

Cash impact from foreign exchange fluctuations

    (57 )      —       (51 )      1,037  
 

 

 

   

 

 

   

 

 

   

 

 

 

CASH AND FOREIGN CURRENCY

       

Net increase (decrease) in restricted and unrestricted cash and foreign currency

    (40,478 )      735,228       214,569       690,456  

Restricted and unrestricted cash and foreign currency at beginning of period

    58,926       30,000       1,737       4,905,770  
 

 

 

   

 

 

   

 

 

   

 

 

 

Restricted and unrestricted cash and foreign currency at end of period

  $ 18,448     $ 765,228     $ 216,306     $ 5,596,226  
 

 

 

   

 

 

   

 

 

   

 

 

 

RECONCILIATION OF RESTRICTED AND UNRESTRICTED CASH AND FOREIGN CURRENCY AT THE END OF PERIOD TO THE STATEMENTS OF ASSETS AND LIABILITIES

       

Cash

  $ —     $ 345,228     $ 214,318     $ 58,596  

Cash pledged

       

Collateral — exchange-traded options written

    —       —       —       4,880,000  

Collateral — OTC derivatives

    —       420,000       —       657,630  

Foreign currency at value

    18,448       —       1,988       —  
 

 

 

   

 

 

   

 

 

   

 

 

 
  $ 18,448     $ 765,228     $ 216,306     $ 5,596,226  
 

 

 

   

 

 

   

 

 

   

 

 

 

See notes to financial statements.

 

 

150  

2 0 2 1   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S


 

Statements of Cash Flows (unaudited) (continued)

Six Months Ended June 30, 2021

 

     BGY     BME     BMEZ     BIGZ  

CASH PROVIDED BY (USED FOR) OPERATING ACTIVITIES

       

Net increase (decrease) in net assets resulting from operations

  $ 57,213,485     $ 39,981,818     $ 53,274,032     $ (31,179,748 ) 

Adjustments to reconcile net increase in net assets resulting from operations to net cash provided by (used for) operating activities

       

Proceeds from sales of long-term investments

    333,235,642       86,517,761       643,279,600       749,920,809  

Purchases of long-term investments

    (313,608,383 )      (107,294,444 )      (539,648,581 )      (5,654,692,384 ) 

Net proceeds from sales (purchases) of short-term securities

    (2,719,546 )      3,468,470       21,680,569       (6,878,413 ) 

Premiums paid on closing options written

    (32,853,531 )      (27,676,110 )      (128,960,399 )      (14,519,339 ) 

Premiums received from options written

    23,391,659       24,068,454       110,646,107       92,377,076  

Net realized (gain) loss on investments and options written

    (45,460,362 )      (13,314,281 )      (181,135,487 )      11,577,449  

Net unrealized (appreciation) depreciation on investments, options written and foreign currency translations

    (1,438,080 )      (26,485,157 )      109,998,089       6,075,606  

(Increase) Decrease in Assets

       

Receivables

       

Dividends — affiliated

    260       261       173       (77 ) 

Dividends — unaffiliated

    28,720       (25,826 )      (493,703 )      (529,235 ) 

Securities lending income — affiliated

    —       (2,034 )      9,187       (61,662 ) 

Prepaid expenses

    —       4,777       20,218       —  

Deferred offering costs

    —       23,665       —       —  

Increase (Decrease) in Liabilities

       

Due to broker

    —       265,000       —       —  

Collateral on securities loaned at value

    —       328,553       (3,332,797 )      796,953  

Payables

       

Deferred capital gain tax

    111,595       —       —       —  

Investment advisory fees

    25,696       38,950       (105,715 )      4,798,750  

Trustees’ and Officer’s fees

    65,155       3,174       37,027       —  

Other accrued expenses

    109,025       74,865       247,905       288,714  
 

 

 

   

 

 

   

 

 

   

 

 

 

Net cash provided by (used for) operating activities

    18,101,335       (20,022,104 )      85,516,225       (4,842,025,501 ) 
 

 

 

   

 

 

   

 

 

   

 

 

 

CASH PROVIDED BY (USED FOR) FINANCING ACTIVITIES

       

Cash dividends paid to shareholders

    (21,140,512 )      (13,847,098 )      (86,901,163 )      (19,740,181 ) 

Payments for offering costs

    —       29,000       —       —  

Increase in bank overdraft

    551,587       9,492       1,352,680       868,091  

Proceeds from issuance of capital shares

    —       34,204,432       —       4,861,948,440  
 

 

 

   

 

 

   

 

 

   

 

 

 

Net cash provided by (used for) for financing activities

    (20,588,925 )      20,395,826       (85,548,483 )      4,843,076,350  
 

 

 

   

 

 

   

 

 

   

 

 

 

CASH IMPACT FROM FOREIGN EXCHANGE FLUCTUATIONS

       

Cash impact from foreign exchange fluctuations

    2,791       8       (37 )      (1 ) 
 

 

 

   

 

 

   

 

 

   

 

 

 

CASH AND FOREIGN CURRENCY

       

Net increase (decrease) in restricted and unrestricted cash and foreign currency

    (2,484,799 )      373,730       (32,295 )      1,050,848  

Restricted and unrestricted cash and foreign currency at beginning of period

    10,735,249       211,696       1,264,005       —  
 

 

 

   

 

 

   

 

 

   

 

 

 

Restricted and unrestricted cash and foreign currency at end of period

  $ 8,250,450     $ 585,426     $ 1,231,710     $ 1,050,848  
 

 

 

   

 

 

   

 

 

   

 

 

 

NON-CASH FINANCING ACTIVITIES

       

Capital shares issued in reinvestment of distributions paid to shareholders

  $ —     $ 944,907     $ —     $ 4,569,561  
 

 

 

   

 

 

   

 

 

   

 

 

 

RECONCILIATION OF RESTRICTED AND UNRESTRICTED CASH AT THE END OF PERIOD TO THE STATEMENTS OF ASSETS AND LIABILITIES

       

Cash

  $ —     $ 320,426     $ —     $ —  

Cash pledged

       

Collateral — exchange-traded options written

    7,091,000       —       —       —  

Collateral — OTC derivatives

    1,159,450       265,000       1,231,000       1,050,000  

Foreign currency at value

    —       —       710       848  
 

 

 

   

 

 

   

 

 

   

 

 

 
  $ 8,250,450     $ 585,426     $ 1,231,710     $ 1,050,848  
 

 

 

   

 

 

   

 

 

   

 

 

 

See notes to financial statements.

 

 

F I N A N C I A L   S T A T E M E N T S

  151


 

Statements of Cash Flows (unaudited) (continued)

Six Months Ended June 30, 2021

 

     BCX     BST     BSTZ     BUI  

CASH PROVIDED BY (USED FOR) OPERATING ACTIVITIES

       

Net increase in net assets resulting from operations

  $ 148,561,101     $ 132,880,897     $ 403,283,172     $ 33,383,398  

Adjustments to reconcile net increase in net assets resulting from operations to net cash provided by (used for) operating activities

       

Proceeds from sales of long-term investments and principal paydowns/payups

    320,489,328       208,593,855       536,835,198       34,558,586  

Purchases of long-term investments

    (272,152,701 )      (197,379,596 )      (419,530,261 )      (60,848,300 ) 

Net proceeds from sales (purchases) of short-term securities

    (10,009,076 )      5,393,990       (14,710,577 )      414,076  

Amortization of premium and accretion of discount on investments and other fees

    —       1,319       (3,495 )      —  

Premiums paid on closing options written

    (67,396,240 )      (64,100,305 )      (145,748,058 )      (21,768,655 ) 

Premiums received from options written

    40,030,213       59,672,597       124,964,368       15,373,179  

Net realized gain on investments and options written

    (24,809,308 )      (124,274,075 )      (232,087,861 )      (3,275,243 ) 

Net unrealized appreciation on investments, options written and foreign currency translations

    (111,183,356 )      (14,669,344 )      (192,599,818 )      (27,567,193 ) 

(Increase) Decrease in Assets

       

Receivables

       

Dividends — affiliated

    (488 )      283       642       205  

Dividends — unaffiliated

    (2,177,915 )      25,222       187,005       (192,019 ) 

Securities lending income — affiliated

    —       (17,419 )      (84,935 )      —  

Prepaid expenses

    —       9,533       2,482       7,830  

Deferred offering costs

    —       5,469       —       44,568  

Increase (Decrease) in Liabilities

       

Collateral on securities loaned at value

    —       3,872,747       4,331,436       —  

Payables

       

Deferred capital gain tax

    —       511,654       2,046,819       —  

Investment advisory fees

    102,856       109,921       204,197       46,694  

Trustees’ and Officer’s fees

    28,223       1,929       38,216       (607 ) 

Other accrued expenses

    122,906       140,152       439,403       58,253  

Reorganization costs

    —       —       —       1,768,301  
 

 

 

   

 

 

   

 

 

   

 

 

 

Net cash provided by (used for) operating activities

    21,605,543       10,778,829       67,567,933       (27,996,927 ) 
 

 

 

   

 

 

   

 

 

   

 

 

 

CASH PROVIDED BY (USED FOR) FINANCING ACTIVITIES

       

Cash dividends paid to shareholders

    (21,199,392 )      (29,960,694 )      (70,721,121 )      (13,373,154 ) 

Payments for offering costs

    —       29,000       —       29,000  

Net payments on redemption of capital shares

    (542,457 )      —       —       —  

Increase in bank overdraft

    2,502       2,558,708       229,186       20,608  

Proceeds from issuance of capital shares

    —       14,638,394       —       40,903,113  
 

 

 

   

 

 

   

 

 

   

 

 

 

Net cash provided by (used for) for financing activities

    (21,739,347 )      (12,734,592 )      (70,491,935 )      27,579,567  
 

 

 

   

 

 

   

 

 

   

 

 

 

CASH IMPACT FROM FOREIGN EXCHANGE FLUCTUATIONS

       

Cash impact from foreign exchange fluctuations

    (106 )      (51 )      (83 )      162  
 

 

 

   

 

 

   

 

 

   

 

 

 

CASH AND FOREIGN CURRENCY

       

Net decrease in restricted and unrestricted cash and foreign currency

    (133,910 )      (1,955,814 )      (2,924,085 )      (417,198 ) 

Restricted and unrestricted cash and foreign currency at beginning of period

    223,552       4,607,407       19,435,857       1,028,657  
 

 

 

   

 

 

   

 

 

   

 

 

 

Restricted and unrestricted cash and foreign currency at end of period

  $ 89,642     $ 2,651,593     $ 16,511,772     $ 611,459  
 

 

 

   

 

 

   

 

 

   

 

 

 

NON-CASH FINANCING ACTIVITIES

       

Capital shares issued in reinvestment of distributions paid to shareholders

  $ —     $ 2,217,548     $ —     $ 779,595  
 

 

 

   

 

 

   

 

 

   

 

 

 

RECONCILIATION OF RESTRICTED AND UNRESTRICTED CASH AND FOREIGN CURRENCY AT THE END OF PERIOD TO THE STATEMENTS OF ASSETS AND LIABILITIES

       

Cash

  $ —     $ —     $ —     $ 428,359  

Cash pledged

       

Collateral — OTC derivatives

    —       2,650,000       16,510,000       183,100  

Foreign currency at value

    89,642       1,593       1,772       —  
 

 

 

   

 

 

   

 

 

   

 

 

 
  $ 89,642     $ 2,651,593     $ 16,511,772     $ 611,459  
 

 

 

   

 

 

   

 

 

   

 

 

 

See notes to financial statements.

 

 

152  

2 0 2 1   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S


 

Financial Highlights

(For a share outstanding throughout each period)

 

    BGR  
    Six Months Ended
06/30/21
(unaudited)
    Year Ended December 31,  
     2020     2019     2018     2017     2016  
             

Net asset value, beginning of period

  $ 8.17     $ 12.57     $ 11.98     $ 15.79     $ 16.33     $ 14.05  
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net investment income(a)

    0.12       0.32       0.34       0.28       0.40 (b)       0.27  

Net realized and unrealized gain (loss)

    2.13       (4.06 )      1.18       (3.16 )      (0.01 )      3.01  
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net increase (decrease) from investment operations

    2.25       (3.74 )      1.52       (2.88 )      0.39       3.28  
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Distributions(c)

           

From net investment income

    (0.23 )(d)       (0.32 )      (0.34 )      (0.27 )      (0.40 )      (0.27 ) 

Return of capital

    —       (0.34 )      (0.59 )      (0.66 )      (0.53 )      (0.73 ) 
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total distributions

    (0.23 )      (0.66 )      (0.93 )      (0.93 )      (0.93 )      (1.00 ) 
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net asset value, end of period

  $ 10.19     $ 8.17     $ 12.57     $ 11.98     $ 15.79     $ 16.33  
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Market price, end of period

  $ 9.81     $ 7.10     $ 11.88     $ 10.45     $ 14.18     $ 14.44  
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total Return(e)

           

Based on net asset value

    27.87 %(f)(g)      (29.03 )%      13.74 %      (18.84 )%      3.49 %      25.07 % 
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Based on market price

    41.66 %(g)      (34.74 )%      23.23 %      (21.16 )%      5.11 %      24.01 % 
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Ratios to Average Net Assets

           

Total expenses

    1.38 %(h)       1.37 %(i)       1.35 %      1.29 %      1.31 %      1.31 % 
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total expenses after fees waived and/or reimbursed

    1.16 %(h)       1.15 %(i)       1.16 %      1.14 %      1.18 %      1.24 % 
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net investment income

    2.58 %(h)       3.77 %(i)       2.67 %      1.87 %      2.69 %(b)       1.80 % 
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Supplemental Data

           

Net assets, end of period (000)

  $ 296,505     $ 237,868     $ 374,896     $ 357,391     $ 471,062     $ 487,064  
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Portfolio turnover rate

    34 %      62 %      24 %      32 %      24 %      33 % 
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

 

(a) 

Based on average shares outstanding.

(b) 

Net investment income per share and the ratio of net investment income to average net assets include $0.15 per share and 0.99%, respectively, resulting from a special dividend from BakerHughes, Inc. in July 2017.

(c) 

Distributions for annual periods determined in accordance with U.S. federal income tax regulations.

(d) 

A portion of the distributions from net investment income may be deemed a return of capital or net realized gain at fiscal year-end.

(e) 

Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where applicable, excludes the effects of any sales charges and assumes the reinvestment of distributions at actual reinvestment prices.

(f) 

Includes payment from an affiliate, which had no impact on the Trust’s total return.

(g) 

Aggregate total return.

(h) 

Annualized.

(i) 

Excludes expenses incurred indirectly as a result of investments in underlying funds of 0.01%.

See notes to financial statements.

 

 

F I N A N C I A L   H I G H L I G H T S

  153


 

Financial Highlights (continued)

(For a share outstanding throughout each period)

 

    CII  
    Six Months Ended
06/30/21
(unaudited)
   

Year Ended December 31,

 
     2020     2019     2018     2017     2016  
             

Net asset value, beginning of period

  $ 19.12     $ 17.96     $ 15.28     $ 17.19     $ 15.08     $ 15.11  
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net investment income(a)

    0.03       0.13       0.18       0.17       0.15       0.13  

Net realized and unrealized gain (loss)

    2.82       2.08       3.50       (1.09 )      2.95       0.99  
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net increase (decrease) from investment operations

    2.85       2.21       3.68       (0.92 )      3.10       1.12  
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Distributions(b)

           

From net investment income

    (0.53 )      (0.13 )      (0.19 )      (0.17 )(c)       (0.15 )      (0.13 ) 

From net realized gain

    —       (0.92 )      (0.44 )      (0.28 )(c)       —       (0.04 ) 

Return of capital

    —       —       (0.37 )      (0.54 )      (0.84 )      (0.98 ) 
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total distributions

    (0.53 )      (1.05 )      (1.00 )      (0.99 )      (0.99 )      (1.15 ) 
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net asset value, end of period

  $ 21.44     $ 19.12     $ 17.96     $ 15.28     $ 17.19     $ 15.08  
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Market price, end of period

  $ 20.59     $ 17.40     $ 17.25     $ 14.08     $ 16.38     $ 13.71  
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total Return(d)

           

Based on net asset value

    15.17 %(e)      13.94 %      25.08 %      (5.44 )%      21.69 %      8.66 % 
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Based on market price

    21.54 %(e)      7.97 %      30.38 %      (8.56 )%      27.54 %      5.56 % 
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Ratios to Average Net Assets

           

Total expenses

    0.91 %(f)       0.91 %      0.91 %      0.90 %      0.93 %      0.95 % 
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total expenses after fees waived and/or reimbursed

    0.91 %(f)       0.91 %      0.91 %      0.90 %      0.93 %      0.95 % 
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net investment income

    0.32 %(f)       0.78 %      1.08 %      1.00 %      0.94 %      0.89 % 
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Supplemental Data

           

Net assets, end of period (000)

  $ 946,158     $ 843,673     $ 792,638     $ 674,077     $ 758,400     $ 665,159  
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Portfolio turnover rate

    15 %      46 %      32 %      27 %      32 %      54 % 
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

 

(a)

Based on average shares outstanding.

(b)

Distributions for annual periods determined in accordance with U.S. federal income tax regulations.

(c)

Amount previously presented incorrectly as solely distributions from net investment income has been revised to reflect the proper classification of distributions between net realized gain and net investment income.

(d)

Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where applicable, excludes the effects of any sales charges and assumes the reinvestment of distributions at actual reinvestment prices.

(e)

Aggregate total return.

(f) 

Annualized.

See notes to financial statements.

 

 

 

154  

2 0 2 1   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S


 

Financial Highlights (continued)

(For a share outstanding throughout each period)

 

    BDJ  
   

Six Months Ended

06/30/21

(unaudited)

          Year Ended December 31,  
          2020     2019      2018     2017      2016  
               

Net asset value, beginning of period

  $ 9.35       $ 10.03     $ 8.74      $ 9.96     $ 9.22      $ 8.70  
 

 

 

     

 

 

   

 

 

    

 

 

   

 

 

    

 

 

 

Net investment income(a)

    0.08         0.18       0.18        0.18 (b)       0.16        0.17  

Net realized and unrealized gain (loss)

    1.31         (0.26 )      1.86        (0.84 )      1.14        0.91  
 

 

 

     

 

 

   

 

 

    

 

 

   

 

 

    

 

 

 

Net increase (decrease) from investment operations

    1.39         (0.08 )      2.04        (0.66 )      1.30        1.08  
 

 

 

     

 

 

   

 

 

    

 

 

   

 

 

    

 

 

 

Distributions(c)

               

From net investment income

    (0.30 )        (0.15 )      (0.08 )       (0.18 )(d)       (0.17 )       (0.17 ) 

From net realized gain

    —         (0.45 )      (0.67 )       (0.38 )(d)       (0.39 )       —  

Return of capital

    —         —       —        —       —        (0.39 ) 
 

 

 

     

 

 

   

 

 

    

 

 

   

 

 

    

 

 

 

Total distributions

    (0.30 )        (0.60 )      (0.75 )       (0.56 )      (0.56 )       (0.56 ) 
 

 

 

     

 

 

   

 

 

    

 

 

   

 

 

    

 

 

 

Net asset value, end of period

  $ 10.44       $ 9.35     $ 10.03      $ 8.74     $ 9.96      $ 9.22  
 

 

 

     

 

 

   

 

 

    

 

 

   

 

 

    

 

 

 

Market price, end of period

  $ 10.13       $ 8.47     $ 9.92      $ 7.77     $ 9.23      $ 8.15  
 

 

 

     

 

 

   

 

 

    

 

 

   

 

 

    

 

 

 

Total Return(e)

               

Based on net asset value

    15.22 %(f)         0.77 %      24.52 %       (6.59 )%      15.06 %       13.90 % 
 

 

 

     

 

 

   

 

 

    

 

 

   

 

 

    

 

 

 

Based on market price

    23.41 %(f)         (7.70 )%      38.53 %       (10.39 )%      20.63 %       15.11 % 
 

 

 

     

 

 

   

 

 

    

 

 

   

 

 

    

 

 

 

Ratios to Average Net Assets

               

Total expenses

    0.86 %(g)         0.86 %      0.87 %       0.85 %      0.86 %       0.87 % 
 

 

 

     

 

 

   

 

 

    

 

 

   

 

 

    

 

 

 

Total expenses after fees waived and/or reimbursed

    0.86 %(g)         0.86 %      0.87 %       0.85 %      0.86 %       0.85 % 
 

 

 

     

 

 

   

 

 

    

 

 

   

 

 

    

 

 

 

Net investment income

    1.57 %(g)         2.15 %      1.99 %       1.85 %(b)       1.73 %       1.91 % 
 

 

 

     

 

 

   

 

 

    

 

 

   

 

 

    

 

 

 

Supplemental Data

               

Net assets, end of period (000)

  $ 1,942,755       $ 1,739,122     $ 1,881,675      $ 1,638,237     $ 1,868,457      $ 1,741,649  
 

 

 

     

 

 

   

 

 

    

 

 

   

 

 

    

 

 

 

Portfolio turnover rate

    21 %        48 %      40 %       34 %      42 %       33 % 
 

 

 

     

 

 

   

 

 

    

 

 

   

 

 

    

 

 

 

 

(a) 

Based on average shares outstanding.

(b) 

Net investment income per share and the ratio of net investment income to average net assets includes $0.01 per share and 0.14%, respectively, resulting from a special dividend.

(c) 

Distributions for annual periods determined in accordance with U.S. federal income tax regulations.

(d) 

Amount previously presented incorrectly as solely distributions from net investment income has been revised to reflect the proper classification of distributions between net realized gain and net investment income.

(e) 

Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where applicable, excludes the effects of any sales charges and assumes the reinvestment of distributions at actual reinvestment prices.

(f) 

Aggregate total return.

(g) 

Annualized.

See notes to financial statements.

 

 

 

F I N A N C I A L   H I G H L I G H T S

  155


 

Financial Highlights (continued)

(For a share outstanding throughout each period)

 

    BOE  
   

Six Months Ended
06/30/21

(unaudited)

          Year Ended December 31,  
          2020      2019      2018     2017     2016  
               

Net asset value, beginning of period

  $ 12.28       $ 12.32      $ 11.07      $ 13.22     $ 13.38     $ 14.25  
 

 

 

     

 

 

    

 

 

    

 

 

   

 

 

   

 

 

 

Net investment income(a)

    0.11         0.26        0.30        0.31       0.17       0.15  

Net realized and unrealized gain (loss)

    1.27         0.46        1.71        (1.61 )      1.96       0.03  
 

 

 

     

 

 

    

 

 

    

 

 

   

 

 

   

 

 

 

Net increase (decrease) from investment operations

    1.38         0.72        2.01        (1.30 )      2.13       0.18  
 

 

 

     

 

 

    

 

 

    

 

 

   

 

 

   

 

 

 

Distributions(b)

               

From net investment income

    (0.38 )        (0.26 )       (0.31 )       (0.31 )(c)       (0.19 )      (0.10 ) 

From net realized gain

    —         —        —        (0.52 )(c)       (2.10 )      —  

Return of capital

    —         (0.50 )       (0.45 )       (0.02 )      —       (0.95 ) 
 

 

 

     

 

 

    

 

 

    

 

 

   

 

 

   

 

 

 

Total distributions

    (0.38 )        (0.76 )       (0.76 )       (0.85 )      (2.29 )      (1.05 ) 
 

 

 

     

 

 

    

 

 

    

 

 

   

 

 

   

 

 

 

Net asset value, end of period

  $ 13.28       $ 12.28      $ 12.32      $ 11.07     $ 13.22     $ 13.38  
 

 

 

     

 

 

    

 

 

    

 

 

   

 

 

   

 

 

 

Market price, end of period

  $ 12.55       $ 10.91      $ 10.99      $ 9.37     $ 12.51     $ 11.57  
 

 

 

     

 

 

    

 

 

    

 

 

   

 

 

   

 

 

 

Total Return(d)

               

Based on net asset value

    11.67 %(e)        7.65 %       19.54 %       (9.63 )%      17.22 %(f)      2.62 % 
 

 

 

     

 

 

    

 

 

    

 

 

   

 

 

   

 

 

 

Based on market price

    18.78 %(e)        7.22 %       25.98 %       (19.16 )%      28.28 %      (0.90 )% 
 

 

 

     

 

 

    

 

 

    

 

 

   

 

 

   

 

 

 

Ratios to Average Net Assets(g)

               

Total expenses

    1.10 %(h)         1.09 %       1.12 %       1.08 %      1.09 %      1.10 % 
 

 

 

     

 

 

    

 

 

    

 

 

   

 

 

   

 

 

 

Total expenses after fees waived and/or reimbursed

    0.93 %(h)         0.92 %       0.94 %       0.94 %      1.02 %      1.05 % 
 

 

 

     

 

 

    

 

 

    

 

 

   

 

 

   

 

 

 

Net investment income

    1.74 %(h)         2.33 %       2.62 %       2.52 %      1.20 %      1.15 % 
 

 

 

     

 

 

    

 

 

    

 

 

   

 

 

   

 

 

 

Supplemental Data

               

Net assets, end of period (000)

  $ 849,970       $ 786,230      $ 807,712      $ 754,602     $ 911,227     $ 929,897  
 

 

 

     

 

 

    

 

 

    

 

 

   

 

 

   

 

 

 

Portfolio turnover rate

    46 %        61 %       26 %       28 %      133 %      64 % 
 

 

 

     

 

 

    

 

 

    

 

 

   

 

 

   

 

 

 

 

(a) 

Based on average shares outstanding.

(b) 

Distributions for annual periods determined in accordance with U.S. federal income tax regulations.

(c) 

Amount previously presented incorrectly as solely distributions from net investment income has been revised to reflect the proper classification of distributions between net realized gain and net investment income.

(d) 

Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where applicable, excludes the effects of any sales charges and assumes the reinvestment of distributions at actual reinvestment prices.

(e) 

Aggregate total return.

(f) 

Includes payment from an affiliate, which had no impact on the Trust’s total return.

(g) 

Excludes expenses incurred indirectly as a result of investments in underlying funds as follows:

 

   

Six Months Ended
06/30/21

(unaudited)

          Year Ended December 31,  
          2020      2019      2018      2017      2016  

Investments in underlying funds

    — %              — %       — %       — %       0.01 %       — % 
 

 

 

     

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

 

(h) 

Annualized.

See notes to financial statements.

 

 

156  

2 0 2 1   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S


 

Financial Highlights (continued)

(For a share outstanding throughout each period)

 

    BGY  
   

Six Months Ended

06/30/21

(unaudited)

         Year Ended December 31,  
         2020     2019     2018     2017     2016  
               

Net asset value, beginning of period

  $ 6.49        $ 6.47     $ 5.79     $ 7.06     $ 6.28     $ 6.95  
 

 

 

      

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net investment income(a)

    0.06          0.12       0.16       0.17 (b)       0.09       0.09  

Net realized and unrealized gain (loss)

    0.49          0.31       0.93       (1.00 )      1.15       (0.24 ) 
 

 

 

      

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net increase (decrease) from investment operations

    0.55          0.43       1.09       (0.83 )      1.24       (0.15 ) 
 

 

 

      

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Distributions(c)

              

From net investment income

    (0.20 )         (0.13 )      (0.16 )      (0.16 )(d)       (0.09 )      (0.07 ) 

From net realized gain

    —          —       (0.19 )      (0.28 )(d)       —       —  

Return of capital

    —          (0.28 )      (0.06 )      —       (0.37 )      (0.45 ) 
 

 

 

      

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total distributions

    (0.20 )         (0.41 )      (0.41 )      (0.44 )      (0.46 )      (0.52 ) 
 

 

 

      

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net asset value, end of period

  $ 6.84        $ 6.49     $ 6.47     $ 5.79     $ 7.06     $ 6.28  
 

 

 

      

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Market price, end of period

  $ 6.55        $ 5.87     $ 5.89     $ 4.98     $ 6.52     $ 5.51  
 

 

 

      

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total Return(e)

              

Based on net asset value

    8.87 %(f)          8.18 %      20.20 %      (11.48 )%      20.88 %(g)      (1.12 )% 
 

 

 

      

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Based on market price

    15.26 %(f)         7.49 %      27.22 %      (17.55 )%      27.23 %      (3.37 )% 
 

 

 

      

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Ratios to Average Net Assets(h)

              

Total expenses

    1.12 %(i)          1.10 %      1.13 %      1.09 %      1.12 %      1.12 % 
 

 

 

      

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total expenses after fees waived and/or reimbursed

    1.02 %(i)          1.00 %      1.03 %      0.99 %      1.02 %      1.02 % 
 

 

 

      

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net investment income

    1.83 %(i)          1.99 %      2.57 %      2.59 %(b)       1.31 %      1.41 % 
 

 

 

      

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Supplemental Data

              

Net assets, end of period (000)

  $ 713,023        $ 676,949     $ 683,247     $ 623,234     $ 769,678     $ 690,628  
 

 

 

      

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Portfolio turnover rate

    46 %         60 %      28 %      60 %      90 %      74 % 
 

 

 

      

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

 

(a) 

Based on average shares outstanding.

(b) 

Net investment income per share and the ratio of net investment income to average net assets includes $0.10 per share and 29%, respectively, resulting from a non-recurring dividend.

(c) 

Distributions for annual periods determined in accordance with U.S. federal income tax regulations.

(d) 

Amount previously presented incorrectly as solely distributions from net investment income has been revised to reflect the proper classification of distributions between net realized gain and net investment income.

(e) 

Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where applicable, excludes the effects of any sales charges and assumes the reinvestment of distributions at actual reinvestment prices.

(f) 

Aggregate total return.

(g) 

Includes payment from an affiliate, which had no impact on the Trust’s total return.

(h) 

Excludes expenses incurred indirectly as a result of investments in underlying funds as follows:

 

     

Six Months Ended

06/30/21

(unaudited)

       

 

     Year Ended December 31,  
     2020      2019      2018      2017      2016  

Investments in underlying funds

     — %                      — %             — %             — %           0.02 %           0.01 % 
  

 

 

       

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

 

(i) 

Annualized.

See notes to financial statements.

 

 

F I N A N C I A L   H I G H L I G H T S

  157


 

Financial Highlights (continued)

(For a share outstanding throughout each period)

 

    BME  
   

Six Months Ended
06/30/21

(unaudited)

          Year Ended December 31,  
            2020      2019      2018      2017      2016  

Net asset value, beginning of period

  $ 45.66       $ 41.19      $ 35.87      $ 35.69      $ 31.30      $ 36.19  
 

 

 

     

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Net investment income(a)

    0.01         0.01        0.06        0.07        0.02        0.02  

Net realized and unrealized gain (loss)

    3.26         6.86        7.66        2.51        6.77        (1.91 ) 
 

 

 

     

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Net increase (decrease) from investment operations

    3.27         6.87        7.72        2.58        6.79        (1.89 ) 
 

 

 

     

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Distributions(b)

                 

From net investment income

    (1.20 )        (0.05 )       (0.12 )       (0.07 )(c)        (0.04 )       (0.03 ) 

From net realized gain

    —         (2.35 )       (2.28 )       (2.33 )(c)        (2.11 )       (2.97 ) 

Return of capital

    —         —        —        —        (0.25 )       —  
 

 

 

     

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total distributions

    (1.20 )        (2.40 )       (2.40 )       (2.40 )       (2.40 )       (3.00 ) 
 

 

 

     

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Net asset value, end of period

  $ 47.73       $ 45.66      $ 41.19      $ 35.87      $ 35.69      $ 31.30  
 

 

 

     

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Market price, end of period

  $ 48.50       $ 47.59      $ 42.50      $ 36.45      $ 36.50      $ 31.75  
 

 

 

     

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total Return(d)

                 

Based on net asset value

    7.29 %(e)         17.50 %       22.26 %       7.26 %       22.17 %       (5.36 )% 
 

 

 

     

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Based on market price

    4.60 %(e)         18.69 %       24.15 %       6.57 %       23.17 %       (11.71 )% 
 

 

 

     

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Ratios to Average Net Assets(f)

                 

Total expenses

    1.10 %(g)         1.10 %       1.09 %       1.11 %       1.12 %       1.15 %(h)  
 

 

 

     

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total expenses after fees waived and/or reimbursed

    1.09 %(g)         1.10 %       1.09 %       1.11 %       1.12 %       1.14 % 
 

 

 

     

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Net investment income

    0.06 %(g)         0.01 %       0.16 %       0.19 %       0.06 %       0.07 % 
 

 

 

     

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Supplemental Data

                 

Net assets, end of period (000)

  $ 606,134       $ 545,936      $ 446,773      $ 352,675      $ 331,858      $ 270,693  
 

 

 

     

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Portfolio turnover rate

    15 %        28 %       47 %       37 %       38 %       59 % 
 

 

 

     

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

 

(a) 

Based on average shares outstanding.

(b) 

Distributions for annual periods determined in accordance with U.S. federal income tax regulations.

(c) 

Amount previously presented incorrectly as solely distributions from net investment income has been revised to reflect the proper classification of distributions between net realized gain and net investment income.

(d) 

Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where applicable, excludes the effects of any sales charges and assumes the reinvestment of distributions at actual reinvestment prices.

(e) 

Aggregate total return.

(f) 

Excludes expenses incurred indirectly as a result of investments in underlying funds as follows:

 

    

Six Months Ended
06/30/21

(unaudited)

           Year Ended December 31,  
    2020      2019      2018      2017      2016  

Investments in underlying funds

    — %                    — %           0.01 %           0.01 %           0.01 %             — % 
 

 

 

     

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

 

(g) 

Annualized.

(h) 

Offering costs were not annualized in the calculation of the expense ratios. If these expenses were annualized, the total expenses would have been 1.16%.

See notes to financial statements.

 

 

158  

2 0 2 1   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S


 

Financial Highlights (continued)

(For a share outstanding throughout each period)

 

    BMEZ  
     

Six Months Ended

06/30/21

(unaudited

 

 

) 

   

Period from

01/30/20

to 12/31/20

 

(a) 

 

Net asset value, beginning of period

  $ 30.73     $ 20.00  
 

 

 

   

 

 

 

Net investment loss(b)

    (0.16 )      (0.22 ) 

Net realized and unrealized gain

    0.64       11.85  
 

 

 

   

 

 

 

Net increase from investment operations

    0.48       11.63  
 

 

 

   

 

 

 

Distributions(c)

   

From net investment income

    (0.78 )      —  

From net realized gain

    —       (0.90 ) 
 

 

 

   

 

 

 

Total distributions

    (0.78 )      (0.90 ) 
 

 

 

   

 

 

 

Net asset value, end of period

  $ 30.43     $ 30.73  
 

 

 

   

 

 

 

Market price, end of period

  $ 28.92     $ 28.65  
 

 

 

   

 

 

 

Total Return(d)(e)

   

Based on net asset value

    1.79 %      59.62 %(f)  
 

 

 

   

 

 

 

Based on market price

    3.78 %      48.82 % 
 

 

 

   

 

 

 

Ratios to Average Net Assets(g)

   

Total expenses

    1.29 %      1.29 %(h)  
 

 

 

   

 

 

 

Total expenses after fees waived and/or reimbursed

    1.29 %      1.28 %(h)  
 

 

 

   

 

 

 

Net investment loss

    (1.06 )%      (1.00 )%(h)  
 

 

 

   

 

 

 

Supplemental Data

   

Net assets, end of period (000)

  $ 3,428,030     $ 3,462,638  
 

 

 

   

 

 

 

Portfolio turnover rate

    16 %      43 % 
 

 

 

   

 

 

 

 

(a) 

Commencement of operations.

(b) 

Based on average shares outstanding.

(c) 

Distributions for annual periods determined in accordance with U.S. federal income tax regulations.

(d) 

Aggregate total return.

(e)

Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where applicable, excludes the effects of any sales charges and assumes the reinvestment of distributions at actual reinvestment prices.

(f)

Includes payment from an affiliate, which had no impact on the Trust’s total return.

(g) 

Annualized.

(h)

Excludes expenses incurred indirectly as a result of investments in underlying funds of 0.02%.

See notes to financial statements.

 

 

F I N A N C I A L   H I G H L I G H T S

  159


 

Financial Highlights (continued)

(For a share outstanding throughout each period)

 

    BIGZ  
     


Period from

03/29/21

to 06/30/21
(unaudited)

 

(a) 

 
 

Net asset value, beginning of period

  $ 20.00  
 

 

 

 

Net investment loss(b)

    (0.06 ) 

Net realized and unrealized loss

    (0.07 ) 
 

 

 

 

Net decrease from investment operations

    (0.13 ) 
 

 

 

 

Distributions from net investment income(c)

    (0.10 )(d)  
 

 

 

 

Net asset value, end of period

  $ 19.77  
 

 

 

 

Market price, end of period

  $ 20.31  
 

 

 

 

Total Return(e)

 

Based on net asset value

    (0.65 )%(f)  
 

 

 

 

Based on market price

    2.06 %(f)  
 

 

 

 

Ratios to Average Net Assets

 

Total expenses

    1.28 %(g)(h)  
 

 

 

 

Total expenses after fees waived and/or reimbursed

    1.25 %(g)(h)  
 

 

 

 

Net investment loss

    (1.17 )%(g)(h)  
 

 

 

 

Supplemental Data

 

Net assets, end of period (000)

  $ 4,811,029  
 

 

 

 

Portfolio turnover rate

    21 % 
 

 

 

 

 

(a)

Commencement of operations.

(b) 

Based on average shares outstanding.

(c) 

Distributions for annual periods determined in accordance with U.S. federal income tax regulations.

(d) 

A portion of the distributions from net investment income may be deemed a return of capital or net realized gain at fiscal year-end.

(e) 

Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where applicable, excludes the effects of any sales charges and assumes the reinvestment of distributions at actual reinvestment prices.

(f) 

Aggregate total return.

(g) 

Annualized.

(h) 

Excludes expenses incurred indirectly as a result of investments in underlying funds of 0.01%.

See notes to financial statements.

 

 

160  

2 0 2 1   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S


 

Financial Highlights (continued)

(For a share outstanding throughout each period)

 

    BCX  
    Six Months  Ended
06/30/21

(unaudited)
    Year Ended December 31,  
     2020     2019     2018     2017     2016  
             

Net asset value, beginning of period

  $ 8.45     $ 9.04     $ 8.44     $ 10.64     $ 9.86     $ 8.35  
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net investment income(a)

    0.13       0.20       0.23       0.22       0.20 (b)       0.14  

Net realized and unrealized gain (loss)

    1.56       (0.26 )      0.99       (1.80 )      1.19       1.95  
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net increase (decrease) from investment operations

    1.69       (0.06 )      1.22       (1.58 )      1.39       2.09  
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Distributions(c)

           

From net investment income

    (0.24 )(d)       (0.23 )      (0.23 )      (0.19 )      (0.24 )      (0.15 ) 

Return of capital

    —       (0.30 )      (0.39 )      (0.43 )      (0.37 )      (0.43 ) 
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total distributions

    (0.24 )      (0.53 )      (0.62 )      (0.62 )      (0.61 )      (0.58 ) 
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net asset value, end of period

  $ 9.90     $ 8.45     $ 9.04     $ 8.44     $ 10.64     $ 9.86  
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Market price, end of period

  $ 9.42     $ 7.41     $ 8.07     $ 7.06     $ 9.77     $ 8.27  
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total Return(e)

           

Based on net asset value

    20.22 %(f)      1.56 %      15.88 %      (14.90 )%      15.60 %      27.41 % 
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Based on market price

    30.44 %(f)      (0.23 )%      23.67 %      (22.47 )%      26.55 %      25.50 % 
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Ratios to Average Net Assets

           

Total expenses

    1.09 %(g)       1.09 %      1.11 %      1.08 %      1.08 %      1.08 % 
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total expenses after fees waived and/or reimbursed

    1.09 %(g)       1.09 %      1.11 %      1.08 %      1.08 %      1.08 % 
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net investment income

    2.73 %(g)       2.62 %      2.56 %      2.17 %      2.06 %(b)       1.61 % 
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Supplemental Data

           

Net assets, end of period (000)

  $ 873,981     $ 746,615     $ 822,754     $ 798,282     $ 1,027,472     $ 976,899  
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Portfolio turnover rate

    33 %      78 %      69 %      66 %      73 %      101 % 
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

 

(a) 

Based on average shares outstanding.

(b) 

Net investment income per share and the ratio of net investment income to average net assets include less than $0.04 per share and 0.39% respectively, resulting from a special dividend from Baker Hughes Inc. in July 2017.

(c) 

Distributions for annual periods determined in accordance with U.S. federal income tax regulations.

(d) 

A portion of the distributions from net investment income may be deemed a return of capital or net realized gain at fiscal year-end.

(e) 

Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where applicable, excludes the effects of any sales charges and assumes the reinvestment of distributions at actual reinvestment prices.

(f) 

Aggregate total return.

(g) 

Annualized.

See notes to financial statements.

 

 

F I N A N C I A L   H I G H L I G H T S

  161


 

Financial Highlights (continued)

(For a share outstanding throughout each period)

 

    BST  
   

Six Months Ended

06/30/21

(unaudited)

 

 

(a)  

    Year Ended December 31,  
      2020 (a)       2019       2018       2017       2016  
             

Net asset value, beginning of period

  $ 51.94     $ 32.45     $ 26.21     $ 27.73     $ 20.10     $ 19.70  
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net investment loss(b)

    (0.22 )      (0.28 )      (0.17 )      (0.13 )      (0.05 )      0.00 (c)  

Net realized and unrealized gain

    5.50       21.82       9.92       0.37       8.96       1.60  
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net increase from investment operations

    5.28       21.54       9.75       0.24       8.91       1.60  
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Distributions(d)

           

From net investment income

    (1.28 )      —       —       — (e)       (0.05 )      —  

From net realized gain

    —       (2.05 )      (3.51 )      (1.76 )(e)       (0.22 )      —  

Return of capital

    —       —       —       —       (1.01 )      (1.20 ) 
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total distributions

    (1.28 )      (2.05 )      (3.51 )      (1.76 )      (1.28 )      (1.20 ) 
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net asset value, end of period

  $ 55.94     $ 51.94     $ 32.45     $ 26.21     $ 27.73     $ 20.10  
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Market price, end of period

  $ 59.59     $ 53.30     $ 33.27     $ 27.48     $ 26.69     $ 17.94  
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total Return(f)

           

Based on net asset value

    10.26 %(g)       68.76 %(h)       37.82 %      0.24 %      45.73 %      9.36 % 
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Based on market price

    14.46 %(g)       68.92 %      34.77 %      9.18 %      57.15 %      11.08 % 
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Ratios to Average Net Assets

           

Total expenses

    1.07 %(i)       1.09 %      1.08 %      1.09 %      1.09 %      1.10 % 
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total expenses after fees waived and/or reimbursed

    1.02 %(i)       0.99 %      0.92 %      0.89 %      0.89 %      0.90 % 
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net investment income (loss)

    (0.83 )%(i)       (0.73 )%      (0.52 )%      (0.43 )%      (0.19 )%      0.02 % 
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Supplemental Data

           

Net assets, end of period (000)

  $ 1,413,079     $ 1,297,344     $ 742,672     $ 587,908     $ 620,300     $ 452,443  
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Portfolio turnover rate

    15 %      20 %      32 %      53 %      41 %      74 % 
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

 

(a) 

Consolidated Financial Highlights.

(b) 

Based on average shares outstanding.

(c) 

Amount is less than $0.005 per share.

(d) 

Distributions for annual periods determined in accordance with U.S. federal income tax regulations.

(e) 

Amount previously presented incorrectly as solely distributions from net investment income has been revised to reflect the proper classification of distributions between net realized gain and net investment income.

(f) 

Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where applicable, excludes the effects of any sales charges and assumes the reinvestment of distributions at actual reinvestment prices.

(g) 

Aggregate total return.

(h) 

For financial reporting purposes, the market value of a certain investment was adjusted as of the report date. Accordingly, the net asset value (“NAV”) per share and total return performance based on NAV presented herein are different than the information previously published as of December 31, 2020.

(i) 

Annualized.

See notes to consolidated financial statements.

 

 

162  

2 0 2 1   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S


 

Financial Highlights (continued)

(For a share outstanding throughout each period)

 

    BSTZ  
     

Six Months Ended

06/30/21

(unaudited

 

(a) 

) 

   

Year Ended

12/31/20

(a) 

 

   

Period from

06/27/19

to 12/31/19

 

(b) 

 

Net asset value, beginning of period

  $ 38.72     $ 20.95     $ 20.00  
 

 

 

   

 

 

   

 

 

 

Net investment loss(c)

    (0.24 )      (0.30 )      (0.05 ) 

Net realized and unrealized gain

    5.40       19.32       1.50  
 

 

 

   

 

 

   

 

 

 

Net increase from investment operations

    5.16       19.02       1.45  
 

 

 

   

 

 

   

 

 

 

Distributions(d)

     

From net investment income

    (0.91 )      —       —  

From net realized gain

    —       (1.10 )      —  

Return of capital

    —       (0.15 )      (0.50 ) 
 

 

 

   

 

 

   

 

 

 

Total distributions

    (0.91 )      (1.25 )      (0.50 ) 
 

 

 

   

 

 

   

 

 

 

Net asset value, end of period

  $ 42.97     $ 38.72     $ 20.95  
 

 

 

   

 

 

   

 

 

 

Market price, end of period

  $ 41.71     $ 36.38     $ 20.50  
 

 

 

   

 

 

   

 

 

 

Total Return(e)

     

Based on net asset value

    13.65 %(f)       94.60 %(g)       7.40 %(f)  
 

 

 

   

 

 

   

 

 

 

Based on market price

    17.42 %(f)       86.85 %      5.10 %(f)  
 

 

 

   

 

 

   

 

 

 

Ratios to Average Net Assets

     

Total expenses

    1.31 %(h)       1.33 %      1.32 %(h)(i)  
 

 

 

   

 

 

   

 

 

 

Total expenses after fees waived and/or reimbursed

    1.31 %(h)       1.33 %      1.30 %(h)(i)  
 

 

 

   

 

 

   

 

 

 

Net investment loss

    (1.23 )%(h)       (1.16 )%      (0.48 )%(h)(i) 
 

 

 

   

 

 

   

 

 

 

Supplemental Data

     

Net assets, end of period (000)

  $ 3,355,653     $ 3,023,744     $ 1,635,966  
 

 

 

   

 

 

   

 

 

 

Portfolio turnover rate

    14 %      45 %      16 % 
 

 

 

   

 

 

   

 

 

 

 

(a) 

Consolidated Financial Highlights.

(b) 

Commencement of operations.

(c) 

Based on average shares outstanding.

(d) 

Distributions for annual periods determined in accordance with U.S. federal income tax regulations.

(e) 

Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where applicable, excludes the effects of any sales charges and assumes the reinvestment of distributions at actual reinvestment prices.

(f) 

Aggregate total return.

(g) 

Includes payment from an affiliate, which had no impact on the Trust’s total return.

(h) 

Annualized.

(i) 

Excludes expenses incurred indirectly as a result of investments in underlying funds of approximately 0.04%.

See notes to consolidated financial statements.

 

 

F I N A N C I A L   H I G H L I G H T S

  163


Financial Highlights (continued)

(For a share outstanding throughout each period)

 

    BUI  
   

Six Months Ended
06/30/21

(unaudited)

          Year Ended December 31,  
          2020      2019      2018     2017      2016  
               

Net asset value, beginning of period

  $ 23.80       $ 22.02      $ 18.77      $ 21.12     $ 19.42      $ 19.50  
 

 

 

     

 

 

    

 

 

    

 

 

   

 

 

    

 

 

 

Net investment income(a)

    0.11         0.33        0.37        0.49       0.56        0.56  

Net realized and unrealized gain (loss)

    1.69         2.90        4.33        (1.39 )      2.59        0.81  
 

 

 

     

 

 

    

 

 

    

 

 

   

 

 

    

 

 

 

Net increase (decrease) from investment operations

    1.80         3.23        4.70        (0.90 )      3.15        1.37  
 

 

 

     

 

 

    

 

 

    

 

 

   

 

 

    

 

 

 

Distributions(b)

                

From net investment income

    (0.73 )(c)         (0.20 )       (0.24 )       (0.63 )(d)       (0.47 )       (0.49 ) 

From net realized gain

    —         (1.08 )       (1.06 )       (0.81 )(d)       (0.98 )       (0.53 ) 

Return of capital

    —         (0.17 )       (0.15 )       (0.01 )      —        (0.43 ) 
 

 

 

     

 

 

    

 

 

    

 

 

   

 

 

    

 

 

 

Total distributions

    (0.73 )        (1.45 )       (1.45 )       (1.45 )      (1.45 )       (1.45 ) 
 

 

 

     

 

 

    

 

 

    

 

 

   

 

 

    

 

 

 

Net asset value, end of period

  $ 24.87       $ 23.80      $ 22.02      $ 18.77     $ 21.12      $ 19.42  
 

 

 

     

 

 

    

 

 

    

 

 

   

 

 

    

 

 

 

Market price, end of period

  $ 25.75       $ 25.04      $ 22.31      $ 19.76     $ 21.62      $ 18.41  
 

 

 

     

 

 

    

 

 

    

 

 

   

 

 

    

 

 

 

Total Return(e)

                

Based on net asset value

    7.60 %(f)         15.87 %       25.63 %       (4.40 )%      16.62 %       7.57 % 
 

 

 

     

 

 

    

 

 

    

 

 

   

 

 

    

 

 

 

Based on market price

    5.89 %(f)         20.32 %       20.91 %       (1.68 )%      25.93 %       18.50 % 
 

 

 

     

 

 

    

 

 

    

 

 

   

 

 

    

 

 

 

Ratios to Average Net Assets

                

Total expenses

    1.10 %(g)         1.13 %       1.12 %       1.12 %      1.11 %       1.13 % 
 

 

 

     

 

 

    

 

 

    

 

 

   

 

 

    

 

 

 

Total expenses after fees waived and/or reimbursed

    1.08 %(g)         1.10 %       1.10 %       1.09 %      1.09 %       1.13 % 
 

 

 

     

 

 

    

 

 

    

 

 

   

 

 

    

 

 

 

Net investment income

    0.90 %(g)         1.58 %       1.78 %       2.46 %      2.70 %       2.83 % 
 

 

 

     

 

 

    

 

 

    

 

 

   

 

 

    

 

 

 

Supplemental Data

                

Net assets, end of period (000)

  $ 505,299       $ 444,526      $ 383,337      $ 318,933     $ 357,776      $ 328,297  
 

 

 

     

 

 

    

 

 

    

 

 

   

 

 

    

 

 

 

Portfolio turnover rate

    7 %        39 %       39 %       28 %      31 %       8 % 
 

 

 

     

 

 

    

 

 

    

 

 

   

 

 

    

 

 

 

 

(a) 

Based on average shares outstanding.

(b) 

Distributions for annual periods determined in accordance with U.S. federal income tax regulations.

(c) 

A portion of the distributions from net investment income may be deemed a return of capital or net realized gain at fiscal year-end.

(d) 

Amount previously presented incorrectly as solely distributions from net investment income has been revised to reflect the proper classification of distributions between net realized gain and net investment income.

(e) 

Total returns based on market price, which can be significantly greater or less than the net asset value, may result in substantially different returns. Where applicable, excludes the effects of any sales charges and assumes the reinvestment of distributions at actual reinvestment prices.

(f) 

Aggregate total return.

(g) 

Annualized.

See notes to financial statements.

 

 

164  

2 0 2 1   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S


Notes to Financial Statements (unaudited)

 

1.

ORGANIZATION

The following are registered under the Investment Company Act of 1940, as amended (the “1940 Act”), as closed-end management investment companies and are referred to herein collectively as the “Trusts”, or individually as a “Trust”:

 

Trust Name   Herein Referred To As    Organized    Diversification
Classification

BlackRock Energy and Resources Trust

  BGR    Delaware    Non-diversified

BlackRock Enhanced Capital and Income Fund, Inc.

  CII    Maryland    Diversified

BlackRock Enhanced Equity Dividend Trust

  BDJ    Delaware    Diversified

BlackRock Enhanced Global Dividend Trust

  BOE    Delaware    Diversified

BlackRock Enhanced International Dividend Trust

  BGY    Delaware    Diversified

BlackRock Health Sciences Trust

  BME    Delaware    Diversified

BlackRock Health Sciences Trust II

  BMEZ    Delaware    Non-diversified

BlackRock Innovation and Growth Trust(a)

  BIGZ    Delaware    Non-diversified

BlackRock Resources & Commodities Strategy Trust

  BCX    Delaware    Non-diversified

BlackRock Science and Technology Trust

  BST    Delaware    Diversified

BlackRock Science and Technology Trust II

  BSTZ    Delaware    Non-diversified

BlackRock Utilities, Infrastructure & Power Opportunities Trust

  BUI    Delaware    Diversified

 

  (a)

BlackRock Innovation and Growth Trust commenced operations on March 29, 2021.

 

The Boards of Directors and Boards of Trustees of the Trusts are collectively referred to throughout this report as the “Board,” and the trustees thereof are collectively referred to throughout this report as “Trustees”. The Trusts determine and make available for publication the net asset values (“NAVs”) of their Common Shares on a daily basis.

The Trusts, together with certain other registered investment companies advised by BlackRock Advisors, LLC (the “Manager”) or its affiliates, are included in a complex of non-index fixed-income mutual funds and all BlackRock-advised closed-end funds referred to as the BlackRock Fixed-Income Complex.

Prior to commencement of operations on March 29, 2021, BIGZ had no operations other than those relating to organizational matters and the sale of 5,000 common shares on February 05, 2021 to BlackRock Financial Management, Inc., an affiliate of BIGZ, for $100,000. Investment operations for BIGZ commenced on March 29, 2021.

Basis of Consolidation: The accompanying consolidated financial statements of BST include the accounts of BST Subsidiary, LLC (the “BST Taxable Subsidiary”), which is a wholly-owned taxable subsidiary of BST. The BST Taxable Subsidiary enables BST to hold an investment in an operating partnership and satisfy Regulated Investment Company (“RIC”) tax requirements. Income earned and gains realized on the investment held by the BST Taxable Subsidiary are subject to US federal and state taxes to such subsidiary. A tax provision for income, if any, is shown as income tax in the Consolidated Statement of Operations for BST. A tax provision for realized and unrealized gains, if any, is included as a reduction of realized and/or unrealized gain (loss) in the Consolidated Statement of Operations for BST. BST may invest up to 25% of its total assets in the BST Taxable Subsidiary. The net assets of the BST Taxable Subsidiary as of period end were $5,894,561, which is 0.4% of BST’s consolidated net assets. Intercompany accounts and transactions, if any, have been eliminated. The BST Taxable Subsidiary is subject to the same investment policies and restrictions that apply to BST.

The accompanying consolidated financial statements of BSTZ include the accounts of BSTZ Subsidiary, LLC (the “BSTZ Taxable Subsidiary”), which is a wholly-owned taxable subsidiary of BSTZ. The BSTZ Taxable Subsidiary enables BSTZ to hold an investment in an operating partnership and satisfy Regulated Investment Company (“RIC”) tax requirements. Income earned and gains realized on the investment held by the BSTZ Taxable Subsidiary are subject to US federal and state taxes to such subsidiary. A tax provision for income, if any, is shown as income tax in the Consolidated Statement of Operations for BSTZ. A tax provision for realized and unrealized gains, if any, is included as a reduction of realized and/or unrealized gain (loss) in the Consolidated Statement of Operations for BSTZ. BSTZ may invest up to 25% of its total assets in the BSTZ Taxable Subsidiary. The net assets of the BSTZ Taxable Subsidiary as of period end were $23,580,583, which is 0.7% of BSTZ’s consolidated net assets. Intercompany accounts and transactions, if any, have been eliminated. The BSTZ Taxable Subsidiary is subject to the same investment policies and restrictions that apply to BSTZ.

 

2.

SIGNIFICANT ACCOUNTING POLICIES

The financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”), which may require management to make estimates and assumptions that affect the reported amounts of assets and liabilities in the financial statements, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of increases and decreases in net assets from operations during the reporting period. Actual results could differ from those estimates. Each Trust is considered an investment company under U.S. GAAP and follows the accounting and reporting guidance applicable to investment companies. Below is a summary of significant accounting policies:

Investment Transactions and Income Recognition: For financial reporting purposes, investment transactions are recorded on the dates the transactions are executed. Realized gains and losses on investment transactions are determined using the specific identification method. Dividend income and capital gain distributions, if any, are recorded on the ex-dividend dates. Non-cash dividends, if any, are recorded on the ex-dividend dates at fair value. Dividends from foreign securities where the ex-dividend dates may have passed are subsequently recorded when the Trusts are informed of the ex-dividend dates. Under the applicable foreign tax laws, a withholding tax at various rates may be imposed on capital gains, dividends and interest. Upon notification from issuers, a portion of the dividend income received from a real estate investment trust may be redesignated as a reduction of cost of the related investment and/or realized gain. Interest income, including amortization and accretion of premiums and discounts on debt securities, is recognized daily on an accrual basis.

Foreign Currency Translation: Each Trust’s books and records are maintained in U.S. dollars. Securities and other assets and liabilities denominated in foreign currencies are translated into U.S. dollars using exchange rates determined as of the close of trading on the New York Stock Exchange (“NYSE”). Purchases and sales of investments are

 

 

N O T E S   T O   F I N A N C I A L   S T A T E M E N T S

  165


Notes to Financial Statements (unaudited) (continued)

 

recorded at the rates of exchange prevailing on the respective dates of such transactions. Generally, when the U.S. dollar rises in value against a foreign currency, the investments denominated in that currency will lose value; the opposite effect occurs if the U.S. dollar falls in relative value.

Each Trust does not isolate the effect of fluctuations in foreign exchange rates from the effect of fluctuations in the market prices of investments for financial reporting purposes. Accordingly, the effects of changes in exchange rates on investments are not segregated in the Statements of Operations from the effects of changes in market prices of those investments, but are included as a component of net realized and unrealized gain (loss) from investments. Each Trust reports realized currency gains (losses) on foreign currency related transactions as components of net realized gain (loss) for financial reporting purposes, whereas such components are generally treated as ordinary income for U.S. federal income tax purposes.

Segregation and Collateralization: In cases where a Trust enters into certain investments (e.g., options written) that would be treated as “senior securities” for 1940 Act purposes, a Trust may segregate or designate on its books and records cash or liquid assets having a market value at least equal to the amount of its future obligations under such investments. Doing so allows the investment to be excluded from treatment as a “senior security.” Furthermore, if required by an exchange or counterparty agreement, the Trusts may be required to deliver/deposit cash and/or securities to/with an exchange, or broker-dealer or custodian as collateral for certain investments or obligations.

Distributions: Distributions paid by the Trusts are recorded on the ex-dividend dates. Subject to the Trusts’ managed distribution plan, the Trusts intend to make monthly cash distributions to shareholders, which may consist of net investment income, and net realized and unrealized gains on investments and/or return of capital.

The character of distributions is determined in accordance with U.S. federal income tax regulations, which may differ from U.S. GAAP. The portion of distributions that exceeds a Trust’s current and accumulated earnings and profits, which are measured on a tax basis, will constitute a non-taxable return of capital.

Deferred Compensation Plan: Under the Deferred Compensation Plan (the “Plan”) approved by each Trust’s Board, the trustees who are not “interested persons” of the Trusts, as defined in the 1940 Act (“Independent Trustees”), may defer a portion of their annual complex-wide compensation. Deferred amounts earn an approximate return as though equivalent dollar amounts had been invested in common shares of certain funds in the BlackRock Fixed-Income Complex selected by the Independent Trustees. This has the same economic effect for the Independent Trustees as if the Independent Trustees had invested the deferred amounts directly in certain funds in the BlackRock Fixed-Income Complex.

The Plan is not funded and obligations thereunder represent general unsecured claims against the general assets of each Trust, as applicable. Deferred compensation liabilities, if any, are included in the Trustees’ and Officer’s fees payable in the Statements of Assets and Liabilities and will remain as a liability of the Trusts until such amounts are distributed in accordance with the Plan.

Organization and Offering Costs: Prior to commencement of operations, organization costs associated with the establishment of BIGZ and offering expenses of BIGZ with respect to the issuance of shares in the amounts of $150,500 and $1,225,050, respectively, were paid by the Manager. BIGZ is not obligated to repay any such organizational costs or offering expenses paid by the Manager.

Indemnifications: In the normal course of business, a Trust enters into contracts that contain a variety of representations that provide general indemnification. A Trust’s maximum exposure under these arrangements is unknown because it involves future potential claims against a Trust, which cannot be predicted with any certainty.

Other: Expenses directly related to a Trust are charged to that Trust. Other operating expenses shared by several funds, including other funds managed by the Manager, are prorated among those funds on the basis of relative net assets or other appropriate methods.

 

3.

INVESTMENT VALUATION AND FAIR VALUE MEASUREMENTS

Investment Valuation Policies: Each Trust’s investments are valued at fair value (also referred to as “market value” within the financial statements) each day that the Trust is open for business and, for financial reporting purposes, as of the report date. U.S. GAAP defines fair value as the price a fund would receive to sell an asset or pay to transfer a liability in an orderly transaction between market participants at the measurement date. Each Trust determines the fair values of its financial instruments using various independent dealers or pricing services under policies approved by the Board. If a security’s market price is not readily available or does not otherwise accurately represent the fair value of the security, the security will be valued in accordance with a policy approved by the Board as reflecting fair value. The BlackRock Global Valuation Methodologies Committee (the “Global Valuation Committee”) is the committee formed by management to develop global pricing policies and procedures and to oversee the pricing function for all financial instruments.

Fair Value Inputs and Methodologies: The following methods and inputs are used to establish the fair value of each Trust’s assets and liabilities:

 

  •  

Equity investments traded on a recognized securities exchange are valued at that day’s official closing price, as applicable, on the exchange where the stock is primarily traded. Equity investments traded on a recognized exchange for which there were no sales on that day may be valued at the last available bid (long positions) or ask (short positions) price.

Generally, trading in foreign instruments is substantially completed each day at various times prior to the close of trading on the NYSE. Occasionally, events affecting the values of such instruments may occur between the foreign market close and the close of trading on the NYSE that may not be reflected in the computation of the Trusts’ net assets. Each business day, the Trusts use a pricing service to assist with the valuation of certain foreign exchange-traded equity securities and foreign exchange-traded and over-the-counter (“OTC”) options (the “Systematic Fair Value Price”). Using current market factors, the Systematic Fair Value Price is designed to value such foreign securities and foreign options at fair value as of the close of trading on the NYSE, which follows the close of the local markets.

 

  •  

Fixed-income investments for which market quotations are readily available are generally valued using the last available bid price or current market quotations provided by independent dealers or third party pricing services. Pricing services generally value fixed-income securities assuming orderly transactions of an institutional round lot size, but a fund may hold or transact in such securities in smaller, odd lot sizes. Odd lots may trade at lower prices than institutional round lots. The pricing services

 

 

166  

2 0 2 1   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S


Notes to Financial Statements (unaudited) (continued)

 

 

may use matrix pricing or valuation models that utilize certain inputs and assumptions to derive values, including transaction data (e.g., recent representative bids and offers), market data, credit quality information, perceived market movements, news, and other relevant information. Certain fixed-income securities, including asset-backed and mortgage related securities may be valued based on valuation models that consider the estimated cash flows of each tranche of the entity, establish a benchmark yield and develop an estimated tranche specific spread to the benchmark yield based on the unique attributes of the tranche. The amortized cost method of valuation may be used with respect to debt obligations with sixty days or less remaining to maturity unless the Manager determines such method does not represent fair value.

 

  •  

Investments in open-end U.S. mutual funds (including money market funds) are valued at that day’s published NAV.

 

  •  

The Trusts value their investment in SL Liquidity Series, LLC, Money Market Series (the “Money Market Series”) at fair value, which is ordinarily based upon their pro rata ownership in the underlying fund’s net assets.

 

  •  

Exchange-traded options are valued at the mean between the last bid and ask prices at the close of the options market in which the options trade. An exchange-traded option for which there is no mean price is valued at the last bid (long positions) or ask (short positions) price. If no bid or ask price is available, the prior day’s price will be used, unless it is determined that the prior day’s price no longer reflects the fair value of the option. OTC options and options on swaps (“swaptions”) are valued by an independent pricing service using a mathematical model, which incorporates a number of market data factors, such as the trades and prices of the underlying instruments.

If events (e.g., a market closure, market volatility, company announcement or a natural disaster) occur that are expected to materially affect the value of such investment, or in the event that application of these methods of valuation results in a price for an investment that is deemed not to be representative of the market value of such investment, or if a price is not available, the investment will be valued by the Global Valuation Committee, or its delegate, in accordance with a policy approved by the Board as reflecting fair value (“Fair Valued Investments”). The fair valuation approaches that may be used by the Global Valuation Committee include market approach, income approach and cost approach. Valuation techniques such as discounted cash flow, use of market comparables and matrix pricing are types of valuation approaches and are typically used in determining fair value. When determining the price for Fair Valued Investments, the Global Valuation Committee, or its delegate, seeks to determine the price that each Trust might reasonably expect to receive or pay from the current sale or purchase of that asset or liability in an arm’s-length transaction. Fair value determinations shall be based upon all available factors that the Global Valuation Committee, or its delegate, deems relevant and consistent with the principles of fair value measurement. The pricing of all Fair Valued Investments is subsequently reported to the Board or a committee thereof on a quarterly basis.

For investments in equity or debt issued by privately held companies or funds (“Private Company” or collectively, the “Private Companies”) and other Fair Valued Investments, the fair valuation approaches that are used by the Global Valuation Committee and third party pricing services utilize one or a combination of, but not limited to, the following inputs.

 

     Standard Inputs Generally Considered By Third Party Pricing Services

Market approach

 

(i)  recent market transactions, including subsequent rounds of financing, in the underlying investment or comparable issuers;

(ii)   recapitalizations and other transactions across the capital structure; and

(iii)  market multiples of comparable issuers.

Income approach

 

(i)  future cash flows discounted to present and adjusted as appropriate for liquidity, credit, and/or market risks;

(ii)   quoted prices for similar investments or assets in active markets; and

(iii)  other risk factors, such as interest rates, yield curves, volatilities, prepayment speeds, loss severities, credit risks, recovery rates, liquidation amounts and/or default rates.

Cost approach

 

(i)  audited or unaudited financial statements, investor communications and financial or operational metrics issued by the Private Company;

(ii)   changes in the valuation of relevant indices or publicly traded companies comparable to the Private Company;

(iii)  relevant news and other public sources; and

(iv)  known secondary market transactions in the Private Company’s interests and merger or acquisition activity in companies comparable to the Private Company.

Investments in series of preferred stock issued by Private Companies are typically valued utilizing market approach in determining the enterprise value of the company. Such investments often contain rights and preferences that differ from other series of preferred and common stock of the same issuer. Enterprise valuation techniques such as an option pricing model (“OPM”), a probability weighted expected return model (“PWERM”), current value method or a hybrid of those techniques are used, as deemed appropriate under the circumstances. The use of these valuation techniques involve a determination of the exit scenarios of the investment in order to appropriately allocate the enterprise value of the company among the various parts of its capital structure.

The Private Companies are not subject to the public company disclosure, timing, and reporting standards applicable to other investments held by a Trust. Typically, the most recently available information by a Private Company is as of a date that is earlier than the date a Trust is calculating its NAV. This factor may result in a difference between the value of the investment and the price a Trust could receive upon the sale of the investment.

Fair Value Hierarchy: Various inputs are used in determining the fair value of financial instruments. These inputs to valuation techniques are categorized into a fair value hierarchy consisting of three broad levels for financial reporting purposes as follows:

 

  •  

Level 1 – Unadjusted price quotations in active markets/exchanges for identical assets or liabilities that each Trust has the ability to access;

 

  •  

Level 2 – Other observable inputs (including, but not limited to, quoted prices for similar assets or liabilities in markets that are active, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the assets or liabilities (such as interest rates, yield curves, volatilities, prepayment speeds, loss severities, credit risks and default rates) or other market–corroborated inputs); and

 

 

N O T E S   T O   F I N A N C I A L   S T A T E M E N T S

  167


Notes to Financial Statements (unaudited) (continued)

 

  •  

Level 3 – Unobservable inputs based on the best information available in the circumstances, to the extent observable inputs are not available (including the Global Valuation Committee’s assumptions used in determining the fair value of financial instruments).

The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). Accordingly, the degree of judgment exercised in determining fair value is greatest for instruments categorized in Level 3. The inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the fair value hierarchy classification is determined based on the lowest level input that is significant to the fair value measurement in its entirety. Investments classified within Level 3 have significant unobservable inputs used by the Global Valuation Committee in determining the price for Fair Valued Investments. Level 3 investments include equity or debt issued by Private Companies that may not have a secondary market and/or may have a limited number of investors. The categorization of a value determined for financial instruments is based on the pricing transparency of the financial instruments and is not necessarily an indication of the risks associated with investing in those securities.

As of June 30, 2021, certain investments of BME, BMEZ, BIGZ, BST and BSTZ were fair valued using NAV per share as no quoted market value is available and therefore have been excluded from the fair value hierarchy.

 

4.

SECURITIES AND OTHER INVESTMENTS

Preferred Stocks: Preferred stock has a preference over common stock in liquidation (and generally in receiving dividends as well), but is subordinated to the liabilities of the issuer in all respects. As a general rule, the market value of preferred stock with a fixed dividend rate and no conversion element varies inversely with interest rates and perceived credit risk, while the market price of convertible preferred stock generally also reflects some element of conversion value. Because preferred stock is junior to debt securities and other obligations of the issuer, deterioration in the credit quality of the issuer will cause greater changes in the value of a preferred stock than in a more senior debt security with similar stated yield characteristics. Unlike interest payments on debt securities, preferred stock dividends are payable only if declared by the issuer’s board of directors. Preferred stock also may be subject to optional or mandatory redemption provisions.

Warrants: Warrants entitle a fund to purchase a specified number of shares of common stock and are non-income producing. The purchase price and number of shares are subject to adjustment under certain conditions until the expiration date of the warrants, if any. If the price of the underlying stock does not rise above the strike price before the warrant expires, the warrant generally expires without any value and a fund will lose any amount it paid for the warrant. Thus, investments in warrants may involve more risk than investments in common stock. Warrants may trade in the same markets as their underlying stock; however, the price of the warrant does not necessarily move with the price of the underlying stock.

Commitments: Commitments are agreements to acquire an investment at a future date (subject to conditions) in connection with a potential public or non-public offering. Such agreements may obligate the Trusts to make future cash payments. As of June 30, 2021, BMEZ, BST, BSTZ, and BUI had outstanding commitments of $20,000,000, $14,887,750, $43,111,290 and $6,610,000, respectively. These commitments are not included in the net assets of the Trusts as of June 30, 2021.

Securities Lending: Certain Trusts may lend their securities to approved borrowers, such as brokers, dealers and other financial institutions. The borrower pledges and maintains with the Trusts collateral consisting of cash, an irrevocable letter of credit issued by a bank, or securities issued or guaranteed by the U.S. Government. The initial collateral received by each Trust is required to have a value of at least 102% of the current value of the loaned securities for securities traded on U.S. exchanges and a value of at least 105% for all other securities. The collateral is maintained thereafter at a value equal to at least 100% of the current market value of the securities on loan. The market value of the loaned securities is determined at the close of each business day of the Trust and any additional required collateral is delivered to the Trust, or excess collateral returned by the Trust, on the next business day. During the term of the loan, the Trusts are entitled to all distributions made on or in respect of the loaned securities, but do not receive interest income on securities received as collateral. Loans of securities are terminable at any time and the borrower, after notice, is required to return borrowed securities within the standard time period for settlement of securities transactions.

As of period end, any securities on loan were collateralized by cash and/or U.S. Government obligations. Cash collateral invested by the securities lending agent, BlackRock Investment Management, LLC (“BIM”), if any, is disclosed in the Schedules of Investments. Any non-cash collateral received cannot be sold, re-invested or pledged by the Trust, except in the event of borrower default. The securities on loan, if any, are disclosed in the Trusts’ Schedules of Investments. The market value of any securities on loan and the value of any related collateral are shown separately in the Statements of Assets and Liabilities as a component of investments at value – unaffiliated, and collateral on securities loaned at value, respectively.

Securities lending transactions are entered into by the Trusts under Master Securities Lending Agreements (each, an “MSLA”), which provide the right, in the event of default (including bankruptcy or insolvency), for the non-defaulting party to liquidate the collateral and calculate a net exposure to the defaulting party or request additional collateral. In the event that a borrower defaults, the Trusts, as lender, would offset the market value of the collateral received against the market value of the securities loaned. When the value of the collateral is greater than that of the market value of the securities loaned, the lender is left with a net amount payable to the defaulting party. However, bankruptcy or insolvency laws of a particular jurisdiction may impose restrictions on or prohibitions against such a right of offset in the event of an MSLA counterparty’s bankruptcy or insolvency. Under the MSLA, absent an event of default, the borrower can resell or re-pledge the loaned securities, and the Trusts can reinvest cash collateral received in connection with loaned securities. Upon an event of default, the parties’ obligations to return the securities or collateral to the other party are extinguished, and the parties can resell or re-pledge the loaned securities or the collateral received in connection with the loaned securities in order to satisfy the defaulting party’s net payment obligation for all transactions under the MSLA. The defaulting party remains liable for any deficiency.

As of period end, the following table is a summary of the Trusts’ securities on loan by counterparty which are subject to offset under an MSLA:

 

Trust Name/Counterparty    
Securities
Loaned at Value
 
 
    
Cash Collateral
Received
 
(a)  
   
Net
Amount
 
(b) 

BME

      

Citigroup Global Markets, Inc.

  $ 94,642      $ (94,642 )    $ —  

 

 

168  

2 0 2 1   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S


Notes to Financial Statements (unaudited) (continued)

 

Trust Name/Counterparty    
Securities
Loaned at Value
 
 
    

Cash Collateral

Received

 

(a)  

   
Net
Amount
 
(b) 

BME (continued)

      

Goldman Sachs & Co.

  $ 204,718      $ (202,491 )    $ 2,227  

Morgan Stanley & Co. LLC

    129,641        (129,641 )      —  
 

 

 

    

 

 

   

 

 

 
  $ 429,001      $ (426,774 )    $ 2,227  
 

 

 

    

 

 

   

 

 

 

BMEZ

      

Citigroup Global Markets, Inc.

  $ 572,678      $ (572,678 )    $ —  

Credit Suisse Securities (USA) LLC

    408,866        (408,866 )      —  

Goldman Sachs & Co.

    626,984        (626,984 )      —  

Morgan Stanley & Co. LLC

    2,166,296        (2,166,296 )      —  

State Street Bank & Trust Company

    16,890        (16,771 )      119  
 

 

 

    

 

 

   

 

 

 
  $ 3,791,714      $ (3,791,595 )    $ 119  
 

 

 

    

 

 

   

 

 

 

BIGZ

      

BNP Paribas Securities Corp.

  $ 759,490      $ (759,490 )    $ —  

Nomura Securities International, Inc.

    11,625        (11,625 )      —  
 

 

 

    

 

 

   

 

 

 
  $ 771,115      $ (771,115 )    $ —  
 

 

 

    

 

 

   

 

 

 

BST

      

BNP Paribas Securities Corp.

  $ 3,748,552      $ (3,748,552 )    $ —  
 

 

 

    

 

 

   

 

 

 

BSTZ

      

Morgan Stanley & Co. LLC

  $ 4,245,125      $ (4,245,125 )    $ —  

State Street Bank & Trust Company

    27,513        (27,513 )      —  
 

 

 

    

 

 

   

 

 

 
  $ 4,272,638      $ (4,272,638 )    $ —  
 

 

 

    

 

 

   

 

 

 

 

  (a) 

Collateral received in excess of the market value of securities on loan is not presented in this table. The total cash collateral received by each Trust is disclosed in the Trust’s Statements of Assets and Liabilities.

 
  (b) 

The market value of the loaned securities is determined as of June 30, 2021. Additional collateral is delivered to each Trust on the next business day in accordance with the MSLA. The net amount would be subject to the borrower default indemnity in the event of default by the counterparty.

 

The risks of securities lending include the risk that the borrower may not provide additional collateral when required or may not return the securities when due. To mitigate these risks, the Trusts benefit from a borrower default indemnity provided by BIM. BIM’s indemnity allows for full replacement of the securities loaned to the extent the collateral received does not cover the value on the securities loaned in the event of borrower default. Each Trust could incur a loss if the value of an investment purchased with cash collateral falls below the market value of loaned securities or if the value of an investment purchased with cash collateral falls below the value of the original cash collateral received. Such losses are borne entirely by the Trusts.

 

5.

DERIVATIVE FINANCIAL INSTRUMENTS

The Trusts engage in various portfolio investment strategies using derivative contracts both to increase the returns of the Trusts and/or to manage their exposure to certain risks such as credit risk, equity risk, interest rate risk, foreign currency exchange rate risk, commodity price risk or other risks (e.g., inflation risk). Derivative financial instruments categorized by risk exposure are included in the Schedules of Investments. These contracts may be transacted on an exchange or OTC.

Options: The Trusts may purchase and write call and put options to increase or decrease their exposure to the risks of underlying instruments, including equity risk, interest rate risk and/or commodity price risk and/or, in the case of options written, to generate gains from options premiums.

A call option gives the purchaser (holder) of the option the right (but not the obligation) to buy, and obligates the seller (writer) to sell (when the option is exercised) the underlying instrument at the exercise or strike price at any time or at a specified time during the option period. A put option gives the holder the right to sell and obligates the writer to buy the underlying instrument at the exercise or strike price at any time or at a specified time during the option period.

Premiums paid on options purchased and premiums received on options written, as well as the daily fluctuation in market value, are included in investments at value –unaffiliated and options written at value, respectively, in the Statements of Assets and Liabilities. When an instrument is purchased or sold through the exercise of an option, the premium is offset against the cost or proceeds of the underlying instrument. When an option expires, a realized gain or loss is recorded in the Statements of Operations to the extent of the premiums received or paid. When an option is closed or sold, a gain or loss is recorded in the Statements of Operations to the extent the cost of the closing transaction exceeds the premiums received or paid. When the Trusts write a call option, such option is typically “covered,” meaning that they hold the underlying instrument subject to being called by the option counterparty. When the Trusts write a put option, cash is segregated in an amount sufficient to cover the obligation. These amounts, which are considered restricted, are included in cash pledged as collateral for options written in the Statements of Assets and Liabilities.

In purchasing and writing options, the Trusts bear the risk of an unfavorable change in the value of the underlying instrument or the risk that they may not be able to enter into a closing transaction due to an illiquid market. Exercise of a written option could result in the Trusts purchasing or selling a security when they otherwise would not, or at a price different from the current market value.

Master Netting Arrangements: In order to define its contractual rights and to secure rights that will help it mitigate its counterparty risk, a Trust may enter into an International Swaps and Derivatives Association, Inc. Master Agreement (“ISDA Master Agreement”) or similar agreement with its counterparties. An ISDA Master Agreement is a bilateral agreement between a Trust and a counterparty that governs certain OTC derivatives and typically contains, among other things, collateral posting terms and netting provisions

 

 

N O T E S   T O   F I N A N C I A L   S T A T E M E N T S

  169


Notes to Financial Statements (unaudited) (continued)

 

in the event of a default and/or termination event. Under an ISDA Master Agreement, a Trust may, under certain circumstances, offset with the counterparty certain derivative financial instruments’ payables and/or receivables with collateral held and/or posted and create one single net payment. The provisions of the ISDA Master Agreement typically permit a single net payment in the event of default including the bankruptcy or insolvency of the counterparty. However, bankruptcy or insolvency laws of a particular jurisdiction may impose restrictions on or prohibitions against the right of offset in bankruptcy, insolvency or other events.

Collateral Requirements: For derivatives traded under an ISDA Master Agreement, the collateral requirements are typically calculated by netting the mark-to-market amount for each transaction under such agreement and comparing that amount to the value of any collateral currently pledged by the Trust and the counterparty.

Cash collateral that has been pledged to cover obligations of the Trusts and cash collateral received from the counterparty, if any, is reported separately in the Statements of Assets and Liabilities as cash pledged as collateral and cash received as collateral, respectively. Non-cash collateral pledged by the Trusts, if any, is noted in the Schedules of Investments. Generally, the amount of collateral due from or to a counterparty is subject to a certain minimum transfer amount threshold before a transfer is required, which is determined at the close of business of the Trusts. Any additional required collateral is delivered to/pledged by the Trusts on the next business day. Typically, the counterparty is not permitted to sell, re-pledge or use cash and non-cash collateral it receives. A Trust generally agrees not to use non-cash collateral that it receives but may, absent default or certain other circumstances defined in the underlying ISDA Master Agreement, be permitted to use cash collateral received. In such cases, interest may be paid pursuant to the collateral arrangement with the counterparty. To the extent amounts due to the Trusts from the counterparties are not fully collateralized, each Trust bears the risk of loss from counterparty non-performance. Likewise, to the extent the Trusts have delivered collateral to a counterparty and stand ready to perform under the terms of their agreement with such counterparty, each Trust bears the risk of loss from a counterparty in the amount of the value of the collateral in the event the counterparty fails to return such collateral. Based on the terms of agreements, collateral may not be required for all derivative contracts.

For financial reporting purposes, the Trusts do not offset derivative assets and derivative liabilities that are subject to netting arrangements, if any, in the Statements of Assets and Liabilities.

 

6.

INVESTMENT ADVISORY AGREEMENT AND OTHER TRANSACTIONS WITH AFFILIATES

Investment Advisory: Each Trust entered into an Investment Advisory Agreement with the Manager, the Trusts’ investment adviser and an indirect, wholly-owned subsidiary of BlackRock, Inc. (“BlackRock”), to provide investment advisory and administrative services. The Manager is responsible for the management of each Trust’s portfolio and provides the personnel, facilities, equipment and certain other services necessary to the operations of each Trust.

For such services, each Trust, except BCX pays the Manager a monthly fee at the following annual rates:

Average weekly value of each Trust’s net assets:

 

     BGR     BDJ      BOE      BME  

Investment advisory fees

    1.20 %      0.80 %       1.00 %       1.00 % 

Average daily value of each Trusts’s net assets:

 

     CII      BGY      BUI  

Investment advisory fees

    0.85 %       1.00 %       1.00 % 

Average daily value of each Trusts’s managed assets:

 

     BMEZ     BIGZ      BST      BSTZ  

Investment advisory fees

    1.25 %      1.25 %       1.00 %       1.25 % 

For such services, BCX pays the Manager a monthly fee of 1.00% of the sum of the average daily value of the net assets of the Trust (excluding the value of the Trust’s interest in the Subsidiary) and the average daily value of the net assets of its subsidiary, which fee is allocated pro rata between the Trust and the Subsidiary based on the average daily value of their respective net assets (excluding, in the case of the Trust, the value of the Trust’s interest in the Subsidiary).

For purposes of calculating these fees, “net assets” mean the total assets of BGR, BDJ, BOE, BME, CII, BGY, BUI and BCX minus the sum of its accrued liabilities.

For purposes of calculating these fees, “managed assets” are determined as total assets of BMEZ, BIGZ, BST and BSTZ (including any assets attributable to money borrowed for investment purposes) less the sum of its accrued liabilities (other than money borrowed for investment purposes).

With respect to BGR, BOE, BGY, BCX and BUI, the Manager entered into separate sub-advisory agreements with BlackRock International Limited (“BIL”), an affiliate of the Manager. The Manager pays BIL for services it provides for that portion of each Trust for which BIL acts as sub-adviser, a monthly fee that is equal to a percentage of the investment advisory fees paid by each Trust to the Manager.

 

 

170  

2 0 2 1   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S


Notes to Financial Statements (unaudited) (continued)

 

The Manager provides investment management and other services to BIGZ, BST and BSTZ Subsidiary. The Manager does not receive separate compensation from the Subsidiary for providing investment management or administrative services. However, BIGZ, BST and BSTZ pays the Manager based on the Trust’s net assets, which includes the assets of the Subsidiary.

Distribution Fees: BME, BST and BUI have entered into Distribution Agreements with BlackRock Investments, LLC (“BRIL”), an affiliate of the Manager, to provide for distribution of BME’s, BST’s and BUI’s common shares on a reasonable best efforts basis through an equity shelf offering (a “Shelf Offering”) (the “Distribution Agreement”). Pursuant to the Distribution Agreement, BME, BST and BUI will compensate BRIL with respect to sales of common shares at a commission rate of 1.00% of the gross proceeds of the sale of BME’s, BST’s and BUI’s common shares and a portion of such commission is re-allowed to broker-dealers engaged by BRIL. The commissions retained by BRIL during the six months ended June 30, 2021 amounted to $68,862, $25,900, and $82,439 for each of BME, BST and BUI, respectively.

Expense Limitations, Waivers and Reimbursements: The Manager has contractually agreed to waive a portion of the investment advisory fees on BST as a percentage of its average daily managed assets as follows:

 

             Expiration Date  

BST

    0.05 %       December 31, 2021  

The Manager voluntarily agreed to waive a portion of the investment advisory fees on the following Trusts as a percentage of their average weekly net assets (BGR and BOE) or average daily net assets (BGY and BUI), as follows:

 

     BGR   BOE      BGY      BUI  
    0.220%     0.175 %       0.100 %       0.025 % 

These voluntary waivers may be reduced or discontinued at any time without notice.

For the six months ended June 30, 2021, the investment advisory fees waived, which are included in fees waived and/or reimbursed by the Manager in the Statements of Operations, were as follows:

 

Trust Name   Fees Waived and/or Reimbursed
by the Manager
 

BGR

  $ 301,397  

BOE

    710,274  

BGY

    345,848  

BST

    331,966  

BUI

    59,319  

With respect to each Trust, the Manager contractually agreed to waive its investment advisory fees by the amount of investment advisory fees each Trust pays to the Manager indirectly through its investment in affiliated money market funds (the “affiliated money market fund waiver”) through June 30, 2023. The contractual agreement may be terminated upon 90 days’ notice by a majority of the Independent trustees, or by a vote of a majority of the outstanding voting securities of a Trust. These amounts are included in fees waived and/or reimbursed by the Manager in the Statements of Operations. For the six months ended June 30, 2021, the amounts waived were as follows:

 

Trust Name   Fees Waived and/or Reimbursed
by the Manager
 

BGR

  $ 581  

CII

    2,673  

BDJ

    2,923  

BOE

    1,371  

BGY

    1,387  

BME

    2,530  

BMEZ

    9,915  

BIGZ

    66,931  

BCX

    1,871  

BST

    3,577  

BSTZ

    10,015  

BUI

    1,936  

The Manager contractually agreed to waive its investment advisory fee with respect to any portion of each Trust’s assets invested in affiliated equity and fixed-income mutual funds and affiliated exchange-traded funds that have a contractual management fee through June 30, 2023. The agreement can be renewed for annual periods thereafter, and may be terminated on 90 days’ notice, each subject to approval by a majority of the Trusts’ Independent Trustees. These amounts are included in fees waived and/or reimbursed by the Manager in the Statements of Operations. For the six months ended June 30, 2021, the amounts waived were as follows:

 

Trust Name  

Fees Waived and/or Reimbursed

by the Manager

 

BIGZ

  $ 295,091  

 

 

N O T E S   T O   F I N A N C I A L   S T A T E M E N T S

  171


Notes to Financial Statements (unaudited) (continued)

 

Securities Lending: The U.S. Securities and Exchange Commission (“SEC”) has issued an exemptive order which permits BIM, an affiliate of the Manager, to serve as securities lending agent for the Trusts, subject to applicable conditions. As securities lending agent, BIM bears all operational costs directly related to securities lending. The Trusts are responsible for expenses in connection with the investment of cash collateral received for securities on loan (the “collateral investment expenses”). The cash collateral is invested in a private investment company, Money Market Series, managed by the Manager or its affiliates. However, BIM has agreed to cap the collateral investment expenses of the Money Market Series to an annual rate of 0.04%. The investment adviser to the Money Market Series will not charge any advisory fees with respect to shares purchased by the Trusts. The Money Market Series may, under certain circumstances, impose a liquidity fee of up to 2% of the value withdrawn or temporarily restrict withdrawals for up to 10 business days during a 90 day period, in the event that the private investment company’s weekly liquid assets fall below certain thresholds. The Money Market Series seeks current income consistent with maintaining liquidity and preserving capital. Although the Money Market Series is not registered under the 1940 Act, its investments may follow the parameters of investments by a money market fund that is subject to Rule 2a-7 under the 1940 Act.

Securities lending income is equal to the total of income earned from the reinvestment of cash collateral, net of fees and other payments to and from borrowers of securities, and less the collateral investment expenses. Each Trust retains a portion of securities lending income and remits a remaining portion to BIM as compensation for its services as securities lending agent.

Pursuant to the current securities lending agreement, BIM may lend securities only when the difference between the borrower rebate rate and the risk free rate exceeds a certain level (such securities, the “specials only securities”). Each Trust retains 82% of securities lending income (which excludes collateral investment expenses).

In addition, commencing the business day following the date that the aggregate securities lending income earned across the BlackRock Fixed-Income Complex in a calendar year exceeds a specified threshold, each Trust, pursuant to the securities lending agreement, will retain for the remainder of that calendar year securities lending income (which excludes collateral investment expenses) in an amount equal to 85% of securities lending income.

The share of securities lending income earned by each Trust is shown as securities lending income — affiliated — net in the Statements of Operations. For the six months ended June 30, 2021, each Trust paid BIM the following amounts for securities lending agent services:

 

Trust Name   Amounts  

BME

  $ 1,333  

BMEZ

    19,682  

BIGZ

    10,881  

BST

    8,460  

BSTZ

    35,339  

Trustees and Officers: Certain trustees and/or officers of the Trusts are directors and/or officers of BlackRock or its affiliates. The Trusts reimburse the Manager for a portion of the compensation paid to the Trusts’ Chief Compliance Officer, which is included in Trustees and Officer in the Statements of Operations.

Other Transactions: During the six months ended June 30, 2021, BGR received a reimbursement of $25,456 from an affiliate, which is included in payment by affiliate in the Statements of Operations, related to an operating event.

The Trusts may purchase securities from, or sell securities to, an affiliated fund provided the affiliation is due solely to having a common investment adviser, common officers, or common trustees. For the six months ended June 30, 2021, the purchase and sale transactions and any net realized gains (losses) with affiliated funds in compliance with Rule 17a-7 under the 1940 Act were as follows:

 

Trust Name   Purchases      Sales      Net Realized
Gain (Loss)
 

BOE

  $ 1,063,708      $ —      $ —  

BGY

    1,779,537        —        —  

BME

    —        124,568        60,786  

BMEZ

    4,139,432        —        —  

 

7.

PURCHASES AND SALES

For the six months ended June 30, 2021, purchases and sales of investments, excluding short-term investments, were as follows:

 

Trust Name   Purchases      Sales  

BGR

  $ 92,314,029      $  102,498,790  

CII

    134,023,742        173,377,822  

BDJ

    393,557,321        540,633,815  

BOE

    375,968,739        408,519,026  

BGY

    313,608,383        333,225,522  

BME

    107,497,744        86,780,660  

BMEZ

    523,907,182        645,620,203  

BIGZ

    5,659,043,204        750,210,796  

BCX

    271,983,058        316,341,856  

BST

    197,378,598        210,655,804  

BSTZ

    437,381,863        547,631,530  

BUI

    60,590,382        34,558,586  

 

 

172  

2 0 2 1   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S


Notes to Financial Statements (unaudited) (continued)

 

8.

INCOME TAX INFORMATION

It is each Trust’s policy to comply with the requirements of the Internal Revenue Code of 1986, as amended, applicable to regulated investment companies, and to distribute substantially all of its taxable income to its shareholders. Therefore, no U.S. federal income tax provision is required.

Each Trust files U.S. federal and various state and local tax returns. No income tax returns are currently under examination. The statute of limitations on each Trust’s U.S. federal tax returns generally remains open for a period of three fiscal years after they are filed. The statutes of limitations on each Trust’s state and local tax returns may remain open for an additional year depending upon the jurisdiction.

Management has analyzed tax laws and regulations and their application to the Trusts as of June 30, 2021, inclusive of the open tax return years, and does not believe that there are any uncertain tax positions that require recognition of a tax liability in the Trusts’ financial statements.

As of December 31, 2020, the Trusts had non-expiring capital loss carryforwards available to offset future realized capital gains as follows:

 

Trust Name   Non-Expiring  

BGR

  $  249,097,412  

BOE

    36,829,140  

BGY

    34,422,227  

BCX

    459,136,748  

As of June 30, 2021, gross unrealized appreciation and depreciation based on cost of investments (including short positions and derivatives, if any) for U.S. federal income tax purposes were as follows:

 

Trust Name   Tax Cost      Gross Unrealized
Appreciation
     Gross Unrealized
Depreciation
    Net Unrealized
Appreciation
(Depreciation)
 

BGR

  $ 278,125,212      $ 59,664,230      $ (37,359,113 )    $ 22,305,117  

CII

    578,744,905        388,311,518        (9,856,974 )      378,454,544  

BDJ

    1,422,042,724        564,657,787        (24,796,061 )      539,861,726  

BOE

    714,953,251        158,653,391        (22,120,187 )      136,533,204  

BGY

    587,155,758        148,442,691        (25,423,134 )      123,019,557  

BME

    370,535,221        247,040,543        (5,707,478 )      241,333,065  

BMEZ

    2,381,154,990        1,150,009,385        (66,066,659 )      1,083,942,726  

BIGZ

    4,869,050,177        267,889,839        (273,965,442 )      (6,075,603 ) 

BCX

    663,524,468        251,193,630        (33,638,246 )      217,555,384  

BST

    530,194,540        919,129,213        (20,517,776 )      898,611,437  

BSTZ

    1,615,000,007        1,822,402,355        (48,187,991 )      1,774,214,364  

BUI

    331,360,686        178,619,729        (2,253,620 )      176,366,109  

 

9.

PRINCIPAL RISKS

In the normal course of business, the Trusts invest in securities or other instruments and may enter into certain transactions, and such activities subject each Trust to various risks, including among others, fluctuations in the market (market risk) or failure of an issuer to meet all of its obligations. The value of securities or other instruments may also be affected by various factors, including, without limitation: (i) the general economy; (ii) the overall market as well as local, regional or global political and/or social instability; (iii) regulation, taxation or international tax treaties between various countries; or (iv) currency, interest rate and price fluctuations. Local, regional or global events such as war, acts of terrorism, the spread of infectious illness or other public health issues, recessions, or other events could have a significant impact on the Trusts and their investments. BME’s, BST’s and BUI’s prospectuses provide details of the risks to which each Trust is subject.

The Trusts may be exposed to additional risks when reinvesting cash collateral in money market funds that do not seek to maintain a stable NAV per share of $1.00, which may be subject to redemption gates or liquidity fees under certain circumstances.

Each Trust may invest without limitation in illiquid or less liquid investments or investments in which no secondary market is readily available or which are otherwise illiquid, including private placement securities. A Trust may not be able to readily dispose of such investments at prices that approximate those at which a Trust could sell such investments if they were more widely traded and, as a result of such illiquidity, a Trust may have to sell other investments or engage in borrowing transactions if necessary to raise funds to meet its obligations. Limited liquidity can also affect the market price of investments, thereby adversely affecting a Trust’s NAV and ability to make dividend distributions. Privately issued debt securities are often of below investment grade quality, frequently are unrated and present many of the same risks as investing in below investment grade public debt securities.

Rights Offering Dilution Risk: BST’s shareholders who do not fully exercise their rights will, at the completion of the rights offering, own a smaller proportional interest in BST than owned prior to the rights offering. The completion of the rights offering will result in immediate voting dilution for such shareholders. In addition, if the subscription price is less than the NAV per Common Share as of the expiration date, the completion of this rights offering will result in an immediate dilution of the NAV per Common Share for all existing Common Shareholders (i.e., will cause the NAV per Common Share to decrease) even if they fully exercise their rights. Such dilution, if any, is not currently

 

 

N O T E S   T O   F I N A N C I A L   S T A T E M E N T S

  173


Notes to Financial Statements (unaudited) (continued)

 

determinable because it is not known how many Common Shares will be subscribed for, what the NAV per Common Share or market price of the Common Shares will be on the expiration date or what the subscription price per Common Share will be. If the subscription price is substantially less than the current NAV per Common Share, this dilution could be substantial. Refer to the Subsequent Events note for results of the rights offering.

Market Risk: An outbreak of respiratory disease caused by a novel coronavirus has developed into a global pandemic and has resulted in closing borders, quarantines, disruptions to supply chains and customer activity, as well as general concern and uncertainty. The impact of this pandemic, and other global health crises that may arise in the future, could affect the economies of many nations, individual companies and the market in general in ways that cannot necessarily be foreseen at the present time. This pandemic may result in substantial market volatility and may adversely impact the prices and liquidity of a fund’s investments. The duration of this pandemic and its effects cannot be determined with certainty.

Valuation Risk: The market values of equities, such as common stocks and preferred securities or equity related investments, such as futures and options, may decline due to general market conditions which are not specifically related to a particular company. They may also decline due to factors which affect a particular industry or industries. A Trust may invest in illiquid investments. An illiquid investment is any investment that a Trust reasonably expects cannot be sold or disposed of in current market conditions in seven calendar days or less without the sale or disposition significantly changing the market value of the investment. A Trust may experience difficulty in selling illiquid investments in a timely manner at the price that it believes the investments are worth. Prices may fluctuate widely over short or extended periods in response to company, market or economic news. Markets also tend to move in cycles, with periods of rising and falling prices. This volatility may cause each Trust’s NAV to experience significant increases or decreases over short periods of time. If there is a general decline in the securities and other markets, the NAV of a Trust may lose value, regardless of the individual results of the securities and other instruments in which a Trust invests.

The price a Trust could receive upon the sale of any particular portfolio investment may differ from a Trust’s valuation of the investment, particularly for securities that trade in thin or volatile markets or that are valued using a fair valuation technique or a price provided by an independent pricing service. Changes to significant unobservable inputs and assumptions (i.e., publicly traded company multiples, growth rate, time to exit) due to the lack of observable inputs may significantly impact the resulting fair value and therefore a Trust’s results of operations. As a result, the price received upon the sale of an investment may be less than the value ascribed by a Trust, and a Trust could realize a greater than expected loss or lesser than expected gain upon the sale of the investment. A Trust’s ability to value its investments may also be impacted by technological issues and/or errors by pricing services or other third party service providers.

Counterparty Credit Risk: The Trusts may be exposed to counterparty credit risk, or the risk that an entity may fail to or be unable to perform on its commitments related to unsettled or open transactions, including making timely interest and/or principal payments or otherwise honoring its obligations. The Trusts manage counterparty credit risk by entering into transactions only with counterparties that the Manager believes have the financial resources to honor their obligations and by monitoring the financial stability of those counterparties. Financial assets, which potentially expose the Trusts to market, issuer and counterparty credit risks, consist principally of financial instruments and receivables due from counterparties. The extent of the Trusts’ exposure to market, issuer and counterparty credit risks with respect to these financial assets is approximately their value recorded in the Statements of Assets and Liabilities, less any collateral held by the Trusts.

A derivative contract may suffer a mark-to-market loss if the value of the contract decreases due to an unfavorable change in the market rates or values of the underlying instrument. Losses can also occur if the counterparty does not perform under the contract.

For OTC options purchased, each Trust bears the risk of loss in the amount of the premiums paid plus the positive change in market values net of any collateral held by the Trusts should the counterparty fail to perform under the contracts. Options written by the Trusts do not typically give rise to counterparty credit risk, as options written generally obligate the Trusts, and not the counterparty, to perform. The Trusts may be exposed to counterparty credit risk with respect to options written to the extent each Trust deposits collateral with its counterparty to a written option.

Concentration Risk: A diversified portfolio, where this is appropriate and consistent with a fund’s objectives, minimizes the risk that a price change of a particular investment will have a material impact on the NAV of a fund. The investment concentrations within each Trust’s portfolio are disclosed in its Schedule of Investments.

As of period end, the Trusts listed below invested a significant portion of their assets in securities in the following sectors:

 

Sectors   Trust Name  

Energy

    BGR, BCX  

Financials

    BDJ  

Health Care

    BME, BMEZ  

Information Technology

    BST, BSTZ  

Materials

    BCX  

Utilities

    BUI  

Changes in economic conditions affecting such sectors would have a greater impact on the Trusts and could affect the value, income and/or liquidity of positions in such securities.

Certain Trusts invest a substantial amount of their assets in issuers located in a single country or a limited number of countries. When a Trust concentrates its investments in this manner, it assumes the risk that economic, regulatory, political and social conditions in those countries may have a significant impact on their investment performance and could affect the income from, or the value or liquidity of, the Trust’s portfolio. Foreign issuers may not be subject to the same uniform accounting, auditing and financial reporting standards and practices as used in the United States. Foreign securities markets may also be more volatile and less liquid than U.S. securities and may be less subject to governmental supervision not typically associated with investing in U.S. securities. Investment percentages in specific countries are presented in the Schedules of Investments.

 

 

174  

2 0 2 1   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S


Notes to Financial Statements (unaudited) (continued)

 

Certain Trusts invest a significant portion of their assets in securities of issuers located in Europe or with significant exposure to European issuers or countries. The European financial markets have recently experienced volatility and adverse trends due to concerns about economic downturns in, or rising government debt levels of, several European countries. These events may spread to other countries in Europe and may affect the value and liquidity of certain of the Trusts’ investments.

Responses to the financial problems by European governments, central banks and others, including austerity measures and reforms, may not work, may result in social unrest and may limit future growth and economic recovery or have other unintended consequences. Further defaults or restructurings by governments and others of their debt could have additional adverse effects on economies, financial markets and asset valuations around the world. In addition, the United Kingdom has withdrawn from the European Union, and one or more other countries may withdraw from the European Union and/or abandon the Euro, the common currency of the European Union. The impact of these actions, especially if they occur in a disorderly fashion, is not clear but could be significant and far reaching.

LIBOR Transition Risk: The United Kingdom’s Financial Conduct Authority announced a phase out of the London Interbank Offered Rate (“LIBOR”). Although many LIBOR rates will be phased out by the end of 2021, a selection of widely used USD LIBOR rates will continue to be published through June 2023 in order to assist with the transition. The Trusts may be exposed to financial instruments tied to LIBOR to determine payment obligations, financing terms, hedging strategies or investment value. The transition process away from LIBOR might lead to increased volatility and illiquidity in markets for, and reduce the effectiveness of new hedges placed against, instruments whose terms currently include LIBOR. The ultimate effect of the LIBOR transition process on the Trusts is uncertain.

 

10.

CAPITAL SHARE TRANSACTIONS

Each Trust is authorized to issue an unlimited number of shares, with the exception of CII, all of which were initially classified as Common Shares. CII is authorized to issue 200 million Common Shares. The par value for each Trust’s Common Shares is $0.001, except for CII, which is $0.10. The Board is authorized, however, to reclassify any unissued Common Shares to Preferred Shares without the approval of Common Shareholders.

BME, BST and BUI have each filed a prospectus with the SEC allowing it to issue an additional 5,000,000, 10,414,581 and 2,347,341 Common Shares, respectively, through an equity Shelf Offering. Under the Shelf Offerings, BME, BST and BUI, subject to market conditions, may raise additional equity capital from time to time in varying amounts and utilizing various offering methods at a net price at or above each Trust’s NAV per Common Share (calculated within 48 hours of pricing). As of period end, 2,722,707, 10,414,581 and 1,834,558 Common Shares, respectively, remain available for issuance under the Shelf Offerings. See Additional Information — Shelf Offering Program for additional information about the Shelf Offerings.

Initial costs incurred by each of BME, BST and BUI in connection with its Shelf Offering are recorded as “Deferred offering cost” in the Statements of Assets and Liabilities. As shares are sold, a portion of the costs attributable to the shares sold will be charged against paid-in-capital. Any remaining deferred charges at the end of the shelf offering period will be charged to expense. Any subsequent costs incurred to keep the filing active will be charged to expense as incurred.

For the periods shown, shares issued and outstanding increased by the following amounts as a result of shares issued through the Shelf Offering:

 

Trust Name   Six Months Ended
06/30/21
     Year Ended
12/31/20
 

BME

    724,148        1,066,906  

BMEZ

    —        112,664,825  

BST

    242,731        2,038,416  

BUI

    1,610,124        1,205,766  

For the periods shown, shares issued and outstanding increased by the following amounts as a result of dividend reinvestment:

 

Trust Name   Six Months Ended
06/30/21
     Year Ended
12/31/20
 

BME

    20,500        42,015  

BIGZ

    231,136        —  

BST

    40,859        52,101  

BUI

    31,508        59,571  

The Trusts participate in an open market share repurchase program (the “Repurchase Program”). From December 1, 2020 through November 30, 2021, each Trust (other than BSTZ and BMEZ) may repurchase up to 5% of its outstanding common shares under the Repurchase Program, based on common shares outstanding as of the close of business on November 30, 2020, subject to certain conditions. There is no assurance that the Trusts will purchase shares in any particular amounts. For the six months ended June 30, 2021, BGR, CII, BDJ, BGY, BME, BIGZ, BCX, BSTZ and BUI did not repurchase any shares.

The total cost of the shares repurchased is reflected in the Trusts’ Statements of Changes in Net Assets. For the periods shown, shares repurchased and cost, including transaction costs, were as follows:

 

     BGR  
     Shares      Amounts  

Six Months Ended June 30, 2021

    —      $ —  

Year Ended December 31, 2020

    716,855        4,813,281  

 

 

N O T E S   T O   F I N A N C I A L   S T A T E M E N T S

  175


Notes to Financial Statements (unaudited) (continued)

 

     BDJ  
     Shares      Amounts  

Six Months Ended June 30, 2021

    —      $ —  

Year Ended December 31, 2020

    1,538,971        11,354,242  

 

     BOE  
     Shares      Amounts  

Six Months Ended June 30, 2021

    18,558      $ 205,246  

Year Ended December 31, 2020

    1,539,117        14,886,112  

 

     BGY  
     Shares      Amounts  

Six Months Ended June 30, 2021

    —      $ —  

Year Ended December 31, 2020

    1,441,544        7,486,085  

 

     BCX  
     Shares      Amounts  

Six Months Ended June 30, 2021

    —      $ —  

Year Ended December 31, 2020

    2,744,110            17,262,335  

With respect to BIGZ, for the period ended June 30, 2021, shares issued and outstanding increased by 231,136 as a result of dividend reinvestment, 220,000,000 from the initial public offering and 23,092,422 from the underwriters’ exercising the over-allotment option.

As of June 30, 2021, BlackRock Financial Management, Inc., an affiliate of the Trust, owned 5,000 Shares of BIGZ.

For the six months ended June 30, 2021 and year ended December 31, 2020, shares issued and outstanding remained constant for CII and BSTZ. For the six months ended June 30, 2021, shares issued and outstanding remained constant for BGR, BDJ, BGY, BMEZ and BCX.

As of the close of business on June 18, 2021, BST issued transferrable rights to its Common Shareholders of record, entitling the holders of those rights to subscribe for shares of BST’s common stock (the “Offer”). Shareholders received one right for each outstanding Common Share owned on the record date. The rights entitle their holders to purchase one new Common Share for every three rights held (1-for-3). The expiration date of the Offer is expected to be July 14, 2021. All expenses of the Offer, including sales commissions, will be borne by the Manager, and not by BST or any of BST’s shareholders. Refer to the Subsequent Events note for results of the Offer.

 

11.

SUBSEQUENT EVENTS

Management’s evaluation of the impact of all subsequent events on the Trusts’ financial statements was completed through the date the financial statements were issued and the following items were noted:

BST’s rights offering expired on July 14, 2021. BST received from the Offer gross proceeds of $359,278,213 for the issuance of 6,822,923 Common Shares. The rights offering resulted in $(0.68) or (1.24)% NAV dilution. BST received the entire proceeds from the shares issued under the Offer since the Manager agreed to pay for all expenses (including sales commissions) related to the Offer.

The Trusts declared and paid or will pay distributions to Common Shareholders as follows:

 

Trust Name   Declaration
Date
     Record
Date
     Payable/
Paid Date
     Dividend Per
Common Share
 

BGR

          
    07/01/21        07/15/21        07/30/21      $ 0.037500  
    08/02/21        08/16/21        08/31/21        0.037500  

CII

          
    07/01/21        07/15/21        07/30/21        0.093000  
    08/02/21        08/16/21        08/31/21        0.093000  

BDJ

          
    07/01/21        07/15/21        07/30/21        0.050000  
    08/02/21        08/16/21        08/31/21        0.050000  

BOE

          
    07/01/21        07/15/21        07/30/21        0.063000  
    08/02/21        08/16/21        08/31/21        0.063000  

BGY

          
    07/01/21        07/15/21        07/30/21        0.033800  
    08/02/21        08/16/21        08/31/21        0.033800  

BME

          
    07/01/21        07/15/21        07/30/21        0.200000  
    08/02/21        08/16/21        08/31/21        0.200000  

BMEZ

                                  

 

 

176  

2 0 2 1   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S


Notes to Financial Statements (unaudited) (continued)

 

Trust Name   Declaration
Date
     Record
Date
     Payable/
Paid Date
     Dividend Per
Common Share
 
    07/01/21        07/15/21        07/30/21      $ 0.145000  
    08/02/21        08/16/21        08/31/21        0.145000  

BIGZ

          
    07/01/21        07/15/21        07/30/21        0.100000  
    08/02/21        08/16/21        08/31/21        0.100000  

BCX

          
    07/01/21        07/15/21        07/30/21        0.040000  
    08/02/21        08/16/21        08/31/21        0.040000  

BST

          
    06/09/21        07/06/21        07/30/21        0.226000  
    08/02/21        08/16/21        08/31/21        0.226000  

BSTZ

          
    07/01/21        07/15/21        07/30/21        0.171000  
    08/02/21        08/16/21        08/31/21        0.171000  

BUI

          
    07/01/21        07/15/21        07/30/21        0.121000  
      08/02/21        08/16/21        08/31/21        0.121000  

 

 

N O T E S   T O   F I N A N C I A L   S T A T E M E N T S

  177


Disclosure of Investment Advisory Agreements and Sub-Advisory  Agreements 

 

The Boards of Directors/Trustees, as applicable (collectively, the “Board,” the members of which are referred to as “Board Members”) of BlackRock Energy and Resources Trust (“BGR”), BlackRock Enhanced Capital and Income Fund, Inc. (“CII”), BlackRock Enhanced Equity Dividend Trust (“BDJ”), BlackRock Enhanced Global Dividend Trust (“BOE”), BlackRock Enhanced International Dividend Trust (“BGY”), BlackRock Health Sciences Trust (“BME”), BlackRock Health Sciences Trust II (“BMEZ”), BlackRock Resources & Commodities Strategy Trust (“BCX”), BlackRock Science and Technology Trust (“BST”), BlackRock Utilities, Infrastructure & Power Opportunities Trust (“BUI”) and BlackRock Science and Technology Trust II (“BSTZ” and together with BGR, CII, BDJ, BOE, BGY, BME, BMEZ, BCX, BST and BUI, the “Funds” and each, a “Fund”) met on May 4, 2021 (the “May Meeting”) and June 8-9, 2021 (the “June Meeting”) to consider the approval to continue the investment advisory agreements (the “Advisory Agreements”) between each Fund and BlackRock Advisors, LLC (the “Manager”), each Fund’s investment advisor. The Board also considered the approval to continue the sub-advisory agreements (the “Sub-Advisory Agreements”) between the Manager, BlackRock International Limited (the “Sub-Advisor”) and each of BGR, BOE, BGY, BCX and BUI. The Manager and the Sub-Advisor are referred to herein as “BlackRock.” The Advisory Agreements and the Sub-Advisory Agreements are referred to herein as the “Agreements.”

The Approval Process

Consistent with the requirements of the Investment Company Act of 1940 (the “1940 Act”), the Board considers the approval of the continuation of the Agreements for each Fund on an annual basis. The Board members whom are not “interested persons” of each Fund, as defined in the 1940 Act, are considered independent Board members (the “Independent Board Members”). The Board’s consideration entailed a year-long deliberative process during which the Board and its committees assessed BlackRock’s various services to each Fund, including through the review of written materials and oral presentations, and the review of additional information provided in response to requests from the Independent Board Members. The Board had four quarterly meetings per year, each typically extending for two days, as well as additional ad hoc meetings and executive sessions throughout the year, as needed. The committees of the Board similarly met throughout the year. The Board also had a fifth one-day meeting to consider specific information surrounding the renewal of the Agreements. In particular, the Board assessed, among other things, the nature, extent and quality of the services provided to each Fund by BlackRock, BlackRock’s personnel and affiliates, including (as applicable): investment management services; accounting oversight; administrative and shareholder services; oversight of each Fund’s service providers; risk management and oversight; and legal, regulatory and compliance services. Throughout the year, including during the contract renewal process, the Independent Board Members were advised by independent legal counsel, and met with independent legal counsel in various executive sessions outside of the presence of BlackRock’s management.

During the year, the Board, acting directly and through its committees, considered information that was relevant to its annual consideration of the renewal of the Agreements, including the services and support provided by BlackRock to each Fund and its shareholders. BlackRock also furnished additional information to the Board in response to specific questions from the Board. Among the matters the Board considered were: (a) investment performance for one-year, three-year, five-year, and/or since inception periods, as applicable, against peer funds, relevant benchmarks, and other performance metrics, as applicable, as well as BlackRock senior management’s and portfolio managers’ analyses of the reasons for any outperformance or underperformance relative to its peers, benchmarks, and other performance metrics, as applicable; (b) leverage management, as applicable; (c) fees, including advisory, administration, if applicable, and other amounts paid to BlackRock and its affiliates by each Fund for services; (d) Fund operating expenses and how BlackRock allocates expenses to each Fund; (e) the resources devoted to risk oversight of, and compliance reports relating to, implementation of each Fund’s investment objective, policies and restrictions, and meeting regulatory requirements; (f) BlackRock’s and each Fund’s adherence to applicable compliance policies and procedures; (g) the nature, character and scope of non-investment management services provided by BlackRock and its affiliates and the estimated cost of such services, as available; (h) BlackRock’s and other service providers’ internal controls and risk and compliance oversight mechanisms; (i) BlackRock’s implementation of the proxy voting policies approved by the Board; (j) execution quality of portfolio transactions; (k) BlackRock’s implementation of each Fund’s valuation and liquidity procedures; (l) an analysis of management fees paid to BlackRock for products with similar investment mandates across the open-end fund, closed-end fund, sub-advised mutual fund, collective investment trust and institutional separate account product channels, as applicable, and the similarities and differences between these products and the services provided as compared to each Fund; (m) BlackRock’s compensation methodology for its investment professionals and the incentives and accountability it creates, along with investment professionals’ investments in the fund(s) they manage; (n) periodic updates on BlackRock’s business; and (o) each Fund’s market discount/premium compared to peer funds.

Prior to and in preparation for the May Meeting, the Board received and reviewed materials specifically relating to the renewal of the Agreements. The Independent Board Members are continuously engaged in a process with their independent legal counsel and BlackRock to review the nature and scope of the information provided to the Board to better assist its deliberations. The materials provided in connection with the May Meeting included, among other things: (a) information independently compiled and prepared by Broadridge Financial Solutions, Inc. (“Broadridge”), based on Lipper classifications, regarding each Fund’s fees and expenses as compared with a peer group of funds as determined by Broadridge (“Expense Peers”) and the investment performance of each Fund as compared with a peer group of funds (“Performance Peers”); (b) information on the composition of the Expense Peers and Performance Peers and a description of Broadridge’s methodology; (c) information on the estimated profits realized by BlackRock and its affiliates pursuant to the Agreements and a discussion of fall-out benefits to BlackRock and its affiliates; (d) a general analysis provided by BlackRock concerning investment management fees received in connection with other types of investment products, such as institutional accounts, sub-advised mutual funds, closed-end funds, and open-end funds, under similar investment mandates, as applicable; (e) a review of non-management fees; (f) the existence, impact and sharing of potential economies of scale, if any, with each Fund; (g) a summary of aggregate amounts paid by each Fund to BlackRock; and (h) various additional information requested by the Board as appropriate regarding BlackRock’s and each Fund’s operations.

At the May Meeting, the Board reviewed materials relating to its consideration of the Agreements. As a result of the discussions that occurred during the May Meeting, and as a culmination of the Board’s year-long deliberative process, the Board presented BlackRock with questions and requests for additional information. BlackRock responded to these questions and requests with additional written information in advance of the June Meeting.

At the June Meeting, the Board concluded its assessment of, among other things: (a) the nature, extent and quality of the services provided by BlackRock; (b) the investment performance of each Fund as compared to its Performance Peers and to other metrics, as applicable; (c) the advisory fee and the estimated cost of the services and estimated profits realized by BlackRock and its affiliates from their relationship with each Fund; (d) each Fund’s fees and expenses compared to its Expense Peers; (e) the existence and sharing of potential economies of scale; (f) any fall-out benefits to BlackRock and its affiliates as a result of BlackRock’s relationship with each Fund; and (g) other factors deemed relevant by the Board Members.

 

 

178  

2 0 2 1   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S


Disclosure of Investment Advisory Agreements and Sub-Advisory Agreements (continued)

 

The Board also considered other matters it deemed important to the approval process, such as other payments made to BlackRock or its affiliates relating to securities lending and cash management, and BlackRock’s services related to the valuation and pricing of Fund portfolio holdings. The Board noted the willingness of BlackRock’s personnel to engage in open, candid discussions with the Board. The Board Members did not identify any particular information, or any single factor as determinative, and each Board Member may have attributed different weights to the various items and factors considered.

A. Nature, Extent and Quality of the Services Provided by BlackRock

The Board, including the Independent Board Members, reviewed the nature, extent and quality of services provided by BlackRock, including the investment advisory services, and the resulting performance of each Fund. Throughout the year, the Board compared Fund performance to the performance of a comparable group of closed-end funds, relevant benchmarks, and performance metrics, as applicable. The Board met with BlackRock’s senior management personnel responsible for investment activities, including the senior investment officers. The Board also reviewed the materials provided by each Fund’s portfolio management team discussing each Fund’s performance, investment strategies and outlook.

The Board considered, among other factors, with respect to BlackRock: the number, education and experience of investment personnel generally and each Fund’s portfolio management team; research capabilities; investments by portfolio managers in the funds they manage; portfolio trading capabilities; use of technology; commitment to compliance; credit analysis capabilities; risk analysis and oversight capabilities; and the approach to training and retaining portfolio managers and other research, advisory and management personnel. The Board also considered BlackRock’s overall risk management program, including the continued efforts of BlackRock and its affiliates to address cybersecurity risks and the role of BlackRock’s Risk & Quantitative Analysis Group. The Board engaged in a review of BlackRock’s compensation structure with respect to each Fund’s portfolio management team and BlackRock’s ability to attract and retain high-quality talent and create performance incentives.

In addition to investment advisory services, the Board considered the nature and quality of the administrative and other non-investment advisory services provided to each Fund. BlackRock and its affiliates provide each Fund with certain administrative, shareholder and other services (in addition to any such services provided to each Fund by third parties) and officers and other personnel as are necessary for the operations of each Fund. In particular, BlackRock and its affiliates provide each Fund with administrative services including, among others: (i) responsibility for disclosure documents, such as the prospectus and the statement of additional information in connection with the initial public offering, registration statements in connection with each of BME’s, BUI’s and BST’s equity shelf program and periodic shareholder reports; (ii) preparing communications with analysts to support secondary market trading of each Fund; (iii) oversight of daily accounting and pricing; (iv) responsibility for periodic filings with regulators and stock exchanges; (v) overseeing and coordinating the activities of third-party service providers including, among others, each Fund’s custodian, fund accountant, transfer agent, and auditor; (vi) organizing Board meetings and preparing the materials for such Board meetings; (vii) providing legal and compliance support; (viii) furnishing analytical and other support to assist the Board in its consideration of strategic issues such as the merger, consolidation or repurposing of certain closed-end funds; and (ix) performing or managing administrative functions necessary for the operation of each Fund, such as tax reporting, expense management, fulfilling regulatory filing requirements, and shareholder call center and other services. The Board reviewed the structure and duties of BlackRock’s fund administration, shareholder services, and legal and compliance departments and considered BlackRock’s policies and procedures for assuring compliance with applicable laws and regulations. The Board considered the operation of BlackRock’s business continuity plans, including in light of the ongoing COVID-19 pandemic.

B. The Investment Performance of each Fund and BlackRock

The Board, including the Independent Board Members, reviewed and considered the performance history of each Fund throughout the year and at the May Meeting. In preparation for the May Meeting, the Board was provided with reports independently prepared by Broadridge, which included an analysis of each Fund’s performance as of December 31, 2020, as compared to its Performance Peers. The performance information is based on net asset value (NAV), and utilizes Lipper data. Lipper’s methodology calculates a fund’s total return assuming distributions are reinvested on the ex-date at a fund’s ex-date NAV. Broadridge ranks funds in quartiles, ranging from first to fourth, where first is the most desirable quartile position and fourth is the least desirable. In connection with its review, the Board received and reviewed information regarding the investment performance of each Fund as compared to its Performance Peers and certain performance metrics including Fund return, Sharpe Ratio, stability of distribution, and yield (“Performance Metrics”). The Board and its Performance Oversight Committee regularly review and meet with Fund management to discuss the performance of each Fund throughout the year.

In evaluating performance, the Board focused particular attention on funds with less favorable performance records. The Board also noted that while it found the data provided by Broadridge generally useful, it recognized the limitations of such data, including in particular, that notable differences may exist between a fund and its Performance Peers (for example, the investment objectives and strategies). Further, the Board recognized that the performance data reflects a snapshot of a period as of a particular date and that selecting a different performance period could produce significantly different results. The Board also acknowledged that long-term performance could be impacted by even one period of significant outperformance or underperformance, and that a single investment theme could have the ability to disproportionately affect long-term performance.

The Board reviewed and considered BGR’s performance relative to BGR’s Performance Metrics. Based on an overall rating relative to the Performance Metrics, BGR generally performed in line with expectations. The Board noted that BlackRock believes that the Performance Metrics are an appropriate performance comparison for BGR, and that BlackRock has explained its rationale for this belief to the Board.

The Board reviewed and considered CII’s performance relative to CII’s Performance Metrics. Based on an overall rating relative to the Performance Metrics, CII generally performed above expectations. The Board noted that BlackRock believes that the Performance Metrics are an appropriate performance comparison for CII, and that BlackRock has explained its rationale for this belief to the Board.

The Board reviewed and considered BDJ’s performance relative to BDJ’s Performance Metrics. Based on an overall rating relative to the Performance Metrics, BDJ generally performed above expectations. The Board noted that BlackRock believes that the Performance Metrics are an appropriate performance comparison for BDJ, and that BlackRock has explained its rationale for this belief to the Board.

 

 

D I S C L O S U R E   O F   I N V E S T M E N T   A D V I S O R Y   A G R E E M E N T S   A N D   S U B - A D V I S O R Y   A G R E E M E N T S

  179


Disclosure of Investment Advisory Agreements and Sub-Advisory Agreements (continued)

 

The Board reviewed and considered BOE’s performance relative to BOE’s Performance Metrics. Based on an overall rating relative to the Performance Metrics, BOE generally performed below expectations. The Board noted that BlackRock believes that the Performance Metrics are an appropriate performance comparison for BOE, and that BlackRock has explained its rationale for this belief to the Board. The Board and BlackRock reviewed BOE’s underperformance relative to the Performance Metrics.

The Board reviewed and considered BGY’s performance relative to BGY’s Performance Metrics. Based on an overall rating relative to the Performance Metrics, BGY generally performed above expectations. The Board noted that BlackRock believes that the Performance Metrics are an appropriate performance comparison for BGY, and that BlackRock has explained its rationale for this belief to the Board.

The Board reviewed and considered BME’s performance relative to BME’s Performance Metrics. Based on an overall rating relative to the Performance Metrics, BME generally performed above expectations. The Board noted that BlackRock believes that the Performance Metrics are an appropriate performance comparison for BME, and that BlackRock has explained its rationale for this belief to the Board.

The Board reviewed and considered BMEZ’s performance relative to BMEZ’s Performance Metrics over the since-inception period. The Board noted that BlackRock believes that the Performance Metrics are an appropriate performance comparison for BMEZ, and that BlackRock has explained its rationale for this belief to the Board.

The Board reviewed and considered BCX’s performance relative to the BCX’s Performance Metrics. Based on an overall rating relative to the Performance Metrics, BCX generally performed above expectations. The Board noted that BlackRock believes that the Performance Metrics are an appropriate performance comparison for BCX, and that BlackRock has explained its rationale for this belief to the Board.

The Board reviewed and considered BST’s performance relative to BST’s Performance Metrics. Based on an overall rating relative to the Performance Metrics, BST generally performed above expectations. The Board noted that BlackRock believes that the Performance Metrics are an appropriate performance comparison for BST, and that BlackRock has explained its rationale for this belief to the Board.

The Board reviewed and considered BSTZ’s performance relative to BSTZ’s Performance Metrics. Based on an overall rating relative to the Performance Metrics, BSTZ generally performed above expectations. The Board noted that BlackRock believes that the Performance Metrics are an appropriate performance comparison for BSTZ, and that BlackRock has explained its rationale for this belief to the Board.

The Board reviewed and considered BUI’s performance relative to BUI’s Performance Metrics. Based on an overall rating relative to the Performance metrics, BUI generally performed above expectations. The Board noted that BlackRock believes that the Performance Metrics are an appropriate performance comparison for BUI, and that BlackRock has explained its rationale for this belief to the Board.

C. Consideration of the Advisory/Management Fees and the Estimated Cost of the Services and Estimated Profits Realized by BlackRock and its Affiliates from their Relationship with each Fund

The Board, including the Independent Board Members, reviewed each Fund’s contractual management fee rate compared with those of its Expense Peers. The contractual management fee rate represents a combination of the advisory fee and any administrative fees, before taking into account any reimbursements or fee waivers. The Board also compared each Fund’s total expense ratio, as well as its actual management fee rate as a percentage of managed assets, which is the total assets of each Fund (including any assets attributable to money borrowed for investment purposes) minus the sum of each Fund’s accrued liabilities (other than money borrowed for investment purposes) to those of its Expense Peers. The total expense ratio represents a fund’s total net operating expenses, excluding any investment related expenses. The total expense ratio gives effect to any expense reimbursements or fee waivers, and the actual management fee rate gives effect to any management fee reimbursements or waivers. The Board considered the services provided and the fees charged by BlackRock and its affiliates to other types of clients with similar investment mandates, as applicable, including institutional accounts and sub-advised mutual funds (including mutual funds sponsored by third parties).

The Board received and reviewed statements relating to BlackRock’s financial condition. The Board reviewed BlackRock’s profitability methodology and was also provided with an estimated profitability analysis that detailed the revenues earned and the expenses incurred by BlackRock for services provided to each Fund. The Board reviewed BlackRock’s estimated profitability with respect to each Fund and other funds the Board currently oversees for the year ended December 31, 2020 compared to available aggregate estimated profitability data provided for the prior two years. The Board reviewed BlackRock’s estimated profitability with respect to certain other U.S. fund complexes managed by the Manager and/or its affiliates. The Board reviewed BlackRock’s assumptions and methodology of allocating expenses in the estimated profitability analysis, noting the inherent limitations in allocating costs among various advisory products. The Board recognized that profitability may be affected by numerous factors including, among other things, fee waivers and expense reimbursements by the Manager, the types of funds managed, precision of expense allocations and business mix. The Board thus recognized that calculating and comparing profitability at the individual fund level is difficult.

The Board noted that, in general, individual fund or product line profitability of other advisors is not publicly available. The Board reviewed BlackRock’s overall operating margin, in general, compared to that of certain other publicly traded asset management firms. The Board considered the differences between BlackRock and these other firms, including the contribution of technology at BlackRock, BlackRock’s expense management, and the relative product mix.

The Board considered whether BlackRock has the financial resources necessary to attract and retain high quality investment management personnel to perform its obligations under the Agreements and to continue to provide the high quality of services that is expected by the Board. The Board further considered factors including but not limited to BlackRock’s commitment of time, assumption of risk, and liability profile in servicing each Fund, including in contrast to what is required of BlackRock with respect to other products with similar investment mandates across the open-end fund, closed-end fund, sub-advised mutual fund, collective investment trust, and institutional separate account product channels, as applicable.

The Board noted that BGR’s contractual management fee rate ranked in the fourth quartile, and that the actual management fee rate and total expense ratio each ranked in the first quartile, relative to the Expense Peers. In addition, the Board noted that BlackRock had agreed to voluntarily waive a portion of the advisory fee payable by BGR. An

 

 

180  

2 0 2 1   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S


Disclosure of Investment Advisory Agreements and Sub-Advisory Agreements (continued)

 

advisory fee waiver has been in effect since 2015, the amount of which may have varied from time to time. After discussions between the Board, including Independent Board Members, and BlackRock, the Board and BlackRock agreed to a continuation of the current 22 basis points voluntary advisory fee waiver.

The Board noted that CII’s contractual management fee rate ranked in the first quartile, and that the actual management fee rate and total expense ratio each ranked in the first quartile, relative to the Expense Peers.

The Board noted that BDJ’s contractual management fee rate ranked in the first quartile, and that the actual management fee rate and total expense ratio each ranked in the first quartile, relative to the Expense Peers.

The Board noted that BOE’s contractual management fee rate ranked in the second quartile, and that the actual management fee rate and total expense ratio each ranked in the first quartile, relative to the Expense Peers. In addition, the Board noted that BlackRock had agreed to voluntarily waive a portion of the advisory fee payable by BOE. An advisory fee waiver has been in effect since 2015, the amount of which may have varied from time to time. After discussion between the Board, including the Independent Board Members, and BlackRock, the Board and BlackRock agreed to a continuation of the current 17.5 basis points voluntary advisory fee waiver.

The Board noted that BGY’s contractual management fee rate ranked in the second quartile, and that the actual management fee rate and total expense ratio each ranked in the second quartile, relative to the Expense Peers. The Board also noted that BlackRock had agreed to voluntarily waive a portion of the advisory fee payable by BGY. An advisory fee waiver has been in effect since 2013, the amount of which may have varied from time to time. After discussions between the Board, including Independent Board Members, and BlackRock, the Board and BlackRock agreed to a continuation of the current 10 basis points voluntary advisory fee waiver.

The Board noted that BME’s contractual management fee rate ranked in the second quartile, and that the actual management fee rate and total expense ratio ranked in the second and first quartiles, respectively, relative to the Expense Peers.

The Board noted that BMEZ’s contractual management fee rate ranked in the third quartile, and that the actual management fee rate and total expense ratio ranked in the third and second quartiles, respectively, relative to the Expense Peers.

The Board noted that BCX’s contractual management fee rate ranked in the first quartile, and that the actual management fee rate and total expense ratio each ranked in the first quartile relative to the Expense Peers.

The Board noted that BST’s contractual management fee rate ranked in the second quartile, and that the actual management fee rate and total expense ratio each ranked in the first quartile relative to the Expense Peers. The Board also noted that, in connection with BST’s launch, BlackRock has contractually agreed to waive a portion of the advisory fee payable by BST through December 31, 2021. The contractual advisory fee waiver is 15 basis points through December 31, 2019, will be 10 basis points through December 31, 2020, and then will be 5 basis points through December 31, 2021.

The Board noted that BSTZ’s contractual management fee rate ranked in the third quartile, and that the actual management fee rate and total expense ratio ranked in the third and second quartiles, respectively, relative to the Expense Peers.

The Board noted that BUI’s contractual management fee rate ranked in the third quartile, and that the actual management fee rate and total expense ratio ranked in the first and second quartile, respectively, relative to the Expense Peers.

D. Economies of Scale

The Board, including the Independent Board Members, considered the extent to which economies of scale might be realized as the assets of each Fund increase. The Board also considered the extent to which each Fund benefits from such economies of scale in a variety of ways, and whether there should be changes in the advisory fee rate or breakpoint structure in order to enable each Fund to more fully participate in these economies of scale. The Board considered each Fund’s asset levels and whether the current fee was appropriate.

Based on the Board’s review and consideration of the issue, the Board concluded that most closed-end funds do not have fund level breakpoints because closed-end funds generally do not experience substantial growth after the initial public offering. Closed-end funds are typically priced at scale at a fund’s inception. The Board noted that although each of BME, BUI and BST may from time-to-time make additional share offerings pursuant to its equity shelf program, the growth of each of BME, BUI and BST’s assets will occur primarily through the appreciation of its investment portfolio.

E. Other Factors Deemed Relevant by the Board Members

The Board, including the Independent Board Members, also took into account other ancillary or “fall-out” benefits that BlackRock or its affiliates may derive from BlackRock’s respective relationships with each Fund, both tangible and intangible, such as BlackRock’s ability to leverage its investment professionals who manage other portfolios and its risk management personnel, an increase in BlackRock’s profile in the investment advisory community, and the engagement of BlackRock’s affiliates as service providers to each Fund, including for administrative, securities lending and cash management services. The Board also considered BlackRock’s overall operations and its efforts to expand the scale of, and improve the quality of, its operations. The Board also noted that, subject to applicable law, BlackRock may use and benefit from third-party research obtained by soft dollars generated by certain registered fund transactions to assist in managing all or a number of its other client accounts.

In connection with its consideration of the Agreements, the Board also received information regarding BlackRock’s brokerage and soft dollar practices. The Board received reports from BlackRock which included information on brokerage commissions and trade execution practices throughout the year.

The Board noted the competitive nature of the closed-end fund marketplace, and that shareholders are able to sell their Fund shares in the secondary market if they believe that each Fund’s fees and expenses are too high or if they are dissatisfied with the performance of each Fund.

 

 

D I S C L O S U R E   O F   I N V E S T M E N T   A D V I S O R Y   A G R E E M E N T S   A N D   S U B - A D V I S O R Y   A G R E E M E N T S

  181


Disclosure of Investment Advisory Agreements and Sub-Advisory Agreements (continued)

 

The Board also considered the various notable initiatives and projects BlackRock performed in connection with its closed-end fund product line. These initiatives included developing equity shelf programs; efforts to eliminate product overlap with fund mergers; ongoing services to manage leverage that has become increasingly complex; periodic evaluation of share repurchases and other support initiatives for certain BlackRock funds; and continued communication efforts with shareholders, fund analysts and financial advisers. With respect to the latter, the Independent Board Members noted BlackRock’s continued commitment to supporting the secondary market for the common shares of its closed-end funds through a comprehensive secondary market communication program designed to raise investor and analyst awareness and understanding of closed-end funds. BlackRock’s support services included, among other things: sponsoring and participating in conferences; communicating with closed-end fund analysts covering the BlackRock funds throughout the year; providing marketing and product updates for the closed-end funds; and maintaining and enhancing its closed-end fund website.

Conclusion

The Board, including the Independent Board Members, unanimously approved the continuation of the Advisory Agreements between the Manager and each Fund for a one-year term ending June 30, 2022, and the Sub-Advisory Agreements among the Manager, the Sub-Advisor and each of BGR, BOE, BGY, BCX and BUI for a one-year term ending June 30, 2022. Based upon its evaluation of all of the aforementioned factors in their totality, as well as other information, the Board, including the Independent Board Members, was satisfied that the terms of the Agreements were fair and reasonable and in the best interest of each Fund and its shareholders. In arriving at its decision to approve the Agreements, the Board did not identify any single factor or group of factors as all-important or controlling, but considered all factors together, and different Board Members may have attributed different weights to the various factors considered. The Independent Board Members were also assisted by the advice of independent legal counsel in making this determination.

 

 

182  

2 0 2 1   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S


Disclosure of Investment Advisory Agreement

 

The Board of Trustees (the “Board,” the members of which are referred to as “Board Members”) of BlackRock Innovation and Growth Trust (the “Fund”) met on January 28, 2021 (the “Meeting”) to consider the approval of the proposed investment advisory agreement (the “Advisory Agreement” or the “Agreement”) between the Fund and BlackRock Advisors, LLC (the “Manager” or “BlackRock”), the Fund’s investment advisor.

The Approval Process:

Pursuant to the Investment Company Act of 1940 (the “1940 Act”), the Board is required to consider the initial approval of the Agreement. The Board members whom are not “interested persons” of the Fund, as defined in the 1940 Act, are considered independent Board members (the “Independent Board Members”). In connection with this process, the Board assessed, among other things, the nature, extent and quality of the services to be provided to the Fund by BlackRock, BlackRock’s personnel and affiliates, including (as applicable): investment management services; accounting oversight; administrative and shareholder services; oversight of the Fund’s service providers; risk management and oversight; legal and compliance services; and ability to meet applicable legal and regulatory requirements.

At the Meeting, the Board received and reviewed materials relating to its consideration of the Agreement. The Board considered all factors it believed relevant with respect to the Fund, including, among other factors: (a) the nature, extent and quality of the services to be provided by BlackRock; (b) the investment performance of BlackRock portfolio management; (c) the advisory fee and the estimated cost of the services to be provided and profits to be realized by BlackRock and its affiliates from their relationship with the Fund; (d) the sharing of potential economies of scale; (e) potential fall-out benefits to BlackRock and BlackRock’s affiliates as a result of its relationship with the Fund; (f) the policies and practices of BlackRock with respect to portfolio transactions for the Fund; and (g) other factors deemed relevant by the Board Members.

In determining whether to approve the Agreement, the Board met with the relevant investment advisory personnel from BlackRock and considered all information it deemed reasonably necessary to evaluate the terms of the Agreement. The Board received materials in advance of the Meeting relating to its consideration of the Agreement, including, among other things, (a) fees and estimated expense ratios of the Fund in comparison to the fees and expense ratios of a peer group of funds as determined by Broadridge Financial Solutions, Inc. (“Broadridge”) and other metrics, as applicable; (b) information on the composition of the peer group of funds and a description of Broadridge’s methodology; (c) information regarding BlackRock’s economic outlook for the Fund and its general investment outlook for the markets; (d) information regarding fees paid to service providers that are affiliates of BlackRock; and (e) information outlining the legal duties of the Board under the 1940 Act with respect to the consideration and approval of the Agreement. The Board also noted information received at prior Board meetings concerning compliance records and regulatory matters relating to BlackRock.

The Board also considered other matters it deemed important to the approval process, such as other payments to be made to BlackRock or its affiliates relating to securities lending and cash management, and BlackRock’s services related to the valuation and pricing of Fund portfolio holdings, and advice from independent legal counsel with respect to the review process and materials submitted for the Board’s review. The Board noted the willingness of BlackRock’s personnel to engage in open, candid discussions with the Board. The Board Members did not identify any particular information or any single factor as determinative, and each Board Member may have attributed different weights to the various items and factors considered.

A. Nature, Extent and Quality of the Services Provided by BlackRock

The Board, including the Independent Board Members, reviewed the nature, extent and quality of services to be provided by BlackRock, including the investment advisory services to be provided to the Fund. The Board received information concerning the investment philosophy and investment process to be used by BlackRock in managing the Fund, as well as a description of the capabilities, personnel and services of BlackRock. In connection with this review, the Board considered BlackRock’s in-house research capabilities as well as other resources available to its personnel. The Board considered the scope of the services to be provided by BlackRock to the Fund under the Agreement relative to services typically provided by third parties to other funds. The Board noted that the standard of care applicable under the Agreement was comparable to that found generally in investment company advisory agreements. The Board concluded that the scope of BlackRock’s services to be provided to the Fund was consistent with the Fund’s operational requirements, including, in addition to seeking to meet its investment objective, compliance with investment restrictions, tax and reporting requirements and related shareholder services.

The Board, including the Independent Board Members, also considered the quality of the administrative and other non-investment advisory services to be provided by BlackRock and its affiliates to the Fund. The Board evaluated the procedures of BlackRock designed to fulfill its fiduciary duty to the Fund with respect to possible conflicts of interest, including BlackRock’s code of ethics (regulating the personal trading of BlackRock’s officers and employees), the procedures by which BlackRock allocates trades among its various investment advisory clients, the integrity of the systems in place to ensure compliance with the foregoing and the record of BlackRock in these matters. The Board also noted information received at prior meetings of the boards of directors/trustees of other funds in the BlackRock Fixed-Income Complex concerning the standards of BlackRock with respect to the execution of portfolio transactions.

The Board, including the Independent Board Members, considered, among other factors, with respect to BlackRock: the number, education and experience of investment personnel generally and the Fund’s portfolio management team; BlackRock’s research capabilities; the history of investments by portfolio managers in the funds they manage; portfolio trading capabilities; use of technology; commitment to compliance; credit analysis capabilities; risk analysis and oversight capabilities; and the approach to training and retaining portfolio managers and other research, advisory and management personnel. The Board also considered BlackRock’s overall risk management program, including the continued efforts of BlackRock and its affiliates to address cybersecurity risks and the role of BlackRock’s Risk & Quantitative Analysis Group. The Board engaged in a review of BlackRock’s compensation structure with respect to the Fund’s portfolio management team and BlackRock’s ability to attract and retain high-quality talent and create performance incentives. The Board also considered the business reputation of BlackRock and its financial resources and concluded that BlackRock would be able to meet any reasonably foreseeable obligation under the Agreement.

In addition to investment advisory services, the Board, including the Independent Board Members, considered the nature and quality of the administrative and other non-investment advisory services to be provided by BlackRock and its affiliates to the Fund. The Board noted that BlackRock and its affiliates will provide the Fund with certain administrative, shareholder and other services (in addition to any such services provided to the Fund by third parties) and officers and other personnel as are necessary for the operations of the Fund. In particular, the Board noted that BlackRock and its affiliates will provide the Fund with administrative services including, among others: (i) responsibility for disclosure documents, such as the prospectus and the statement of additional information in connection with the initial public offering and periodic

 

 

D I S C L O S U R E   O F   I N V E S T M E N T   A D V I S O R Y   A G R E E M E N T

  183


Disclosure of Investment Advisory Agreement (continued)

 

shareholder reports; (ii) preparing communications with analysts to support secondary market trading of the Fund; (iii) oversight of daily accounting and pricing; (iv) responsibility for periodic filings with regulators and stock exchanges; (v) overseeing and coordinating the activities of third-party service providers including, among others, the Fund’s custodian, fund accountant, transfer agent, and auditor; (vi) organizing Board meetings and preparing the materials for such Board meetings; (vii) providing legal and compliance support; (viii) furnishing analytical and other support to assist the Board in its consideration of strategic issues; and (ix) performing or managing administrative functions necessary for the operation of the Fund, such as tax reporting, expense management, fulfilling regulatory filing requirements and shareholder call center and other services. The Board reviewed the structure and duties of BlackRock’s fund administration, shareholder services, and legal and compliance departments and considered BlackRock’s policies and procedures for assuring compliance with applicable laws and regulations.

B. The Investment Performance of the Fund and BlackRock

In their capacity as members of the boards of directors or trustees of certain other BlackRock-advised funds, the Board, including the Independent Board Members, previously received and considered information about BlackRock’s investment performance for other funds. The Board, however, could not consider the performance history of the Fund because the Fund had not yet commenced operations as of the date of the Meeting.

C. Consideration of the Advisory/Management Fees and the Estimated Cost of the Services and Estimated Profits Realized by BlackRock and its Affiliates from their Relationship with the Fund

In connection with the initial approval of the Agreement, the Board, including the Independent Board Members, reviewed the Fund’s proposed contractual management fee rate compared with the other funds in its Broadridge category. The contractual management fee rate represents a combination of the advisory fee and any administrative fees, before taking into account any reimbursements or fee waivers. In addition, the Board, including the Independent Board Members, considered the Fund’s estimated total net expense ratio, as well as the actual management fee rate as a percentage of total assets, to those of other funds in its Broadridge category. The estimated total expense ratio represents a fund’s total net operating expenses, excluding any investment related expenses. The estimated total expense ratio gives effect to any expense reimbursements or fee waivers that benefit a fund, and the actual management fee rate gives effect to any management fee reimbursements or waivers that benefit a fund. The Board considered the services provided and the fees charged by BlackRock and its affiliates to other types of clients with similar investment mandates, as applicable, including institutional separate accounts and sub-advised mutual funds (including mutual funds sponsored by third parties).

The Board noted that it had previously received and reviewed statements relating to BlackRock’s financial condition in connection with their duties as trustees or directors of other funds in the BlackRock family of closed-end funds. The Board considered whether BlackRock has the financial resources necessary to attract and retain high quality investment management personnel to perform its obligations under the Agreement and to provide the high quality of services that is expected by the Board. The Board further considered factors including but not limited to BlackRock’s commitment of time, assumption of risk, and liability profile in servicing the Fund in contrast to what is required of BlackRock with respect to other products with similar investment mandates, as applicable, across the open-end fund, closed-end fund, sub-advised mutual fund, collective investment trust and institutional separate account product channels.

The Board noted that the Fund’s contractual management fee rate ranked in the fourth quartile and the Fund’s estimated actual management fee rate and estimated total expenses would both rank in the fourth quartile relative to the Fund’s peers. The Board also noted that the Fund is differentiated from the Broadridge-selected peers given the Fund’s exposure to equity securities of “innovative” mid- and small-cap growth companies and access to private markets.

Following consideration of this information, the Board, including the Independent Board Members, concluded that the fees to be paid pursuant to the Agreement were fair and reasonable in light of the services to be provided.

As the Fund has not commenced operations as of the date of the Meeting, BlackRock was not able to provide the Board with specific information concerning the expected profits to be realized by BlackRock and its affiliates from their relationships with the Fund. BlackRock, however, will provide the Board with such information at future meetings.

D. Economies of Scale

The Board, including the Independent Board Members, considered the extent to which economies of scale might be realized as the assets of the Fund increase. The Board also considered the extent to which the Fund may benefit from such economies in a variety of ways, and whether there should be changes in the advisory fee rate or breakpoint structure in order to enable the Fund to more fully participate in these economies of scale.

Based on the Board’s review and consideration of the issue, the Board concluded that most closed-end funds do not have fund level breakpoints because closed-end funds generally do not experience substantial growth after the initial public offering. Closed-end funds are typically priced at scale at a fund’s inception.

E. Other Factors Deemed Relevant by the Board Members

The Board, including the Independent Board Members, also took into account other potential ancillary or “fall-out” benefits that BlackRock or its affiliates may derive from BlackRock’s respective relationships with the Fund, both tangible and intangible, such as BlackRock’s ability to leverage its investment professionals who manage other portfolios and risk management personnel, an increase in BlackRock’s profile in the investment advisory community, and the engagement of BlackRock’s affiliates as service providers to the Fund, including for administrative, securities lending and cash management services. The Board also considered BlackRock’s overall operations and its efforts to expand the scale of, and improve the quality of, its operations. The Board also noted that, subject to applicable law, BlackRock may use and benefit from third-party research obtained by soft dollars generated by certain registered fund transactions to assist in managing all or a number of its other client accounts.

In connection with its consideration of the Agreement, the Board also received information regarding BlackRock’s brokerage and soft dollar practices. The Board received reports from BlackRock which included information on brokerage commissions and trade execution practices for BlackRock closed-end funds throughout the year.

The Board noted the competitive nature of the closed-end fund marketplace, and that shareholders are able to sell their Fund shares in the secondary market if they believe that the Fund’s fees and expenses are too high or if they are dissatisfied with the performance of the Fund.

 

 

184  

2 0 2 1   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S


Disclosure of Investment Advisory Agreement (continued)

 

The Board also considered the various notable initiatives and projects BlackRock performed in connection with its closed-end fund product line. These initiatives included developing equity shelf programs; efforts to eliminate product overlap with fund mergers; ongoing services to manage leverage that has become increasingly complex; periodic evaluation of share repurchases and other support initiatives for certain BlackRock funds; and continued communications efforts with shareholders, fund analysts and financial advisers. With respect to the latter, the Independent Board Members noted BlackRock’s continued commitment to supporting the secondary market for the common shares of its closed-end funds through a comprehensive secondary market communication program designed to raise investor and analyst awareness and understanding of closed-end funds. BlackRock’s support services included, among other things: sponsoring and participating in conferences; communicating with closed-end fund analysts covering the BlackRock funds throughout the year; providing marketing and product updates for the closed-end funds; and maintaining and enhancing its closed-end fund website.

The Board, including a majority of the Independent Board Members, concluded that these potential ancillary benefits that BlackRock and its affiliates could receive with regard to providing investment advisory and other services to the Fund were consistent with those generally available to other fund sponsors.

Conclusion

The Board, including all the Independent Board Members, approved the Agreement between the Manager and the Fund, for a two-year term beginning on the effective date of the Agreement. Based upon its evaluation of all of the aforementioned factors in their totality, as well as other information, the Board, including the Independent Board Members, was satisfied that the terms of the Agreement were fair and reasonable and in the best interest of the Fund and its shareholders. In arriving at its decision to approve the Agreement, the Board did not identify any single factor or group of factors as all-important or controlling, but considered all factors together, and different Board Members may have attributed different weights to the various factors considered. The Independent Board Members were also assisted by the advice of independent legal counsel in making this determination.

 

 

D I S C L O S U R E   O F   I N V E S T M E N T   A D V I S O R Y   A G R E E M E N T

  185


Additional Information

 

Trust Certification

The Trusts are listed for trading on the NYSE and have filed with the NYSE their annual chief executive officer certification regarding compliance with the NYSE’s listing standards. The Trusts filed with the SEC the certification of its chief executive officer and chief financial officer required by Section 302 of the Sarbanes-Oxley Act.

Regulation Regarding Derivatives

On October 28, 2020, the Securities and Exchange Commission (the “SEC”) adopted new regulations governing the use of derivatives by registered investment companies (“Rule 18f-4”). The Trusts will be required to implement and comply with Rule 18f-4 by August 19, 2022. Once implemented, Rule 18f-4 will impose limits on the amount of derivatives a fund can enter into, eliminate the asset segregation framework currently used by funds to comply with Section 18 of the 1940 Act, treat derivatives as senior securities and require funds whose use of derivatives is more than a limited specified exposure amount to establish and maintain a comprehensive derivatives risk management program and appoint a derivatives risk manager.

Environmental, Social and Governance (“ESG”) Integration

Although a Trust does not seek to implement a specific ESG, impact or sustainability strategy unless otherwise disclosed, Trust management will consider ESG characteristics as part of the investment process for actively managed Trusts. These considerations will vary depending on a Trust’s particular investment strategies and may include consideration of third-party research as well as consideration of proprietary BlackRock research across the ESG risks and opportunities regarding an issuer. Trust management will consider those ESG characteristics it deems relevant or additive when making investment decisions for a Trust. The ESG characteristics utilized in a Trust’s investment process are anticipated to evolve over time and one or more characteristics may not be relevant with respect to all issuers that are eligible for investment. ESG characteristics are not the sole considerations when making investment decisions for a Trust. Further, investors can differ in their views of what constitutes positive or negative ESG characteristics. As a result, a Trust may invest in issuers that do not reflect the beliefs and values with respect to ESG of any particular investor. ESG considerations may affect a Trust’s exposure to certain companies or industries and a Trust may forego certain investment opportunities. While Trust management views ESG considerations as having the potential to contribute to a Trust’s long-term performance, there is no guarantee that such results will be achieved.

Dividend Policy

Each Trust’s policy is to make monthly distributions to shareholders. In order to provide shareholders with a more stable level of dividend distributions, each Trust employs a managed distribution plan (the “Plan”), the goal of which is to provide shareholders with consistent and predictable cash flows by setting distribution rates based on expected long-term returns of each Trust.

The distributions paid by a Trust for any particular month may be more or less than the amount of net investment income earned by a Trust during such month. Furthermore, the final tax characterization of distributions is determined after the year-end of a Trust and is reported in each Trust’s annual report to shareholders. Distributions can be characterized as ordinary income, capital gains and/or return of capital. Each Trust’s taxable net investment income and net realized capital gains (“taxable income”) may not be sufficient to support the level of distributions paid. To the extent that distributions exceed the Trust’s current and accumulated earnings and profits, the excess may be treated as a non-taxable return of capital.

A return of capital is a return of a portion of an investor’s original investment. A return of capital is not expected to be taxable, but it reduces a shareholder’s tax basis in his or her shares, thus reducing any loss or increasing any gain on a subsequent disposition by the shareholder of his or her shares. It is possible that a substantial portion of the distributions paid during a calendar year may ultimately be classified as return of capital for U.S. federal income tax purposes when the final determination of the source and character of the distributions is made.

Such distributions, under certain circumstances, may exceed a Trust’s total return performance. When total distributions exceed total return performance for the period, the difference reduces the Trust’s total assets and net asset value per share (“NAV”) and, therefore, could have the effect of increasing the Trust’s expense ratio and reducing the amount of assets the Trust has available for long term investment.

General Information

The Trusts, other than BME, BST and BUI, do not make available copies of their Statements of Additional Information because the Trusts’ shares, other than BME, BST and BUI, are not continuously offered, which means that the Statement of Additional Information of each Trust, other than BME, BST and BUI, has not been updated after completion of the respective Trust’s offerings and the information contained in each Trust’s Statement of Additional Information may have become outdated.

BME’s, BST’s and BUI’s Statements of Additional Information include additional information about the Board and are available, without charge upon request by calling (800)882-0052.

The following information is a summary of certain changes since December 31, 2020. This information may not reflect all of the changes that have occurred since you purchased the relevant Trust.

Except if noted otherwise herein, there were no changes to the Trusts’ charters or by-laws that would delay or prevent a change of control of the Trusts that were not approved by the shareholders.

In accordance with Section 23(c) of the Investment Company Act of 1940, each Trust may from time to time purchase shares of its common stock in the open market or in private transactions.

 

 

186  

2 0 2 1   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S


Additional Information (continued)

 

General Information (continued)

Quarterly performance, semi-annual and annual reports, current net asset value and other information regarding the Trusts may be found on BlackRock’s website, which can be accessed at blackrock.com. Any reference to BlackRock’s website in this report is intended to allow investors public access to information regarding the Trusts and does not, and is not intended to, incorporate BlackRock’s website in this report.

Electronic Delivery

Shareholders can sign up for e-mail notifications of quarterly statements, annual and semi-annual shareholder reports and, for BME, BST and BUI only, prospectuses, by enrolling in the electronic delivery program. Electronic copies of shareholder reports and, for BME, BST and BUI only, prospectuses, are available on BlackRock’s website.

To enroll in electronic delivery:

Shareholders Who Hold Accounts with Investment Advisers, Banks or Brokerages:

Please contact your financial adviser. Please note that not all investment advisers, banks or brokerages may offer this service.

Householding

The Trusts will mail only one copy of shareholder documents, including for BME, BST and BUI only, prospectuses, annual and semi-annual reports, Rule 30e-3 notices and proxy statements, to shareholders with multiple accounts at the same address. This practice is commonly called “householding” and is intended to reduce expenses and eliminate duplicate mailings of shareholder documents. Mailings of your shareholder documents may be householded indefinitely unless you instruct us otherwise. If you do not want the mailing of these documents to be combined with those for other members of your household, please call the Trusts at (800) 882-0052.

Availability of Quarterly Schedule of Investments

The Trusts file their complete schedules of portfolio holdings with the SEC for the first and third quarters of each fiscal year as an exhibit to their reports on Form N-PORT. The Trusts’ Forms N-PORT are available on the SEC’s website at sec.gov. Additionally, each Trust makes its portfolio holdings for the first and third quarters of each fiscal year available at blackrock.com/fundreports.

Availability of Proxy Voting Policies, Procedures and Voting Records

A description of the policies and procedures that the Trusts use to determine how to vote proxies relating to portfolio securities and information about how the Trusts voted proxies relating to securities held in the Trusts’ portfolios during the most recent 12-month period ended June 30 is available without charge, upon request (1) by calling (800) 882-0052; (2) on the BlackRock website at blackrock.com; and (3) on the SEC’s website at sec.gov.

Availability of Trust Updates

None of the Trusts, other than BME, BST and BUI, have filed a registration statement with respect to any current Shelf Offerings. This report is not an offer to sell these Trusts’ Common Shares and is not a solicitation of an offer to buy these Trusts’ Common Shares. If any of the Trusts other than BME, BST and BUI file a registration statement with respect to any current Shelf Offering, the prospectus contained therein will contain more complete information about such Trusts and should be read carefully before investing. BME, BST and BUI each have filed a final base prospectus dated April 30, 2021 and BST and BUI each have filed a final prospectus supplement dated April 30, 2021 with the SEC in connection with their Shelf Offering. This report and the base prospectuses of BME, BST and BUI and prospectus supplements of BST and BUI are not offers to sell these Trusts’ Common Shares or solicitations of an offer to buy these Trusts’ Common Shares in any jurisdiction where such offers or sales are not permitted. The base prospectuses of these Trusts and prospectus supplements of BST and BUI contains important information about the Trusts, including its investment objective, risks, charges and expenses. Investors are urged to read the base prospectuses of these Trusts and prospectus supplements of BST and BUI carefully and in its entirety before investing. Copies of the base prospectuses for these Trusts and prospectus supplements of BST and BUI can be obtained from BlackRock at blackrock.com.

BlackRock will update performance and certain other data for the Trusts on a monthly basis on its website in the “Closed-end Funds” section of blackrock.com as well as certain other material information as necessary from time to time. Investors and others are advised to check the website for updated performance information and the release of other material information about the Trusts. This reference to BlackRock’s website is intended to allow investors public access to information regarding the Trusts and does not, and is not intended to, incorporate BlackRock’s website in this report.

Shelf Offering Program

From time-to-time, BME, BST and BUI may seek to raise additional equity capital through an equity shelf program (a “Shelf Offering”). In a Shelf Offering, BME, BST and BUI may, subject to market conditions, raise additional equity capital by issuing new Common Shares from time to time in varying amounts at a net price at or above BME’s, BST’s and BUI’s net asset value (“NAV”) per Common Share (calculated within 48 hours of pricing). While any such Shelf Offering may allow BME, BST and BUI to pursue additional investment opportunities without the need to sell existing portfolio investments, it could also entail risks – including that the issuance of additional Common Shares may limit the extent to which the Common Shares are able to trade at a premium to NAV in the secondary market.

 

 

A D D I T I O N A L   I N F O R M A T I O N

  187


Additional Information (continued)

 

BlackRock Privacy Principles

BlackRock is committed to maintaining the privacy of its current and former fund investors and individual clients (collectively, “Clients”) and to safeguarding their non-public personal information. The following information is provided to help you understand what personal information BlackRock collects, how we protect that information and why in certain cases we share such information with select parties.

If you are located in a jurisdiction where specific laws, rules or regulations require BlackRock to provide you with additional or different privacy-related rights beyond what is set forth below, then BlackRock will comply with those specific laws, rules or regulations.

BlackRock obtains or verifies personal non-public information from and about you from different sources, including the following: (i) information we receive from you or, if applicable, your financial intermediary, on applications, forms or other documents; (ii) information about your transactions with us, our affiliates, or others; (iii) information we receive from a consumer reporting agency; and (iv) from visits to our websites.

BlackRock does not sell or disclose to non-affiliated third parties any non-public personal information about its Clients, except as permitted by law or as is necessary to respond to regulatory requests or to service Client accounts. These non-affiliated third parties are required to protect the confidentiality and security of this information and to use it only for its intended purpose.

We may share information with our affiliates to service your account or to provide you with information about other BlackRock products or services that may be of interest to you. In addition, BlackRock restricts access to non-public personal information about its Clients to those BlackRock employees with a legitimate business need for the information. BlackRock maintains physical, electronic and procedural safeguards that are designed to protect the non-public personal information of its Clients, including procedures relating to the proper storage and disposal of such information.

Trust and Service Providers

 

Investment Adviser

BlackRock Advisors, LLC

Wilmington, DE 19809

Sub-Adviser

BlackRock International Limited(a)

Edinburgh, EH3 8BL

United Kingdom

Accounting Agent and Custodian

State Street Bank and Trust Company

Boston, MA 02111

Transfer Agent

Computershare Trust Company, N.A.

Canton, MA 02021

 

Distributor

BlackRock Investments, LLC(b)

New York, NY 10022

Independent Registered Public Accounting Firm

Deloitte & Touche LLP

Boston, MA 02116

Legal Counsel

Willkie Farr & Gallagher LLP

New York, NY 10019

Address of the Trusts

100 Bellevue Parkway

Wilmington, DE 19809

 

(a) For BGR, BOE, BGY, BCX and BUI.

(b) For BME, BST and BUI.

 

 

188  

2 0 2 1   B L A C K R O C K   S E M I - A N N U A L   R E P O R T   T O   S H A R E H O L D E R S


Glossary of Terms Used in this Report

 

Currency Abbreviation
AUD   Australian Dollar
CAD   Canadian Dollar
CHF   Swiss Franc
DKK   Danish Krone
EUR   Euro
GBP   British Pound
HKD   Hong Kong Dollar
JPY   Japanese Yen
MXN   Mexican Peso
NOK   Norwegian Krone
SEK   Swedish Krona
SGD   Singapore Dollar
USD   United States Dollar
Portfolio Abbreviation
ADR   American Depositary Receipt
GDR   Global Depositary Receipt
LP   Limited Partnership
PJSC   Public Joint Stock Company
REIT   Real Estate Investment Trust
SAB   Special Assessment Bonds

 

 

G L O S S A R Y   O F   T E R M S   U S E D   I N   T H I S   R E P O R T

  189


 

 

 

Want to know more?

blackrock.com    |    800-882-0052

This report is intended for current holders. It is not a prospectus. Past performance results shown in this report should not be considered a representation of future performance. Statements and other information herein are as dated and are subject to change.

CEF-BK9-06/21-SAR

 

LOGO

  LOGO


(b) Not Applicable

 

Item 2 –

Code of Ethics – Not Applicable to this semi-annual report

 

Item 3 –

Audit Committee Financial Expert – Not Applicable to this semi-annual report

 

Item 4 –

Principal Accountant Fees and Services – Not Applicable to this semi-annual report

 

Item 5 –

Audit Committee of Listed Registrants – Not Applicable to this semi-annual report

 

Item 6 –

Investments

(a) The registrant’s Schedule of Investments is included as part of the Report to Stockholders filed under Item 1(a) of this Form.

(b) Not Applicable due to no such divestments during the semi-annual period covered since the previous Form N-CSR filing.

 

Item 7 –

Disclosure of Proxy Voting Policies and Procedures for Closed-End Management Investment Companies – Not Applicable to this semi-annual report

 

Item 8 –

Portfolio Managers of Closed-End Management Investment Companies

(a) Not Applicable to this semi-annual report

(b) As of the date of this filing, there have been no changes in any of the portfolio managers identified in the most recent annual report on Form N-CSR.

 

Item 9 –

Purchases of Equity Securities by Closed-End Management Investment Company and Affiliated Purchasers – Not Applicable due to no such purchases during the period covered by this report.

 

Item 10 –

Submission of Matters to a Vote of Security Holders – There have been no material changes to these procedures.

 

Item 11 –

Controls and Procedures

(a) The registrant’s principal executive and principal financial officers, or persons performing similar functions, have concluded that the registrant’s disclosure controls and procedures (as defined in Rule 30a-3(c) under the Investment Company Act of 1940, as amended (the “1940 Act”)) are effective as of a date within 90 days of the filing of this report based on the evaluation of these controls and procedures required by Rule 30a-3(b) under the 1940 Act and Rule 13a-15(b) under the Securities Exchange Act of 1934, as amended.

(b) There were no changes in the registrant’s internal control over financial reporting (as defined in Rule 30a-3(d) under the 1940 Act) that occurred during the period covered by this report that have materially affected, or are reasonably likely to materially affect, the registrant’s internal control over financial reporting.

 

Item 12 –

Disclosure of Securities Lending Activities for Closed-End Management Investment Companies – Not applicable to this semi-annual report

 

Item 13 –

Exhibits attached hereto

(a)(1) Code of Ethics – Not Applicable to this semi-annual report

(a)(2) Section 302 Certifications are attached

 

2


(a)(3) Not Applicable

(a)(4) Not Applicable

(b) Section  906 Certifications are attached

(c) Notices to the registrant’s common shareholders in accordance with the order under Section 6(c) of the 1940 Act granting an exemption from Section 19(b) of the 1940 Act and Rule 19b-1 under the 1940 Act, dated May 9, 20091

 

1    The Fund has received exemptive relief from the Securities and Exchange Commission permitting it to make periodic distributions of long-term capital gains with respect to its outstanding common stock as frequently as twelve times each year, and as frequently as distributions are specified by or in accordance with the terms of its outstanding preferred stock. This relief is conditioned, in part, on an undertaking by the Fund to make the disclosures to the holders of the Fund’s common shares, in addition to the information required by Section 19(a) of the 1940 Act and Rule 19a-1 thereunder. The Fund is likewise obligated to file with the SEC the information contained in any such notice to shareholders and, in that regard, has attached hereto copies of each such notice made during the period.

 

3


Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

BlackRock Energy and Resources Trust

 

  By:     

/s/ John M. Perlowski                                

       John M. Perlowski
      

Chief Executive Officer (principal executive officer) of

BlackRock Energy and Resources Trust

Date: September 2, 2021

Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

 

  By:     

/s/ John M. Perlowski                            

       John M. Perlowski
      

Chief Executive Officer (principal executive officer) of

BlackRock Energy and Resources Trust

Date: September 2, 2021

 

  By:     

/s/ Trent Walker                            

       Trent Walker
      

Chief Financial Officer (principal financial officer) of

BlackRock Energy and Resources Trust

Date: September 2, 2021

 

4

EX-99. CERT

CERTIFICATION PURSUANT TO RULE 30a-2(a) UNDER THE 1940 ACT AND SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

 

I, John M. Perlowski, Chief Executive Officer (principal executive officer) of BlackRock Energy and Resources Trust, certify that:

1.            I have reviewed this report on Form N-CSR of BlackRock Energy and Resources Trust;

2.            Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.            Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, changes in net assets, and cash flows (if the financial statements are required to include a statement of cash flows) of the registrant as of, and for, the periods presented in this report;

4.            The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Rule 30a-3(c) under the Investment Company Act of 1940) and internal control over financial reporting (as defined in Rule 30a-3(d) under the Investment Company Act of 1940) for the registrant and have:

a)            designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)            designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)            evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of a date within 90 days prior to the filing date of this report based on such evaluation; and

d)            disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the period covered by this report that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.            The registrant’s other certifying officer(s) and I have disclosed to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a)            all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize, and report financial information; and

b)            any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: September 2, 2021

/s/ John M. Perlowski        

John M. Perlowski

Chief Executive Officer (principal executive officer) of

BlackRock Energy and Resources Trust


EX-99. CERT

CERTIFICATION PURSUANT TO RULE 30a-2(a) UNDER THE 1940 ACT AND SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

 

I, Trent Walker, Chief Financial Officer (principal financial officer) of BlackRock Energy and Resources Trust, certify that:

1.            I have reviewed this report on Form N-CSR of BlackRock Energy and Resources Trust;

2.            Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.            Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, changes in net assets, and cash flows (if the financial statements are required to include a statement of cash flows) of the registrant as of, and for, the periods presented in this report;

4.            The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Rule 30a-3(c) under the Investment Company Act of 1940) and internal control over financial reporting (as defined in Rule 30a-3(d) under the Investment Company Act of 1940) for the registrant and have:

a)            designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)            designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)            evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of a date within 90 days prior to the filing date of this report based on such evaluation; and

d)            disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the period covered by this report that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.            The registrant’s other certifying officer(s) and I have disclosed to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a)            all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize, and report financial information; and

b)            any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: September 2, 2021    

/s/ Trent Walker        

Trent Walker

Chief Financial Officer (principal financial officer) of

BlackRock Energy and Resources Trust

Exhibit 99.906CERT

Certification Pursuant to Rule 30a-2(b) under the 1940 Act and

Section 906 of the Sarbanes-Oxley Act of 2002

Pursuant to 18 U.S.C. § 1350, the undersigned officer of BlackRock Energy and Resources Trust (the “registrant”), hereby certifies, to the best of his knowledge, that the registrant’s Report on Form N-CSR for the period ended June 30, 2021 (the “Report”) fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934, as amended, and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the registrant.

Date: September 2, 2021

/s/ John M. Perlowski        

John M. Perlowski

Chief Executive Officer (principal executive officer) of

BlackRock Energy and Resources Trust

Pursuant to 18 U.S.C. § 1350, the undersigned officer of BlackRock Energy and Resources Trust (the “registrant”), hereby certifies, to the best of his knowledge, that the registrant’s Report on Form N-CSR for the period ended June 30, 2021 (the “Report”) fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934, as amended, and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the registrant.

Date: September 2, 2021

/s/ Trent Walker        

Trent Walker

Chief Financial Officer (principal financial officer) of

BlackRock Energy and Resources Trust

This certification is being furnished pursuant to Rule 30a-2(b) under the Investment Company Act of 1940, as amended, and 18 U.S.C. § 1350 and is not being filed as part of the Form N-CSR with the Securities and Exchange Commission.

BlackRock Energy and Resources Trust

 

Cusip: 09250U101

 

Ticker: BGR

 

Record Date

    June 15, 2021  

Pay Date

    June 30, 2021  

Distribution Amount per share

  $             0.037500  

The following table sets forth the estimated amounts of the current distribution and the cumulative distributions paid this fiscal year to date from the following sources: net income, net realized short-term capital gains, net realized long-term capital gains and return of capital. All amounts are expressed per common share.

 

    Current Distribution      % Breakdown
of the Current
Distribution
     Total Cumulative
Distributions for the
Fiscal Year to Date
     % Breakdown of the
Total Cumulative
Distributions for the
Fiscal Year to Date
 

Net Income

  $ 0.030883        82%      $ 0.153140        68%  

Net Realized Short-Term Capital Gains

  $ —        0%      $ —        0%  

Net Realized Long-Term Capital Gains

  $ —        0%      $ —        0%  

Return of Capital

  $ 0.006617        18%      $ 0.071860        32%  
 

 

 

    

 

 

    

 

 

    

 

 

 

Total (per common share)

  $ 0.037500        100%      $ 0.225000        100%  
 

 

 

    

 

 

    

 

 

    

 

 

 

Average annual total return (in relation to NAV) for the 5-year period ending on May 31, 2021

 

     -0.98%  
          

 

 

 

Annualized current distribution rate expressed as a percentage of NAV as of May 31, 2021

 

     4.52%  
          

 

 

 

Cumulative total return (in relation to NAV) for the fiscal year through May 31, 2021

 

     24.39%  
          

 

 

 

Cumulative fiscal year distributions as a percentage of NAV as of May 31, 2021

 

     1.88%  
          

 

 

 

You should not draw any conclusions about the Trust’s investment performance from the amount of this distribution or from the terms of the Trust’s Managed Distribution Plan.

The Fund estimates that it has distributed more than its net income and net realized capital gains; therefore, a portion of your distribution may be a return of capital. A return of capital may occur, for example, when some or all of the money that you invested in the Fund is paid back to you. A return of capital does not necessarily reflect the Fund’s investment performance and should not be confused with ‘yield’ or ‘income’.

When distributions exceed total return performance, the difference will reduce the Fund’s net asset value per share.

The amounts and sources of distributions reported in this Notice are only estimates and are not being provided for tax reporting purposes. The actual amounts and sources of the amounts for tax reporting purposes will depend upon the Fund’s investment experience during its fiscal year and may be subject to changes based on tax regulations. The Fund will send you a Form 1099-DIV for the calendar year that will tell you how to report these distributions for federal income tax purposes.

Contact Number:  800-882-0052


BlackRock Energy and Resources Trust

 

Cusip: 09250U101

 

Ticker: BGR

 

Record Date

    July 15, 2021  

Pay Date

    July 30, 2021  

Distribution Amount per share

  $             0.037500  

The following table sets forth the estimated amounts of the current distribution and the cumulative distributions paid this fiscal year to date from the following sources: net income, net realized short-term capital gains, net realized long-term capital gains and return of capital. All amounts are expressed per common share.

 

    Current Distribution      % Breakdown
of the Current
Distribution
     Total Cumulative
Distributions for the
Fiscal Year to Date
     % Breakdown of the
Total Cumulative
Distributions for the
Fiscal Year to Date
 

Net Income

  $ —        0%      $ 0.122304        47%  

Net Realized Short-Term Capital Gains

  $ —        0%      $ —        0%  

Net Realized Long-Term Capital Gains

  $ —        0%      $ —        0%  

Return of Capital

  $ 0.037500        100%      $ 0.140196        53%  
 

 

 

    

 

 

    

 

 

    

 

 

 

Total (per common share)

  $ 0.037500        100%      $ 0.262500        100%  
 

 

 

    

 

 

    

 

 

    

 

 

 

Average annual total return (in relation to NAV) for the 5-year period ending on June 30, 2021

 

     -1.05%  
          

 

 

 

Annualized current distribution rate expressed as a percentage of NAV as of June 30, 2021

 

     4.42%  
          

 

 

 

Cumulative total return (in relation to NAV) for the fiscal year through June 30, 2021

 

     27.87%  
          

 

 

 

Cumulative fiscal year distributions as a percentage of NAV as of June 30, 2021

 

     2.21%  
          

 

 

 

You should not draw any conclusions about the Trust’s investment performance from the amount of this distribution or from the terms of the Trust’s Managed Distribution Plan.

The Fund estimates that it has distributed more than its net income and net realized capital gains; therefore, a portion of your distribution may be a return of capital. A return of capital may occur, for example, when some or all of the money that you invested in the Fund is paid back to you. A return of capital does not necessarily reflect the Fund’s investment performance and should not be confused with ‘yield’ or ‘income’.

When distributions exceed total return performance, the difference will reduce the Fund’s net asset value per share.

The amounts and sources of distributions reported in this Notice are only estimates and are not being provided for tax reporting purposes. The actual amounts and sources of the amounts for tax reporting purposes will depend upon the Fund’s investment experience during its fiscal year and may be subject to changes based on tax regulations. The Fund will send you a Form 1099-DIV for the calendar year that will tell you how to report these distributions for federal income tax purposes.

Contact Number:  800-882-0052